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Summary	Previous	 research	 has	 suggested	 a	 role	 for	 vitamin	 D	 in	 non-alcoholic	fatty	 liver	 disease	 (NAFLD)	 pathogenesis.	 	 Several	 observational	 studies	 have	observed	 low	vitamin	D	status	(25OHD)	with	poorer	histological	 findings.	 	The	principal	aims	of	this	study	were	to	assess	diet	and	lifestyle,	25OHD	status,	gene	variants	 in	 vitamin	 D	metabolism	 in	 UK	 children,	 and	 separately	 examine	 the	effect	of	vitamin	D	in	an	in	vitro	NAFLD	model.	Dietary	 results	 from	 the	 case	 control	 study	 (n=32)	 indicated	 vitamin	 D	intakes	of	paediatric	patient	with	biopsy-proven	NAFLD	and	ultrasound-cleared	obese	patients	were	1.7μg/day	and	3.5μg/day,	respectively,	well	below	the	new	UK	 recommendation.	 	 Children	 failed	 to	 meet	 current	 UK	 government	recommendations	for	physical	activity.	In	our	UK	paediatric	biopsy-proven	NAFLD	cohort	(n=103),	the	majority	of	 patients	 presented	 with	 deficient	 (<25nmol/L,	 25.5%)	 or	 insufficient	(<50nmol/L,	 80.8%)	 mean	 serum	 25OHD	 levels.	 	 Furthermore,	 patients	 had	significantly	 lower	 25OHD	 levels	 during	 winter	 months	 in	 comparison	 to	summer	 (p=0.0001)	 and	 autumn	 (p=0.0026),	 while	 25OHD	 levels	 were	 non-significantly	 lower	 in	 NASH	 compared	 to	 non-NASH	 patients	 (p=0.0576).	 We	observed	 that	 single	 nucleotide	 polymorphisms	 (SNPs)	 involved	 in	 vitamin	 D	metabolism	 were	 associated	 with	 poorer	 liver	 histology	 grading;	 specifically,	three	 SNPs	 were	 associated	 with	 increased	 steatosis	 and	 one	 with	 increased	inflammation	score	in	Caucasian	patients.		Finally,	 LX-2	 cells,	 an	 immortalised	 human	 hepatic	 stellate	 cell	 line,	demonstrated	significantly	reduced	cell	proliferation	(p=0.0005)	with	increasing	doses	of	1α,25(OH)2D3	after	10	days	of	incubation	in	clonogenic	assays.		 In	conclusion,	we	found	that	NAFLD	children	have	extremely	low	levels	of	25OHD	throughout	the	year,	with	little	dietary	contribution.		In	addition,	several	vitamin	D	related	SNPs	were	associated	with	poorer	histological	findings.	These	novel	data	suggest	an	important	role	for	vitamin	D	in	the	pathogenesis	and	progression	of	NAFLD	in	a	paediatric	population.			
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Chapter	1:	Introduction	
1.1 Research	Relevance	Overview	Non-alcoholic	fatty	liver	disease	(NAFLD)	is	a	global	health	problem,	and	is	now	the	most	common	cause	of	chronic	liver	disease	in	Western	children	with	an	estimated	prevalence	of	10%	in	the	general	paediatric	population	(Takahashi	and	Fukusato	2010),	 increasing	 to	80%	in	obese	children	(Giorgio,	Prono	et	al.	2013).	 Here	 child	 is	 defined	 as	 anyone	 under	 the	 age	 of	 majority,	 but	 for	 the	purpose	of	this	thesis,	all	children	and	adolescents	aged	up	to	and	including	18	years	 and	 attending	 school	 are	 included	 as	 a	 paediatric	 population.	 Left	untreated,	 NAFLD	 has	 the	 potential	 to	 progress	 to	 hepatocellular	 carcinoma	(HCC)	 and/or	 end-stage	 liver	 disease	 (Chalasani,	 Younossi	 et	 al.	 2012).	 	 There	are	no	NAFLD-specific	pharmacological	agents,	 first	 line	 treatment	of	NAFLD	is	based	 around	 dietary	 and	 lifestyle	 advice,	 targeting	 increased	 physical	 activity	and	reduced	caloric	intake,	leading	to	weight	loss.	The	 role	 of	 specific	 macro-	 and	 micronutrients	 in	 disease	 progression	remains	 uncertain,	 and	 there	 is	 growing	 research	 into	 the	 use	 of	 nutritional	supplementation	 in	 the	 management	 of	 NAFLD.	 Vitamin	 E,	 probiotics	 and	omega-3	fatty	acids	have	all	been	trialed	in	paediatric	populations	with	varying	success.	 	More	 recently,	 vitamin	 D	 has	 been	 implicated	 in	 the	 development	 of	NAFLD,	 with	 low	 levels	 of	 serum	 25-hydroxyvitamin	 D	 (25OHD)	 strongly	associated	 with	 features	 of	 the	 metabolic	 syndrome;	 including	 dyslipidaemia,	insulin	 resistance	 (IR),	 hyperglycaemia	 and	 hepatic	 inflammation	 (Eliades,	Spyrou	et	al.	2013).	Vitamin	D	is	unique,	in	that	the	main	source	in	the	UK	is	not	the	diet,	but	rather	 the	 cutaneous	 synthesis	 of	 vitamin	 D	 under	 the	 surface	 of	 the	 skin	 on	exposure	 to	 ultraviolet	 B	 (UVB)	 rays	 from	 sunlight.	 It	 was	 previously	 thought	that	sufficient	vitamin	D	was	made	during	spring	and	summer	months	from	sun	exposure	on	 the	 skin	 to	maintain	 sufficient	 levels	 through	 autumn	and	winter.		However,	it	is	now	clear	that	this	is	not	necessarily	the	case	and	there	are	many	individuals	 who	 have	 deficient	 levels	 all	 year	 round,	 not	 just	 during	 winter.		According	to	the	National	Diet	and	Nutrition	Survey	(NDNS),	22%	of	UK	children	
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aged	 between	 11	 and	 18	 years	 presented	with	 deficient	 25-hydroxyvitamin	 D	(25OHD)	 status	 (<25nmol/L),	 and	 deficient	 cases	 increased	 to	 40%	 during	winter	 (Bates	2014).	 	This	 is	not	 a	unique	problem	 to	 the	UK.	 	Across	Europe,	vitamin	D	deficiency	 is	estimated	at	26-51%	of	adolescents	 (Spiro	and	Buttriss	2014).	The	mechanisms	behind	the	role	of	vitamin	D	in	NAFLD	pathogenesis	are	not	 yet	 fully	 understood.	 Animal	 and	 in	 vitro	 studies	 have	 demonstrated	 that	vitamin	D	has	an	important	role	in	the	regulation	of	oxidative	stress,	production	of	 pro-inflammatory	 cytokines	 (Roth,	 Elfers	 et	 al.	 2012),	 hepatic	 apoptosis	(Zhang,	Wang	et	al.	2007,	Nakano,	Cheng	et	al.	2011),	hepatic	steatosis	(Yin,	Yu	et	al.	 2012)	 and	 liver	 fibrosis	 (Abramovitch,	 Dahan-Bachar	 et	 al.	 2011,	 Nakano,	Cheng	 et	 al.	 2011,	 Potter,	 Liu	 et	 al.	 2013).	 Further	more,	 genetic	 variations	 in	NAFLD	 related	 genes,	 namely	PNPLA3	 (Romeo,	Kozlitina	 et	 al.	 2008,	 Speliotes,	Butler	et	al.	2010,	Valenti,	Alisi	et	al.	2010)	have	been	identified	for	their	role	in	NAFLD	 severity,	with	more	 recent	work	 highlighting	 variants	 in	 the	 vitamin	D	metabolic	pathway	and	associations	with	chronic	liver	disease	including	NAFLD	(Grünhage,	 Hochrath	 et	 al.	 2012).	 Previously,	 children	 with	 NAFLD	 have	presented	with	low	25OHD	status.		In	an	Italian	population	(Nobili,	Giorgio	et	al.	2014),	 children	 presented	with	 a	mean	 25OHD	 of	 50nmol/L,	 while	 Australian	adolescents	(Black,	Jacoby	et	al.	2014)	presented	between	67-80nmol/L.	Despite	these	 ‘sufficient’	 serum	 levels,	 it	 is	 important	 to	 note	 the	 latitude	 of	 these	countries,	41oN	and	32oS	respectively,	while	the	UK	is	51oN,	further	adding	to	the	likelihood	of	 insufficient	year	 long	25OHD	 levels	due	 to	reduced	UVB	exposure	during	 autumn	 and	winter.	 	 In	 this	work	 I	 investigate	 previously	 unaddressed	questions	regarding	the	vitamin	D	intakes,	nutrient	status	and	lifestyle	habits	of	NAFLD	 children	 in	 the	UK;	 as	well	 as	whether	polymorphisms	 associated	with	vitamin	D	metabolism	impact	on	NAFLD	severity.	
1.1.1 Current	Relevance	In	2015,	the	UK	Government’s	Scientific	Advisory	Committee	on	Nutrition	(SACN)	published	a	draft	report	for	consultation	on	Vitamin	D	and	Health	(SACN	2015)	resulting	in	the	introduction	of	a	dietary	reference	value	(DRV)	for	all	age	groups,	 rather	 than	 one	 for	 vulnerable	 groups	 as	 previously	 used.	 	 The	 new	
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recommended	 nutrient	 intake	 (RNI)	 of	 10μg/d	 has	 now	 been	 set	 for	 the	 UK	population	aged	4	years	and	over	(SACN	2016),	and	 is	 the	amount	required	by	97.5%	 of	 the	 population	 in	 order	 to	 maintain	 serum	 25OHD	 levels	 above	25nmol/L,	the	general	global	consensus	for	defining	vitamin	D	deficiency.	 	This	brings	the	UK	into	alignment	with	many	other	countries	around	the	world	where	dietary	recommendations	have	been	in	place	for	some	time.	A	primary	public	health	concern	 is	 to	how	the	UK	population	 in	general	can	 achieve	 this	 DRV,	 as	 obtaining	 10μg/d	 from	 natural	 food	 sources	 alone	 is	difficult.	 	 NAFLD	 patients	 are	 of	 particular	 concern	 as	 vitamin	 D	 deficiency	 is	common	 in	 this	 population.	 	 Possible	 strategies	 are	 oral	 supplementation,	 or	intravenous	 injections	 of	 vitamin	D	 to	 correct	 chronic	 deficiencies.	 	 Increasing	vitamin	D	 intakes	 through	supplementation	 in	addition	 to	 supporting	 the	need	for	 increased	 physical	 activity,	 which	 could	 take	 place	 outside	 thus	 increasing	UVB	exposure,	could	help	correct	vitamin	D	deficiency	 in	UK	paediatric	NAFLD	patients.	There	is	ongoing	controversy	as	to	whether	low	vitamin	D	status	results	in	 the	 progression	 of	 NAFLD	 to	 the	 more	 severe	 form	 of	 non-alcoholic	steatohepatitis	(NASH),	or	if	in	fact	development	of	fatty	liver	disease	results	in	reduced	 vitamin	 D	metabolism.	 25-hydroxylation	 occurs	 predominantly	 in	 the	liver,	 thus	 changes	 in	 liver	 morphology	 may	 disrupt	 the	 metabolic	 pathway.	Determining	 the	 mechanisms	 of	 vitamin	 D	 dysregulation	 and	 role	 in	 NAFLD	pathogenesis	 will	 be	 key	 to	 building	 a	 greater	 understanding	 of	 the	 potential	therapeutic	effects	of	vitamin	D	in	the	management	of	NAFLD.	
1.2 Non-Alcoholic	Fatty	Liver	Disease	
1.2.1	History	of	Disease	Fatty	liver	disease	was	perhaps	first	described	by	Westwater	and	Fainer	in	 1958,	 who	 observed	 that	 health	 related	 diseases	 including	 fatty	 liver	 were	associated	with	obesity.	 	The	report	showed	that	obese	males	and	 females	had	increased	mortality	 rates	 of	 249%	 and	 147%	 respectively	 in	 comparison	with	healthy	 weight	 individuals	 (Westwater	 and	 Fainer	 1958).	 	 However,	 it	 wasn’t	until	1979	that	Alder	and	Schaffner	described	fatty	liver,	hepatitis	and	cirrhosis	in	 a	 group	 of	 overweight	 individuals	 with	 diabetes	 and	 abnormal	 lipid	 levels	
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(Adler	and	Schaffner	1979).		The	term	NAFLD	was	defined	the	following	year	by	Ludwig	and	colleagues	 (1980);	who,	after	 following	20	patients	over	a	10-year	period,	 described	 a	 liver	 disease	 that	 was	 ‘morphologically	 indistinguishable	from	alcoholic	hepatitis’.		They	noted	that	these	patterns	were	found	in	patients	who	did	not	drink	excessive	alcohol	 (<20g/d),	had	no	bypass	surgery	nor	 took	any	steatohepatitis-inducing	 therapeutic	drugs.	 	This	 ‘new’	disease	was	 termed	NASH,	 which	 encompassed	 both	 the	 absence	 of	 alcohol	 with	 the	 fatty	morphological	changes	and	lobular	hepatitis	(Ludwig,	Viggiano	et	al.	1980).		 NAFLD	 is	defined	by	 the	accumulation	of	 fat	 in	 the	 liver,	 conventionally	set	 at	 ≥5%	 hepatocytes	 containing	 macrovesicular	 fatty	 based	 on	histopathological	 findings	 (Brunt	 2001),	 in	 the	 absence	 of	 secondary	 causes	including	alcohol	abuse.	Worldwide,	the	diagnosis	of	NAFLD	has	risen	markedly	in	recent	years	in	line	with	the	increasing	prevalence	of	global	obesity,	and	is	the	most	 common	 cause	 of	 chronic	 liver	 disease	 in	 Western	 countries	 (Petta,	Muratore	 et	 al.	 2009,	 Loomba	 and	 Sanyal	 2013).	 It	 is	 estimated	 that	 there	 are	approximately	one	billion	cases	of	NAFLD	worldwide;	however,	this	is	 likely	an	underestimation	given	the	 limited	staging	and	grading	methods	for	NAFLD	and	so	 true	 population	 prevalence	 of	 the	 disease	 remains	 unknown	 (Loomba	 and	Sanyal	 2013).	 NAFLD	 is	 often	 referred	 to	 as	 the	 hepatic	 manifestation	 of	 the	metabolic	 syndrome	 (Moore	2010),	 as	 it	 is	 closely	 associated	with	obesity	 and	type	 2	 diabetes,	 both	 of	which	 are	 strong	 risk	 factors	 for	NAFLD	development	(Machado,	Marques-Vidal	et	al.	2006,	Vernon,	Baranova	et	al.	2011),	in	addition	to	 high	 blood	 pressure,	 hypertriglycerideamia,	 hyperglycaemia	 and	 low	 high-density	lipoprotein	cholesterol	levels	(Ford,	Giles	et	al.	2002).		However,	NAFLD	is	 a	 complex	 disease	 with	 links	 to	 genetic,	 ethnic	 and	 environmental	 factors;	NAFLD	patients	may	be	normal	weight	 (Liu	2012)	and	 individuals	with	 insulin	resistance	do	not	always	develop	NAFLD	(Guerrero,	Vega	et	al.	2009).		Currently	there	 are	 no	 adequate	 pharmaceutical	 therapies	 for	 the	 treatment	 of	 NAFLD.		Therefore	 clinical	 guidelines	 to	 date	 support	 weight	 loss	 through	 lifestyle	modification	as	 the	primary	approach	alongside	management	of	co-morbidities	as	necessary	(Chalasani,	Younossi	et	al.	2012,	Nascimbeni,	Pais	et	al.	2013).	
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1.2.2	NAFLD	Diagnosis	NAFLD	is	an	umbrella	term	describing	a	histological	spectrum	of	diseases	starting	with	 the	accumulation	of	 fat	 in	 the	 liver,	known	as	simple	steatosis,	 to	NASH,	 fibrosis,	 cirrhosis,	 HCC	 and	 end-stage	 liver	 disease	 (Figure	 1.1).	 	While	simple	steatosis	is	considered	a	benign	condition	with	no	significant	increase	in	liver	 related	 complications,	 it	 is	 estimated	 that	 47%	 of	 people	 with	 simple	steatosis	will	progress	to	NASH	(Ekstedt,	Franzen	et	al.	2006),	characterised	by	inflammation	 and	 low	 levels	 of	 fibrosis	 (Pais,	 Charlotte	 et	 al.	 2013).	 	 NASH	 is	associated	 with	 a	 significant	 increase	 in	 risk	 of	 liver-related	 complications	including	 hepatocellular	 carcinoma,	 and	 is	 an	 independent	 risk	 factor	 for	cardiovascular	 disease.	 	 While	 simple	 steatosis	 and	 NASH	 are	 considered	reversible	through	modifiable	factors	such	as	weight-loss	and	lifestyle	changes,	it	is	 estimated	 that	 approximately	 25-30%	 of	 NASH	 patients	 will	 progress	 to	irreversible	 fibrosis	 and	 cirrhosis,	 liver-related	 morbidity,	 risk	 of	 HCC	development	and	the	need	for	liver	transplantation	(Cohen,	Horton	et	al.	2011).		 	
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Figure	 1.1:	 Progression	 and	 Stages	 of	 non-alcoholic	 fatty	 liver	 disease.	 	 Schematic	 of	progression	 of	 NAFLD	 with	 histological	 sections	 illustrating	 normal,	 steatosis,	 NASH	 and	cirrhosis;	collagen	fibres	stained	with	Masson’s	trichrome	stain	(blue)	adapted	from	Cohen	et	al.,	2011.		Dashed	lines	represent	possible	regression	of	the	disease.			 Most	 NAFLD	 cases	 are	 found	 incidentally	 through	 raised	 liver	 enzymes	(ALT	and	AST)	 identified	 through	 routine	biochemical	 tests	or	 echogenicity	on	ultrasound	(Barshop,	Sirlin	et	al.	2008).		A	diagnosis	of	NAFLD	requires	evidence	of	hepatic	fat	accumulation	through	imaging	or	histology	in	the	absence	of	other	causes,	 in	particular	 excess	 alcohol	 consumption,	 or	 other	 causes	of	 secondary	steatosis	such	as	Wilson’s	disease	(Chalasani,	Younossi	et	al.	2012).		On	the	basis	of	a	study	that	used	proton	magnetic	resonance	spectroscopy	(MRS)	to	establish	the	 range	 of	 hepatic	 lipid	 content	 in	 345	 subjects	 with	 low	 risk	 for	 NAFLD	(nonobese,	 nondiabetic,	 normal	 liver	 function	 tests),	 steatosis	 is	 generally	defined	 as	 greater	 than	 5.5%	 hepatic	 triglyceride	 content	 (Szczepaniak,	Nurenberg	 et	 al.	 2005).	 	 Data	 is	 limited	 on	which	 to	 base	 the	 cutoff	 range	 for	acceptable	 alcohol	 consumption	 in	 the	 context	 of	 a	 diagnosis	 of	 NAFLD.	 	 The	conclusions	of	a	consensus	workshop	on	NAFLD	clinical	trial	design	was	that,	for	
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research	 purposes,	 “significant”	 alcohol	 consumption	 is	 defined	 as	 >21	units/week	(24	g/d)	for	men	and	>14	units/week	(16	g/d)	for	women	(Sanyal,	Brunt	 et	 al.	 2011).	 	 Other	 causes	 of	 fatty	 liver	 disease	 should	 be	 ruled	 out	including	 genetic,	 nutritional,	 viral,	 autoimmune	 response,	metabolic	 and	 drug	factors	(Day	2006).		 Liver	 biopsy	 remains	 the	 gold	 standard	 for	 diagnosis	 and	 staging	 of	NAFLD	 severity,	 particularly	 for	 clinical	 research	 trials,	 as	 it	 can	 distinguish	simple	steatosis	from	NASH	and	fibrosis.		However,	biopsies	are	both	costly	and	invasive,	causing	pain,	anxiety	and	discomfort	for	the	patient,	with	heterogeneity	in	 the	 distribution	 of	 lesions	 leading	 to	 possible	 sampling	 errors	 (Ratziu,	Charlotte	et	al.	2005,	Chalasani,	Younossi	et	al.	2012,	Merat,	Sotoudehmanesh	et	al.	 2012).	 	 Additionally,	 biopsy	 is	 occasionally	 associated	 with	 complications	including	 morbidity	 (1-3%)	 and	 mortality	 (0.01%)	 and	 so	 is	 not	 conducted	routinely	 (Gilmore,	 Burroughs	 et	 al.	 1995,	 Cadranel,	 Rufat	 et	 al.	 2000,	 Bravo,	Sheth	et	al.	2001)	and	may	be	delayed	by	treatment	with	lifestyle	modifications.		Despite	 this,	 biopsy	 still	 remains	 the	 most	 sensitive	 and	 specific	 method,	providing	 valuable	 information	 of	 grade	 and	 staging	 of	 disease	 progression	(Angulo	2002,	Loomba,	Sirlin	et	al.	2009).		 Histological	 scoring,	 using	 a	 system	 designed	 and	 validated	 by	 the	American	 NASH	 Clinical	 Research	 Network	 (NASH-CRN),	 is	 typically	 used	 to	describe	the	severity	of	NAFLD	in	clinical	trials	(Kleiner,	Brunt	et	al.	2005).		This	system	scores	14	histological	features,	which	are	assessed	either	qualitatively	or	quantitatively.	 The	 resulting	 NAFLD	 activity	 score	 (NAS),	 is	 primarily	 used	 in	clinical	research,	and	looks	at	lobular	inflammation	(on	a	scale	of	0-3),	steatosis	(0-3)	 and	 ballooning	 (0-2)	 with	 higher	 scores	 relating	 to	 increased	 disease	severity	(Kleiner,	Brunt	et	al.	2005).		The	total	range	is	from	0	to	8,	and	a	score	of	5	or	above	 is	diagnostic	of	NASH;	while	biopsies	with	scores	of	2	or	below	are	usually	 classified	 as	 non-NASH	 and	 those	 with	 a	 score	 of	 3-4	 are	 considered	borderline	 NASH	 (Kleiner,	 Brunt	 et	 al.	 2005).	 	 However,	 diagnosis	 of	 definite	steatosis	 by	 NAS	 is	 not	 always	 accurate	 (Brunt,	 Kleiner	 et	 al.	 2011),	 nor	 a	practical	 tool	 of	 assessment	 due	 to	 its	 invasive	 limitations	 (Nalbantoglu	 and	Brunt	2014).	
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	 Non-invasive	tools	for	NAFLD	diagnosis	include	serum	concentrations	of	ALT	 and	 AST,	 imaging	 and	 diagnostic	 algorithms	 combining	 patient	 variables	and	blood	biomarkers	 (Fitzpatrick	and	Dhawan	2014).	Unfortunately,	ALT	and	AST	levels	are	neither	sensitive	nor	specific	for	NASH	or	advanced	fibrosis	with	area	 under	 the	 receiver	 operating	 characteristics	 (AUROC)	 of	 0.62	 and	 0.46,	respectively	 (Verma,	 Jensen	 et	 al.	 2013).	 	 Furthermore,	 in	 a	 large	 prospective	population-based	 study	 of	 708	 individuals	 diagnosed	 (out	 of	 2,287	 screened)	with	 NAFLD	 by	 MRS,	 normal	 alanine	 aminotransferase	 (ALT)	 levels	 were	observed	 in	 79%	 (Browning,	 Szczepaniak	 et	 al.	 2004).	 Non-invasive	 imaging	techniques	 include	 ultrasound,	 magnetic	 resonance	 imaging	 (MRI)	 and	 MRS.	While	 ultrasound	 is	 the	 most	 widely	 used,	 it	 only	 detects	 >30%	 steatosis,	 is	operator	dependent	and	is	not	reproducibly	quantitative	(Schwenzer,	Springer	et	al.	 2009).	MRI	 and	MRS	 can	 accurately	 quantitate	 steatosis	 but	 these	methods	are	costly,	time	consuming	and	not	always	available	in	a	clinical	setting	(Cobbold,	Patel	et	al.	2012).		Ultrasound	is	estimated	to	have	a	sensitivity	of	60-94%	and	specificity	of	73-93%	 (Patton,	 Sirlin	 et	 al.	 2006).	 	 Although	 ultrasound	 is	 cost	 and	 time	effective,	 it	 is	 unable	 to	 distinguish	 between	 the	 varying	 degrees	 of	 NAFLD	steatosis;	 sensitivity	 declines	 if	 fat	 levels	 in	 the	 liver	 are	 less	 than	 30%,	 and	 a	negative	 ultrasound	 cannot	 be	 used	 to	 exclude	 NAFLD	 diagnosis	 (Mottin,	Moretto	 et	 al.	 2004).	 Ultrasound-based	 transient	 elastography	 and	 magnetic	resonance	elastography	are	imaging	modalities	capable	of	assessing	liver	fibrosis	and	 are	 becoming	 increasingly	 popular	 for	 the	 diagnosis	 of	 suspected	 NAFLD.	While	 these	methods	are	still	under	development	and	validation	 for	 sensitivity	and	 specificity	 relative	 to	 liver	 biopsy	 (Myers,	 Pomier-Layrargues	 et	 al.	 2012,	Myers,	Pomier-Layrargues	et	al.	2012,	Kim,	Kim	et	al.	2013),	magnetic	resonance	elastography	 has	 demonstrated	 accurate	 diagnosis	 with	 sensitivity	 and	specificity	 of	 98%	 and	 99%,	 respectively	 (Yin,	 Talwalkar	 et	 al.	 2007).	 	 More	recently,	ultrasound-based	transient	elastography	has	been	shown	to	be	able	to	stage	 the	 fibrosis	 in	 the	 liver	 through	 a	 measurement	 of	 hepatic	 stiffness	(Foucher,	Chanteloup	et	al.	2006)	and	has	been	validated	for	the	use	in	chronic	hepatitis	 C	 patients	 with	 a	 failure	 rate	 of	 only	 5%	 of	 cases,	 although	 this	increases	in	obesity	(de	Ledinghen	and	Vergniol	2008).			
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		Diagnostic	 algorithms	 that	 combine	 routine	 patient	 parameters	 and	serum	biomarkers	to	predict	steatosis,	NASH	or	fibrosis	continue	to	be	explored	as	 alternatives	 to	 liver	 biopsy,	 including	 the	 Fatty	 Liver	 Index	 (FLI)	 and	Enhanced	 Liver	 Fibrosis	 (ELF)	 test	 (Lichtinghagen,	 Pietsch	 et	 al.	 2013,	 Zelber-Sagi,	Webb	et	al.	2013).	The	conclusion	to	date	is	that	these	algorithms	are	useful	for	 triaging	 patients	 for	 liver	 biopsy	 rather	 than	 completely	 replacing	 liver	biopsy	 and	 evidence-based	 consensus	 guidelines	 for	 the	 use	 of	 liver	 biopsy	 in	clinical	 practice	 exist	 (Rockey,	 Caldwell	 et	 al.	 2009).	 	 Therefore,	 as	 stated	previously	 in	 the	 context	of	hepatitis	C,	 liver	biopsy	 remains	 “the	best,	 not	 the	gold	 standard”	 (Bedossa	 and	 Carrat	 2009)	 for	 NAFLD	 staging.	 It	 remains	 a	research	 priority	 to	 identify	 noninvasive,	 predictive,	 diagnostic	 markers	 to	accurately	assess	NAFLD	and	patient	response	to	treatment.	
1.2.3	NAFLD	Prevalence		 The	 lack	 of	 an	 inexpensive,	 non-invasive	 diagnostic	 method	 for	identifying	 and	 staging	NAFLD	means	 that	 routine	 screening	 for	NAFLD	 is	 not	currently	advised	(Chalasani,	Younossi	et	al.	2012,	Nascimbeni,	Pais	et	al.	2013).		This	 therefore	 means	 that	 the	 true	 prevalence	 of	 NAFLD	 in	 the	 general	population	remains	unclear,	and	estimations	vary	tremendously	depending	both	on	the	diagnostic	 tool	used	and	the	populations	examined	(Loomba	and	Sanyal	2013)	.		Based	on	ultrasound	data	from	over	twelve	thousand	adults	in	the	Third	National	 Health	 and	 Nutrition	 Examination	 Survey	 (NHANES),	 conducted	between	 1988	 and	 1994,	 the	 population	 prevalence	 of	 NAFLD	 in	 the	 United	States	 of	 America	 (USA)	was	 19%	 (Lazo,	Hernaez	 et	 al.	 2013).	 	However,	 data	collected	 using	 the	 more	 sensitive	 method	 of	 MRS,	 and	 based	 on	 a	 screened	sample	of	2287	subjects	from	a	multiethnic	population	in	the	Dallas	Heart	Study,	suggests	that	the	prevalence	is	higher	with	20-35%	of	USA	adults	having	greater	than				5.5%	liver	fat	(Browning,	Szczepaniak	et	al.	2004).		Despite	this,	it	should	be	noted	that	this	study	detected	a	wide	range	of	liver	fats	(0%	-	41.7%;	median	3.6%)	 and	 indicated	 distinct	 ethnic	 differences	 in	 incidence,	 with	 Hispanics	having	 the	 highest	 frequency	 of	 hepatic	 steatosis	 	 	 (45%)	 in	 comparison	 to	Caucasians	 (33%)	 and	 African	 Americans	 (24%).	 	 Nevertheless,	 the	 NAFLD	population	 is	 thought	 to	 be	 growing	 rapidly,	 and	 data	 from	 a	 more	 recent,	
	 10	
prospective	outpatient	cohort	of	328	patients,	 first	screened	by	ultrasound	and	then	given	a	biopsy	 if	 found	ultrasound	positive,	detected	a	46%	prevalence	of	NAFLD	 with	 12%	 of	 the	 cohort	 having	 NASH	 (30%	 of	 ultrasound	 positive	patients)	 (Williams,	 Stengel	 et	 al.	 2011).	 	 Similar	 ethnic	 differences	 were	 also	found	in	this	study,	with	Hispanic	populations	having	the	highest	prevalence	of	NAFLD	 (53%)	 relative	 to	 Caucasians	 (44%)	 and	 African	 Americans	 (35%).	 In	addition,	 Genome	Wide	 Association	 Studies	 (GWAS)	 have	 reported	 the	 role	 of	genetic	variation,	particularly	PNPLA3,	 in	NAFLD	development	and	progression	to	 NASH	 (Romeo,	 Kozlitina	 et	 al.	 2008,	 Chalasani,	 Guo	 et	 al.	 2010,	 Speliotes,	Yerges-Armstrong	 et	 al.	 2011).	 	 Population	 based	 studies	 using	 ALT	 or	ultrasound	diagnosis	across	several	countries	have	estimated	paediatric	NAFLD	prevalence	ranging	between	2.6-7.1%	(Alisi,	Feldstein	et	al.	2012).		 Of	equal	importance,	estimates	of	the	population	prevalence	of	NAFLD	in	Europe	range	between	20	and	33%	(Blachier,	Leleu	et	al.	2013)	and	Asia	 is	 far	from	exempt	from	this	disease	with	estimates	of	prevalence	ranging	from	15-45%	(Farrell,	Wong	et	 al.	 2013).	 	 The	prevalence	of	NAFLD	 in	both	 India	 and	other	parts	of	Asia	varies	depending	on	region,	with	rural	populations	having	lower	(5-10%)	 prevalence	 in	 comparison	 to	 urban	 populations	 (15-30%)	 (Loomba	 and	Sanyal	2013)	.		This	suggests	that	the	adoption	of	Western	behaviors,	including	a	diet	 of	 excess	 calories	 and	 increasing	 sedentary	 lifestyle,	 promotes	 NAFLD	development.		 Prevalence	of	NAFLD	increases	dramatically	in	obese	and	type	2	diabetic	populations;	it	 is	estimated	that	80-90%	of	obese	adults	and	30-50%	of	patient	with	 diabetes	 could	 be	 affected	 (Bellentani,	 Scaglioni	 et	 al.	 2010).	 	 Obesity	 is	defined	as	having	a	body	mass	index	(BMI)	greater	than	30kg/m2,	calculated	by	taking	that	individual’s	weight	in	kilograms	and	dividing	it	by	the	square	of	their	height	in	meters	(Lean	2000).	 	A	BMI	of	>25	but	<30	is	considered	overweight,	while	 a	 BMI	 of	 between	 18.5	 and	 25	 is	 considered	 in	 the	 healthy	 weight	 for	height	 range.	 A	 systematic	 review	 of	 the	 prevalence	 of	 NAFLD	 and	 NASH	 in	bariatric	surgery	patients	found	NAFLD	present	in	91%	and	NASH	present	in	37%	of	1,620	severely	obese	patients	(Machado,	Marques-Vidal	et	al.	2006).		Research	by	Bellentani	and	colleagues	investigated	the	prevalence	of	hepatic	steatosis,	as	measured	by	ultrasound,	in	groups	of	healthy	weight	and	obese	patients	(n=257)	
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alongside	alcohol	consumption.	When	compared	to	controls,	the	relative	risk	of	steatosis	 was	 significantly	 higher	 in	 the	 obese	 group	 rather	 than	 in	 the	 lean	heavy	 drinkers,	 defined	 as	 30g	 of	 alcohol	 or	 more	 a	 day.	 	 However,	 the	combination	 of	 both	 obesity	 and	 alcohol	 gave	 the	 highest	 relative	 risk	 of	steatosis,	 with	 a	 5.8-fold	 increase	 in	 comparison	 with	 controls	 (Bellentani,	Saccoccio	et	al.	2000).		NASH	prevalence	increases	as	body	weight	increases;	in	a	previous	autopsy	study	by	Wanless	and	Lentz,	2.7%	of	lean	individuals	(<110%	of	their	ideal	body	weight)	had	NASH,	while	NASH	was	found	in	18.5%	of	obese	(>140%	of	their	ideal	body	weight)	cadavers	(Wanless	and	Lentz	1990).	 	In	the	previously	 mentioned	 NHANES	 population	 assessed	 by	 ultrasound,	 the	prevalence	ratios	of	NAFLD	after	adjusting	for	age,	sex	and	ethnicity	increased	to	2.2,	3.3	and	5.0	in	overweight,	obese	and	morbidly	obese	(BMI	>35)	individuals	respectively,	whereas	the	adjusted	prevalence	ratio	was	only	1.6	for	individuals	with	either	insulin	resistance	or	diabetes	(Lazo,	Hernaez	et	al.	2013).		Similarly,	Browning	et	al.	(Browning,	Szczepaniak	et	al.	2004)	investigated	patients	by	MRS	and	revealed	67%	of	those	with	increased	liver	fat	were	obese	compared	to	33%	in	 the	 normal	 group,	 while	 18%	 had	 diabetes	 and	 11%	 had	 impaired	 fasting	glucose.	In	the	prospective	cohort	studied	by	Williams	and	colleagues	(Williams,	Stengel	et	al.	2011),	NAFLD	was	present	in	74%	of	obese	individuals	and	NASH	was	 present	 in	 22%	 of	 type	 2	 diabetics.	 	 However,	 as	 has	 been	 noted	 before	(Moore	 2010),	 NAFLD	 and	 NASH	 can	 occur	 in	 both	 lean	 and	 non-diabetic	individuals.	 	 In	 evaluating	 populations	 from	 the	 Asia-Pacific	 region,	 it	 is	important	 to	 account	 for	 ethnic-specific	 anthropometric	 guidelines	 (Chitturi,	Farrell	et	al.	2007).	 	 It	 is	notable	 that	a	significant	prevalence	(12%)	of	NAFLD	has	been	identified	even	in	very	lean	(BMI	<	18.5),	non-affluent	Indian	subjects	(Chitturi	 and	 Farrell	 2007).	 However,	 it	 has	 become	 apparent	 that	 waist	circumference	 has	 a	 critical	 role	 and	 has	 previously	 been	 shown	 to	 correlate	with	 NAFLD	 diagnosis	 more	 than	 BMI	 alone	 (Willner,	 Waters	 et	 al.	 2001,	Jakobsen,	 Berentzen	 et	 al.	 2007).	 	 These	 data	 underscore	 both	 the	 complex	multifactorial	 nature	 of	 this	 disease	 and	 the	 likelihood	 that	 underlying	 genetic	susceptibility	may	well	vary	between	ethnic	groups.		 Of	 particular	 concern	 is	 the	 increasing	 frequency	 of	 paediatric	 NAFLD.		The	 precise	 prevalence	 of	 paediatric	 NAFLD	 remains	 unknown	 as	 there	 are	
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relatively	few	studies	examining	this	population.		As	with	adult	NAFLD,	diagnosis	is	limited	by	current	diagnostic	methodology;	values	derived	from	liver	function	enzymes	or	ultrasound-based	diagnoses	are	likely	to	be	greatly	underestimated.	In	 a	 seminal	 study	 by	 Schwimmer	 and	 colleagues	 (Schwimmer,	 Deutsch	 et	 al.	2006),	 742	 retrospective	 autopsy	 samples	 were	 assessed	 by	 biopsy.	 	 Results	estimated	 that	 9.6%	of	 children	had	 fatty	 liver	 after	 adjusting	 for	 age,	 sex	 and	ethnicity,	 rising	 to	 38%	 in	 children	 who	 were	 obese.	 	 Robust	 evidence	 that	paediatric	NAFLD	prevalence	has	increased	sharply	in	recent	years	comes	from	the	cross-sectional	analysis	of	NHANES	data	from	1988-1994	compared	to	2007-2010	(Welsh,	Karpen	et	al.	2013).	Suspected	NAFLD,	defined	as	overweight	with	elevated	 ALT	 levels,	 rose	 from	 3.9%	 in	 1988-1994	 to	 10.7%	 in	 2007-2010.		Prevalence	 of	 suspected	 NAFLD	 rose	 from	 13%	 to	 27%	 in	 obese	 females	 and	from	30%	to	48%	 in	obese	males.	 	As	20%	of	 the	cohort	examined	was	obese,	this	represents	an	alarming	number	of	affected	adolescents	at	a	population	level.				Data	 from	 Europe	 based	 on	 ALT	 levels	 of	 over	 16,000	 children	 in	Germany,	Switzerland	and	Austria,	estimates	11.5%	of	children	have	suspected	NAFLD	 (Wiegand,	 Keller	 et	 al.	 2010).	 Similar	 estimates	 have	 come	 from	ultrasound-based	 studies	 in	 Italian	 children,	 with	 12.5%	 of	 11-13	 year	 olds	(n=676)	 (Caserta,	 Pendino	 et	 al.	 2010)	 and	44%	of	 obese	 adolescents	 (n=268)	(Sartorio,	 Del	 Col	 et	 al.	 2007)	 presenting	with	NAFLD.	 	 However,	 one	 autopsy	series	conducted	in	256	Polish	children	reported	5.4%	with	steatosis	as	assessed	by	histopathalogical	examinations	(Rorat,	 Jurek	et	al.	2013),	which	could	relate	to	the	comparatively	lower	levels	of	childhood	obesity	observed	in	Poland	(EASO	2005).	Exacerbating	the	concerns	of	liver-related	risks	in	these	children,	are	data	that	clearly	show	NAFLD	in	overweight	and	obese	children	around	the	world	is	also	associated	with	cardiovascular	risk	factors	(Schwimmer,	Pardee	et	al.	2008)	including	 increased	 carotid	 intima-media	 thickness,	 a	 recognized	 marker	 of	atherosclerosis	(Pacifico,	Cantisani	et	al.	2008,	Caserta,	Pendino	et	al.	2010,	Alp,	Karaarslan	 et	 al.	 2013).	 Therefore	 paediatric	 NAFLD	 warrants	 significant	 and	immediate	clinical	and	research	attention.	
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1.2.4	NAFLD	Pathogenesis		 The	pathogenesis	of	NAFLD	is	not	fully	understood.		Previously	the	classic	view	of	pathogenesis	was	described	as	a	“two	hit”	process	(Day	and	James	1998),	where	infiltration	of	fat	into	the	liver	occurred	first,	then	oxidative	stress	was	the	second	 “hit”	 leading	 to	 lipid	 peroxidation	 and	 downstream	 inflammatory	processes,	necrosis	and	apotosis	(Festi,	Colecchia	et	al.	2004).		Consequently	for	many	 years	 the	 spectrum	 of	 NAFLD	 was	 viewed	 as	 linear,	 with	 steatosis	occurring	first,	then	steatohepatitis,	then	fibrosis	and	cirrhosis	leading	to	either	HCC	or	end	stage	liver	disease.		In	light	of	natural	history	data	that	shows	NASH,	rather	 than	 steatosis,	 is	 associated	 with	 dramatically	 increased	 mortality	 risk	(Musso,	Gambino	et	al.	2011),	some	researchers	have	questioned	whether	or	not	steatosis	 and	 steatohepatitis	 are	 distinct	 entities	 rather	 than	 points	 on	 a	spectrum	(Yilmaz	2012).	Although	research	has	shown	that	patients	with	simple	steatosis	have	the	lowest	risk	for	progression,	patients	with	steatosis	can	and	do	progress	 to	 NASH	 in	 a	 relatively	 short	 period	 of	 time,	 arguing	 the	 point	 that	steatosis	 is	not	benign	and	NASH	is	the	progressive	form	of	the	disease.	 	 In	the	most	 recent	 case	 studies	 by	 Wong	 (Wong,	 Wong	 et	 al.	 2010)	 and	 Pais	 (Pais,	Charlotte	et	al.	2013),	62%	and	63%	of	patients	with	NAFLD	on	initial	biopsy	had	developed	NASH	within	3	and	3.7	years	of	follow-up	respectively.		Equally,	all	of	the	 follow-up	 studies	 with	 repeat	 biopsies	 (Adams,	 Sanderson	 et	 al.	 2005,	Ekstedt,	Franzen	et	al.	2006,	Wong,	Wong	et	al.	2010,	Pais,	Charlotte	et	al.	2013)	show	that	both	patients	with	steatosis	and	steatohepatitis	can	have	histological	improvement	highlighting	the	dynamic	nature	of	the	NAFLD	disease	spectrum.		 As	 the	 appreciation	 of	 the	 complexity	 of	 the	 factors	 involved	 in	NAFLD	progression	 has	 grown,	 hypothetical	 models	 of	 pathogenesis	 have	 been	expanded	 from	 “three	 hits	 at	 least”	 (Charlton	 2007)	 to	 “multiple	 parallel	 hits”	(Tilg	 and	 Moschen	 2010).	 	 Whether	 or	 not	 steatohepatitis	 occurs	 in	 parallel,	rather	 than	 sequentially,	 to	 steatosis	 in	 a	 subset	 of	 susceptible	 individuals	remains	unknown.		Indeed	recent	data	(Ertle,	Dechene	et	al.	2011,	Leung,	Yeoh	et	al.	2015)	suggesting	 that	HCC	can	develop	 in	NAFLD	patients	without	cirrhosis	adds	 more	 questions	 about	 the	 pathogenesis	 of	 NAFLD.	 	 	 	 In	 the	 few	 natural	history	 studies	 that	 have	 examined	 factors	 associated	 with	 histological	progression	weight	gain	 is	 a	 consistent	driving	 factor	 (Adams,	Sanderson	et	al.	
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2005,	Ekstedt,	Franzen	et	al.	2006,	Wong,	Wong	et	al.	2010,	Pais,	Charlotte	et	al.	2013,	 Ekstedt,	 Hagstrom	 et	 al.	 2015).	 Equally,	 weight	 loss,	 whether	 through	dietary	or	physical	activity	interventions,	has	consistently	been	demonstrated	to	improve	histopathology	 (Musso,	Cassader	et	 al.	2012,	Thoma,	Day	et	 al.	2012).		While	data	from	well-designed	randomized	trials	are	limited,	most	trials	to	date	have	 generally	 been	 of	 short	 duration	with	 a	 high	 degree	 of	 bias	 and	 the	 true	effects	of	weight	loss	on	long-term	prognosis	of	NAFLD	remain	unknown	(Peng,	Wang	et	al.	2011).	
1.2.5	The	Role	of	Nutrition	in	NAFLD	Treatment		 At	present	there	are	no	specific	guidelines	or	pharmacological	treatment	for	paediatric	patients	with	NAFLD.		Primary	treatment	is	the	management	of	co-morbidities	along	with	encouraging	a	healthy	 lifestyle;	 in	particular,	 losing	and	maintaining	 a	 healthy	 weight	 through	 diet	 and	 exercise	 to	 prevent	 further	disease	progression	(Nobili,	Marcellini	et	al.	2006).		Several	lifestyle	intervention	trials	 have	 demonstrated	 positive	 results	 in	 both	 adults	 and	 children	 from	weight	loss	including	improved	insulin	resistance	(Huang,	Greenson	et	al.	2005,	Nobili,	Manco	et	al.	2008),	improved	serum	ALT	and	aspartate	aminotransferase	(AST)	 levels	 (Huang,	 Greenson	 et	 al.	 2005,	 Nobili,	 Manco	 et	 al.	 2008,	 Reinehr,	Schmidt	 et	 al.	 2009)	 and	 reduced	 NASH	 scores	 (Huang,	 Greenson	 et	 al.	 2005,	Nobili,	 Manco	 et	 al.	 2008).	 	 Therefore	 changes	 in	 lifestyle	 provide	 a	 basic	approach	in	the	treatment	of	NAFLD	and	should	be	considered	as	the	first	step	in	its	management.		 However,	not	all	studies	have	shown	positive	effects	of	weight	loss	on	the	degree	 of	 fatty	 infiltration	 in	 the	 liver,	 and	 older	 studies	 suggest	 that	 rate	 of	weight	loss	may	be	an	important	factor	in	treatment	efficacy.		In	1967	Rozental	looked	at	the	consequences	of	total	starvation	in	five	obese	males	and	its	effect	on	 liver	 morphology	 and	 function	 tests.	 	 Changes	 were	 established	 by	 liver	function	tests	(LFTs)	and	biopsies	performed	before,	during	and	after	periods	of	starvation.	 	 Results	 showed	 a	 reduction	 in	 fat	 in	 biopsies	 in	 three	 patients,	however,	four	patients	presented	with	advanced	fibrosis	after	starvation	periods	(Rozental,	Biava	et	al.	1967).	 	This	effect	could	be	due	 to	 the	rapid	weight	 loss	resulting	 in	 a	 rapid	 excess	 of	 fat	 infiltration	 into	 the	 liver,	 which	 exacerbates	
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portal	fibrosis	and	inflammation	(Andersen,	Gluud	et	al.	1991,	Luyckx,	Desaive	et	al.	 1998).	 	 Slow	 weight	 loss	 of	 0.5kg	 per	 week	 in	 children	 is	 recommended	(Franzese,	 Vajro	 et	 al.	 1997)	while	 in	 adults	 higher	 recommendations	 of	 up	 to	1.6kg	per	week	through	calorie	controlled	diets	have	been	shown	to	be	effective	(Andersen,	Gluud	et	al.	1991).		 There	is	growing	research	into	the	use	of	nutritional	supplementation	for	NAFLD	 treatment.	 Vitamin	 E	 (Vajro,	 Mandato	 et	 al.	 2004,	 Nobili,	 Manco	 et	 al.	2006,	 Nobili,	 Manco	 et	 al.	 2008,	Wang,	 Liang	 et	 al.	 2008,	 Akcam,	 Boyaci	 et	 al.	2011,	 Lavine,	 Schwimmer	 et	 al.	 2011),	 probiotics	 (Vajro,	Mandato	 et	 al.	 2011,	Alisi,	 Bedogni	 et	 al.	 2014)	 and	 omega-3	 docosahexaenoic	 acid	 (DHA)	 (Nobili,	Bedogni	 et	 al.	 2011,	 Nobili,	 Alisi	 et	 al.	 2013)	 have	 been	 trialed	 in	 paediatric	populations	 with	 varying	 outcomes.	 Optimising	 diet	 quality	 may	 assist	 with	NAFLD	 management,	 with	 data	 from	 Ramon-Krauel	 et	 al.	 (Ramon-Krauel,	Salsberg	et	al.	2013)	suggesting	that	a	low	glycaemic	load	(GL)	diet	may	regulate	postprandial	blood	glucose	levels,	reducing	the	risk	of	insulin	resistance	(IR)	and	NAFLD	development.	Furthermore,	considering	the	proposed	role	of	fructose	in	NAFLD	 pathogenesis	 (Lim,	 Mietus-Snyder	 et	 al.	 2010),	 a	 reduction	 in	 overall	fructose	intake	in	an	isocaloric	diet	may	improve	hepatic	biomarkers	(Jin,	Le	et	al.	2012,	 Sullivan,	 Le	 et	 al.	 2014).	 Previously	 Musso	 and	 colleagues	 showed	 that	dietary	 intakes	of	NASH	patients	were	 richer	 in	 saturated	 fats	 and	 cholesterol,	but	 were	 lower	 in	 polyunsaturated	 fatty	 acids	 (PUFA),	 fibre	 and	 anti-oxidant	vitamins	 C	 and	 E	 than	 age,	 BMI	 and	 gender	matched	 healthy	 controls	 (Musso,	Gambino	et	al.	2003).				 Antioxidant	 therapy	 has	 been	 shown	 to	 reduce	 oxidative	 stress	 and	therefore	might	possibly	have	a	beneficial	effect	at	reducing	progression	to	NASH.		In	particular,	vitamin	E	protects	vulnerable	components	of	cellular	membranes	from	lipid	peroxidation	(Barshop,	Sirlin	et	al.	2008).		In	one	open-label	pilot	trial,	vitamin	 E	 was	 able	 to	 normalise	 aminotransferases	 and	 alkaline	 phosphatase	levels	in	11	obese	children	with	NASH.		Patients	received	400	international	units	(IU)	vitamin	E	per	day	for	a	month	before	measuring	aminotransferase	levels.		If	there	was	no	improvement,	patients	received	increments	of	400	IU	vitamin	E,	up	to	 1200	 IU/day	 for	 up	 to	 four	 months	 with	 the	 endpoint	 of	 a	 reduction	 of	aminotransferase	 levels.	 	 Five	 of	 the	 11	 children	 enrolled	 showed	 reduced	
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aminotransferase	 levels	 in	 the	 first	month	when	 receiving	 400	 IU/day	 (Lavine	2000).	 	However,	 the	double-blinded	and	placebo-controlled	 treatment	of	non-alcoholic	 fatty	 liver	 disease	 in	 children	 (TONIC)	 trial	 showed	 improvement	 of	ALT	 levels	 in	paediatric	patients	 treated	with	vitamin	E,	metformin	or	placebo	(Lavine,	 Schwimmer	 et	 al.	 2011).	 	Meanwhile,	 a	 trial	 by	 Sanyal	 and	 colleagues	looked	at	247	adults	with	NASH	and	treated	them	with	pioglitazone,	vitamin	E	or	placebo.	 	 Vitamin	 E	 appeared	 to	 be	 the	 most	 effective	 supplementation	 for	improving	 the	 histological	 features	 of	 NASH	 against	 pioglitazone	 (Sanyal,	Chalasani	et	al.	2010).		 A	study	by	Kim	et	al.	suggested	specific	dietary	interventions	should	aim	to	 reduce	 intakes	 of	 low-nutrient	 and	 high	 sodium	 containing	 foods,	 alongside	high	intakes	of	animal	fats	(Kim,	Kallman	et	al.	2010)	while	other	studies	suggest	improvements	in	histology	with	increased	PUFA	(Spadaro,	Magliocco	et	al.	2008,	Nobili,	 Alisi	 et	 al.	 2012).	 	 PUFAs,	 in	 particular	 omega-3	 fatty	 acids,	 have	 been	investigated	in	60	NAFLD	children	receiving	250mg,	500mg	docosahexanoic	acid	(DHA)	or	placebo	over	24	months.		Changes	in	liver	fat	content	were	detected	by	ultrasound	at	6,	12,	18	and	24	months	with	250mg	and	500mg	resulting	 in	the	same	degree	of	reduction	in	hepatic	steatosis	(Nobili,	Alisi	et	al.	2012).		 Dietary	 carbohydrates	have	 also	been	 linked	with	 the	pathogenesis	 and	development	of	 steatosis.	 	One	observational	 study	 in	 Japan	 looked	at	patients	with	 NAFLD	 and	 NASH	 and	 identified	 that	 carbohydrates,	 particularly	 sugars,	were	 consumed	 in	 excess	 by	 patients	with	 NASH	 (Toshimitsu,	Matsuura	 et	 al.	2007).	 	 Fructose	 is	 a	 simple	 carbohydrate	 of	 particular	 interest,	 whose	consumption	 has	 increased	 in	 recent	 years	 (Elliott,	 Keim	 et	 al.	 2002).	 	 One	dietary	study	looking	into	the	differences	in	fructose	intakes	identified	a	2-	to	3-fold	 increased	 intake	 of	 fructose	 in	 NAFLD	 patients	 compared	 to	 controls	(Ouyang,	 Cirillo	 et	 al.	 2008).	 	 Similarly,	 a	 study	 looking	 at	 fructose	 intakes	 as	assessed	 by	 food	 questionnaires	 in	 adults	 with	 NAFLD	 identified	 that	 higher	intakes	 of	 fructose	were	 linked	with	 increased	hepatic	 fibrosis	 and	hepatocyte	ballooning	 (Abdelmalek,	 Suzuki	 et	 al.	 2010),	 while	 fructose	 overfeeding	 in	healthy	 subjects	 for	 a	 period	 of	 one	 week	 	 resulted	 in	 increased	 intracellular	hepatic	fat	when	compared	to	the	same	diet	without	added	fructose	(Sobrecases,	Le	et	al.	2010).		However,	despite	many	individuals	consuming	fructose	in	excess,	
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not	 all	 subjects	 will	 develop	 steatosis	 (Tappy	 and	 Le	 2012),	 suggesting	 other	factors	may	play	a	role	in	the	development	and	progression	of	NAFLD.	
1.2.6	The	Role	of	Physical	Activity	in	NAFLD	Management	
	 Physical	 inactivity	 is	believed	to	contribute	to	NAFLD	pathogenesis	with	studies	 in	 both	 adults	 (Zelber-Sagi,	 Nitzan-Kaluski	 et	 al.	 2008,	 Gerber,	Otgonsuren	 et	 al.	 2012,	 Hallsworth,	 Thoma	 et	 al.	 2015)	 and	 children	 (Hattar,	Wilson	 et	 al.	 2011)	 showing	 that	 individuals	 with	 NAFLD	 are	 less	 physically	active	 than	controls	without	 liver	disease.	Current	 information	 for	 lifestyle	and	exercise	 recommendations	 is	 insufficient,	 despite	 the	 high	 prevalence	 of	overweight	or	obese	subjects.	However,	Mager	and	colleagues	(Mager,	Patterson	et	al.	2010)	recorded	suboptimal	physical	activity	levels	in	children	with	NAFLD	when	 compared	with	physical	 activity	 guidelines;	with	 an	 average	of	 66.9%	of	waking	hours	spent	in	sedentary	activities.	A	number	of	adult	studies	have	noted	metabolic	 benefits	 of	 regular,	 moderate-intensity	 activity	 in	 NAFLD	 patients,	including	decreases	in	visceral	adiposity	and	hepatic	TG	concentration,	without	observing	a	change	to	BMI	(Whitsett	and	VanWagner	2015).	Furthermore,	adult	studies	have	shown	short	sleep	duration	and	disordered	sleep	to	be	associated	with	 NAFLD	 risk	 (Kim,	 Yun	 et	 al.	 2013).	 	 However,	 a	 study	 by	 Lee	 et	al.	 (Lee,	Bacha	et	al.	2012)	revealed	 that	 increased	moderate	 to	vigorous	activity	 led	 to	decreased	 steatosis	 despite	 no	 overall	 change	 in	 BMI	 in	 adolescent	 boys,	suggesting	 that	 physical	 activity	 may	 be	 more	 important	 that	 weight	 loss	 in	NAFLD	management.		 In	 the	 absence	 of	 more	 definitive	 evidence	 the	 first	 line	 of	 treatment	remains	 reduction	 of	 weight	 through	 diet,	 exercise	 and	 behavioral	 therapy	(Bellentani,	 Dalle	 Grave	 et	 al.	 2008,	 Chalasani,	 Younossi	 et	 al.	 2012).	 	 Lifestyle	interventions	 can	 significantly	 improve	 insulin	 resistance,	 aminotransferase	levels	and	liver	damage,	and	have	been	shown	in	previous	studies	investigating	low	 fat,	 low	 glycaemic	 index	 and	 high	 fiber	 diets	 in	 conjunction	with	 physical	activity	 for	30	minutes	3	to	5	times	a	week	(Spieth,	Harnish	et	al.	2000,	Nobili,	Marcellini	et	al.	2006,	Nobili	and	Pinzani	2010).		Despite	this,	poor	adherence	to	lifestyle	 modifications	 often	 fails	 to	 slow	 or	 regress	 the	 occurrence	 of	 liver	
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damage	during	NASH	progression,	and	therefore	development	of	possible	multi-targeted	therapies	are	fundamental	objectives	for	NAFLD	treatment.		 Considering	 the	 role	 of	 diet	 and	 activity	 in	 the	 development	 and	pathogenesis	of	NAFLD,	 it	 is	essential	 that	evidence-based	strategies	guide	and	develop	 diet	 and	 exercise	 therapies	 for	 use	 in	NAFLD	 treatment.	 	 However,	 to	date,	to	the	best	of	our	knowledge,	no	systematic	evaluation	of	the	nutrition	and	physical	 activity	 interventions	 has	 been	 conducted	 in	 a	 paediatric	 NAFLD	population.	 	 Consequentially	 here,	 I	 aim	 to	 systematically	 review	 and	 appraise	current	 randomized	 control	 trials	 (RCTs)	 that	 have	 investigated	 nutritional	and/or	physical	activity	interventions	in	NAFLD-diagnosed	paediatric	patients.	
1.3	Systematic	Review	This	review	was	restricted	to	RCTs	reporting	the	effects	of	nutrition	and	physical	 activity	 interventions	on	 liver	biomarkers	 in	 children	 and	adolescents	diagnosed	with	NAFLD.			Any	definition	of	NAFLD	was	accepted	for	the	purpose	of	this	review.				 Eligible	studies	included	publications	written	in	English	from	any	country	conducted	in	a	paediatric	population	<19	years	of	age,	with	a	diagnosis	of	NAFLD.	Studies	assessing	 food	groups,	nutrient	 intake,	nutritional	 supplements,	weight	loss	and/or	physical	activity	were	included.	Only	study	arms	where	medications	were	used	as	part	of	standard	treatment	protocol,	without	a	reported	increase	in	dose,	and	where	participants	were	receiving	medication	prior	to	the	intervention	were	 included.	 	 	 There	 were	 no	 restrictions	 on	 the	 length	 of	 intervention	 or	follow-up	period.		 Studies	 involving	participants	with	 late	stage	 liver	disease	or	conditions	not	commonly	associated	with	NAFLD,	and/or	that	 influence	dietary	behaviour	such	as	coeliac	disease	and	severe	malnutrition,	were	excluded.	Studies	involving	participants	receiving	enteral	and/or	parenteral	nutrition	were	also	excluded.	
1.3.1	Literature	Search	Two	 independent	 researchers	 conducted	 separate	 literature	 searches	 to	identify	 and	 appraise	 studies.	 Databases	 were	 searched	 from	 their	 inception	until	 18th	 January	 2016.	 Databases	 include	Medline,	 CINAHL,	 EMBASE,	 Scopus	
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and	 The	 Cochrane	 Collaboration	 Libraries.	 Search	 results	 were	 verified	 and	discrepancies	resolved	by	group	discussion.		 The	selected	search	terms	included:	(NAFLD	OR	“non	alcoholic	fatty	liver	disease”	OR	“non-alcoholic	 fatty	 liver	disease”	OR	NAFL	OR	“non	alcoholic	 fatty	liver”	OR	“non-alcoholic	fatty	liver”	OR	NASH	OR	“non	alcoholic	steatohepatitis”	OR	“non-alcoholic	steatohepatitis”)	AND	(diet*	OR	nutri*	OR	food	OR	weigh*	OR	overweight	OR	 obes*	OR	BMI	OR	 “Body	Mass	 Index”	OR	 “physical	 activit*”	OR	exercis*	OR	fitness)	AND	(Child*	OR	P#ediat*	OR	Adolescen*	OR	infan*).	Related	MeSH	headings	were	used	 in	Medline,	 CINAHL,	 Scopus	 and	Cochrane	 libraries.		Searches	 for	EMBASE	and	Cochrane	were	modified	to	 include	the	search	terms	pediat*	OR	paediat*.				 All	 articles	 were	managed	 in	 a	 citation	management	 software	 program	(Endnote).	 	All	 coding	of	 articles	 for	 the	 first	 and	 second	pass	were	 completed	using	 Endnote.	 	 Any	 study	 published	 only	 in	 abstract	 format	 or	 unpublished	reports	 were	 excluded	 from	 the	 analysis.	 Titles	 and	 abstracts	 were	 evaluated	against	 eligibility	 criteria.	 	 Studies	 appearing	 to	 be	 eligible	 based	 on	 abstract	were	 read	 in	 full.	 	 Reference	 lists	 of	 eligible	 articles	 were	 hand-searched	 for	additional	articles	that	met	the	inclusion	and	exclusion	criteria.	
1.3.2	Data	Extraction	and	Study	Quality	Data	 were	 extracted	 into	 Endnote	 independently	 by	 two	 researchers	using	 an	 adaptation	 of	 the	 Cochrane	 Data	 Extraction	 Tool	 (The	 Cochrane	Collaboration	 2011).	 	 Data	 extracted	 from	 the	 articles	 included:	 study	 setting,	study	 population,	 participant	 demographics	 and	 baseline	 characteristics,	inclusion	 and	 exclusion	 criteria,	 diagnosis	 criteria	 for	 NAFLD,	 details	 of	 the	intervention	and	control	 conditions	and	any	co-treatments,	 study	methodology	and	 blinding,	 recruitment	 and	 study	 completion	 rates,	 outcomes	 and	 times	 of	measurement	and	effect	size.	The	same	two	researchers	independently	assessed	the	 risk	 of	 publication	 bias	 and	 study	 quality	 using	 the	 American	 Dietetic	Association	(ADA)	Quality	Criteria	Checklist	(Academy	of	Nutrition	and	Dietetics	2012).	 Any	 discrepancies	 were	 discussed	 and	 resolved	 by	 consensus.	 	 This	checklist	 includes	 ten	 validity	 questions	 based	 on	 the	 Agency	 for	 Health	 and	Research	 Quality,	 Important	 Elements	 for	 Research	 Studies.	 These	 elements	
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identify	sound	study	design	and	execution.	If	most	of	the	answers	to	the	validity	questions	(6	or	more)	were	‘no’,	the	study	was	deemed	‘negative’;	if	the	answers	to	questions	2,	3,	6	and	7	did	not	indicate	that	the	study	was	exceptionally	strong,	the	report	was	deemed	 ‘neutral’;	and	 if	most	questions,	 including	the	 four	core	questions	 with	 at	 least	 one	 additional	 question	were	 answered	 ‘yes’,	 then	 the	study	was	deemed	‘positive’	(Academy	of	Nutrition	and	Dietetics	2012).		
1.3.3	Primary	Outcome	Measures	The	 primary	 outcome	 measures	 included	 changes	 to	 liver	 steatosis	measured	 using	 either	 imaging	 (ultrasound,	 MRS),	 histology	 (biopsy)	 and/or	serum	transaminases	(ALT,	AST	or	gamma-glutamyl	transpeptidase	(GGT)).				 Considering	 the	 role	 of	 dyslipidaemia,	 IR	 and	 adiposity	 in	 NAFLD	pathogenesis	 (Chalasani,	 Younossi	 et	 al.	 2012),	 secondary	 outcome	 measures	included	changes	to	markers	of	cardiovascular	risk	[HDL,	LDL,	triglycerides,	total	cholesterol],	IR	[2-hour	oral	glucose	tolerance	testing	(2-h	OGTT),	fasting	insulin	levels	 (FI),	 fasting	 serum	 glucose	 (FSG),	 fasting	 glucose	 or	 insulin	 ratio’s]	 and	anthropometry	 [weight,	 BMI,	 BMI	 z-score	 and	 waist	 circumference	 (WC)].	Secondary	 outcome	 measures	 were	 only	 collected	 from	 eligible	 studies	 when	available.	
1.3.4	Results	A	 total	 of	 8441	 records	 were	 derived	 from	 database	 searches.	 1003	duplicates	 were	 removed,	 3921	 papers	 were	 excluded	 by	 title	 and	 3402	 by	abstract.	 	 Of	 the	 114	 articles	 reviewed	 in	 full,	 five	 articles	 were	 conference	abstracts,	82	articles	were	not	in	a	population	of	interest	and	12	did	not	report	on	 an	 outcome	 of	 interest	 (Figure	 1.2).	 	 15	 articles	 met	 the	 inclusion	 and	exclusion	criteria.	Two	of	the	eligible	articles	reported	data	from	an	extension	of	a	RCT	(Nobili,	Manco	et	al.	2008,	Nobili,	Alisi	et	al.	2012).		Results	from	the	initial	trial	and	extension	have	been	combined	for	the	purpose	of	this	review	(excluding	ADA	quality	checks)	(Nobili,	Manco	et	al.	2006,	Nobili,	Manco	et	al.	2008,	Nobili,	Bedogni	et	al.	2011,	Nobili,	Alisi	et	al.	2012).		Consequently,	13	trials	have	been	appraised	and	evaluated	(Table	1.1).	
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Figure	1.2:	Preferred	Reporting	Items	for	Systematic	Reviews	and	Meta-Analyses	(PRISMA)	
flow	diagram	of	study	selection	process	for	systematic	literature	review	
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Table	1.1:	Sum
m
ary	of	random
ised	control	trials	retrieved	
Author	
(Year);	
Country	
Intervention	[Co-
intervention	and	
Control]	
Age	Range;	
Sample	Size	
(%	male)	
Study	Duration	
[Control]	
Outcome	
Measures	
Changes	to	Outcome	Measures	Post-
Intervention	
Vitam
in	E	
Vajro	et	al.	
(2004);	
Italy	
Oral	α-acetatetocopherol	
(400mg/d	2	months,	
100mg/d	3	months,	2	
month	washout)	[Low	
calorie	diet	(Italian	
Recommended	Dietary	
Allowanced)	+	
exercise]	
NR;	28	(75%)	7	months	
[Placebo]	
Prim
ary:	US,	
ALT	Secondary:	
BMI	
Stratified	results	based	on	w
eight	loss;	
1. Decrease	BMI	+	vitamin	E:	improved	liver	
echogenicity,	↓ALT a	
2. Decrease	BMI	+	placebo:	improved	liver	
echogenicity,	↓ALT b	
3. Stable	BMI	+	vitamin	E:	improved	liver	
echogenicity,	↓ALT b	
4. Stable	BMI	+	placebo;	No	change	ALT	or	liver	
echogenicty a	
Nobili	et	al.	
(2006,	
2008);	Italy	 Alpha-tocopherol	
(600ID/d)	+	Ascorbic	
Acid	(500mg/d)	[1	hr	
monthly	nutritional	
counselling.		Hypo-/	
Iso-caloric	diet	(Italian	
Recommended	Dietary	
Allowance)	+	
45min/day	aerobic	
exercise]	
3-18;	90	
(32%)	
24	months	
[Placebo]	
Prim
ary:	
NAS #,	ALT,	
AST	Secondary:	Z-
BMI,	BMI,	TG,	
TC,	FSG,	FI,	
HOMA-IR	
Prim
ary:	↓	NAFLD	Activity	Score,	↓	ALT,	AST	in	
intervention	and	control	 b	
Secondary:	↓	Z-BMI,	BMI	in	intervention	and	
control	 b	↑FSG,	FI,	TC,	TG,	HOMA-IR	in	
intervention	and	control	 b	
Wang	et	al.	
(2008);	
China	
Vitamin	E	(100mg/d)	+	
low	calorie	diet	+	
exercise/	aerobic	
exercise	+	reduced	
caloric	intake/	no	
10-17;	66	
(64%)	
1	month	
[Lifestyle	
control/	
control]	
Prim
ary:	US,	
ALT,	AST	
Secondary:	Z-
BMI,	TG,	TC,	
FSG,	FI,	
Prim
ary:	No	change	to	liver	echogenicity	 b.	↓	
ALT	and	AST	in	intervention	group	 a	
Secondary:	↓	Z-BMI,	TG,	TC,	FI,	FSG	and	HOMA-
IR	in	intervention	group	 a	
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intervention	[NA]	
HOMA		
Akcam	et	al.	
(2011);	
Turkey	
400IU/d	Vitamin	E	
[Tailored	dietary	
advice	+	30	minutes	
aerobic	PA/day]	
9-17;	67	(NR)	6	months	
[Control]	
Prim
ary:	US	
Secondary:	
BMI,	TG,	TC,	
FSG,	FI,	
HOMA-IR	
Prim
ary:	↓	steatosis	in	intervention	and	control	
a	Secondary:	↓	BMI	in	intervention	 a	↓	TC,	LDL,	TG,	
HOMA-IR	in	intervention	and	control	 b	No	
change	FSG,	FI	in	intervention	and	control	 b	
Lavine	et	al.	
(2011);	USA	 RRR-α-tocopherol	
(800IU/d)	[Uniform	
standard-of-care	advice	
on	diet	and	exercise	at	
each	visit	by	physicians	
and	dietitians]	
8-17;	173	
(81%)	
120	weeks	
[Placebo]	
Prim
ary:	
NAS #,	ALT,	
AST,	GGT,	
ALP	Secondary:	
QOL,	Z-BMI,	
BMI,	BW,	WC,	
TG,	TC,	FSG,	
HOMA-IR,	
HDL,	LDL	
Prim
ary:	Improved	NAFLD	Activity	Score	in	
intervention	group	 a,↓	ALT,	AST,	GGT,	ALP	in	
intervention	and	control	 b	Resolution	of	NASH	
was	significantly	greater	in	children	treated	
with	vitamin	E	than	placebo	 a	
Secondary:	↑TG,	BW,	BMI,	WC,	QOL	in	
intervention	and	control	 b		No	change	Z-BMI,	
FSH,	HOMA-IR	in	intervention	and	control	 b↓	TC,	
HDL,	LDL	in	intervention	and	control	 b	
Probiotic	
Vajro	et	al.	
(2011);	
Italy	
Oral	Lactobacillus	
rham
nosus	strain	GG	
(12	billion	CFU/day)	
[NA]	
NR;	20	(90%)	8	weeks	
[Placebo]	
Prim
ary:	US,	
ALT,	AST	
Secondary:	
TG,	TC,	Z-BMI	
Prim
ary:	No	change	in	liver	echogenicity,	AST	in	
both	groups.	↓ALT	in	intervention	group	 a	
Secondary:	No	change	to	secondary	outcome	
measures	in	both	groups	
Alisi	et	al.	
(2014);	
Italy		
2	sachets	VSL#3/day		
[Low	Calorie	Diet	
(Italian	Recommended	
Dietary	Allowances)	+	
aerobic	exercise	(3	x	
30-40	mins/week)]	 NR;	44	(55%)	4	months	
[Placebo]	
Prim
ary:	US,	
ALT	Secondary:	
TG,	HOMA,	
BMI	
Prim
ary:	↓	risk	of	severe	NASH	(OR	0.001)	 a.	↓	
ALT	in	intervention	and	control	 b	
Secondary:	↓	TG,	HOMA	in	intervention	and	
control	 b	↓	BMI	in	intervention	group	 a	
O
m
ega-3	Fatty	Acids	
Nobili	et	al.	250mg	vs.	500mg	
<18	years;	60	24	months	
Prim
ary:	US,	
Prim
ary:	↓	risk	of	severe	steatosis	(250mg	=	OR	
	
24	
(2011,	
2013);	Italy	 DHA/day	[Low	calorie	
diet]	
(42%)	
[Placebo	
290mg/day	
linolenic	acid]	 ALT	Secondary:	
HOMA-IR,	
BMI,	TG	
0.01/	500mg	=	OR	0.04)	 a,	↓	ALT	with	no	
difference	between	dosages	 a	
Secondary:	↓	TG,	BMI,	HOMA-IR	with	no	
difference	between	dosages	 a,	↓	BMI	in	
intervention	and	controls	 b	
Bohraz	et	al.	
(2015);	
1000mg/day	omega-3	
[American	Heart	
Association	diet	(50%	
CHO,	20%	protein,	30%	
fat)	with	reduced	
caloric	intake	and	PA	3	
times	a	week	with	
intention	for	weight	
loss]	
9-17;	108	
(51%)	
12	months	
[Placebo]	
Prim
ary:	US,	
ALT,	AST	
Secondary:	
BMI,	HDL-C,	
TG,	TC,	FI,	FG,	
IS,	HOMA-IR,	
SBP		
Prim
ary:	↓	steatosis,	ALT	and	AST	in	both	
intervention	and	control	groups	 a	
Secondary:	↑	HDL-C	 a,↓	TG,	FI	and	HOMA-IR	 a,	↓	
BMI	in	intervention	and	control	groups	 b,	↓	SBP	
in	intervention	group	 a	
Janczyk	et	
al.	(2015)	 450-1300mg/day	3:2	
DHA:EPA	[Individually	
prescribed	diet	in	
conjunction	with	
increased	PA	with	
intention	of	weight	
loss]	
>5	and	<19;	
76	(86%)	
6	months	
[Placebo	
omega-6	
sunflower	oil]	
Prim
ary:	ALT,	
AST,	GGT	
Secondary:	
FSG,	FI,	
HOMA-IR,	
adiponectin,	
cholesterol,	
steatosis	(US),	
BMI,	WC	
Prim
ary:	↓	ALT	levels	in	intervention	and	
control	 b	
Secondary:	↓	AST	and	GGT		 a	↑	adiponectin	in	
omega-3	group	 a	.		No	changes	in	ALT,	steatosis,	
FSG,	FI,	HOMA-IR,	BMI	z-score	or	WC	z-score	 b	
Pacifico	et	
al.	(2015)	 250mg/day	DHA	[Low	
calorie	diet	(Italian	
Recommended	Dietary	
Allowanced)	+	60	mins	
PA	5	times	a	week]	
<18	years;	51	
(59%)	
6	months	
[Placebo	
290mg/day	
linoleic	acid]	
Prim
ary:	
Hepatic	fat	
(MRS),	ALT	
Secondary:	
TG,	Z-BMI,	FI,	
HOMA-IR	
Prim
ary:	↓	Hepatic	fat	by	MRS	in	intervention	
group	 a	↓	ALT	in	intervention	group 	b	
Secondary:	↓	FI,	TG	 a,	↓	BMI,	BMI-SDS,	FI,	HOMA-
IR	in	intervention	group	 b	
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a:	statistically	significantly	difference	when	compared	to	the	control	
b:	no	statistical	difference	between	intervention	and	control	
*:	VSL#3	is	eight	strains	of	probiotics	(Streptococcus	therm
ophilus,	bifidobacteria	[B.	breve,	B.	infantis,	B.	longum],	Lactobacillus	acidophilus,	L.	plantarum,	L.	
paracasei	and	L.	delbrueckii	subsp.	bulgaricus)	
#:	NAFLD	Activity	Score	is	a	numerical	score	of	NAFLD	severity	[sum	of	separate	scores	for	steatosis	(0-3),	hepatocellular	ballooning	(0-2)	and	lobular	inflammation	
(0-2)]	Abbreviations:	ALP	=	alkaline	phosphatase;	ALT	=	alanine	transaminase;	AST	=	aspartate	transaminase;	BMI	=	body	mass	index;	CFU	=	colony	forming	units;	CHO	=	
carbohydrate;	DHA	=	docosahexanoic	acid;	EPA	=	eicosapentaenoic	acid;	FI	=	fasting	insulin;	FSG	=	fasting	serum	glucose;	GGT	=	gamma-glutamyl	transpeptidase;	
HDL	=	high	density	lipoprotein;	HOMA-IR	=	homeostatic	model	assessment	of	insulin	resistance;	IU	=	international	units;	LDL	=	low	density	lipoprotein;	LV	=	left	
ventricular	function;	NA	=	not	available;	OR	=	odds	ration;	MRS	=	magnetic	resonance	spectroscopic	imaging;	NAS	=	NAFLD	activity	score;	NR	=	not	reported;	NRT	=	
non-randomised	control	trial;	PA	=	physical	activity;	QOL	=	quality	of	life;	RCT	=	randomised	control	trial;	SBP	=	systolic	blood	pressure;	TC	=	total	cholesterol;	TG	=	
triglycerides;	US	=	ultrasound;	VAT	=	visceral	adipose	tissue;	WC	=	waist	circumference;	Z-BMI	=	BMI	Z-score.	
D
ietary	M
odification	
Ramon-
Krauel	et	al.	
(2013);	USA	 Low	Glycaemic	Load	
diet	[nutritional	
education,	exercise,	
grocery	lists,	food	
preparation	
demonstrations]	
7-18;	17	
(82%)	
6	months	
[Conventional	
low	fat	diet]	
Prim
ary:	
Hepatic	Fat	
(MRS),	ALT,	
AST	Secondary:	
BMI,	HDL,	
LDL,	TG,	FI,	
FSG,	HOMA-
IR	
Prim
ary:	↓	hepatic	fat	(%),	ALT,	AST	in	
intervention	and	control	 b	
Secondary:	↓	BMI,	FI,	FSG,	HOMA-IR,	LDL,	HDL,	
TG	in	intervention	and	control	 b	
Jin	et	al.	
(2014);	USA	 Consumption	of	3	x	
8floz	bottles/d	(33g	
glucose/bottle)	[no	
change	to	diet	or	
physical	activity]	
11-18;	21	
(52%)	
4	weeks	
[Consumption	
of	3	x	8floz	
bottles/d	
(33g	fructose/	
bottle)]	
Prim
ary:	
Hepatic	Fat	
(MRS),	ALT,	
AST	Secondary:	
BW,	TG,	FI,	
HOMA-IR,	
FFA,	LDL	
Prim
ary:	No	change	to	hepatic	fat	(%),	ALT,	AST	
in	intervention	and	control	 b	
Secondary:	↓	HOMA-IR,	plasma	FFA,	LCL,	FI	in	
intervention	group	 a	No	change	in	BW,	TG	in	
intervention	and	control	 b	
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1.3.5	Study	Characteristics	Overall,	821	individuals	participated	in	13	RCTs	ranging	in	duration	from	4	weeks	to	24	months	(Table	1.1).		Of	the	studies	that	met	eligibility	criteria,	11	studies	 investigated	 nutrient	 or	 nutritional	 supplementation	 (vitamin	 E	 (Vajro,	Mandato	et	al.	2004,	Nobili,	Manco	et	al.	2006,	Nobili,	Manco	et	al.	2008,	Wang,	Liang	 et	 al.	 2008,	 Akcam,	 Boyaci	 et	 al.	 2011,	 Lavine,	 Schwimmer	 et	 al.	 2011),	probiotics	 (Vajro,	Mandato	et	 al.	 2011,	Alisi,	Bedogni	 et	 al.	 2014)	 and	omega-3	DHA	 (Nobili,	 Bedogni	 et	 al.	 2011,	Nobili,	 Alisi	 et	 al.	 2012,	 Boyraz,	 Pirgon	 et	 al.	2015,	 Janczyk,	 Lebensztejn	 et	 al.	 2015,	 Pacifico,	 Bonci	 et	 al.	 2015))	 and	 two	studies	 assessed	 dietary	modification	 (low	 glycaemic	 load	 diet	 (Ramon-Krauel,	Salsberg	et	al.	2013)	and	a	reduction	of	fructose	intake	(Jin,	Le	et	al.	2012)).		 Inclusion	 and	 exclusion	 criteria	 varied	 between	 studies;	 nine	 studies	required	participants	 to	be	 classified	as	obese	with	a	BMI	 centile	over	 the	85th	(Jin,	Le	et	al.	2012,	Alisi,	Bedogni	et	al.	2014,	Pacifico,	Bonci	et	al.	2015)	or	95th	(Vajro,	Mandato	et	al.	2004,	Wang,	Liang	et	al.	2008,	Akcam,	Boyaci	et	al.	2011,	Vajro,	Mandato	et	al.	2011,	Ramon-Krauel,	Salsberg	et	al.	2013,	Boyraz,	Pirgon	et	al.	2015)	centile	for	gender	and	age.		The	mean/median	BMI	and	BMI	z-score	of	participants	 in	 each	 study	 arm	at	 baseline	 ranged	 from	24.4	 to	34.7kg/m2	 and	2.01	 to	 3.44	 respectively.	 	 Jin	 et	 al.	 (Jin,	 Le	 et	 al.	 2012)	 and	 Alisi	 et	 al.	 (Alisi,	Bedogni	 et	 al.	 2014)	 only	 included	 participants	 who	 identified	 as	 being	 of	Hispanic	 (Jin,	 Le	 et	 al.	 2012)	 or	 Caucasian	 (Alisi,	 Bedogni	 et	 al.	 2014)	 descent,	respectively,	 while	 the	 remaining	 RCTs	 did	 not	 exclude	 participants	 based	 on	ethnicity.		 To	 meet	 eligibility	 criteria	 of	 this	 review,	 all	 participants	 required	 a	confirmed	 diagnosis	 of	 NAFLD.	 However,	 diagnosis	 criteria	 varied	 between	studies.	 	Seven	trials	required	histological	evidence	of	steatosis	or	fibrosis,	with	six	 trials	 also	 diagnosing	 in	 conjunction	 with	 elevated	 transaminases	 (Nobili,	Manco	 et	 al.	 2006,	 Nobili,	 Manco	 et	 al.	 2008,	 Lavine,	 Schwimmer	 et	 al.	 2011,	Nobili,	 Alisi	 et	 al.	 2012,	 Alisi,	 Bedogni	 et	 al.	 2014,	 Pacifico,	 Bonci	 et	 al.	 2015),	whereas	five	trials	included	participants	with	diagnosis	of	NAFLD	via	ultrasound	alongside	elevated	transaminases	(Vajro,	Mandato	et	al.	2004,	Wang,	Liang	et	al.	2008,	Vajro,	Mandato	et	al.	2011,	Boyraz,	Pirgon	et	al.	2015,	Janczyk,	Lebensztejn	
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et	al.	2015).		Two	studies	(Jin,	Le	et	al.	2012,	Ramon-Krauel,	Salsberg	et	al.	2013)	made	 a	 NAFLD	 diagnosis	 using	 MRS	 whereas	 one	 study	 (Akcam,	 Boyaci	 et	 al.	2011)	 based	 the	 NAFLD	 diagnosis	 on	 evidence	 of	 hepatic	 steatosis	 using	ultrasound	exclusively.	Additionally,	Alisi	et	al.	 (Alisi,	Bedogni	et	 al.	2014)	only	included	participants	with	NASH.		 Twelve	 studies	 recommended	 lifestyle	modification	 as	 a	 co-intervention	(Vajro,	Mandato	et	al.	2004,	Nobili,	Manco	et	al.	2006,	Nobili,	Manco	et	al.	2008,	Akcam,	Boyaci	et	al.	2011,	Lavine,	Schwimmer	et	al.	2011,	Nobili,	Bedogni	et	al.	2011,	Nobili,	Alisi	et	al.	2012,	Ramon-Krauel,	Salsberg	et	al.	2013,	Alisi,	Bedogni	et	al.	2014,	Boyraz,	Pirgon	et	al.	2015,	Janczyk,	Lebensztejn	et	al.	2015,	Pacifico,	Bonci	et	al.	2015).		The	details	and	dietary	targets	guiding	lifestyle	modification	were	 often	 limited,	 with	 three	 publications	 completely	 failing	 to	 outline	 the	dietary	and	physical	activity	recommendations	(Lavine,	Schwimmer	et	al.	2011,	Nobili,	Bedogni	et	al.	2011,	Janczyk,	Lebensztejn	et	al.	2015).		
1.3.6	Study	Findings	
Vitamin	E	Supplementation	We	 identified	 six	 studies	 prescribing	 vitamin	 E	 supplementation	with	 a	total	of	424	participants	in	the	intervention	and	control	arms	(Vajro,	Mandato	et	al.	2004,	Nobili,	Manco	et	al.	2006,	Nobili,	Manco	et	al.	2008,	Wang,	Liang	et	al.	2008,	 Akcam,	 Boyaci	 et	 al.	 2011,	 Lavine,	 Schwimmer	 et	 al.	 2011).	 	 The	formulation	 and	dosage	of	 vitamin	E	 varied	between	 studies	with	Ackam	et	al.	(Akcam,	 Boyaci	 et	 al.	 2011)	 and	 Wang	 et	 al.	 (Wang,	 Liang	 et	 al.	 2008)	 not	specifying	the	formulation	of	vitamin	E	prescribed.		Nobili	et	al.	(Nobili,	Manco	et	al.	 2006,	Nobili,	Manco	et	 al.	 2008)	prescribed	alpha-tocopherol	 in	 conjunction	with	ascorbic	acid	while	Vajro	et	al.	 (Vajro,	Mandato	et	al.	2004)	prescribed	D-alpha-tocopherol	acetate.	While	five	studies	noted	a	decrease	in	ALT	levels	post-intervention	(Vajro,	Mandato	et	al.	2004,	Nobili,	Manco	et	al.	2006,	Nobili,	Manco	et	al.	2008,	Wang,	Liang	et	al.	2008,	Lavine,	Schwimmer	et	al.	2011),	there	was	no	significant	difference	between	 intervention	and	control	groups	(Vajro,	Mandato	et	 al.	 2004,	 Nobili,	 Manco	 et	 al.	 2006,	 Nobili,	 Manco	 et	 al.	 2008,	 Lavine,	Schwimmer	et	al.	2011).	 	Only	Wang	et	al.	 (Wang,	Liang	et	al.	2008)	 found	that	the	decrease	in	ALT	levels	was	greater	in	the	intervention	arm	compared	to	the	
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controls	who	received	no	lifestyle	intervention.		Three	studies	measured	changes	to	 liver	 imaging	post-supplementation;	Vajro	et	al.	 (Vajro,	Mandato	et	al.	2004)	and	 Akcam	 et	 al.	 (Akcam,	 Boyaci	 et	 al.	 2011)	 noted	 improvements	 to	 liver	hyperechogenicity	on	ultrasound	whereas	Wang	et	al.	(Wang,	Liang	et	al.	2008)	noted	 no	 change	 in	 hepatic	 fat	 as	 assessed	 by	 ultrasound.	 3	 studies	 analysed	histological	 changes	 post-intervention;	 Nobili	 et	 al.	 (Nobili,	 Manco	 et	 al.	 2006,	Nobili,	Manco	et	al.	2008)	noted	that	improvements	to	NAS	on	liver	biopsy	were	similar	between	 intervention	and	control	groups	whereas	Lavine	et	al.	 (Lavine,	Schwimmer	et	al.	2011)	found	that	resolution	of	NASH	was	significantly	greater	among	children	treated	with	Vitamin	E	compared	to	a	placebo	(p=0.006).			 All	 studies	 reported	 positive	 improvements	 in	 secondary	 outcome	measures,	 but	 these	 changes	 generally	 did	 not	 reach	 statistical	 significance	between	 control	 and	 treatment	 arms.	 	 Only	 Akcam	 et	 al.	 showed	 a	 significant	improvement	 in	 BMI	 for	 the	 vitamin	 E	 group	 (Akcam,	 Boyaci	 et	 al.	 2011).	Furthermore,	 Vajro	 et	al.	 (Vajro,	Mandato	 et	 al.	 2004)	 and	Nobili	 et	al.	 (Nobili,	Manco	et	al.	2006,	Nobili,	Manco	et	al.	2008)	assessed	for	the	influence	of	weight	loss	on	primary	and	secondary	outcome	measures	and	found	that	decreased	BMI	was	associated	with	improvements	to	ALT	levels	and	HOMA-IR.	
Probiotic	Supplementation	Two	studies	prescribing	probiotic	supplementation	were	identified	(Vajro,	Mandato	 et	 al.	 2011,	 Alisi,	 Bedogni	 et	 al.	 2014).	 	 Probiotics	 trialed	 included	
Lactobacillus	rhamnosus	Strain	GG	(n=20)	and	VSL#3	(n=44),	which	is	comprised	of	eight	probiotic	strains	including	Streptococcus	thermophilus,	bifidobacteria	[B.	
breve,	B.	infantis,	B.	longum],	Lactobacillus	acidophilus,	L.	plantarum,	L.	paracasei	and	 L.	 delbrueckii	 subsp.	 bulgaricus.	 Supplementation	 with	 Lactobacillus	
rhamnosus	Strain	GG	over	eight	weeks	resulted	in	no	change	to	liver	echogenicity	on	ultrasound	(Vajro,	Mandato	et	al.	2011),	whereas	supplementation	of	VSL#3	led	to	improvements	in	fatty	liver,	as	evaluated	by	ultrasound,	after	four	months	(Alisi,	Bedogni	et	al.	2014).			
Omega-3	Supplementation	In	total,	five	studies	investigating	the	effect	of	omega-3	with	a	total	of	295	participants	 in	both	 the	control	and	 interventions	arms	were	 identified	(Nobili,	Bedogni	et	al.	2011,	Nobili,	Alisi	et	al.	2012,	Boyraz,	Pirgon	et	al.	2015,	Janczyk,	
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Lebensztejn	et	al.	2015,	Pacifico,	Bonci	et	al.	2015)	ranging	from	six	months	up	to	24	months	in	length.		The	dosage	and	formulation	of	omega-3	fatty	acids	varied	between	the	studies,	with	omega-3	concentrations	ranging	between	250mg	and	1300mg/day,	while	fish	oil	composition	included	DHA	only	(Nobili,	Bedogni	et	al.	2011,	Nobili,	Alisi	et	al.	2012,	Pacifico,	Bonci	et	al.	2015)	or	a	combination	of	DHA	and	 eicosapentaenoic	 acid	 (EPA)	 (Janczyk,	 Lebensztejn	 et	 al.	 2015).	 	 3	 studies	used	linoleic	acid	as	placebo	(Nobili,	Bedogni	et	al.	2011,	Nobili,	Alisi	et	al.	2012,	Pacifico,	Bonci	et	al.	2015)	while	one	study	used	sunflower	oil	containing	omega-6	 long	 chain	 polyunsaturated	 fatty	 acid	 (LC-PUFA)	 (Janczyk,	 Lebensztejn	 et	 al.	2015).	 	 Boyraz	 et	al.	 did	 not	 describe	 either	 the	 PUFA	 composition	 or	 placebo	content	of	their	supplements	(Boyraz,	Pirgon	et	al.	2015).		All	5	studies	used	pill	counts	to	evaluate	compliance	with	treatment	(Nobili,	Bedogni	et	al.	2011,	Nobili,	Alisi	 et	 al.	 2012,	 Boyraz,	 Pirgon	 et	 al.	 2015,	 Janczyk,	 Lebensztejn	 et	 al.	 2015,	Pacifico,	 Bonci	 et	 al.	 2015)	 while	 only	 three	 studies	 used	 blood	 DHA	concentration	pre-	and	post-intervention	as	an	objective	measure	of	compliance	(Nobili,	Bedogni	et	al.	2011,	Nobili,	Alisi	et	al.	2012,	Pacifico,	Bonci	et	al.	2015).		 All	 five	 studies	used	 liver	 enzyme	 levels	 to	 assess	NAFLD	 severity	post-intervention.		ALT	(Nobili,	Alisi	et	al.	2012,	Janczyk,	Lebensztejn	et	al.	2015),	AST	(Janczyk,	 Lebensztejn	 et	 al.	 2015)	 and	 GGT	 (Janczyk,	 Lebensztejn	 et	 al.	 2015)	levels	 were	 significantly	 reduced	 in	 the	 intervention	 when	 compared	 to	 the	placebo	group	while	Boyraz	et	al.	found	no	difference	between	intervention	and	placebo	groups	in	ALT	and	AST	reduction	(Boyraz,	Pirgon	et	al.	2015).		While	all	the	 studies	 used	 liver	 imaging	 as	 the	 method	 of	 detection	 post-intervention,	Pacifico	 et	 al.	was	 the	 only	 study	 to	 use	 MRS	 as	 a	 primary	 outcome	 measure	(Pacifico,	Bonci	et	al.	2015).	 	Patients	 in	this	study	randomised	to	the	DHA	arm	demonstrated	a	significant	decrease	in	hepatic	fat	fraction	(from	14.0%	to	6.5%;	
p=0.036)	after	six	months,	while	the	placebo	group	showed	no	significant	change	(15.5%	 to	 12.0%;	 p=0.39).	 	 Independently	 the	 work	 of	 Nobili	 et	 al.	 (Nobili,	Bedogni	 et	 al.	 2011,	 Nobili,	 Alisi	 et	 al.	 2012)	 examining	 two	 different	concentrations	of	 omega-3	DHA	 (250mg	vs.	 500mg)	 alongside	placebo	 showed	that	 after	 six	 months	 of	 DHA	 supplementation,	 the	 risk	 of	 severe	 steatosis	 as	assessed	by	ultrasound	was	 reduced	 (250mg	=	OR	0.01,	p<0.01	/	500mg	=	OR	0.04,	p=0.01)	with	no	difference	observed	between	doses.	 	Boyraz	et	al.	showed	
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decreased	liver	steatosis	as	assessed	by	ultrasound	in	PUFA	group	as	compared	to	 the	control	group	after	12	months	of	 treatment	 (Boyraz,	Pirgon	et	al.	2015).		Janczyk	et	al.	did	not	observe	any	difference	in	degree	of	liver	steatosis	between	omega-3	and	placebo	groups	(Janczyk,	Lebensztejn	et	al.	2015).		 While	 all	 studies	 reported	 decreases	 in	 BMI	 and	 improvements	 in	secondary	 outcome	 measures	 with	 intervention,	 these	 were	 not	 statistically	significant	 between	 groups.	 	 Interestingly,	 in	 one	 study	 investigating	 the	effectiveness	 of	 DHA	 concentration,	 HOMA-IR	 was	 significantly	 lower	 in	 the	250mg/day	subgroup	when	compared	to	placebo	after	six	months	of	treatment,	however,	the	500mg/day	subgroup	did	not	show	the	same	effect	(Nobili,	Alisi	et	al.	2012).	
Dietary	Modifications	Two	studies	prescribing	changes	 to	dietary	composition	were	 identified,	with	a	total	of	41	participants	in	the	intervention	and	control	arms	(Jin,	Le	et	al.	2012,	Ramon-Krauel,	 Salsberg	et	 al.	 2013).	 	 Jin	et	al.	 (Jin,	Le	et	 al.	 2012)	 found	that	 four	weeks	 of	 reduced	 fructose	 consumption	 in	 an	 isocaloric	 diet	 did	 not	improve	hepatic	fat	content	as	measured	by	MRS.	However,	Ramon-Krauel	et	al.	(Ramon-Krauel,	Salsberg	et	al.	2013)	found	that	both	a	low	GL	diet,	or	a	low	fat	diet	 improved	 hepatic	 fat	 content	 in	 both	 arms	 of	 the	 trial	 from	 baseline,	although,	there	were	no	significant	differences	between	the	two	groups	after	six	months	(p=0.76)	as	detected	by	MRS.		 Both	 the	 low	 fat	 and	 low	 GI	 diets	 led	 to	 a	 decrease	 in	 BMI	 with	 no	significant	 differences	 between	 the	 two	 groups	 (Ramon-Krauel,	 Salsberg	 et	 al.	2013),	 while	 Jin	 et	 al.	 reported	 no	 difference	 in	 body	 weight	 for	 either	 the	fructose	or	glucose	arms	of	their	trial	(Jin,	Le	et	al.	2012).		The	glucose	arm	of	the	Jin	 et	al.	 study,	 reflecting	 reduced	 fructose	 consumption,	 revealed	 significantly	improved	 adipose	 IR	 (p=0.04)	 despite	 no	 change	 in	 overall	 BMI	 (Jin,	 Le	 et	 al.	2012).					Ramon-Krauel	et	al.	showed	both	low	fat	and	low	GI	diets	improved	ALT	levels	while	 the	 low	 fat	group	also	 showed	significant	 improvements	 in	 insulin	sensitivity	(FI,	HOMA).		The	low	fat	group	also	showed	significant	improvements	in	both	the	waist	circumference	(p=0.02)	and	waist	to	hip	ratio	(p=0.01)	after	six	months,	which	could	contribute	to	these	findings	(Ramon-Krauel,	Salsberg	et	al.	2013).	
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1.3.7	Study	Quality	Overall,	 the	 ADA	 Quality	 Criteria	 Checklist	 identified	 four	 positive,	 10	neutral	and	one	negative	article	(Table	1.2).		The	11	articles	deemed	of	‘neutral’	or	 ‘negative’	 quality	 were	 classified	 as	 such	 due	 to:	 unclear	 method	 of	randomisation	(Nobili,	Manco	et	al.	2006,	Wang,	Liang	et	al.	2008,	Akcam,	Boyaci	et	al.	2011,	Jin,	Le	et	al.	2012,	Ramon-Krauel,	Salsberg	et	al.	2013,	Boyraz,	Pirgon	et	al.	2015);	poor	description	of	methodology	(Vajro,	Mandato	et	al.	2004,	Nobili,	Manco	 et	 al.	 2006,	 Nobili,	 Manco	 et	 al.	 2008,	Wang,	 Liang	 et	 al.	 2008,	 Akcam,	Boyaci	et	al.	2011,	Janczyk,	Lebensztejn	et	al.	2015);	unclear	system	of	blinding	(Ramon-Krauel,	 Salsberg	 et	 al.	 2013);	 failing	 to	measure	 effect	 size	 [excluding	pilot	studies]	(Vajro,	Mandato	et	al.	2004,	Wang,	Liang	et	al.	2008,	Akcam,	Boyaci	et	 al.	 2011);	 failing	 to	 declare	 conflicts	 of	 interest	 (Vajro,	Mandato	 et	 al.	 2004,	Nobili,	Manco	et	al.	2006,	Wang,	Liang	et	al.	2008)	and	no	indication	of	funding	source	(Nobili,	Manco	et	al.	2008,	Nobili,	Alisi	et	al.	2012).		Ackam	et	al.	(Akcam,	Boyaci	 et	 al.	 2011)	 violated	 statistical	 assumptions	 and	 based	 conclusions	 on	findings	 that	 were	 not	 statistically	 significant.	 	 Compliance	 to	 study	 protocols	was	poorly	measured;	pill	count,	pill	diaries	and/or	patient	interviews	were	only	used	 in	 eight	 trials	 to	 measure	 participant	 adherence	 to	 supplementation	regimes	(Nobili,	Manco	et	al.	2006,	Nobili,	Manco	et	al.	2008,	Akcam,	Boyaci	et	al.	2011,	Nobili,	 Bedogni	 et	 al.	 2011,	Nobili,	 Alisi	 et	 al.	 2012,	 Boyraz,	 Pirgon	 et	 al.	2015,	 Janczyk,	Lebensztejn	et	al.	2015,	Pacifico,	Bonci	et	al.	2015).	 	 In	addition,	only	 one	 vitamin	 E	 study	 (Vajro,	Mandato	 et	 al.	 2004)	 assessed	 compliance	 to	vitamin	E	supplementation	via	serum	levels	of	vitamin	E.		Similarly,	three	studies	assessed	 compliance	 by	 blood	 DHA	 levels	 pre-	 and	 post-intervention	 (Nobili,	Bedogni	 et	 al.	 2011,	Nobili,	 Alisi	 et	 al.	 2012,	 Pacifico,	 Bonci	 et	 al.	 2015).	 	 Four	trials	 assessed	 compliance	 with	 dietary	 recommendations	 using	 objective	nutritional	assessment	tools	(Nobili,	Manco	et	al.	2008,	Akcam,	Boyaci	et	al.	2011,	Ramon-Krauel,	 Salsberg	 et	 al.	 2013,	 Janczyk,	 Lebensztejn	 et	 al.	 2015)	 with	findings	 reported	 in	 two	 publications	 (Ramon-Krauel,	 Salsberg	 et	 al.	 2013,	Janczyk,	 Lebensztejn	 et	 al.	 2015).	 	 Weight	 loss	 was	 used	 to	 assess	 dietary	compliance	in	three	studies	(Vajro,	Mandato	et	al.	2004,	Nobili,	Manco	et	al.	2006,	Nobili,	Manco	et	al.	2008).		Compliance	with	supplementation	recommendations	
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or	lifestyle	modification	was	not	measured	by	any	means	in	two	studies	(Wang,	Liang	et	al.	2008,	Vajro,	Mandato	et	al.	2011).	
	
Table	 1.2:	 Quality	 rating	 and	 risk	 of	 bias	 determined	 using	 the	 American	 Dietetic	
Association	Quality	Criteria	Checklist	
Theme	 Author	 Validity	Questions1	 Overall	Quality	
Rating	1	 2	 3	 4	 5	 6	 7	 8	 9	 10	Vitamin	E	 Nobili	(2006)	 	 	 	 	 	 	 	 	 	 	 Neutral	Nobili	(2008)	 	 	 	 	 	 	 	 	 	 	 Neutral	Lavine(2011)	 	 	 	 	 	 	 	 	 	 	 Positive	Vajro	(2004)	 	 	 	 	 	 	 	 	 	 	 Neutral	Wang	(2008)	 	 	 	 	 	 	 	 	 	 	 Negative	Ackam	(2011)	 	 	 	 	 	 	 	 	 	 	 Neutral	Probiotics	 Vajro	(2011)	 	 	 	 	 	 	 	 	 	 	 Neutral	Alisi	(2014)	 	 	 	 	 	 	 	 	 	 	 Neutral	Omega-3	 Nobili	(2010)	 	 	 	 	 	 	 	 	 	 	 Positive	Nobili	(2013)	 	 	 	 	 	 	 	 	 	 	 Positive	Boyraz	(2015)	 	 	 	 	 	 	 	 	 	 	 Neutral	Janczyk	(2015)	 	 	 	 	 	 	 	 	 	 	 Neutral	Pacifico	(2015)	 	 	 	 	 	 	 	 	 	 	 Positive	Low	Glycaemic	Load	Diet	 Ramon-Krauel	(2013)	 	 	 	 	 	 	 	 	 	 	 Neutral	Fructose	 Jin	(2014)	 	 	 	 	 	 	 	 	 	 	 Neutral			Low	Risk	of	Bias		 	 	Risk	of	Bias	
	
1Validity	 Questions:	 1)	 Clear	 Research	 Question;	 2)	 Unbiased	 Selection	 Of	 Participants;	 3)	Randomization/	 Group	 Comparability;	 4)	 Description	 Of	 Withdrawals;	 5)	 Blinding;	 6)	 Study	Procedures	 Described;	 7)	 Clearly	 Defined	 Outcomes;	 8)	 Appropriate	 Statistical	 Analysis;	 9)	Results	Support	Conclusion;	10)	Funding	Or	Sponsorship	Bias	Unlikely		
1.3.8	Discussion	The	eligible	RCTs	for	this	systematic	review	include	a	variety	of	nutrition	interventions	 for	 the	 management	 of	 paediatric	 NAFLD	 with	 considerable	heterogeneity	 in	 study	 protocols	 and	 outcomes.	 Eligible	 trials	 assessed	 the	impact	of	various	nutritional	components	or	supplementation	on	NAFLD	severity.		While	six	of	the	RCTs	evaluated	the	role	of	vitamin	E	supplementation	in	NAFLD	treatment,	 it	 is	difficult	 to	directly	compare	 trials	as	a	 result	of:	differing	doses	and/or	 unclear	 formulations	 of	 vitamin	 E;	 supplementation	 of	 vitamin	 E	 in	conjunction	 with	 other	 antioxidants;	 variable	 intervention	 periods;	 and	 poor	reporting	of	study	results.		The	high	quality	TONIC	trial	by	Lavine	et	al.	(Lavine,	Schwimmer	 et	 al.	 2011)	 found	 no	 significant	 differences	 in	 ALT	 levels,	 their	primary	outcome	measure,	between	the	intervention	and	control	group	after	96	
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weeks	 of	 supplementation.	 However,	 the	 authors	 noted	 significant	improvements	in	liver	histology	among	participants	with	biopsy-proven	NASH.			 Furthermore,	 vitamin	 E	 supplementation	 may	 be	 beneficial	 in	 children	with	poor	adherence	to	lifestyle	recommendations.			Vajro	et	al.	(Vajro,	Mandato	et	 al.	 2011)	 stratified	data	based	on	 compliance	 to	 lifestyle	modification,	 using	weight	 loss	 as	 an	 indicator	 of	 compliance.	 	 Normalisation	 of	 ALT	was	 seen	 in	control	children	who	strictly	adhered	to	lifestyle	intervention	and	children	who	only	 complied	 with	 the	 supplementation	 regime	 with	 minimal	 adherence	 to	dietary	and	physical	activity	recommendations.		As	poor	compliance	with	weight	reduction	 initiatives	 is	 a	 widespread	 issue	 among	 overweight	 and	 obese	paediatric	populations	(Baxter,	Ware	et	al.	2013),	a	targeted	strategy	for	children	with	poor	compliance	to	 lifestyle	recommendations	would	be	useful.	 	However,	high	 dosages	 of	 vitamin	E	 in	 adults	 has	 been	 associated	with	 increased	 risk	 of	stroke	 and	 prostate	 cancer	 and	 may	 have	 a	 pro-oxidative	 effect	 causing	vulnerability	 to	 oxidative	 damage	 (Miller,	 Pastor-Barriuso	 et	 al.	 2005,	 Albanes,	Till	et	al.	2014)	and	long-term	supplementation	may	be	problematic.		 There	 is	 increasing	 understanding	 of	 the	 role	 of	 the	 gut	 microbiota	 in	NAFLD	pathogenesis.		In	light	of	the	positive	effect	of	probiotic	supplementation	on	histological	markers	of	NAFLD	 in	 animals,	 a	 2009	 systematic	 review	by	 the	Cochrane	 Collaboration	 identified	 the	 need	 for	 further	 research	 into	 probiotic	supplementation	 as	 a	 treatment	 for	 NAFLD.	 	 Only	 two	 RCTs	 in	 children	 were	identified,	 evaluating	 the	 influence	 of	 either	 single	 strain	 (Lactobacillus	
rhamnosus	 strain	GG)	 (Vajro,	Mandato	 et	 al.	 2011)	 or	multistrain	VSL#3	 (Alisi,	Bedogni	et	al.	2014)	probiotic	supplementation	on	hepatic	biomarkers.		Although	Vajro	 et	 al.	 (Vajro,	 Mandato	 et	 al.	 2011)	 reported	 no	 effect	 of	 Lactobacillus	
rhamnosus	strain	GG	on	liver	echogenicity,	Alisi	et	al.	(Alisi,	Bedogni	et	al.	2014)	found	 that	 VSL#3	 supplementation	 reduced	 the	 risk	 of	 severe	 steatosis.		Participants	supplemented	with	VSL#3	also	experienced	a	significant	decrease	in	BMI	 that	 would	 likely	 also	 contribute	 to	 changes	 in	 gut	 flora	 composition.		Despite	 this,	 no	 objective	measures	were	 used	 to	 assess	 adherence	 to	 lifestyle	recommendations,	 with	 changes	 to	 diet	 and	 physical	 activity	 in	 either	 study	potentially	confounding	results.		Furthermore,	the	RCTs	at	8	and	16	weeks	were	of	 short	 duration,	 preventing	 assessment	 of	 the	 long-term	 effects	 of	 probiotic	
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supplementation.		We	also	note	that	long	term	follow	up	examining	the	effect	of	discontinuing	 probiotic	 supplementation	 is	 warranted	 in	 light	 of	 evidence	showing	resilience	by	 the	microbiome	 to	short-term	dietary	 interventions	with	rapid	 return	 to	 baseline	 composition	 observed	 (Lozupone,	 Stombaugh	 et	 al.	2012).		 Intakes	of	PUFAs,	 in	particular	omega-3,	have	been	implicated	 in	NAFLD	pathogenesis,	with	deficiency	believed	to	contribute	to	hepatic	fat	accumulation	and	the	progression	of	steatosis	to	NASH.		We	identified	five	RCTs	testing	omega-3	supplementation	in	paediatric	NAFLD	patients.	These	were	well-designed	trials	with	three	out	of	 the	 five	studies	 (Nobili,	Bedogni	et	al.	2011,	Nobili,	Alisi	et	al.	2012,	 Pacifico,	 Bonci	 et	 al.	 2015)	 considered	 positive	 for	 overall	 quality	 rating	based	 on	 the	 American	 Dietetic	 Association	 Quality	 Criteria	 Checklist.	 	 Direct	comparison	of	the	studies	is	again	difficult,	given	differences	in	the	concentration	and	 composition	 of	 omega-3	 supplements	 used,	 and	 the	 variable	 treatment	periods.	 	 Four	 of	 the	 five	 studies	 reported	 reduced	 steatosis	 after	supplementation	 with	 omega-3	 (Nobili,	 Bedogni	 et	 al.	 2011,	 Nobili,	 Alisi	 et	 al.	2012,	Boyraz,	Pirgon	et	al.	2015,	Pacifico,	Bonci	et	al.	2015)	with	the	remaining	study	only	reporting	improvements	in	AST	and	GGT	levels	(Janczyk,	Lebensztejn	et	al.	2015).	 	Similar	findings	have	been	described	in	a	recent	RCT	conducted	in	adults,	 with	 a	 significant	 reduction	 in	 liver	 fat	 percentage	 in	 NAFLD	 patients	supplemented	 with	 4g	 DHA/EPA	 for	 15	 to	 18	 months	 (Scorletti,	 Bhatia	 et	 al.	2014).	 	 Interestingly,	 a	 study	 evaluating	 the	 consumption	 of	 fish	 and	 omega-3	fatty	 acids	 in	 children	 with	 NAFLD	 demonstrated	 very	 low	 intakes	 of	 fish,	alongside	 low	 intakes	 of	 omega-3,	which	was	 associated	with	 increased	 portal	and	lobular	inflammation	(St-Jules,	Watters	et	al.	2013).				 Although	 lifestyle	 and	 dietary	 modification	 aimed	 at	 weight	 loss	 is	 the	first-line	 treatment	 for	 NAFLD,	 we	 only	 identified	 two	 RCTs	 evaluating	 diet-based	 interventions.	 	 Ramon-Krauel	 et	al.	 compared	 a	 low-GL	diet	 to	 a	 low	 fat	diet	with	authors	noting	no	significant	differences	in	diet	effectiveness	(Ramon-Krauel,	 Salsberg	 et	 al.	 2013).	 	 Furthermore,	 despite	 the	 growing	 evidence	implicating	 fructose	 in	 NAFLD	 pathogenesis,	 we	 only	 identified	 one	 study	assessing	 fructose	 intake	 (Jin,	Welsh	 et	 al.	 2014),	which	 ultimately	 showed	 no	effect	 of	 reduced	 dietary	 fructose	 consumption	 on	 hepatic	 fat,	 as	measured	 by	
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MRS	or	 serum	 concentrations	 of	ALT	 and	AST	 enzymes.	 	Notably,	 eleven	 trials	recommended	 a	 co-intervention	 involving	 dietary	 modification,	 but	 only	 two	studies	 used	 objective	 measures	 to	 assess	 participant	 compliance	 with	 these	recommendations.	Reporting	of	results	in	line	with	recent	recommendations	for	paediatric	 obesity	 interventions	 to	 assist	 with	 future	 meta-analysis	 should	 be	encouraged	 for	 future	studies	 (Burrows,	Golley	et	al.	2012).	 	Nevertheless,	 it	 is	important	 to	 acknowledge	 that	 of	 the	 nine	 studies	 recommending	 a	 lifestyle	intervention	that	successfully	 led	to	a	decrease	 in	BMI	 in	the	control,	 five	trials	noted	 improvements	 to	 primary	 outcome	 measures	 and	 all	 nine	 trials	 noted	improvements	 to	 secondary	 outcome	 measures.	 	 This	 confirms	 that	 the	interventions	 that	 encourage	 general	 healthy	 eating	 strategies,	 which	 promote	weight	 loss,	 are	 an	 appropriate	 treatment	 for	 overweight	 and	 obese	 children	with	 NAFLD.	 	 There	 was	 considerable	 heterogeneity	 in	 terms	 of	 assessing	outcome	measures,	with	plasma	concentrations	of	ALT	and	AST,	ultrasound	and	MRI/	MRS	in	addition	to	histology	all	being	used.	This	makes	the	true	efficacy	of	the	 interventions	difficult	 to	compare	between	studies,	particularly	considering	the	 resolution	 or	 improvement	 of	 NASH	with	 fibrosis	 and	 of	 steatosis	 are	 two	different	processes.		 Although	 a	 significant	 body	 of	 evidence	 in	 adults	 suggests	 that	 physical	activity	may	influence	NAFLD	severity	(Keating,	Hackett	et	al.	2012),	we	did	not	identify	 any	 RCTs	 assessing	 the	 impact	 of	 exercise	 on	 hepatic	 biomarkers	 in	children	diagnosed	with	NAFLD.		However,	trials	in	obese	paediatric	populations	(without	 NAFLD	 diagnosis	 per	 se)	 have	 demonstrated	 the	 positive	 effects	 of	physical	 activity	 on	 steatosis	 as	 assessed	 by	MRI	 (Lee,	 Bacha	 et	 al.	 2012,	 Lee,	Deldin	et	al.	2013)	or	MRS	(Van	Der	Heijden,	Wang	et	al.	2010,	van	der	Heijden,	Wang	 et	 al.	 2010).	 One	 cohort	 study	 investigated	 lifestyle	 modifications	 in	 84	Italian	 children	 with	 biopsy	 proven	 NAFLD	 and	 prescribed	 a	 balanced,	 low	calorie	 diet	 with	 moderate	 aerobic	 activity	 (Nobili,	 Marcellini	 et	 al.	 2006).		Results	 showed	 significant	 improvements	 in	 serum	 ALT	 and	 steatosis	 with	 a	weight	 loss	of	over	20%	body	weight	over	a	one-year	period.	 	The	same	group	then	 went	 on	 to	 show	 lifestyle	 interventions	 with	 diet	 and	 physical	 activity	induced	weight	loss,	and	were	associated	with	significant	improvements	in	liver	histology	(Nobili,	Manco	et	al.	2008).		Twelve	of	the	fifteen	RCTs	included	in	this	
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review	prescribed	exercise	recommendations	as	a	co-intervention.	Unfortunately,	the	type	and	duration	of	physical	activity	prescribed	to	participants	was	poorly	described	with	 little	or	no	 rationale	 to	 justify	 recommendations.	 	 Furthermore,	only	 Janczyk	 et	al.	 used	 an	 objective	 assessment	 tool	 to	 evaluate	 adherence	 to	physical	 activity	 recommendations	 (Janczyk,	 Lebensztejn	 et	 al.	 2015).	 	 We	recommend	that	a	high	quality	RCT	should	be	undertaken	to	assess	the	influence	of	 physical	 activity	 on	 relevant	 clinical	 markers,	 such	 as	 LFTs	 and	 imaging	techniques,	in	children	with	diagnosed	NAFLD.		 Overall,	 the	majority	 of	 RCTs	 included	 in	 this	 review	were	 evaluated	 as		‘neutral’	quality;	therefore	the	results	of	these	studies	should	be	interpreted	with	caution	(Academy	of	Nutrition	and	Dietetics	2012).		Based	on	our	critique	of	the	eligible	studies	it	is	apparent	that	future	RCTs	should	aim	to	be	more	transparent	in	 their	 reporting	 of	 diagnostic	 criteria	 and	 in	 the	 inclusion/exclusion	 criteria	used	 to	 recruit	 study	 participants.	 	 Studies	 should	 complete	 a	 thorough	assessment	of	participants’	characteristics	and	behaviours	that	may	contribute	to	NAFLD	or	confound	study	results.		In	addition,	while	dietary	and	physical	activity	may	confound	study	results,	adherence	to	 lifestyle	recommendations	should	be	measured	using	an	objective	measure	with	results	clearly	reported.	
1.3.9	Conclusions	This	systematic	review	has	 identified	 the	heterogeneity	of	studies	assessing	dietary	 and	 physical	 activity	 interventions	 in	 paediatric	 NAFLD	 patients.		Findings	suggest	that:	
• Vitamin	 E	 supplementation	 may	 be	 a	 possible	 treatment	 option	 for	patients	 with	 biopsy	 proven	 NASH	 or	 poor	 compliance	 with	 lifestyle	recommendations.	
• Probiotic	 or	 omega-3	 supplementation	 may	 be	 possible	 nutritional	interventions	 to	 improve	 primary	 and	 secondary	 outcome	 measures	 in	children	with	NAFLD.	
• A	 low	 glycaemic	 load	 diet	 and	 a	 low	 fat	 diet	 promoting	weight	 loss	 are	equally	effective	in	improving	primary	and	secondary	outcome	measures	in	children	with	NAFLD.	
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• Short-term	 reduction	 of	 fructose	 intake	 does	 not	 improve	 steatosis	 as	assessed	by	MRS	and	ALT	levels	over	4	weeks.	
• There	is	a	need	for	high	quality	RCTs	to	determine	the	type,	frequency	and	duration	 of	 physical	 activity	 that	 should	 be	 prescribed	 to	 children	with	NAFLD.	
1.4	Rationale	for	Study	To	 date,	 there	 is	 insufficient	 evidence	 to	 prioritise	 a	 single	 approach	effective	for	the	management	of	paediatric	NAFLD.		Additionally,	results	from	our	systematic	 review	 highlight	 the	 lack	 of	 RCTs	 investigating	 vitamin	 D	supplementation	 in	 a	 paediatric	 NAFLD	 population.	 	 Generalised	 lifestyle	modification	targeting	weight	loss	through	reduced	energy	intake	and	increased	physical	activity	should	remain	 the	 first	 line	of	 treatment	 for	paediatric	NAFLD	until	additional	high	quality	evidence	is	available.	Furthermore,	 to	 date	 there	 has	 been	 no	 research	 examining	 lifestyle	factors	 in	 a	 UK	 paediatric	NAFLD	 population.	 	 The	work	 contained	 here	 is	 the	first	to	assess	the	dietary	intakes	and	physical	activity	levels	of	UK	children	with	NAFLD.	 	 In	 addition,	 only	 three	 studies	 have	 investigated	 vitamin	 D	 status	 in	paediatric	NAFLD	populations,	none	of	which	are	in	a	UK	population.		This	study	characterises	 serum	 25OHD	 status	 in	 this	 clinical	 population,	 as	 well	 as	 the	potential	underlying	mechanisms,	investigating	genes	in	the	vitamin	D	metabolic	pathway	and	screening	for	select	polymorphisms.		Finally,	we	examine	the	effect	of	 vitamin	 D	 on	 cell	 proliferation	 in	 the	 liver	 through	 culturing	 and	 treating	hepatic	stellate	cells.	
1.5	Hypotheses,	Aims	and	objectives	
1.5.1	Hypotheses		 The	nutrient	intakes,	physical	activity	levels,	vitamin	D	status	and	genetic	polymorphisms	 influencing	NAFLD	 and	 vitamin	D	metabolism	 in	 children	with	NAFLD	will	be	different	to	children	with	simple	obesity.	1,25(OH)2D3	will	reduce	cell	proliferation	in	human	hepatocytes	and	hepatic	stellate	cells.	
1.5.2	Aims	The	aims	of	this	project	were	to:	
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1.	Assess	dietary	intakes	and	physical	activity	of	paediatric	NAFLD	patients	in	the	UK	in	comparison	to	a	group	of	BMI-matched	children	with	no	evidence	of	liver	disease;	2.	In	a	cohort	of	biopsy	proven	NAFLD,	assess	the	vitamin	D	status	and	compare	variations	 in	 genes	 associated	 with	 vitamin	 D	 metabolism	 against	 histological	scoring;		3.	 Characterise	 the	 effects	 of	 vitamin	 D	 treatment	 on	 human	 hepatocytes	 and	hepatic	stellate	cells.		
1.5.3	Objectives	
• To	recruit	a	representative	sample	of	paediatric	NAFLD	patients	and	BMI-matched	obese	controls	from	those	attending	the	King’s	College	Hospital	Paediatric	 Liver	 Unit	 and	 Obesity	 clinic	 and	 assess	 anthropometric	measurements,	macro-	and	micronutrient	intakes,	physical	activity	levels	and	 eating	 behaviours	 using	 24	 hour	 recalls,	 7	 day	 food	 and	 activity	diaries	 along	 with	 pedometer	 readings,	 Physical	 Activity	 Questionnaire	(PAQ)	and	the	Dutch	Eating	Behavior	Questionnaire	(DEBQ)	
• To	 assess	 vitamin	 D	 status	 through	 measurement	 of	 25OHD	 in	 serum	samples	 of	 biopsy	 proven	 paediatric	 NAFLD	 patients,	 and	 genotype	 for	select	polymorphisms	in	genes	associated	with	vitamin	D	metabolism	
• To	 assess	 the	 effects	 of	 1α,	 25(OH)2D3	 treatment	 on	 cultured	 hepatic	stellate	cells	through	RNA	and	protein	analysis	alongside	cell	proliferation			 	
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Chapter	 2:	 Diet	 and	 Physical	 Activity	 Levels	 in	 Paediatric	 NAFLD	
Patients:	a	Case	Control	Study	
2.1	Background		 NAFLD	is	a	condition	characterised	by	fat	accumulation	 in	the	 liver	with	or	 without	 inflammation	 and	 fibrosis	 (NASH),	 which	 has	 the	 potential	 to	progress	 to	 end	 stage	 liver	 disease	 and/or	 HCC	 (Moore	 2010).	 NAFLD	 is	currently	 the	 most	 common	 form	 of	 chronic	 liver	 disease	 in	 children	 and	adolescents	 in	 Western	 countries,	 with	 prevalence	 rising	 alongside	 rates	 of	childhood	obesity	(Giorgio,	Prono	et	al.	2013).	The	gold	standard	for	diagnosis	of	NASH	is	liver	biopsy,	which,	due	to	its	invasive	nature	and	associated	risks,	has	made	 establishing	 accurate	 population	 prevalence	 data	 for	 paediatric	 NAFLD	difficult	 (Loomba,	 Sirlin	 et	 al.	 2009).	 However,	 in	 an	 autopsy	 study	 of	 742	children	who	died	from	unnatural	causes	in	the	United	States,	Schwimmer	et	al.	found	 a	NAFLD	prevalence	of	 9.6%,	which	 increased	 to	38%	 in	 obese	 children	(Schwimmer,	Deutsch	et	al.	2006).		 Diet	 and	 physical	 activity	 plays	 a	 key	 role	 in	 NAFLD	 development	 and	management.	 Due	 to	 the	 strong	 association	 between	NAFLD	 and	 obesity,	 first-line	 treatment	 is	 the	promotion	of	gradual	weight	 loss	 through	reduced	energy	intake	and	increased	physical	activity	(Dongiovanni,	Lanti	et	al.	2016),	with	the	aim	of	improving	LFTs,	IR,	fasting	glucose	and	lipid	profiles	(Berardis	and	Sokal	2013).	 Additionally,	 literature	 to	 date	 has	 identified	 a	 number	 of	 dietary	 and	physical	activity	factors	which	may	protect	against	or	exacerbate	NAFLD.		
2.1.1	Physical	Activity		 There	 has	 been	 considerable	 research	 interest	 in	 the	 role	 of	 physical	inactivity	in	NAFLD	development,	a	relationship	that	has	been	primarily	explored	in	adults	(Zelber-Sagi,	Nitzan-Kaluski	et	al.	2008,	Gerber,	Otgonsuren	et	al.	2012,	Hallsworth,	 Thoma	 et	 al.	 2015).	 Results	 from	 these	 studies	 have	 consistently	shown	participants	with	NAFLD	to	be	less	physically	active	than	controls	without	liver	 disease.	 Although	 similar	 research	 in	 the	 paediatric	 population	 has	 been	limited,	a	questionnaire-based	study	also	identified	lower	physical	activity	scores	in	 obese	 children	 with	 NASH	 compared	 with	 obese	 and	 lean	 control	 children	
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(Hattar,	Wilson	et	al.	2011).	Mager	and	colleagues	(Mager,	Patterson	et	al.	2010)	also	recorded	suboptimal	physical	activity	levels	in	children	with	NAFLD,	with	an	average	 of	 66.9%	 of	 waking	 hours	 spent	 in	 sedentary	 activities.	 In	 the	 most	recent	 investigations	 into	 the	 role	 of	 physical	 activity,	 through	 a	 lifestyle	intervention,	 in	 a	 paediatric	 NAFLD	 population,	 51	 obese	 children	 (mean	 age	14.7	±	 2.4	 years)	with	 steatosis	 as	 assessed	by	MRS	 and	ALT	 levels	were	non-randomly	assigned	to	inpatient,	outpatient	treatment	or	standard	care	for	up	to	6	months	 and	 then	 followed	 for	 a	 further	 18	 months.	 Results	 demonstrated	 a	greater	resolution	of	liver	steatosis	and	ALT	normalization	in	patients	receiving	lifestyle	 treatment,	with	 inpatient	 care	 non-significantly	 superior	 to	 outpatient	care,	 although	 the	 authors	 conclude	 that	 further	 investigations	 are	 required	(Koot,	van	der	Baan-Slootweg	et	al.	2016).	
2.1.2	Dietary	Fructose		 More	recently,	there	has	been	increasing	research	into	the	role	of	fructose	in	NAFLD	pathogenesis	(Moore,	Gunn	et	al.	2014).	Although	high	fructose	intakes	have	 been	 shown	 to	 alter	 hepatic	 insulin	 sensitivity	 and	 increase	 lipogenesis,	whether	 or	 not	 this	 contributes	 to	NAFLD	pathogenesis	 independent	 of	 excess	energy	 consumption	 remains	 uncertain	 (Moore,	 Gunn	 et	 al.	 2014).	 Fructose	metabolism	is	thought	to	contribute	to	increased	hepatic	steatosis	(Lim,	Mietus-Snyder	et	al.	2010,	Jin,	Le	et	al.	2012).	Abdelmalek	et	al.	(Abdelmalek,	Suzuki	et	al.	2010)	reported	an	association	between	higher	fructose	intake	and	younger	age,	male	 gender,	 hypertriglyceridaemia	 and	 low	 HDL-C	 in	 adult	 NAFLD	 patients	(n=427),	 with	 daily	 consumption	 of	 fructose-containing	 beverages	 linked	 to	increased	hepatic	inflammation.	A	randomised,	double-blind	cross-over	study	in	an	 American	 paediatric	 study	 population	 (n=19)	 provided	 evidence	 for	 the	dyslipidaemic	 effects	 of	 fructose-sweetened,	 in	 comparison	 to	 glucose-sweetened	 beverages,	 indicating	 the	 detrimental	 metabolic	 effect	 of	 regular	fructose	intake	in	children	with	NAFLD	(Jin,	Le	et	al.	2012).		
2.1.3	Dietary	Fat		 Quality	of	dietary	fat	is	thought	to	play	a	role	in	hepatic	TG	accumulation	(Mager,	Mazurak	 et	 al.	 2012).	 Papandreou	 et	al.	 (Papandreou,	 Karabouta	 et	 al.	2012)	recorded	a	proportional	increase	in	saturated	fatty	acid	(SFA)	intake	with	
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degree	of	hepatic	steatosis	 in	children	with	NAFLD,	and	an	inverse	relationship	between	 omega-3	 PUFA	 consumption	 and	 steatosis	 severity.	 Consumption	 of	 a	meal	high	in	SFA	and	low	in	PUFA	has	been	associated	with	increased	LFTs	and	postprandial	hyperinsulinaemia	in	children	with	NAFLD,	compared	to	both	obese	and	lean	controls	(Mager,	Mazurak	et	al.	2012).	This	suggests	that	children	with	NAFLD	who	regularly	consume	high	levels	of	SFA	and	low	levels	of	PUFA	may	be	susceptible	 to	 increased	 postprandial	 dyslipidaemia,	 hyperinsulinaemia	 and	altered	lipoprotein	expression.		 Omega-3	 PUFAs	 exhibit	 anti-inflammatory	 properties	 and	 facilitate	 cell	membrane	 stabilization.	 Omega-3	 deficiency	 may	 consequently	 contribute	 to	hepatic	 fat	 accumulation,	 oxidative	 stress	 and	 NASH	 (Masterton,	 Plevris	 et	 al.	2009).	Studies	observing	the	effects	of	omega-3	PUFA	supplementation	in	NAFLD	have	produced	promising	results	(Capanni,	Calella	et	al.	2006,	Nobili,	Alisi	et	al.	2013),	with	a	randomised	controlled	 trial	noting	 that	supplementation	of	up	 to	500mg/day	docosahexaenoic	acid	(DHA)	 for	24	months	may	be	effective	 in	 the	reduction	of	steatosis,	TG	levels	and	IR	in	60	children	with	NAFLD	(Nobili,	Alisi	et	al.	 2013).	 As	 evidence	 is	 not	 yet	 sufficient	 to	 warrant	 routine	 omega-3	supplementation	in	patients	with	NAFLD,	dietary	consumption	of	omega-3	PUFA	is	of	key	interest.	St-Jules	and	colleagues	(St-Jules,	Watters	et	al.	2013)	examined	intakes	 of	 fish	 and	 omega-3	 PUFA	 in	 children	 with	 NAFLD,	 with	 results	suggesting	 that	 only	 a	 minority	 of	 subjects	 consumed	 the	 recommended	 two	portions	of	fish,	inferring	low	intake	of	omega-3	PUFA.	Associations	were	found	between	 reduced	 fish	 consumption	 and	 portal	 inflammation,	 and	 between	reduced	omega-3	PUFA	intake	and	lobular	inflammation	(St-Jules,	Watters	et	al.	2013).		
2.1.4	Vitamin	D		 Vitamin	 D	 has	 been	 implicated	 in	 the	 development	 of	 NAFLD	with	 low	levels	of	serum	25OHD	being	strongly	associated	with	features	of	the	metabolic	syndrome,	 including	 dyslipidaemia,	 IR	 and	 hyperglycaemia,	 and	 hepatic	inflammation	 (Eliades,	 Spyrou	 et	 al.	 2013).	 Recent	 observational	 studies	 have	demonstrated	that	low	vitamin	D	status	is	associated	with	NAFLD	independently	of	BMI	in	Australian	(Black,	Jacoby	et	al.	2014),	and	Italian	(Nobili,	Giorgio	et	al.	
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2014)	 paediatric	 cohorts.	 Additionally,	 a	 case-control	 study	 in	 adults	 found	vitamin	D	consumption	 to	be	 lower	 in	adults	with	NAFLD	compared	 to	healthy	controls	(Hashemi	Kani,	Alavian	et	al.	2013).		 Due	 to	a	 lack	of	 evidence	 to	 support	pharmacological	 treatment	options	for	 NAFLD,	 diet	 and	 physical	 activity	 play	 a	 key	 role	 in	 NAFLD	 management	(Chalasani,	 Younossi	 et	 al.	 2012,	 Nascimbeni,	 Pais	 et	 al.	 2013).	 First-line	treatment	 is	 currently	 the	 promotion	 of	 gradual	 weight	 loss	 through	 reduced	energy	intake	and	increased	physical	activity,	with	the	aim	of	improving	LFTs,	IR,	fasting	 glucose	 and	 lipid	 profiles	 (Chalasani,	 Younossi	 et	 al.	 2012,	 Nascimbeni,	Pais	et	al.	2013).	However,	the	role	of	specific	dietary	nutrients	and	the	influence	of	 physical	 activity	 levels	 on	 NAFLD	 pathogenesis	 remain	 uncertain.	 Nutrients	previously	 investigated	 in	 NAFLD	 pathogenesis	 include	 fructose,	 SFA,	 mono-unsaturated	fatty	acids	(MUFA),	PUFA	and	vitamin	D.	Quality	of	dietary	fat	seems	likely	 to	play	a	 role	 in	NAFLD	development	with	a	significant	body	of	evidence	suggesting	that	consumption	of	a	diet	rich	in	SFA	may	contribute	independent	of	energy	 intake	 to	 hepatic	 fat	 accumulation;	 whereas	 a	 diet	 rich	 in	 PUFA,	 in	particular	 omega-3	 fatty	 acids,	may	 impede	 steatosis	 development	 (Green	 and	Hodson	2014).	
2.1.5	Aims		 The	 aims	 of	 this	 study	 were	 firstly	 to	 characterise	 and	 compare	anthropometry,	macro-	 and	micronutrient	 intakes,	 physical	 activity	 and	 eating	behaviours	 of	 a	 group	 of	 UK	 children	 with	 NAFLD	 to	 those	 of	 obese	 children	without	evidence	of	 liver	disease;	and	secondly	to	relate	nutrient	 intakes	to	UK	recommended	 dietary	 reference	 values	 and	 examine	 if	 excess	 intakes	 or	deficiencies	 of	 nutrients	 previously	 implicated	 in	 NAFLD	 pathogenesis	 are	evident	in	a	UK	paediatric	cohort.	 	
2.1.6	Hypotheses		 NAFLD	patients	will	be	less	physically	active	than	UK	children	with	simple	obesity.	 Eating	 behaviours	 will	 not	 differ	 between	 children	 with	 NAFLD	 and	obese	 children	 without	 evidence	 of	 liver	 disease.	 	 NAFLD	 patients	 will	 report	high	consumption	of	 fructose	and	saturated	 fats,	 in	addition	to	reporting	 lower	
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intakes	 of	 vitamin	 D,	 mono-	 and	 polyunsaturated	 fatty	 acids	 and	 omega-3	 in	comparison	to	obese	controls.	
2.1.7	Objectives	
• To	 evaluate	 and	 compare	 anthropometric	 measurements	 (BMI,	 BMI	 Z-score,	BMI	centiles,	WC,	waist-height	ratio,	mid-upper	arm	circumference	(MUAC),	triceps	skinfold)	of	a	group	of	UK	children	with	NAFLD	to	those	of	obese	children	without	evidence	of	liver	disease.	
• To	evaluate	and	compare	physical	 activity	 levels,	 as	measured	using	 the	PAQ	and	a	7-day	activity	diary	with	pedometer	 readings,	of	UK	children	with	NAFLD	to	those	of	obese	children	without	evidence	of	liver	disease.	
• To	evaluate	and	compare	macro-	and	micronutrient	intakes,	as	measured	using	 one	 24-hour	 dietary	 recall	 and	 a	 7-day	 food	diary,	 of	UK	 children	with	NAFLD	to	obese	children	without	evidence	of	liver	disease.	
• To	 compare	 macro-	 and	 micronutrient	 intakes	 to	 the	 age	 and	 gender	appropriate	DRVs	 to	 establish	whether	 excess	 intakes	 or	 deficiencies	 of	macro-	and	micronutrients	previously	implicated	in	NAFLD	pathogenesis	are	evident	in	a	UK	paediatric	NAFLD	cohort.	
• To	evaluate	and	compare	eating	behaviours,	as	measured	by	the	DEBQ,	of	UK	children	with	NAFLD	 to	 those	of	obese	 children	without	 evidence	of	liver	disease.	
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2.2	Materials	and	Methods	
2.2.1	Participants		 All	 participants	 were	 recruited	 from	 paediatric	 clinics	 at	 King’s	 College	Hospital,	 London	 by	 a	 dietetic	 researcher.	 Children	 with	 NAFLD	 (cases)	 were	recruited	 from	 the	 Paediatric	 Liver	 Centre,	 whereas	 children	 with	 obesity	(controls)	were	recruited	from	a	regional	surgical	weight	 loss	clinic	following	a	diagnosis	of	simple	non-syndromic	obesity.	All	subjects	were	less	than	19	years	of	 age	 at	 recruitment.	 Cases	 required	 a	 diagnosis	 of	NAFLD,	 initially	 suspected	based	 on	 ultrasound	 or	 elevated	 concentration	 of	 ALT	 and	AST	 liver	 enzymes,	confirmed	by	liver	biopsy	within	3-6	months	of	diagnosis.	Patients	underwent	a	full	assessment	for	chronic	liver	disease	including	screening	for	Hepatitis	B	and	C,	Wilson	disease	(including	liver	copper	quantification),	autoimmune	liver	disease	and	alpha	1	antitrypsin	deficiency.	Cases	were	excluded	in	the	presence	of	other	chronic	 liver	 disease,	 or	 if	 they	 had	 previously	 received	 treatment	 for	 NAFLD.	Controls	 were	 excluded	 if	 they	 had	 a	 clinical	 suspicion	 of	 NAFLD,	 based	 on	abnormality	of	liver	function	tests	or	liver	ultrasound.	Children	were	questioned	and	excluded	if	they	reported	consuming	alcohol.			 Written	consent	 from	parents	/	carers	and	assent	 from	participants	was	obtained	prior	to	entering	the	study	[Appendix	A].	Ethical	approval	was	granted	by	 the	National	Health	Service	 (NHS)	Research	Ethics	Service	 (10/H0808/122)	[Appendix	 B]	 and	 the	 University	 of	 Surrey	 Ethics	 Committee	(EC/2010/115/FHMS)	[Appendix	C].		
2.2.2	Demographic	and	Anthropometric	Data		 Participant	 ethnicity	 was	 classified	 according	 to	 the	 Health	 and	 Social	Care	 Information	 Centre,	 Ethnic	 Category	 Code	 by	 King’s	 College	 Hospital	research	 staff.	 All	 anthropometric	 measurements	 were	 collected	 by	 the	 lead	clinician,	trained	dietetic	researchers	and	students.	Weight	(to	the	nearest	0.1kg)	and	 height	 without	 shoes	 (to	 the	 nearest	 0.1cm)	 were	measured	 using	 digital	scales	and	a	commercial	stadiometer	(Marsden	Weighing	Group,	Rotherham,	UK).	BMI	was	calculated	as	weight	(kg)	/	height	(m2).	BMI	centile	was	read	from	the	‘Body	mass	 index	(BMI)	2-20	years’	chart	 from	the	Royal	College	of	Paediatrics	and	 Child	 Health	 (RCPCH),	 using	 BMI,	 gender	 and	 age	 (RCPCH	 2015).	 BMI	 z	 -
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score	was	obtained	using	The	Children’s	Hospital	of	Philadelphia,	 ‘Paediatric	Z-Score	 Calculator’	 (Philadelphia	 2008).	 Weight	 classification	 was	 determined	using	 BMI	 ranges	 published	 by	 the	 NHS	National	 Obesity	 Observatory	 (Mager,	Iniguez	 et	 al.	 2015).	 Waist	 circumference	 was	 measured	 at	 the	 midway	 point	between	 the	 top	 of	 the	 iliac	 crest	 and	 the	 bottom	 of	 the	 rib	 cage,	 using	 a	commercial	 tape	 measure	 and	 reading	 to	 the	 nearest	 0.5	 cm	 (WHO	 2011).	 If	identification	of	 these	points	was	not	possible	 in	 very	overweight	participants,	the	tape	measure	was	placed	around	the	abdomen	at	 the	 level	of	 the	umbilicus	(WHO	2011).	MUAC	was	recorded	to	the	nearest	0.5	cm	with	a	commercial	tape	measure	 and	 triceps	 skinfold	 thickness	 was	 measured	 to	 the	 nearest	 0.1	 mm	using	 callipers	 (Holtain	 Tanner/Whitehouse	 Skinfold	 Calliper,	 Holtain	 Limited,	Pembrokeshire,	UK),	(CDC	2007).	
2.2.3	Dietary	Assessment		 Dietary	 intakes	 were	 assessed	 using	 24-hour	 dietary	 recalls	 and	 7-day	participant-completed	food	and	activity	diaries	(FAD)	[Appendix	D].	One	24-hour	dietary	 recall	 was	 completed	 at	 the	 time	 of	 consent	 by	 a	 research	 dietitian	 or	dietetic	student	using	the	multiple-pass	method	(Moshfegh,	Rhodes	et	al.	2008).	To	complete	 the	7-day	 food	diary,	participants	were	requested	 to	document	all	meals,	 snacks	 and	 beverages	 consumed	 over	 7	 consecutive	 days	 during	 school	term	time;	stating	brand	names	where	applicable	and	using	household	measures	or	food	packaging	information	to	estimate	portion	sizes.	During	the	first	2-3	days	of	their	recording	period,	participants	were	offered	support	via	telephone	call	or	a	 home	 visit	 by	 dietetic	 students	 during	 which	 completion	 of	 the	 diary	 was	checked	 and	 usual	 portion	 sizes	 established.	 After	 completing	 the	 food	 diary,	participants	 were	 contacted	 by	 researchers,	 via	 home	 visit	 or	 phone	 call,	 to	ascertain	missing	information.	This	included	further	clarification	of	portion	sizes,	and	clarification	of	brand	names	and	food	preparation	methods.		 Nutritional	 analyses	 were	 completed	 using	 DietPlan6	 (Forestfield	Software	Limited,	West	Sussex,	UK).	All	dietary	analyses	were	rechecked	before	further	 analysis	 took	 place.	 Dietary	 intakes	 are	 presented	 as	 mean	 absolute	intake	or	a	percentage	of	age-	and	gender-specific	UK	DRVs	where	possible	(DoH	1991).	 Mean	 absolute	 intakes	 are	 given	 for	 nutrients	 that	 do	 not	 have	 DRVs.	
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Under-reporting	 of	 dietary	 intake	 was	 determined	 using	 cut-offs	 described	 by	Goldberg	et	al.	(Goldberg,	Black	et	al.	1991).	If	reported	energy	intake	(EI)	in	the	7-day	food	diary	was	<1.14	x	Basal	Metabolic	Rate	(BMR)	or	24-hour	recall	data	indicated	an	EI	<	0.92	x	BMR,	the	participant	was	assumed	to	be	under-reporting.	BMR	 was	 calculated	 according	 to	 equations	 determined	 by	 Schofield	 et	 al.	(Schofield	1985).		 The	 33-question	 DEBQ	 was	 completed	 by	 each	 participant	 at	 the	conclusion	of	the	7-day	recording	period	to	assess	eating	styles	and	behaviours	that	may	attenuate	the	likelihood	of	being	overweight	(Van	Strien,	Frijters	et	al.	1986)	 [Appendix	E].	Participants	 responded	 to	questions	on	a	 five	point	Likert	scale.	Responses	were	classified	as	expressing	emotional,	external	or	restrained	eating	 behaviours	 (Van	 Strien,	 Frijters	 et	 al.	 1986)	 and	 the	 mean	 score	 from	questions	 in	 each	domain	were	 calculated	 for	 each	participant.	 External	 eating	behaviours	 examines	 eating	 in	 response	 to	 food	 stimuli	 regardless	 of	 internal	state	of	hunger	or	satiety.	Emotional	eating	surveys	consumption	in	response	to	arousal	states	such	as	anger,	fear	or	anxiety	whereas	restrained	eating	involves	restricting	food	intake	independently	of	emotional	or	external	cues	(Van	Strien,	Frijters	et	al.	1986).		
2.2.4	Food-Based	Dietary	Analysis		 In	order	to	conduct	the	food-based	analysis,	foods	from	the	7-day	diaries	were	 assigned	 groups	 and	 portion	 sizes.	 	 An	 extensive	 list	 of	 70	 foods	 were	analysed;	 this	 list	 is	 not	 exhaustive	 but	 includes	 a	 range	 of	 foods	 of	 interest	within	current	NAFLD	research.	 	To	allow	for	more	detailed	analysis,	each	food	group	was	further	divided	into	subsections,	for	example	cereals	were	categorised	according	 to	 their	 sugar	 content,	 aiming	 to	 identify	 any	 differences	 in	 specific	food	 types	 between	 cases	 and	 controls.	 The	 food	 categories	 investigated	were	assigned	 portion	 sizes.	 	 When	 choosing	 the	 portion	 size	 it	 was	 important	 to	consider	 the	 typical	 portion	 consumed	 by	 an	 obese	 paediatric	 population.	 	 It	could	not	be	assumed	that	obese	children	eat	standard	children’s	portion	sizes	as	various	 studies	 show	 a	 positive	 association	 between	 increasing	 BMI	 and	increasing	portion	sizes	(McConahy,	Smiciklas-Wright	et	al.	2002,	Albar,	Alwan	et	al.	 2014).	 	 On	 this	 basis,	 the	 portion	 sizes	 used	 for	 analysis	 were	 based	 on	 a	
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compromise	 between	 adult	 and	 children	 food	 portion	 sizes,	 often	 using	 small	adult	 portions.	 	 The	 resources	 used	 to	 derive	 these	 values	 included	 the	 Food	Standard’s	Agency	(FSA)	food	portion	size	book	(FSA	1994)	in	conjunction	with	Wrieden	et	al.	estimations	of	children’s	portion	sizes	(Wrieden,	Longbottom	et	al.	2008).	 	 The	 7-day	 diaries	 were	 analysed	 by	 counting	 the	 frequency	 of	consumption	of	the	different	food	groups	using	the	allocated	portion	sizes.	
2.2.5	Physical	Activity	Assessment		 Physical	 activity	 was	 assessed	 via	 both	 a	 participant-completed	 7-day	physical	 activity	 diary	 and	 recorded	 steps	 from	 assigned	 pedometers.	Participants	were	instructed	to	document	all	activity	in	10	minute	intervals	on	7	consecutive	 days	 [Appendix	 D].	 Participants	 were	 provided	 with	 a	 pedometer	(OMRON	 Step	 counter	 Walking	 style	 III,	 OMRON	 Healthcare	 Europe	 B.V.,	Hoofddorp,	The	Netherlands)	and	were	 instructed	to	document	 their	daily	step	count	on	each	of	the	7	days.	Participants	received	support	with	diary	completion	during	 the	 first	 2-3	 days	 of	 their	 recording	 period,	 through	 telephone	 calls	and/or	a	home	visit	to	ascertain	missing	information	and	to	clarify	the	intensity	of	activities	reported.			 Upon	return	of	the	diaries,	researchers	assigned	a	metabolic	equivalent	of	task	(MET)	to	each	activity	using	values	described	by	Ainsworth	et	al.	(Ainsworth,	Haskell	 et	 al.	 2011).	 Activity	 was	 categorised	 as:	 sleep	 (0.9	 METs),	 sedentary	(1.0-1.5	METs),	 light	 (1.6-2.9	METs),	moderate	 (3.0-5.9	METs)	 or	 vigorous	 (≥6	METs)	 (Ainsworth,	 Haskell	 et	 al.	 2011).	 Periods	 of	 time	 that	 had	 not	 being	recorded	were	classified	as	 ‘unaccounted’	 time.	Absolute	minutes	spent	 in	each	category	 were	 calculated	 for	 each	 participant,	 along	 with	 7-day,	 weekday	 and	weekend	 averages	 for	 each	 group.	 Data	 are	 presented	 as	 a	 percentage	 of	 24-hours.			 Additionally,	participants	≥15	years	of	age	completed	the	Youth	Physical	Activity	Questionnaire	(Y-PAQ)	[Appendix	F]	and	children	≤14	years	completed	the	Children’s	Physical	Activity	Questionnaire	(C-PAQ)	with	the	aid	of	a	parent	or	guardian	 [Appendix	 G]	 (Telford,	 Salmon	 et	 al.	 2004,	 Corder,	 Van	 Sluijs	 et	 al.	2009).	These	questionnaires	are	adaptations	of	the	Children’s	Leisure	Activities	Study	 Survey	 (CLASS)	 questionnaire,	 which	 has	 been	 validated	 in	 paediatric	
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cohorts	(Telford,	Salmon	et	al.	2004,	Corder,	Van	Sluijs	et	al.	2009).	Participants	recorded	 the	 number	 of	 absolute	 minutes	 spent	 undertaking	 sedentary,	 light,	moderate	or	vigorous	exercise	per	week;	with	data	presented	as	a	percentage	of	total	time	recorded.			 Following	dietary	and	physical	activity	assessment,	participants	received	tailored	dietary	advice	 from	dietetic	 researchers	or	students,	via	 telephone	call	or	 home	 visit.	 All	 recommendations	 were	 based	 on	 the	 FSA	 Eat	 Well	 Healthy	Eating	Guidelines	(FSA	2005)	or	UK	Physical	Activity	Guidelines	(WHO	2011).		
2.2.6	Statistical	Analysis		 Statistical	 analysis	 was	 completed	 using	 SPSS	 v22	 (IBM	 SPSS	 Statistics,	Hampshire,	 UK).	 Graphs	 were	 produced	 using	 GraphPad	 Prism	 6	 (GraphPad	Software,	California,	USA).	Data	are	expressed	as	median	and	interquartile	range	(IQR)	unless	otherwise	 specified.	Due	 to	 the	 small	 sample	 size,	non-parametric	tests	were	used	to	reduce	the	likelihood	of	a	type	1	error.	To	identify	differences	between	 groups,	 continuous	 data	were	 analysed	 using	 the	Mann-Whitney	 test.	Analysis	of	Covariance	 (ANCOVA)	was	used	 to	correct	 for	differences	 in	BMI	z-score	between	groups.	Categorical	baseline	data	and	differences	in	the	number	of	under-reporters	were	analysed	using	the	Fisher’s	Exact	test	or	chi-squared	test.	The	Wilcoxon	paired	rank	test	was	used	to	assess	differences	in	pedometer	data	between	weekdays	and	weekends	within	each	group.	The	Bonferroni	correction	was	used	to	determine	a	p-value	to	assess	for	group	differences	in	food	groups,	macro-	and	micronutrient	intakes.	Otherwise,	a	p-value	of	<0.05	was	considered	statistically	significant.	 	
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2.3	Results	
2.3.1	Study	Population		 During	 the	 study	 period,	 72	 children	 attending	 King’s	 College	 Hospital	paediatric	clinics	with	NAFLD	or	simple	obesity	were	approached	to	take	part	in	the	study.	Of	the	51	participants	who	consented	to	participate,	24	patients	with	NAFLD	(63%)	and	8	children	with	obesity	(61%),	who	had	no	evidence	of	fatty	liver	 disease	 on	 abdominal	 ultrasound	 or	 liver	 function	 tests,	 completed	 the	study	 protocol	 (Figure	 2.1).	 Anthropometric	 and	 demographic	 data	 of	 the	participants	 who	 completed	 the	 study	 protocol	 are	 outlined	 in	 Table	 2.1.	Participants	ranged	from	8	to	18	years	of	age.	Groups	were	evenly	matched	for	most	 characteristics	 (Table	 2.1).	 Although	 the	 BMI	 z-score	 (p<0.01)	 was	significantly	 higher	 in	 the	 obese	 control	 group;	 there	 were	 no	 significant	differences	in	the	distribution	of	weight	classifications	between	groups	(p=0.92)	with	66%	of	the	sample	classified	as	obese	(control:	88%;	NAFLD:	58%).	Self-	(or	parent/carer)	 reported	 ethnicity	 varied	 between	 groups	 with	 predominantly	White	British	participants	in	the	NAFLD	group	(79%)	and	Black	British	children	in	the	obese	group	(75%).		 	
Figure	2.1:	Participant	flow	diagram	for	the	case-control	study	
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Table	2.1:	Population	characteristics	of	NAFLD	and	obese	control	groups	
Characteristics	1	 Unit	 NAFLD	(n	=	24)	 Control	(n	=	8)	 p-Value	2	
Gender	 n	(%)	 Females	12	(50)	 Females	5	(62.5)	 0.69	a	
Males	12	(50)	 Males	3	(37.5)	
Ethnicity	 n	(%)	 Black	British	0	(0)	 Black	British	6	(75)	 <0.001	a	
White	19	(79)	 White	2	(25)	
Asian	5	(21)	 Asian	0	(0)	
Weight	classification	 n	(%)	 Healthy	Weight	Range	1	(4)	 Health	Weight	Range	0	(0)	 0.92	a	
Overweight	4	(17)	 Overweight	1	(12.5)	
Obese	6	(25)	 Obese	2	(25)	
Extremely	Obese	13	(54)	 Extremely	Obese	5	(62.5)	
Age	 years	 13.5	(12.0,15.0)	 12.0	(9.5,16.5)	 0.60	
Weight	 kg	 83.3	(71.2,105.0)	 86.4	(77.2,136.5)	 0.27	
Height	 cm	 163.1	(159.1,170.9)	 161.6	(148.1,173.7)	 0.62	
BMI	 kg/m2	 31.1	(27.1,36.5)	 38.5	(30.8,44.1)	 0.05	
BMI	centile	 -	 99.3	(98.0,99.6)	 99.6	(98.0,99.6)	 0.88	
BMI	z-score	 -	 2.2	(1.9,2.3)	 2.6	(2.4,2.7)	 0.002	
Waist	circumference	 cm	 101.0	(97.5,112.0)	 113.0	(95.0,133.0)	 0.31	
Triceps	skinfold	 mm	 30.5	(23.6,34.5)	 37.0	(32.2,43.6)	 0.08	
MUAC	 cm	 32.0	(30.0,36.4)	 34.5	(29.1,34.5)	 0.62		1	Characteristic	 is	 expressed	as	median	 (1st	quartile,	3rd	quartile)	unless	otherwise	 specified.	 2	P-value	derived	from	Mann-Whitney	Test	unless	otherwise	specified;	a	Fisher’s	exact	test.	p<0.05	is	considered	statistically	significant.	BMI:	Body	Mass	Index,	MUAC:	Mid	Upper	Arm	Circumference		
2.3.2	Dietary	Intakes		 Differences	 in	 macro-	 and	 micronutrient	 intakes,	 expressed	 either	 as	absolute	intake	or	as	a	proportion	of	DRV	are	outlined	in	Table	2.2	and	2.3.	Data	from	the	7-day	food	diaries	suggested	that	controls	had	higher	absolute	median	intakes	of	most	nutrients	analysed	when	compared	to	UK	children	with	NAFLD,	with	the	exception	of	protein	(expressed	as	kg/body	weight	(BW)),	copper	and	folate	 (Table	 2.2).	 Conversely,	 24-hour	 recall	 data	 indicated	 that	 participants	with	NAFLD	had	higher	median	absolute	intake	of	most	nutrients	analysed,	with	the	exception	of	vitamin	E.	 In	particular,	 the	24-hour	 recall	data	 indicated	 that	children	 with	 NAFLD	 had	 comparatively	 higher	 intakes	 of	 protein,	 SFA,	potassium,	iron,	copper,	zinc	and	vitamin	B12	when	compared	to	the	controls.			 Overall,	 both	 cases	 and	 controls	 had	 high	 intakes	 of	 protein,	 sodium,	vitamin	B12	and	vitamin	C;	consuming	well	above	the	DRVs	for	these	nutrients	
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(Table	 2.3).	 However,	 in	 general	 participants	 in	 both	 groups	 did	 not	meet	 the	DRV	for	most	nutrients.	Assessment	of	 the	7-day	 food	diary	and	24-hour	recall	data	indicated	that	both	the	cases	and	controls	consistently	reported	intakes	of	MUFA,	PUFA,	potassium,	calcium,	iron,	zinc	and	folate	below	their	DRVs.			 However,	after	correction	for	multiple	hypotheses	testing,	there	were	no	significant	 differences	 in	macro-	 and	micronutrient	 intakes	 between	 cases	 and	controls	(p>0.001)	as	expressed	as	absolute	intake	or	a	proportion	of	DRV.	There	continued	to	be	no	difference	between	groups	after	controlling	for	differences	in	BMI	z-score	(p>0.0009).		Both	 the	 cases	 and	 controls	 exceeded	 the	 recommended	 percentage	 of	energy	 derived	 from	 saturated	 fat,	 protein	 and	 carbohydrate	 and	 received	 an	insufficient	proportion	of	energy	from	PUFA	and	MUFA	(Table	2.4).	Both	groups	met	 the	 recommendations	 for	 total	 fat	 intake	 and	 non-milk	 extrinsic	 sugar	(NMES),	 deriving	 less	 than	35%	of	 their	 energy	 from	 fat	 and	 less	 than	11%	of	energy	 from	NMES.	 There	were	 no	 significant	 differences	 in	 the	 percentage	 of	energy	derived	from	macronutrients	between	groups,	including	after	controlling	for	differences	in	BMI	Z-score	(p>0.007).		 Under-reporting	was	prevalent	 in	both	groups	with	58%	of	participants	with	NAFLD	and	85%	of	children	with	obesity	under-reporting	dietary	 intakes,	as	assessed	by	24-hour	recall.	Additionally,	75%	of	participants	with	NAFLD	and	87%	of	children	with	obesity	were	deemed	to	have	under-reported	their	dietary	intakes	using	the	7-day	food	diary.	However,	the	number	of	under-reporters	did	not	significantly	differ	between	groups	when	assessed	using	either	the	24-hour	dietary	recall	(p=0.37)	or	the	7-day	food	diary	(p=0.15).	
2.3.3	Eating	Styles	Eating	 styles	 did	 not	 differ	 statistically	 between	 groups	 when	 the	unadjusted	DEBQ	scores	were	analysed	(p>0.05).	However,	after	controlling	for	differences	 in	 BMI	 z-score,	 responses	 to	 the	 DEBQ	 indicated	 that	 restrained	eating	 behaviours	 were	 significantly	 higher	 in	 the	 NAFLD	 group	 (p=0.005)	(Figure	2.2).	Participants	with	NAFLD	reported	comparatively	higher	scores	for	external	(p=0.112)	and	emotional	eating	behaviours	(p=0.068).	
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Table	2.2:	N
utritional	intakes	recorded	via	participant	com
pleted	7-day	food	diary	or	24-hour	recall	expressed	as	absolute	intakes	
1Data	are	unadjusted	and	are	expressed	as	median	(1
st	quartile,	3
rd	quartile).	 2	P-values	from	Mann-Whitney	Test.	Following	Bonferroni	correction,	
p<0.0009	is	considered	statistically	significant.	MUFA:		Monounsaturated	Fatty	Acids;	NSP:	non-starch	polysaccharide,	NMES:	Non-milk	extrinsic	sugars;	
PUFA:	Polyunsaturated	Fatty	Acids;	SFA:	Saturated	Fatty	Acids.	
 	
	
	
N
utrient 1	
N
utritional	intake	as	per	7-day	food	diary	
N
utritional	intake	as	per	24-hour	recall	
N
AFLD
	(n=24)	
							Control	(n=8)	
p-Value
2	
N
AFLD
	(n=24)	
		Control	(n=7)	
p-Value
2	
Energy	(kcal)	
1755		
(1302,2104)	
1894	
(1655,2219)	
0.54	1765	
(1084,2140)	1100	
(858,1734)	
0.11	
Protein	(g)	
66.0	
(55.2,83.1)	
74.8	
(63.9,94.1)	
0.32	66.6	
(53.0,85.5)	
32.8	
(23.7,58.1)	
0.01	
Total	Fat	(g)	
66.7		
(38.8,77.7)	
77.9	
(51.2,90.6)	
0.29	74.1	
(41.8,91.7)	
43.6	
(40.4,54.5)	
0.09	
SFA	(g)	
23.9		
(12.5,30.9)	
26.7	
(20.5,35.2)	
0.45	24.0	
(12.6,38.5)	
14.4	
(9.2,15.7)	
0.04	
MUFA	(g)	
22.4		
(12.4,25.4)	
25.5	
(16.7,30.8)	
0.25	17.0	
(10.6,30.5)	
15.1	
(14.7,16.2)	
0.20	
PUFA	(g)	
9.5		
(6.25,13.1)	
11.7	
(7.0,16.75)	
0.27	6.7	
(5.43,16.1)	
9.1	
(8.2,10.5)	
0.42	
Carbohydrate	(g)	
220.8		
(161.2,272.9)	
246.1	
(228.9,279.1)	
0.26	196.5	
(133.7,306.0)	151.4	
(116.8,215.6)	
0.26	
Sodium	(g)	
2.3		
(1.8,3.0)	
2.7	
(1.7,2.9)	
0.99	2.5	
(1.4,3.7)	
1.7	
(1.3,2.0)	
0.12	
Potassium	(g)	
2.2		
(1.6,2.8)	
2.5	
(2.0,3.2)	
0.34	2.3	
(1.6,3.0)	
1.6	
(1.6,1.9)	
0.06	
Calcium	(mg)	
0.6		
(0.5,1.0)	
0.6	
(0.5,0.7)	
0.95	0.6	
(0.3,0.9)	
0.4	
(0.3,0.5)	
0.22	
Iron	(mg)	
8.7		
(6.1,10.9)	
8.7	
(8.1,9.0)	
0.79	7.5	
(6.0,9.8)	
5.7	
(5.4,6.1)	
0.02	
Copper	(mg)	
1.0		
(0.6,1,1)	
0.9	
(0.8,1.0)	
0.54	0.8	
(0.5,1.25)	
0.5	
(0.4,0.7)	
0.04	
Zinc	(mg)	
7.0		
(5.5,8.8)	
7.7	
(5.9,8.4)	
0.63	5.9	
(4.63,8.7)	
3.0	
(2.3,5.1)	
0.01	
Vitamin	E	(mg)	
6.1		
(4.6,8.0)	
7.1	
(4.9,10.9)	
0.34	4.0	
(3.1,6.9)	
6.2	
(5.2,7.8)	
0.24	
Vitamin	B12	(μg)	
3.1		
(2.0,4.4)	
2.9	
(1.5,5.7)	
0.88	2.2	
(1.3,5.6)	
0.8	
(0.6,1.9)	
0.05	
Folate	(μg)	
174.0		
(121.2,213.2)	
164.5	
(141.5,201.7)	
0.73	138.0	
(104.2,190.7)	93.0	
(76.0,147.0)	
0.14	
Vitamin	C	(mg)	
65.5		
(29.5,106.7)	
69.5	
(56.0,201.7)	
0.60	59.0	
(40.2,114.2)	
33.0	
(22.0,78.0)	
0.30	
Sugar	(g)	
87.5		
(49.5,107.1)	
93.0		
(82.2,102.9)	
0.49	63.5	
(44.9,125.0)	
49.9	
(22.8,80.1)	
0.24	
NMES	(g)	
15.6		
(5.1,25.0)	
20.8	
(11.4,28.7)	
0.46	16.0	
(2.0,36.6)	
9.8		
(0.0,21.4)	
0.32	
Fructose	(g)	
12.7 		
(8.9,18.4)	
16.7	
(10.9,19.4)	
0.62	12.5	
(6.3,20.2)	
9.1	
(2.1,19.4)	
0.38	
NSP	(g)	
10.7		
(8.2,13.1)	
10.1	
(6.3,12.3)	
0.41	8.7	
(7.0,11.3)	
4.1	
(4.0,10.9)	
0.14	
Carotene	(g)	
1.9		
(0.7,3.1)	
3.0	
(0.6,5.8)	
0.32	1.0	
(0.2,2.3)	
0.4	
(0.04,1.3)	
0.22	
Vitamin	D	(μg)	
1.7		
(1.3,2.2)	
3.5	
(1.0,4.4)	
0.01	1.8	
(1.2,3.6)	
1.9	
(0.3,2.9)	
0.45	
Omega-3	fatty	acids	(g)	0.5		
(0.3,0.9)	
0.5	
(0.15,1.4)	
0.91	0.5	
(0.2,0.8)	
0.3	
(0.2,0.4)	
0.59	
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Table	2.3:	N
utritional	intakes	recorded	via	participant	com
pleted	7-day	food	diary	or	24-hour	recall	expressed	as	%
	D
RV		
	N
utrient 1	
N
utritional	intake	as	per	7-day	food	diary	
N
utritional	intake	as	per	24-hour	recall	
			N
AFLD
	(n=24)	
				Control	(n=8)	
p-Value
2	
N
AFLD
	(n=24)	
Control	(n=7)	
p-Value
2	
Energy	(%)	
77.4			
(67.0,101.2)	
86.0	
(74.4,114.1)	
0.41	
84.7		
(56.3,101.7)	
52.1	
(43.6,93.6)	
0.10	
Protein	(%)	
153.6		
(120.2,199.5)	
169.2		
(146.7,233.5)	0.26	
148.6		
(113.8,215.4)	104.9	
(59.4,129.1)	
0.02	
Fat	(%)	
82.7	
(50.1,105.6)	
91.7		
(67.1,118.4)	
0.28	
77.0		
(47.3,105.0)	
60.7	
(39.8,66.5)	
0.13	
SFA	(%)	
97.4	
(50.3,127.2)	
108.3		
(85.7,139.4)	
0.36	
93.6		
(56.7,138.5)	
61.5	
(35.7,73.2)	
0.05	
MUFA	(%)	
79.5	
(40.6,92.7)	
89.7		
(58.5,107.5)	
0.30	
61.9		
(40.7,102.5)	
53.0		
(44.1,60.6)	
0.35	
PUFA	(%)	
67.0	
(46.6,84.7)	
82.0		
(51.4,118.5)	
0.34	
44.0		
(33.4,93.4)	
57.9		
(56.0,83.3)	
0.17	
Carbohydrate	(%)	
73.0	
(56.0,95.2)	
87.3		
(65.4,95.3)	
0.51	
60.2		
(44.8,85.2)	
51.0	
(39.3,83.4)	
0.45	
Sodium	(%)	
156.3	
(110.9,201.4)	
167.9		
(106.2,199.3)	0.86	
154.1		
(91.2,232.0)	
109.8		
(86.1,131.1)	
0.16	
Potassium	(%)	
75.9	
(50.5,90.8)	
75.8	
(63.2,97.7)	
0.32	
73.3		
(51.9,97.23)	
52.5		
(45.3,78.7)	
0.08	
Calcium	(%)	
81.5	
(51.1,114.6)	
79.1		
(72.5,106.3)	
0.79	
74.0		
(32.9,110.8)	
57.8		
(43.7,77.6)	
0.48	
Iron	(%)	
61.4	
(48.5,89.7)	
72.5		
(59.8,91.4)	
0.40	
63.0		
(44.5,79.4)	
43.4		
(39.3,49.1)	
0.05	
Copper	(%)	
100.5	
(78.2,148.2)	
114.1		
(99.7,114.1)	
0.41	
89.4		
(62.5,153.9)	
58.8		
(52.0,75.0)	
0.04	
Zinc	(%)	
78.5	
(61.0,118.3)	
84.4		
(78.4,112.9)	
0.43	
62.4	
(51.4,103.7)	
34.3		
(33.3,56.6)	
0.01	
Vitamin	E	(%)	
101.0	
(63.7,147.5)	
120.4		
(86.0,186.2)	
0.61	
67.5		
(40.6,116.1)	
109.6		
(84.2,155.4)	
0.30	
Vitamin	B12	(%)	
258.3	
(167.7,330.5)	
250.0		
(139.3,545.4)	0.76	
185.0		
(115.3,489.2)	127.5	
(55.3,190.0)	
0.09	
Folate	(%)	
88.0	
(60.6,116.2)	
91.6		
(81.3,100.8)	
0.60	
67.7		
(48.2,95.5)	
50.6		
(46.5,77.0)	
0.32	
Vitamin	C	(%)	
187.1	
(77.2,302.0)	
211.2		
(151.6,312.4)	0.43	
181.0		
(115.5,331.4)	82.5		
(55.0,260.0)	
0.19	
1Data	are	unadjusted	and	are	expressed	as	DRV	%	median	(1
st	quartile,	3
rd	quartile).	 2	P-values	from	Mann-Whitney	Test.	Following	Bonferroni	correction,	
p<0.001	is	considered	statistically	significant.	DRV:	Dietary	Reference	Value;	MUFA:		Monounsaturated	Fatty	Acids;	PUFA:	Polyunsaturated	Fatty	Acids;	
SFA:	Saturated	Fatty	Acids.	
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Table	 2.4:	Percentage	 of	 energy	 derived	 from	 macronutrients	 recorded	 via	 participant	
completed	7-day	food	diary	
Nutrients	
Contributing	 to	
Energy	Intake1		
Recommended	
Daily	 Allowance	
(%)2		
NAFLD	(n=24)	 Control	(n=8)	 p-Value3	
Carbohydrate	 50	 49.6		 (43.6,53.7)	 46.9	 (44.0,49.7)	 0.56								NMES	 11	 3.7	 (1.2,3.7)	 4.2	 (1.9,6.4)	 0.83	Protein		 15	 16.2	 (14.4,18.0)	 16.3	 (15.9,16.9)	 0.78	Total	Fat	 <	35	 33.2	 (28.3,38.7)	 34.6		 (32.6,36.7)	 0.71								SFA	 <	11	 11.8		 (8.8,13.7)	 12.4		 (11.4,13.0)	 0.31								MUFA	 13	 10.6		 (8.9,13.6)	 12.0		 (8.8,12.8)	 0.69								PUFA	 6.5	 4.9		 (4.3,6.2)	 4.9		 (4.1,6.8)	 0.92	Alcohol	 0	 0.0		 (0,0)	 0.0		 (0,0)	 -	1	Data	are	unadjusted	and	are	expressed	as	median	 (1st	Quartile,	3rd	Quartile).	 	 2	Recommended	daily	allowanced	from	dietary	reference	values	(DoH	1991).	3	p-values	from	Mann-Whitney	Test.	Following	 Bonferroni	 Correction,	 p<0.007	 is	 considered	 statistically	 significant.	 MUFA:		Monounsaturated	 Fatty	 Acids;	 NMES:	 Non-milk	 extrinsic	 sugars;	 PUFA:	 Polyunsaturated	 Fatty	Acids;	SFA:	Saturated	Fatty	Acids.	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 2.2:	 Eating	 styles	 in	 NAFLD	 and	 obese	 children	 as	 assessed	 by	 Dutch	 Eating	
Behaviour	Questionnaires.	Data	adjusted	for	differences	in	BMI	Z-score	using	ANCOVA	and	are	expressed	as	estimated	marginal	mean	+	standard	error	of	the	mean	(SEM).	p<0.05	is	considered	statistically	significant.	NAFLD	(n=23)	Obese	Control	(n=8).		 	
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2.3.4	Food	Based	Analysis		 After	analysis	of	food	groups	between	NAFLD	and	obese	controls,	no	food	groups	 showed	 any	 significant	 differences	 between	 NAFLD	 cases	 and	 obese	controls	(Table	2.5).		Quality	of	dietary	intakes	were	assessed	by	quantifying	the	mean	daily	portions	of	food	groups	compared	to	healthy	eating	guidelines	(PHE	2016)	 (Figure	 2.3).	 	 Both	 NAFLD	 and	 control	 groups	 failed	 to	 meet	 the	recommended	 five	 portions	 of	 fruit	 and	 vegetables	 a	 day	 (2.25	 versus	 2.02	portions	 per	 day	 respectively;	p=0.65).	 	 Additionally,	 both	NAFLD	 and	 Control	children	did	not	meet	the	weekly	guideline	of	two	portions	of	fish	per	week	(1.05	versus	 1.77	 portions	 per	 week	 respectively;	 p=0.51).	 	 Only	 a	 minority	 within	both	groups,	29%	(n=6)	of	the	NAFLD	children	and	38%	(n=3)	of	obese	controls,	did	reach	the	recommended	two	portions	of	fish	a	week.			
	
Table	2.5:	Dietary	 intakes	of	 food	groups	recorded	via	participant	completed	7-day	 food	
diary		
Food	Group	 NAFLD	(n=21)	 Control	(n=8)	 p-value1	
Fruit	 	 	 	Citrus	 0.48	±	0.2	 0.50	±	0.3	 0.95	Berries	 0.76	±	0.3	 0.50	±	0.4	 0.61	Tropical	 0.14	±	0.1	 0.00	±	0.0	 0.41	Banana	 1.10	±	0.3	 1.50	±	1.0	 0.59	Temperate	 2.38	±	0.5	 1.88	±	0.7	 0.59	Dried	 0.48	±	0.3	 0.00	±	0.0	 0.30	
Vegetables	 	 	 	Salad	Vegetables	 3.38	±	0.6	 2.88	±	0.9	 0.67	Leaf	Vegetables	 1.76	±	0.4	 2.00	±	0.4	 0.73	Root	vegetables	 3.48	±	0.6	 3.13	±	0.8	 0.74	Tubers	 2.91	±	0.3	 1.50	±	0.3	 0.02	Pulses	 1.81	±	0.4	 1.75	±	0.6	 0.93	
Fish	 	 	 	Oily	Fish	 0.29	±	0.1	 0.13	±	0.1	 0.46	White	Fish	 0.57	±	0.2	 1.38	±	0.7	 0.15	Seafood	 0.19	±	0.1	 0.00	±	0.0	 0.44	White	Fish	Products	 0.71	±	0.2	 0.50	±	0.3	 0.57	Oily	Fish	Products	 0.10	±	0.1	 0.00	±	0.0	 0.38	
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Meat	and	Poultry	 	 	 	Red	Meat	 2.67	±	0.4	 2.00	±	0.7	 0.41	Poultry	 2.14	±	0.4	 4.38	±	1.3	 0.03	Poultry	Meat	Products	 1.33	±	0.3	 0.88	±	0.5	 0.44	Red	Meat	Products	 2.29	±	0.6	 2.75	±	0.9	 0.69	
Eggs	 	 	 	Eggs	 1.57	±	0.4	 1.88	±	0.9	 0.72	Fried	Eggs	 0.38	±	0.2	 0.38	±	0.3	 0.99	
Fats	 	 	 	Butter	 1.91	±	0.8	 2.88	±	0.7	 0.47	Margarine	 1.24	±	0.4	 0.25	±	0.3	 0.14	Cooking	Oils	 1.76	±	0.6	 2.00	±	0.6	 0.83	
Milk	 	 	 	Whole	Milk	 0.29	±	0.1	 0.50	±	0.5	 0.56	Reduced	Fat	Milk	 3.57	±	0.8	 4.88	±	3.9	 0.63	Flavoured	Milk	 0.24	±	0.1	 0.00	±	0.0	 0.23	
Yoghurt	 	 	 	Standard	Yoghurt	 1.14	±	0.5	 1.75	±	1.0	 0.55	Low	Fat	Yoghurt	 0.29	±	0.1	 0.25	±	0.3	 0.90	Luxury	Yoghurt	 0.14	±	0.1	 0.25	±	0.2	 0.51	
Cheese	 	 	 	Hard	Cheese	 2.69	±	0.5	 1.75	±	0.7	 0.34	Reduced	Fat	Cheese	 0.62	±	0.3	 0.00	±	0.0	 0.19	Soft	Cheese	 0.24	±	0.2	 0.00	±	0.0	 0.46	Reduced	Fat	Soft	Cheese	 0.05	±	0.0	 0.00	±	0.0	 0.55	
Bread	 	 	 	White	Bread	 5.33	±	1.4	 7.13	±	2.1	 0.50	Wholemeal	Bread	 3.05	±	1.1	 1.25	±	0.6	 0.34	50:50	Bread	 3.10	±	1.4	 2.63	±	1.3	 0.85	Bread	Products	 4.57	±	1.0	 1.25	±	0.8	 0.06	
Breakfast	Cereals	 	 	 	High	Sugar	Cereals	(>22.5g/100g)	 0.76	±	0.3	 0.88	±	0.5	 0.85	Medium	Sugar	Cereals	(5-22.5g/100g)	 0.90	±	0.3	 0.25	±	0.3	 0.26	Low	Sugar	Cereals	(<5g/100g)	 1.52	±	0.5	 0.50	±0.3	 0.24	
Pasta	and	Grains	 	 	 	White	Pasta	 1.24	±	0.2	 1.25	±	0.5	 0.98	Wholegrain	Pasta	 0.29	±	0.2	 0.13	±	0.1	 0.63	White	Rice	 1.19	±	0.3	 3.25	±	0.8	 0.01	Brown	Rice	 0.05	±	0.0	 0.00	±	0.0	 0.55	
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Noodles	 0.29	±	0.1	 1.00	±	0.8	 0.15	
Snack	Foods	 	 	 	Chocolate	 1.48	±	0.4	 0.88	±	0.4	 0.43	Ice	Cream	 0.81	±	0.3	 2.13	±	1.4	 0.17	Biscuits	 4.00	±	1.1	 9.00	±	6.5	 0.25	Cakes	 1.71	±	0.4	 3.38	±	1.0	 0.06	Crisps	 2.86	±	0.5	 3.38	±	2.5	 0.77	Crackers	 0.71	±	0.3	 0.13	±	0.1	 0.17	Plain	Nuts	 0.29	±	0.2	 0.00	±	0.0	 0.38	Salted	Nuts	 0.00	±	0.0	 0.00	±	0.0	 	Popcorn	 0.10	±	0.1	 0.00	±	0.0	 0.38	
Fast	Food	 	 	 	Burger	 0.33	±	0.2	 0.38	±	0.3	 0.89	Chips	 1.19	±	0.3	 1.13	±	0.4	 0.92	Chicken	Nuggets	 0.43	±	0.2	 0.13	±	0.1	 0.32	Pizza	 0.86	±	0.2	 0.88	±	0.5	 0.97	
Beverages	 	 	 	Carbonated	Sugar	Sweetened	Beverages	 3.38	±	1.5	 5.38	±	3.7	 0.55	Artificially	Sweetened	Beverages	 6.05	±	2.1	 2.25	±	1.3	 0.28	Sweetened	Squash/Water	 1.24	±	0.4	 0.25	±	0.3	 0.15	Fruit	Juice	 2.43	±	0.6	 4.13	±	1.6	 0.22	
Condiments	 	 	 	Mayonnaise	 0.86	±	0.3	 0.75	±	0.3	 0.82	Ketchup	 0.52	±	0.2	 0.13	±	0.1	 0.28	Salad	Dressing	 0.05	±	0.0	 0.13	±	0.1	 0.48	Jam	 0.29	±	0.1	 0.00	±	0.0	 0.23	Marmalade	 0.10	±	0.1	 0.88	±	0.9	 0.16	Sugar	 2.38	±	1.1	 1.00	±	0.6	 0.48		Data	are	expressed	as	mean	number	of	portions	a	week	±	SEM.	 	 1P-values	derived	 from	Mann-Whitney	Test.		Following	Bonferroni	correction,	p<0.001	is	considered	statistically	significant.								
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Figure	2.3:	Average	intake	of	fruit	and	vegetable	per	day	(A)	and	average	intake	of	fish	per	week	(B).	Data	are	plotted	as	individual	values	with	mean	±	SEM.	P-values	derived	from	Mann-Whitney	tests;	p<0.05	is	considered	statistically	significant.	NAFLD	(n=21)	Obese	Control	(n=8).	
2.3.5	Physical	Activity	Levels		 Physical	 activity	 levels,	 assessed	 using	 both	 the	 7-day	 diary	 and	 PAQ,	indicated	that	participants	spent	a	large	proportion	of	their	time	sedentary	with	minimal	vigorous	activity	(Figure	2.4).	Twenty-five	percent	of	participants	in	the	NAFLD	 group	 reported	 meeting	 the	 UK	 physical	 activity	 requirements	 of	 60	minutes	of	moderate	to	vigorous	activity	per	day	(DoH	2011),	using	the	physical	activity	 levels	 recorded	 in	 the	 7-day	 activity	 diary.	 In	 contrast,	 none	 of	 the	children	with	obesity	met	these	guidelines.			 The	 7-day	 activity	 diary	 indicated	 there	were	 no	 significant	 differences	between	 groups	 in	 the	 amount	 of	 time	 spent	 undertaking	 sedentary,	 light,	moderate	or	vigorous	activity	when	assessed	as	a	7-day	average	or	the	weekend	and	weekday	averages	 separately	 (Table	2.6;	 Figure	2.4).	 	These	 findings	were	confirmed	with	the	PAQ	which	indicated	that	over	a	7-day	period	there	were	no	significant	 differences	 in	 the	 amount	 of	 time	 spent	 undertaking	 sedentary	(p=0.17),	 light	 (p=0.39),	 moderate	 (p=0.51)	 or	 vigorous	 (p=0.68)	 intensity	activity	 between	 groups	 (Figure	 2.5).	 There	 continued	 to	 be	 no	 statistical	differences	 in	 physical	 activity	 levels	 between	 groups	 after	 controlling	 for	differences	in	BMI	z-score	(p>0.05).		
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Table	2.6:	Physical	Activity	Levels		Physical	Activity	Levels1	[%	per	day]	 		NAFLD	[n=22-24]	 		Control	[n=8]	 p-Value2	Sedentary		(MET	1.0-1.5)	 7-day	Average	 						25	 (16,32)	 						20	 (13,28)	 0.43	Weekday	Average	 						22	 (16,30)	 						23	 (16,31)	 0.95	Weekend	Average	 						29		 (6,36)	 						16	 (10,22)	 0.22	Light		(MET	1.6-2.9)	 7-day	Average	 						18	 (9,23)	 						13	 (5,26)	 0.73	Weekday	Average	 						25	 (11,28)	 						16	 (6,31)	 0.41	Weekend	Average	 						6	 (1,14)	 						8	 (3,13)	 0.71	Moderate		(MET	3.0-5.9)	 7-day	Average	 						5	 (3,7)	 						3	 (3,4)	 0.31	Weekday	Average	 						5	 (3,7)	 						2	 (1,4)	 0.06	Weekend	Average	 						4	 (1,8)	 						7	 (5,11)	 0.13	Vigorous		(MET	>6)	 7-day	Average	 						2	 (0,3)	 						1	 (0,2)	 0.28	Weekday	Average	 						2	 (0,4)	 						1	 (0,2)	 0.19	Weekend	Average	 						0	 (0,3)	 						0	 (0,1)	 0.48	Sleep	 7-day	Average	 						40	 (38,43)	 						42	 (38,46)	 0.33	(MET	0.9)	 Weekday	Average	 						39	 (36,42)	 						41	 (37,41)	 0.32		 Weekend	Average	 						44	 (42,46)	 						45	 (39,45)	 0.62	Unaccounted		 7-day	Average	 						7	 (7,22)	 						19	 (5,32)	 0.15	Weekday	Average	 						5	 (5,10)	 						22	 (5,30)	 0.08	Weekend	Average	 						6	 (0,21)	 						20	 (9,28)	 0.16	1	 Data	 expressed	 as	 amount	 of	 time	 (%)	 per	 day	 recorded	 using	 7-day	 activity	 diary	 and	 are	unadjusted	and	are	expressed	as	median	(1st	quartile,	3rd	quartile).	2	p-values	from	Mann-Whitney	Test.	p<0.05	is	considered	statistically	significant.	MET:	Metabolic	Equivalent	of	Task	 	
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Figure	2.4:	Physical	activity	 levels	expressed	as	amount	of	 time	during	day	 (%).	Data	are	calculated	using	7-day	average	from	the	PAQ.		Data	are	adjusted	and	expressed	as	median	+	IQR.	
p<0.05	is	considered	statistically	significant.		NAFLD	(n=24)	Obese	control	(n=8).		
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 2.5:	Physical	 activity	 levels	 expressed	 as	 amount	 of	 time	 per	 week	 (%).	Data	 are	calculated	 using	 the	 Youth	 or	 Children’s	 Physical	 Activity	 Questionnaire.	 Data	 are	 unadjusted.	
p<0.05	is	considered	statistically	significant.	NAFLD	(n=16)	Obese	Control	(n=8).	
 	 In	 addition	 to	 the	 physical	 activity	 diary,	 participants	 recorded	 step	counts	using	a	pedometer.	On	average,	 the	NAFLD	group	 took	more	steps	 than	the	 children	 with	 obesity	 in	 total	 (p=0.013;	 Figure	 2.6)	 and	 during	 weekdays	
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(p=0.048;	Figure	2.6).	There	was	no	significant	difference	between	the	number	of	steps	taken	on	a	weekday	and	a	weekend	days	in	the	NAFLD	group	(p=0.071)	or	the	obese	groups	(p=0.063).	None	of	the	controls	exceeded	an	average	of	10,000	steps,	 which	 is	 the	 estimated	 number	 of	 steps	 required	 to	 meet	 the	 physical	activity	guidelines	(Adams,	Caparosa	et	al.	2009).	Only	a	third	of	cases	exceeded	this	recommendation.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 2.6:	 Physical	 activity	 levels	 based	 on	 recorded	 step	 counts.	 Average	 steps	 were	recorded	using	a	pedometer	during	participant	completed	7-day	physical	activity	diary.	Data	are	unadjusted	 and	 expressed	 as	 median	 +	 IQR.	 P-values	 from	 Mann-Whitney	 Test.	 p<0.05	 is	considered	 statistically	 significant.	 NAFLD	 (n=22-23)	 Obese	 Control	 (n=6-8).	 Dashed	 line	represents	 10,000	 steps;	 minimum	 number	 of	 steps	 required	 by	 adolescence	 to	 meet	 60	minutes/day	 moderate-to-vigorous	 physical	 activity	 recommendation	 (Adams,	 Caparosa	 et	 al.	2009).						
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2.4	Discussion	 	 	 						 	 	 		 With	 the	 aim	 of	 identifying	 dietary	 and	 physical	 activity	 patterns	 that	may	 be	associated	with	NAFLD	pathogenesis,	this	study	examined	differences	in	anthropometry,	macro-	 and	micronutrient	 intakes,	 eating	behaviours	 and	physical	 activity	patterns	of	UK	children	with	NAFLD	and	obese	children	without	liver	disease.	
2.4.1	Participant	Demographics		 Overall,	 groups	were	well	matched	 for	 age	 and	 gender.	 Participant	 age	 ranged	from	8	to	18	years	of	age;	with	median	age	being	13.5	years	for	children	with	NAFLD.	A	median	age	above	10	years	was	expected	as	NAFLD	risk	 increases	during	adolescence	secondary	to	hormonal	changes	promoting	deposition	of	adipose	tissue	(Roberts	2007)	and	increased	IR	during	puberty	(Potau,	Ibañez	et	al.	1997).	Furthermore,	adolescents	have	 greater	 control	 over	 their	 behaviour	 and	 food	 choices,	 which	 may	 lead	 to	unhealthy	dietary	choices	and	physical	inactivity	(Roberts	2007).			 A	 significant	 association	 between	 groups	 and	 self-reported	 ethnicity	 was	identified,	 with	 children	with	 NAFLD	 identifying	 as	 predominantly	White	 British	 and	controls	 predominantly	 being	 Black	 British	 of	 Caribbean	 or	 African	 descent.	 Ethnic	variation	in	NAFLD	prevalence	has	previously	been	established,	with	studies	in	the	USA	noting	 higher	 prevalence	 of	 NAFLD	 amongst	 Hispanics,	 followed	 by	white	 European-Americans,	 and	 the	 lowest	 disease	 prevalence	 observed	 in	 black	 African-Americans	(Browning,	 Szczepaniak	 et	 al.	 2004).	 This	 ethnic	 variation	 has	 been	 associated	 with	allelic	 variants	 of	 the	 PNPLA3	 genes	 with	 the	 PNPLA3	 rs738409	 (G)	 allele	 (Romeo,	Kozlitina	et	al.	2008).	Given	 that	 the	majority	of	participants	with	NAFLD	were	White	British,	compared	to	a	majority	of	Black	British	children	in	the	control	group,	it	would	be	interesting	to	explore	whether	a	higher	prevalence	of	PNPLA3	rs738409	(G)	exists	in	this	NAFLD	cohort.	
2.4.2	Anthropometrics	Anthropometric	measurements	were	similar	between	groups	with	the	exception	of	BMI	z-score	and	BMI	centile	being	higher	in	the	obese	control	group.	Considering	that	accumulation	of	visceral	fat	has	been	implicated	in	the	development	and	progression	of	NAFLD	 in	 both	 adults	 and	 children	 (Denzer,	 Thiere	 et	 al.	 2009,	 Eguchi,	 Mizuta	 et	 al.	2010,	Mager,	Yap	et	al.	2012),	it	was	hypothesised	that	waist	circumference,	a	common	
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measure	 of	 visceral	 fat	 (Jakobsen,	 Berentzen	 et	 al.	 2007)	 ,	 would	 be	 higher	 amongst	participants	with	NAFLD.	However,	waist	circumference	and	waist-height	ratio,	another	useful	surrogate	measure	of	abdominal	obesity	(McCarthy	and	Ashwell	2006),	did	not	statistically	differ	between	groups.	It	is	important	to	note	that	waist	circumference	does	not	 distinguish	 between	 visceral	 organs,	 subcutaneous	 abdominal	 fat	 and	 intra-abdominal	fat	(Jakobsen,	Berentzen	et	al.	2007)	.		Notably,	studies	have	shown	that	high	levels	 of	 intra-abdominal	 fat	 may	 be	 a	 greater	 determinant	 of	 IR	 and	 NAFLD	 risk	 in	paediatric	 populations	 (Silveira,	 Monteiro	 et	 al.	 2013,	 Monteiro,	 de	 Moura	 Mello	Antunes	et	al.	2014).	Consequently,	further	assessment	of	distribution	of	adipose	tissue,	using	 techniques	 such	 as	 dual-energy	 X-ray	 absorptiometry	 (Silveira,	 Monteiro	 et	 al.	2013,	Monteiro,	de	Moura	Mello	Antunes	et	al.	2014),	may	have	provided	 insight	 into	whether	body	composition	was	associated	risk	of	NAFLD	development	in	this	cohort.			 Nevertheless,	 the	 median	 waist	 circumference	 of	 the	 children	 enrolled	 in	 this	study	in	both	groups	exceeded	the	World	Health	Organisation	(WHO)	recommendations	for	adults	(WHO	2011).	Furthermore,	median	weight-height	ratio	exceeded	0.5,	which	McCarthy	et	al.	(McCarthy	and	Ashwell	2006)	found	to	be	associated	with	increased	risk	of	childhood	morbidity	in	UK	children.	Consequently,	reducing	waist	circumference	and	waist-height	 ratio,	 using	 targeted	 strategies	 such	 as	 increasing	 moderate-vigorous	activity	 and	 decreasing	 sedentary	 activity	 (Stamatakis,	 Hirani	 et	 al.	 2009),	 should	remain	a	priority	of	clinical	management	in	this	population.			 Certain	 anthropometric	 measurements	 have	 been	 found	 to	 be	 positively	correlated	 with	 NAFLD	 severity	 and	 fibrosis	 risk.	 Measures	 of	 upper	 extremities,	including	MUAC	and	triceps	skinfold,	have	been	shown	to	be	positively	correlated	with	fibrosis	 in	 adult	 NAFLD	 patients	 (Suzuki,	 Abdelmalek	 et	 al.	 2010,	 Subramanian,	Johnston	et	al.	2013).	However,	there	is	little	evidence	to	confirm	that	this	relationship	exists	in	children	and	we	were	unable	to	differentiate	participants	with	simple	steatosis	from	those	with	NASH	due	to	small	sample	size	 for	 the	purpose	of	 this	study.	Further	exploration	of	whether	this	relationship	exists	in	paediatric	cohorts	may	assist	with	the	development	of	an	inexpensive	screening	technique	to	assess	for	risk	of	fibrosis	prior	to	progressing	 to	 ultrasound	 or	 biopsy.	 However,	 the	 high	 rate	 of	 inter-and	 intra-	examiner	 variation	 may	 influence	 test	 accuracy	 and	 would	 need	 to	 be	 taken	 into	consideration	(Subramanian,	Johnston	et	al.	2013).		
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2.4.3	Macro-	and	Micronutrient	Intake		 After	 controlling	 for	 differences	 in	 BMI	 z-score	 and	 correcting	 for	 multiple	hypotheses	testing	using	the	Bonferroni	correction,	we	found	no	significant	differences	in	macro-	or	micronutrient	intake	between	groups	when	expressed	as	absolute	intakes,	proportion	 of	 the	 DRV	 or	 percentage	 of	 energy	 derived	 from	 macronutrients.	 This	includes	 nutrients	 previously	 implicated	 in	 NAFLD	 pathogenesis	 such	 as	 fructose,	dietary	fats,	vitamin	D,	protein,	iron,	copper	and	antioxidants.		 The	 fact	 that	 there	 were	 no	 statistical	 differences	 in	 fructose	 intake	 between	groups	opposes	the	results	of	a	number	of	previous	studies	noting	high	fructose	intake	in	NAFLD	patients	(Ouyang,	Cirillo	et	al.	2008,	Thuy,	Ladurner	et	al.	2008,	Abdelmalek,	Suzuki	et	al.	2010,	Mager,	Patterson	et	al.	2010).	However,	our	findings	are	consistent	with	 a	 2014	 systematic	 review	 and	meta-analysis	 that	 found	 no	 effect	 of	 fructose	 in	isocaloric	 feeding	 intervention	 trials	 (fructose	 exchanged	 for	 other	 forms	 of	carbohydrate),	as	opposed	to	hypercaloric	trials	(dietary	supplementation	with	excess	energy	 from	high	 fructose	doses)	where	both	 intrahepatocellular	 lipids	and	ALT	were	raised	(Chiu,	Sievenpiper	et	al.	2014).	Reviewers	therefore	concluded	that	any	observed	detrimental	effects	of	excess	dietary	fructose	might	be	attributable	to	excessive	energy	intake	 rather	 than	 increased	 fructose	 consumption	 in	 isolation.	 Moreover,	 research	suggests	that	an	 increased	metabolic	sensitivity	to	 fructose	 in	NAFLD	patients	may	be	responsible	for	detrimental	metabolic	effects,	rather	than	excessive	fructose	intakes	(Jin,	Le	 et	 al.	 2012,	 Sullivan,	 Le	 et	 al.	 2014).	 	 Despite	 this,	 our	 data	 indicated	 fructose	consumption	was	lower	than	Canadian	(Mager,	Patterson	et	al.	2010,	Mager,	Iniguez	et	al.	2015)	and	Australian	(O'Sullivan,	Oddy	et	al.	2014)	paediatric	NAFLD	populations.		 Previous	 research	 in	 overweight	 adolescents	 has	 observed	 a	 strong	 positive	association	 between	 consumption	 of	 >35%	 of	 daily	 energy	 from	 fat	 and	 hepatic	steatosis	(Mollard,	Senechal	et	al.	2014).	Additionally,	previous	studies	have	linked	SFA	intake	 in	 excess	 of	 dietary	 recommendations,	 and	 decreased	MUFA	 and	 PUFA	 intake,	with	 decreased	 insulin	 sensitivity	 (IS)	 (Musso,	 Gambino	 et	 al.	 2003),	 dyslipidaemia	(Musso,	 Gambino	 et	 al.	 2003),	 and	 steatosis	 (Toshimitsu,	 Matsuura	 et	 al.	 2007,	Papandreou,	Karabouta	et	al.	2012).	In	this	study,	both	groups	reported	deriving	<	35%	of	total	energy	from	fat.	However,	participants	exceeded	nutritional	recommendations	for	 SFA	 intake,	 and	 reported	 intakes	 of	MUFA	 and	PUFA	below	 recommendations	 for	health.	Intakes	of	omega-3	fatty	acids	were	low	in	both	groups.	Considering	the	growing	
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body	of	evidence	linking	MUFA	with	reduced	hepatic	steatosis	(Ryan,	Itsiopoulos	et	al.	2013)	 and	 improved	 insulin	 sensitivity	 (Ryan,	 Itsiopoulos	 et	 al.	 2013),	 and	 PUFA	 (in	particular	omega-3)	with	improvements	in	LFTs	(Capanni,	Calella	et	al.	2006,	Spadaro,	Magliocco	et	al.	2008),	serum	TG	and	fasting	blood	glucose	levels	(Capanni,	Calella	et	al.	2006);	dietary	deficiencies	 in	MUFA	and	PUFA	in	NAFLD	are	of	concern.	Patients	who	may	 be	 metabolically	 predisposed	 to	 developing	 IR,	 dyslipidaemia	 and	 ectopic	 fat	accumulation	 are	 likely	 to	 benefit	 more	 than	 the	 general	 population	 from	 achieving	recommendations	for	unsaturated	fats.	Education	on	accessible	dietary	sources	should	remain	a	priority	of	clinical	management	for	this	population.		 Previous	research	has	established	an	association	between	vitamin	D	deficiency	and	NAFLD	(Eliades,	Spyrou	et	al.	2013).	Although	the	present	study	found	no	statistical	differences	in	vitamin	D	consumption	between	groups,	overall	 intakes	were	extremely	low.	 Participants	with	NAFLD	 and	 children	with	 obesity	 reported	 a	median	 intake	 of	1.8µg/day	 and	 3.5µg/day	 respectively;	 which	 is	 well	 below	 the	 new	 proposed	 UK	recommended	nutrient	 intake	 for	 vitamin	D	of	 10µg/day	 (SACN	2016).	 Previous	data	from	the	2011/2012	UK	NDNS	data	indicated	that	the	mean	intake	of	vitamin	D	for	girls	and	 boy	was	 1.9	 and	 2.2µg/day	 respectively,	with	 adult	 data	 equally	 as	 bleak	 (Bates	2014).	 As	 vitamin	 D	 is	 derived	 both	 exogenously,	 from	 dietary	 sources,	 and	endogenously,	 by	 dermal	 synthesis	 following	 exposure	 to	 UVB	 radiation	 (Eliades,	Spyrou	 et	 al.	 2013),	 further	 research	 should	 be	 completed	 to	 assess	 the	 influence	 of	both	vitamin	D	intake	and	serum	25OHD	levels	on	NAFLD	pathogenesis	in	a	paediatric	UK	cohort.			 The	 24-hour	 dietary	 recall	 data	 indicated	 comparatively	 higher	 intakes	 of	protein,	zinc,	copper	and	iron	intake	in	the	NAFLD	group.	Although,	animal	studies	have	shown	 high	 protein	 diets	 to	 be	 protective	 against	 hepatic	 fat	 accumulation	 (Schwarz,	Tome	 et	 al.	 2012,	 Garcia	 Caraballo,	 Comhair	 et	 al.	 2014),	 there	 is	 little	 evidence	 to	suggest	 that	 this	 relationship	 exists	 in	 humans.	 The	WHO	 and	 Food	 and	 Agriculture	Organisation	recommend	between	0.66	to	0.75	g	of	protein	per	kg	BW	for	children	aged	between	8	to	18	years	(EFSA	2015).	Children	in	the	present	study	were	consuming	well	above	 recommendations	with	 0.88	 and	 0.80g/kg	 BW	 reported	 by	 cases	 and	 controls	respectively.	Considering	 that	children	with	NAFLD	consistently	 reported	high	overall	protein	 consumption,	 it	 is	 unlikely	 that	 protein	 intake	was	 protective	 against	 hepatic	steatosis	in	this	cohort.		
			 66	
	 Oxidative	stress	 is	believed	 to	be	a	major	determinant	of	 the	progression	 from	steatosis	 to	 steatohepatitis	 in	 NAFLD	 patients	 (Singal,	 Jampana	 et	 al.	 2011).	 Despite	controls	reporting	comparatively	higher	intakes	of	vitamin	E	as	assessed	using	both	24-hour	 recall	 data	 and	 7-day	 FAD,	 overall	 dietary	 intake	 of	 antioxidants	 (vitamin	 C,	vitamin	 E	 and	 carotene)	 did	 not	 statistically	 differ	 between	 groups.	 Considering	 the	growing	 interest	 in	 the	 use	 of	 vitamin	 E	 supplementation	 for	 the	 treatment	 of	 NASH	(Singal,	Jampana	et	al.	2011),	further	analysis	of	differences	in	overall	antioxidant	intake	between	 cases	 with	 steatosis	 and	 NASH	 may	 provide	 insight	 as	 to	 whether	 dietary	intake	of	antioxidants	is	involved	in	NASH	prevention	in	UK	children	with	NAFLD.		 Despite	 a	 lack	 of	 significant	 differences	 in	 macro-	 and	 micronutrient	 intake	between	groups,	the	majority	of	children	in	this	cohort	reported	consuming	well	below	the	DRV	for	numerous	nutrients	(MUFA,	PUFA,	potassium,	calcium,	iron,	zinc	and	folate).	There	 should	 consequently	 be	 a	 focus	 on	 improving	 overall	 dietary	 quality	 and	promoting	 intake	 of	 a	 wide	 range	 of	 nutritious	 foods.	 Considering	 the	 lack	 of	 high-quality	evidence	to	support	specific	dietary	guidelines	for	NAFLD	management,	general	healthy	 eating	 advice	 should	 be	 recommended	 in	 accordance	 with	 UK	 Eat	 Well	Guidelines	(FSA	2005),	alongside	strategies	which	correspond	with	NICE	guidelines	for	obesity	 management	 (NICE	 2014).	 This	 will	 assist	 children	 in	 consuming	 sufficient	macro-	and	micronutrients	to	meet	UK	recommendations	to	promote	general	wellbeing.	
2.4.4	Under-reporting	of	Dietary	Intake		 A	 key	 observation	 was	 the	 severe	 degree	 of	 dietary	 under-reporting.	 Under-reporting	 is	 known	 to	 be	 particularly	 common	 in	 obese	 subjects,	 characterised	 by	reporting	relatively	low	intakes	of	foods	which	may	be	perceived	as	socially	undesirable,	such	as	those	rich	in	simple	carbohydrates	or	fat	(Fisher,	Johnson	et	al.	2000,	Mendez,	Popkin	 et	 al.	 2011).	 In	 addition,	 under-reporting	 may	 have	 been	 unintentional,	 with	reliance	 on	 memory	 and	 inexperience	 of	 portion	 size	 estimation	 known	 to	 limit	accurate	dietary	recall	in	children	(Lu,	Baranowski	et	al.	2012).			 It	was	interesting	to	note	that	fewer	participants	under-reported	dietary	intake	using	 24-hour	 dietary	 recall	 when	 compared	 to	 the	 7-day	 food	 diary.	 This	 may	 be	secondary	 to	 use	 of	 the	multiple-pass	method	when	 obtaining	 24-hour	 dietary	 recall	data,	 with	 Conway	 et	 al.	 (Conway,	 Ingwersen	 et	 al.	 2003)	 showing	 this	 technique	
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improves	 accuracy	of	 dietary	 recall	 in	 overweight	 and	obese	populations,	 shifting	 the	burden	from	participant	to	interviewer.			 Despite	high	rates	of	under-reporting,	the	overall	number	of	under-reporters	did	not	statistically	differ	between	groups	allowing	for	meaningful	comparisons	to	be	made	between	the	cases	and	controls.	Nevertheless,	it	is	important	to	acknowledge	that	actual	intake	may	be	greater	than	reported	intake,	 influencing	the	likelihood	of	being	able	to	accurately	identify	deficiency	or	excessive	intakes	of	key	nutrients	in	this	cohort.		
2.4.5	Eating	Behaviours		 Although	 certain	 eating	 behaviours	 are	 closely	 linked	with	 obesity	 (Birch	 and	Fisher	 1998),	 few	 studies	 have	 assessed	 eating	 behaviours	 amongst	 children	 with	NAFLD.	Snoek	et	al.	(Snoek,	Engels	et	al.	2013)	found	that	restrained	eating	behaviours	are	 more	 common	 amongst	 children	 with	 a	 higher	 BMI	 trajectory.	 It	 would	consequently	be	expected	that	controls	would	report	more	restrained	eating	behaviours	as	 they	 had	 higher	 BMI	 Z-scores.	 	 Interestingly,	 restrained	 eating	 behaviours	 were	higher	in	the	NAFLD	group	after	controlling	for	the	difference	in	BMI	z-score	between	groups.	This	suggests	that	children	with	NAFLD	may	be	more	cautious	of	their	dietary	intake.	Hattar	et	al.	(Hattar,	Wilson	et	al.	2011)	compared	nutrition	attitudes	of	children	with	NASH	to	control	children	with	simple	obesity	and	found	35%	of	the	NASH	group	consistently	read	nutritional	information	labels	on	food/beverages,	compared	to	0%	of	the	controls.	This	greater	awareness	and	restriction	of	dietary	intake	may	be	a	result	of	the	NAFLD	diagnosis.	 This	 novel	 finding	 highlights	 the	 potential	 for	 eating	 styles	 and	behaviours	 to	 be	 further	 researched	 and	 targeted	 in	 the	 management	 of	 paediatric	NAFLD.			 Nevertheless,	 reported	 eating	 behaviours	 in	 both	 the	 cases	 and	 controls	 are	consistent	with	 those	 reported	 in	 other	 overweight	 and	 obese	 paediatric	 populations	(Braet	and	Van	Strien	1997,	Banos,	Cebolla	et	al.	2011).	Accordingly,	behaviour-change	strategies	to	assist	with	weight	maintenance	or	weight	loss,	such	as	cognitive-behaviour	therapy	(Wilfley,	Kolko	et	al.	2011)	and	mindfulness	(Thompson	and	Gauntlett-Gilbert	2008)	should	be	appropriate	 for	managing	detrimental	dietary	behaviours	 in	children	with	NAFLD.	
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2.4.6	Food	Group	Based	Analysis		 Despite	 no	 differences	 being	 observed	 between	NAFLD	 and	 obese	 controls	 for	portions	 of	 fruit	 and	 vegetables	 eaten	 per	 day,	 both	 groups	 failed	 to	 meet	 the	government	recommended	of	5	 fruit	and	vegetables	a	day	(PHE	2016).	 	This	 is	 in	 line	with	 previous	 food-based	 analysis	 studies	 which	 also	 showed	 NAFLD	 subjects	consuming	 fewer	 fruit	 and	 vegetables	 (Ferolla,	 Ferrari	 et	 al.	 2013).	 Vitamin	 C	 and	 E	demonstrate	 an	 oxidative	 protective	 role	 through	 their	 free	 radical	 scavenging	properties,	reducing	oxidative	stress,	a	possible	contributing	factor	for	NAFLD	(Ji,	Sun	et	al.	2014).	 	The	evidence	supporting	 fruit	consumption	 in	NAFLD	is	contradictory;	 in	a	previous	 case	 control	 study,	Miele	 et	al.	 showed	 that	 the	 greater	 the	 consumption	 of	fruit,	the	greater	the	risk	of	NAFLD	(Miele,	Dall'armi	et	al.	2014),	which	could	be	linked	with	intakes	of	fructose.			 Additionally,	portions	of	fish	per	week	demonstrated	no	difference	between	the	two	 groups.	 	 Despite	 this,	 neither	 group	 managed	 to	 meet	 the	 government	recommendation	 of	 2	 portions	 of	 fish	 a	week,	 of	which	 1	 should	 be	 oily	 (PHE	2016).		Oily	fish	is	of	particular	importance	in	the	pathogenesis	of	NAFLD	due	to	the	protective	role	of	PUFAs	(Bouzianas,	Bouziana	et	al.	2013).	 	Previous	studies	have	shown	NAFLD	patients	 consume	 significantly	 less	 oily	 fish	 in	 comparison	 with	 controls	 (Musso,	Gambino	et	al.	2003,	Han,	Jo	et	al.	2014).	 	Supplementation	of	omega-3	fatty	acids	has	shown	 reduced	 hepatic	 steatosis,	 inflammation	 and	 ballooning	 as	 seen	 in	 a	 RCT	 in	paediatric	NAFLD	patients	(Nobili,	Carpino	et	al.	2014).	
2.4.7	Physical	Activity		 Although	 previous	 studies	 have	 noted	 high	 rates	 of	 physical	 inactivity	 in	individuals	with	NAFLD	(Zelber-Sagi,	Nitzan-Kaluski	et	al.	2008,	Mager,	Patterson	et	al.	2010,	 Hattar	 2011,	 Gerber,	 Otgonsuren	 et	 al.	 2012,	 Hallsworth,	 Thoma	 et	 al.	 2014),	participants	 in	 the	 present	 study	 reported	 being	 more	 physically	 active	 than	hypothesized.	 Data	 from	 the	 7-day	 activity	 diary	 suggested	 that	 25%	 of	 participants	with	 NAFLD	 met	 the	 UK	 physical	 activity	 guidelines	 (DoH	 2011),	 whereas	 all	participants	 in	 the	 control	 group	 failed	 to	meet	 this	 recommendation.	 This	 finding	 is	confirmed	with	 pedometer	 data	 indicating	 that	 33%	participants	with	NAFLD	had	 an	average	step	count	over	10,000	steps;	being	 the	estimated	minimum	number	of	 steps	required	by	an	adolescent	 to	meet	 the	60	minutes/day	moderate-to-vigorous	physical	
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activity	recommendation	(Adams,	Caparosa	et	al.	2009).	None	of	the	obese	children	had	an	 average	 step	 count	 exceeding	 10,000	 steps	 per	 day.	 The	 discrepancy	 between	measures	 may	 be	 a	 consequence	 of	 unaccounted	 time	 in	 the	 physical	 activity	 diary;	being	periods	of	time	left	incomplete	by	study	participants.				 However,	results	from	the	Youth	and	Child	PAQ	suggest	that	both	children	with	NAFLD	and	obese	children	without	evidence	of	 liver	disease	 spend	over	60%	of	 their	time	sedentary.	High	rates	of	physical	inactivity	are	positively	correlated	with	reduced	bone	and	muscle	strength,	cardiovascular	disease	and	poor	mental	health	(NICE	2007);	all	of	which	can	track	into	adulthood.	There	should	consequently	be	increased	focus	on	increasing	total	daily	activity	in	all	overweight	and	obese	children	irrespective	of	 liver	comorbidities.			 Additionally,	 there	 should	 be	 a	 particular	 emphasis	 on	 encouraging	 physical	activity	 outside	 of	 school	 hours,	 as	 we	 noted	 a	 substantial	 decline	 in	 steps	 taken	 on	weekends	 compared	 to	 weekdays.	 Fairclough	 et	 al.	 (Fairclough,	 Boddy	 et	 al.	 2015)	found	 that	 English	 children	 with	 low	 overall	 physical	 activity	 levels	 are	 particularly	likely	 to	 be	 sedentary	 on	 weekends.	 This	 is	 believed	 to	 be	 secondary	 to	 a	 lack	 of	structure	after-school	and	on	weekends	compared	to	the	typical	school	day	which	often	results	 in	 adolescence	 choosing	 sedentary	 behaviours	 over	 being	 physical	 active	(Fairclough,	Boddy	et	al.	2015).		This	indicates	the	importance	of	targeting	management	strategies	to	increase	physical	activity	levels	outside	of	school	hours;	general	paediatric	guidelines	for	physical	activity	should	be	encouraged	in	all	overweight/obese	children	until	additional	high	quality	evidence	is	available.	
2.4.8	Study	Strengths	and	Limitations		 A	key	strength	of	this	study	was	the	use	of	liver	biopsy	to	diagnose	NAFLD	rather	than	reliance	on	LFTs	or	US,	which	are	considered	to	be	low	sensitivity	diagnostic	tools	(Chalasani,	Younossi	et	al.	2012).	Although	controls	were	not	precisely	BMI-matched	to	NAFLD	 participants,	 both	 groups	 were	 of	 similar	 weight	 status.	 This	 is	 of	 key	importance	 in	 identifying	 risk	 factors	 other	 than	 obesity,	 which	 may	 contribute	 to	NAFLD	development.	An	additional	strength	was	the	high	levels	of	support	received	by	participants	 in	 completion	 of	 food	 and	 activity	 diaries,	 through	 home	 visits	 and	telephone	calls,	to	maximise	the	quality	and	quantity	of	diary	data	collected.		
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	 A	 key	 limitation	 of	 this	 study	 was	 the	 low	 number	 of	 controls	 compared	 to	NAFLD	participants.	It	was	much	more	difficult	to	successfully	recruit	and	retain	control	subjects,	reflecting	a	wider	issue	of	low	compliance	in	overweight/obese	children	with	weight	 reduction	 initiatives	 (Murtagh,	 Dixey	 et	 al.	 2006).	 Additionally,	 due	 to	 the	absence	 of	 previous	 comparable	 research,	 a	 power	 calculation	 was	 not	 undertaken	prior	to	participant	recruitment.	It	 is	consequently	difficult	to	ascertain	whether	there	were	sufficient	participants	to	ensure	adequate	power	to	detect	differences	in	diet	and	physical	activity	between	cases	and	controls,	increasing	the	risk	of	type	2	error	(O'Keefe	2007).			 Furthermore,	 convenience	 sampling	 may	 have	 introduced	 bias	 into	 study	outcomes,	undermining	our	ability	to	make	generalisations	to	the	broader	UK	paediatric	NAFLD	population.	For	example,	due	to	the	specialised	nature	of	the	paediatric	NAFLD	clinic,	 referrals	 were	 received	 from	 across	 South-West	 England.	 Conversely,	 the	multidisciplinary	obesity	clinic	has	a	significant	proportion	of	referrals	from	a	region	in	London	with	a	large	population	of	individuals	from	African	and	Caribbean	descent	(GLA	2013);	which	may	have	skewed	ethnic	distribution	between	groups.			 Our	findings	are	based	on	self-reported	food	and	activity	diaries.	Although	this	is	a	 standard	 method	 for	 collecting	 dietary	 information,	 our	 findings	 are	 subject	 to	reporting-bias	 and	 inaccuracies,	 especially	 considering	 that	 overweight	 and	 obese	individuals	may	be	likely	to	inaccurately	record	oral	intake	(Fisher,	Johnson	et	al.	2000,	Mendez,	 Popkin	 et	 al.	 2011).	 Consequently,	 further	 analysis	 of	 the	 FAD	 using	 a	 diet	quality	score,	such	as	the	Healthy	Eating	Index	(Guenther,	Reedy	et	al.	2008),	may	have	provided	greater	insight	into	differences	in	dietary	intakes	between	cases	and	controls.		This	 score	 provides	 an	 overall	 rating	 of	 an	 individual's	 dietary	 intake	 in	 reference	 to	nutrients	and/or	government-based	dietary	recommendations.	It	is	often	perceived	as	a	more	holistic	approach	to	assessing	oral	intake	than	specifically	comparing	macro-	and	micronutrient	intake	(Marshall,	Burrows	et	al.	2014).			
2.5	Conclusions	In	 summary,	 no	differences	 in	macro-	 or	micronutrient	 intakes	were	 observed	between	children	with	NAFLD	and	obese	controls	in	this	study.	Under-reporting	in	both	groups	 was	 prevalent.	 Restrained	 eating	 behaviours	 were	 significantly	 higher	 in	 the	NAFLD	 group,	who	were	 also	more	 physically	 active	 and	 took	more	 steps	 than	 their	
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obese	 counterparts.	 Further	 research	 is	 required	 to	 confirm	 the	 role	 of	 particular	nutrients	 in	 the	 development	 and	 progression	 of	 NAFLD	 and	 to	 establish	 optimal	physical	 activity	 guidelines	 for	 children	 with	 NAFLD.	 Only	 a	 minority	 of	 cases	 and	controls	 were	 meeting	 current	 dietary	 and	 physical	 activity	 recommendations	 and	general	 healthy	 eating	 advice,	 alongside	 a	 minimum	 of	 60	 minutes	 of	 moderate-vigorous	 physical	 activity	 per	 day	 should	 continue	 to	 be	 encouraged	 (Kamboh	 and	Ferrell	 1986).	 Additionally,	 the	 fact	 that	 children	 in	 the	 control	 group	 were	 of	significantly	higher	BMI	than	children	in	the	NAFLD	group	suggests	excess	body	weight	is	not	the	only	driving	factor	in	NAFLD	development;	genetic	susceptibility	may	play	a	role	in	the	risk	of	developing	NAFLD.		 	
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Chapter	3:	Assessing	Vitamin	D	status	and	Associated	Genetic	Polymorphisms	
in	a	UK	Paediatric	Population	
3.1	Background	
3.1.1	Vitamin	D	Vitamin	 D	 is	 most	 commonly	 known	 for	 its	 role	 in	 the	 regulation	 and	maintenance	 of	 calcium	 levels	 in	 the	 body;	 it	 is	 essential	 for	 bone	 development	 and	growth	in	children,	the	preservation	of	bone	health	in	adults	and	prevention	of	fracture	in	 the	 elderly.	 	 Sufficient	 exposure	 of	 skin	 to	 UVB	 radiation	 and/or	 adequate	 intakes	through	diet	or	supplementation	 is	required	to	maintain	vitamin	D	status	(Figure	3.1)	(Holick	2007).	The	most	commonly	used	biomarker	of	vitamin	D	status	is	25OHD,	as	it	is	the	most	stable	circulating	form	of	this	molecule	and	reflects	both	dietary	intakes	and	cutaneous	synthesis	(Zerwekh	2008,	Ross	2011),	despite	1,25-dihydroxycholecalciferol	(1,25OHD)	being	the	biologically	active	molecule.		 Vitamin	 D,	 although	 not	 strictly	 a	 vitamin,	 is	 studied	 as	 a	 dietary	 factor,	 is	actually	a	secosteroid	with	the	main	source	of	vitamin	D	made	through	skin	exposure	to	UVB	radiation	(Norman	2008).	 	Metabolism	starts	with	7-dehydrocholesterol	(7-DHC),	which	is	the	precursor	for	cholesterol	biosynthesis.	 	In	the	skin,	7-DHC	is	converted	to	previtamin	D3	when	exposed	to	UVB	radiation	(290-315nm)	from	sunlight,	and	is	then	isomerised	 to	 vitamin	D3	 by	 a	 heat	 dependant	 reaction.	 Vitamin	D3	 (from	 the	 diet	 or	synthesised	 in	 the	 skin)	 is	 transported	 to	 the	 liver	 by	 the	 group	 specific	 component/	vitamin	 D	 binding	 protein	 (GC)	 where	 is	 metabolised	 to	 its	 major	 circulating	 form,	25OHD	 by	 CYP2R1.	 Further	 hydroxylation	 in	 the	 kidneys	 takes	 place	 by	 CYP24A1	 to	form	its	biologically	active	metabolite,	1,25OHD	(Figure	3.1)	(Grünhage,	Hochrath	et	al.	2012,	Kitson	and	Roberts	2012).		
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Figure	 3.1:	Metabolism	 of	 Vitamin	 D.	 UVB	 wavelengths	 of	 290-315	 nm	 rupture	 the	 bond	 between	carbon	 9	 and	 carbon	 1-	 in	 7-dehydrocholesterol,	 resulting	 in	 the	 production	 of	 vitamin	 D3	 or	cholecalciferol	through	heat	dependent	isomerization.		Alternatively,	sources	of	vitamin	D3	or	D2	enter	the	vitamin	D	metabolic	pathway	via	the	diet.	Vitamin	D3	is	then	transported	to	the	parenchymal	cells	in	the	liver	where	 it	 is	 converted	 to	 25OHD	 by	CYP2R1.	 	 25OHD	 is	 then	 transported	 bound	 to	 the	 vitamin	D	binding	 protein	 (GC)	 to	 be	 further	 hydroxylated	 to	 its	 active	 form	1,25(OH)2D	 in	 the	 proximal	 tubular	cells	of	the	kidney.		Adapted	from	Grünhage	et	al.,	2012,	and	Kitson	and	Roberts,	2012.		
3.1.2	Vitamin	D	Status	In	the	UK,	25OHD	status	is	highest	in	the	summer	and	lowest	during	winter	and	spring	months	due	to	the	latitude	(Hypponen	and	Power	2007).		Previously,	data	from	the	 1958	 British	 Birth	 cohort	 (n=7437)	 demonstrated	 the	 prevalence	 of	hypovitaminosis	 D	 during	 winter	 and	 spring	 months	 where	 15.5%	 of	 adults	 had	deficient	 levels	 (Figure	 3.2).	 	 Additionally,	 it	 was	 observed	 that	 25OHD	 levels	 were	markedly	reduced	 in	adult	obese	subjects	regardless	of	season	(Hypponen	and	Power	2007).	In	the	most	recent	UK	NDNS,	22%	of	children	between	the	ages	of	11	and	18	had	circulating	 25OHD	 concentrations	 below	 25nmol/L,	 the	 threshold	 currently	 defining	frank	 vitamin	 D	 deficiency	 (Bates	 2014).	 	 New	 guidelines	 have	 been	 proposed	 for	vitamin	D	RNI,	 set	at	10μg/day	 for	adolescents,	with	 the	aim	of	 raising	25OHD	status	(SACN	2016).		Vitamin	D	status	has	a	strong	hereditary	component	with	distinct	sets	of	common	gene	variants	explaining	some	of	the	differences	observed	in	vitamin	D	status	
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between	different	ethnic	populations	(Hunter,	De	Lange	et	al.	2001,	Batai,	Murphy	et	al.	2014).	 	 Previously,	 single	 nucleotide	 polymorphisms	 (SNPs)	 in	 CYP2R1	 have	 been	associated	with	25OHD	 levels	 in	White	European	patients	 (Ramos-Lopez,	Bruck	 et	 al.	2007),	 the	 GC	 protein	 variants	 in	 African	 Americans	 (Signorello,	 Shi	 et	 al.	 2011)	 and	Chinese	 (Lu,	 Sheng	 et	 al.	 2012),	 and	 NADSYN1/DHCR7	 in	 a	 Chinese	 population	 (Lu,	Sheng	et	al.	2012).			
Figure	 3.2:	 Seasonal	 and	 geographical	 variation	 in	 the	 prevalence	 of	 hypovitaminosis	 D	
(<40nmol/L)	across	the	UK.	Taken	from	Hyppönen	and	Power	(2007).		
3.1.3	Vitamin	D	and	NAFLD		 A	growing	body	of	research	suggests	a	relationship	between	vitamin	D	deficiency	and	 chronic	 liver	 disease,	 in	 particular	 NAFLD	 (Kitson	 and	 Roberts	 2012,	 Eliades,	Spyrou	et	al.	2013,	Kwok,	Torres	et	al.	2013,	Black,	Jacoby	et	al.	2014,	Nobili,	Giorgio	et	al.	2014,	Chung,	Kim	et	al.	2016).	As	previously	discussed,	NAFLD	is	closely	associated	with	 abdominal	 obesity,	 dyslipidaemia,	 IR,	 type-2	 diabetes	 and	 hypertension	(Nascimbeni,	Pais	et	al.	2013),	and	 is	often	referred	to	as	 the	hepatic	manifestation	of	the	metabolic	 syndrome	 (Moore	2010,	 Lazo,	Hernaez	 et	 al.	 2011).	 	 The	prevalence	of	NAFLD	in	children	is	estimated	at	10%	(Schwimmer,	Deutsch	et	al.	2006),	but	rises	to	80%	 in	 overweight	 individuals	 (Giorgio,	 Prono	 et	 al.	 2013).	 	 Development	 and	progression	of	 disease	 are	presumed	 to	be	multifactorial	 in	 nature	 and	 influenced	by	both	genetic	and	nutritional	factors	(Moore	2010,	Tilg	and	Moschen	2010).	Recent	 observational	 studies	 have	 demonstrated	 that	 low	 vitamin	 D	 status	associates	with	paediatric	NAFLD	independently	of	BMI	in	Australian	(Black,	Jacoby	et	
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al.	2014),	and	Italian	(Nobili,	Giorgio	et	al.	2014)	cohorts	diagnosed	by	ultrasound	and	liver	biopsy,	respectively.	 	Notably,	Nobili	and	co-workers	(Nobili,	Giorgio	et	al.	2014)	showed	 an	 inverse	 correlation	 between	 25OHD	 levels	 and	 histological	 severity,	 with	significantly	lower	levels	of	25OHD	associated	with	the	presence	of	NASH	and	fibrosis.		These	 data	 are	 important	 in	 the	 context	 of	 experimental	 data	 demonstrating	 the	antifibrotic	effects	of	vitamin	D	in	both	rodent	(Abramovitch,	Dahan-Bachar	et	al.	2011,	Ding,	Yu	et	al.	2013)	and	human	hepatic	stellate	cells	(HSCs)	(Beilfuss,	Sowa	et	al.	2015).		In	particular,	elegant	work	from	Ding	and	colleagues	(Ding,	Yu	et	al.	2013)	has	shown	how	 the	 vitamin	 D	 receptor	 (VDR)	 competes	 with	 SMAD3	 for	 occupancy	 on	transforming	 growth	 factor	 (TGF)β1	 regulated	 profibrotic	 genes,	 thereby	 regulating	hepatic	 fibrogenesis.	 The	work	 of	 Beilfuss	 (Beilfuss,	 Sowa	 et	 al.	 2015)	 builds	 on	 this,	showing	 that	 NASH	 patients	 express	 lower	 levels	 of	 VDR	 protein	 and	 that	 treatment	with	vitamin	D	ameliorated	the	effect	of	TGFβ	fibrotic	signalling	in	human	primary	HSCs	by	 both	 VDR-dependent	 and	 VDR-independent	 mechanisms.	 	 Moreover,	 the	 authors	show	that	specific	single	nucleotide	polymorphisms	in	the	VDR	gene	affected	both	the	expression	of	VDR	mRNA	and	the	expression	of	profibrogenic	genes	(Beilfuss,	Sowa	et	al.	2015).	While	there	are	clearly	likely	to	be	multiple	pathways	to	fibrogenesis	in	NAFLD	(Skoien,	 Richardson	 et	 al.	 2013),	 these	 studies	 suggest	 that	 vitamin	D	 treatment	may	have	therapeutic	potential	in	paediatric	NAFLD	(Nobili	and	Reif	2015).		
3.1.4	Aims	Given	 the	 association	 between	 low	 vitamin	 D	 status	 and	 NAFLD	 and	 the	hereditary	component	of	vitamin	D	status,	the	aims	of	this	study	were	to	determine	in	children	 with	 biopsy-proven	 NAFLD:	 (i)	 their	 25OHD	 status	 and	 extent	 of	 vitamin	 D	deficiency/insufficiency	throughout	a	given	12	month	period,	and	(ii)	any	interactions	between	 key	 polymorphisms	 related	 to	 vitamin	 D	 metabolism	 and	 NAFLD	 disease	severity.	
3.1.5	Hypothesis		 NAFLD	children	will	present	with	low	serum	levels	of	25OHD.		PNPLA3	risk	allele	will	 have	 a	 high	 prevalence	 in	 this	 population	 and	 be	 associated	 with	 altered	histological	patterns,	while	variants	 in	genes	 involved	 in	 the	metabolism	of	vitamin	D	will	be	associated	with	poorer	histological	grading.	
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3.1.6	Objectives	
• To	 assess	 seasonal	 25OHD	 variation	 in	 a	 UK	 biopsy-proven	 paediatric	 NAFLD	population	
• To	characterise	the	PNPLA3	gene	a	UK	paediatric	NAFLD	population,	and	assess	the	presence	of	the	risk	allele	with	histological	grading	
• To	evaluate	 and	 compare	 select	 SNPs	 involved	 in	 the	metabolism	of	 vitamin	D	against	 biochemical	 (ALT,	 AST,	 GGT	 and	 cholesterol)	 and	 anthropometric	measurements	(weight	and	BMI),	25OHD	status,	and	histological	grading	
3.2	Materials	and	Methods	
3.2.1	Patients	Medical	records	were	examined	from	patients	who	had	attended	King’s	College	Hospital	 Paediatric	 Liver	 Service	 between	 March	 2001	 and	 July	 2013	 who	 had	suspected	NAFLD	confirmed	by	biopsy.		All	patients	included	were	less	than	19	years	of	age	at	sample	collection.	Other	liver	diseases	including	Hepatitis	B	and	C,	Wilson	disease	and	inborn	errors	of	metabolism	were	ruled	out	through	comprehensive	clinical	work	up.	 Children	 underwent	 abdominal	 ultrasound,	 blood	 tests	 including	 viral	 screen,	copper	and	caeruloplasmin,	lactate,	urinary	organic	acids,	serum	amino	acids,	screen	for	lysosomal	 acid	 lipase	 deficiency.	 A	 24	 hour	 urinary	 copper	 collection	 was	 also	undertaken	both	pre	and	post	penicillamine.	Children	also	underwent	an	oral	glucose	tolerance	test	including	both	glucose	and	insulin	levels.	Liver	biopsy	was	undertaken	in	the	case	of	persistently	abnormal	liver	function	tests	over	6	months	and/	or	an	enlarged	spleen	on	ultrasound	on	2	or	more	occasions	 suggesting	 significant	 liver	 injury.	Liver	biopsy	 was	 undertaken	 by	 a	 trained	 paediatric	 hepatologist	 using	 the	 Menghini	technique.	Liver	biopsies	were	fixed	with	formalin	and	embedded	in	paraffin.	Sections	were	 stained	with	haematoxylin	 and	eosin,	Orcein,	 Perl’s	 and	 reticulin.	Tissue	 copper	was	 measured	 in	 a	 small	 piece	 (1mm)	 of	 liver	 biopsy.	 Histological	 assessment	 was	performed	 by	 a	 single	 paediatric	 histopathologist	 who	 was	 blinded	 to	 the	 subject’s	clinical	 information	 and	 patient	 identity,	 and	 scored	 according	 to	 the	 Kleiner/Brunt	system	(Kleiner,	Brunt	et	al.	2005).		Each	biopsy	was	assigned	a	score	for	steatosis	(0-3),	lobular	 inflammation	 (0-3),	 hepatocyte	 ballooning	 (0-2)	 and	 fibrosis	 (0-4).	 BMI	 was	calculated	 by	 dividing	 weight,	 in	 kilograms	 by	 height	 (measured	 with	 a	 fixed	stadiometer)	 in	metres	 squared.	 Participant	 ethnicity	 was	 classified	 according	 to	 the	
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Health	 and	 Social	 Care	 Information	 Centre,	 Ethnic	 Category	 Code	 by	 King’s	 College	Hospital	research	staff.	
3.2.2	Measurement	of	25OHD	Serum	Levels	Serum	25OHD	levels	were	determined	at	King’s	College	Hospital	Department	of	Clinical	 Biochemistry	 using	 a	 chemiluminescent	 immunoassay,	 the	 ADVIA	 Centaur	Vitamin	D	Total	Assay	 (Siemens	Healthcare	Diagnostics,	UK).	 	This	assay	 is	aligned	 to	the	 25OHD	 reference	 measurement	 procedure	 of	 the	 international	 Vitamin	 D	Standardization	Program	(VDSP).	The	sensitivity	of	the	assay	is	estimated	to	range	from	10nmol/L	 to	 375nmol/L,	 while	 the	 inter-assay	 variation	 was	 4.2%-11.9%	 and	 the	percentage	of	 cross	 reactivity	with	vitamin	D2	and	D3	was	1.1%.	 	We	used	 thresholds	defined	 by	 the	UK	Department	 of	Health	 (DoH)	 (DoH	1998)	 and	 the	USA	 Institute	 of	Medicine	 (IOM),	 (Rosen,	 Abrams	 et	 al.	 2012)	 for	 assessing	 vitamin	 D	 status;	 25OHD	concentrations	 below	 25nmol/L	 were	 considered	 deficient	 and	 below	 50	 nmol/L	 as	insufficient	respectively.	Separately,	the	liver	enzymes	ALT,	AST	and	GGT,	and	lipids	were	analysed	using	standard	methods	on	the	ADVIA	2400	analyser	(Seimens	Healthcare	Diagnostics,	UK)	by	the	Department	of	Clinical	Biochemistry	at	King’s	College	Hospital.	
3.2.3	Genotyping	Eight	 candidate	 genes	 were	 selected	 based	 on	 their	 established	 influence	 on	vitamin	D	status	 (Ahn,	Yu	et	al.	2010,	Wang,	Zhang	et	al.	2010,	Lu,	Sheng	et	al.	2012)	and/or	liver	disease	(Romeo,	Kozlitina	et	al.	2008,	Grünhage,	Hochrath	et	al.	2012).		The	SNPs	 selected	 were:	 DHCR7	 -	 rs12785878;	 NADSYN1	 -	 rs3829251;	 GC	 -	 rs2282679,	rs7041	 (G/T,	 Glu416Asp)	 and	 rs4588	 (C/A	Thr420Lys);	CYP2R1	 -	 rs10741657;	VDR	 -	rs2228570	and	rs1544410;	PNPLA3	rs738409	(C/G,	Ile148Met).		 Genomic	 DNA	 was	 extracted	 from	 archival	 buffy	 coats,	 which	 had	 previously	been	 collected	 in	 potassium	 ethylenediaminetetraacetic	 acid	 tubes	 and	 immediately	stored	 at	 -80°C.	 	 Using	 automated	 DNA	 extraction	 kits	 (Promega,	 Southampton,	 UK),	1ml	of	each	sample	was	processed	according	to	manufacturer	instructions	and	stored	at	-20°C	 until	 required	 for	 SNP	 genotyping.	 	 The	 rate	 of	 success	 in	 extracting	 DNA	was	100%.	HepG2	and	Huh7	immortalised	cell	lines	were	cultured	and	DNA	extracted	using	the	PureLink	Genomic	DNA	Extraction	Minikit	(Fisher	Scientific,	Loughborough,	UK)	to	act	 as	 positive	 controls.	 	 DNA	 integrity	 was	 confirmed	 by	 1%	 agarose	 gel	
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electrophoresis.	 	 Samples	were	 loaded	with	 ethidum	bromide	 (Sigma	Aldrich,	Dorset,	UK).	 	 Probe	 primer	 sets	 designed	 by	 Applied	 Biosystems	 (Paisley,	 UK)	 were	 used	according	 to	manufacturer’s	 instructions	with	 20ng	 DNA	 and	 assays	were	 run	 on	 an	ABI7500	 real	 time	 instrument	 (Applied	 Biosystems)	 using	 allelic	 discrimination	through	the	measurement	of	allele-specific	fluorescence.		Rs1544410	failed	at	the	assay	detection	 level	 and	 therefore	 is	 not	 included	 in	 the	 results.	 	 All	 samples	were	 run	 in	duplicate	with	positive	and	no-template	controls;	the	reproducibility	was	>99%.	
3.2.4	Statistical	Analysis	Statistical	analyses	were	performed	using	SPSS	v22	(IBM	corporation,	Armonk,	New	York)	and	Prism	v6	(GraphPad	Software	Inc,	California).		Significance	was	set	at	a	threshold	 of	 P-value	 ≤0.05.	 Data	 were	 checked	 for	 normality	 using	 the	 D’Agostino	 &	Pearson	omnibus	normality	test,	and	outliers	identified	by	the	ROUT	test.	All	continuous	data	 are	 expressed	 as	 mean	 with	 95%	 confidence	 intervals,	 while	 discrete	 data	 are	expressed	 as	 range	 and	 median.	 	 Allele	 and	 genotype	 frequencies	 were	 tested	 for	consistency	with	Hardy-Weinberg	equilibrium	(HWE)	and	the	Chi	Square	test	was	used	to	 test	 the	 distribution	 of	 categorical	 variable	 between	 different	 genotypes	 and	presented	as	specific	percentages.		25OHD	levels	were	evaluated	by	One-way	ANOVA	on	ranks	with	multiple	comparisons	correction.	Ethnicity	was	reclassified	as	Caucasian	and	Non-Caucasian	due	 to	 low	frequencies	 in	other	categories.	 	Serum	25OHD	levels	were	transformed	 using	 the	 equation	 of	 Sachs	 (Sachs,	 Shoben	 et	 al.	 2013)	 and	 estimated	August	values	were	used	 for	all	 comparisons.	 	We	have	estimated	 that	 for	 this	 cohort	(n=103),	considering	an	α	error	=	0.05	and	SD	=	19.33nmol/L	in	serum	vitamin	D	levels,	we	would	have	a	power	of	>80%	to	detect	a	difference	of	5.34nmol/L	within	this	group.		Linear	regression	analysis	was	used	for	analysing	the	association	between	biochemical	variables	and	the	strength	of	the	association	was	reported	as	correlation	coefficient	(r).	
3.3	Results	
3.3.1	Study	Population	A	 total	 of	 103	 paediatric	 NAFLD	 patients	 were	 enrolled	 in	 this	 observational	cohort	 study	 and	 complete	 liver	 histology	 was	 available	 for	 73	 patients	 (Fig.	 3.3).	Patients	were	predominantly	male	 (66%)	and	Caucasian	 (70%)	with	a	mean	age	was	
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13.4	±	0.3	(Table	3.1).	Non-Caucasians	were	from	a	diverse	mix	of	ethnic	backgrounds.		Patients	were	very	overweight	for	age,	with	a	mean	BMI	z-score	of	1.9	±	0.1	(Table	3.1).					
	
	
	
	
	
	
	
	
	
	
	
Figure	3.3:	Participant	Flow	Diagram	
	
Table	3.1:	Population	Characteristics	
	
	
	
						 								
Values	 expressed	as	mean	±	SD	 for	 continuous	data,	 or	median	and	 range	 for	discrete	data.	Data	were	tested	for	normality	using	the	D’Agostino	&	Pearson	omnibus	test,	and	analysed	using	Kruskal-Wallis	test	with	Dunn’s	multiple	 comparison	 test	 for	 continuous	data,	 and	Chi-squared	 test	 for	 categorical	 data	 in	Caucasian	 and	 Non-Caucasian	 populations.	 ALT:	 alanine	 aminotransferase,	 AST:	 aspartate	aminotransferase,	BMI:	body	mass	index	GGT:	gamma-glutamyl	transferase,	
103	available	
samples	genotyped	
53	full	sets	
Caucasian	(n=72)	
70	pa>ents	with	
Vitamin	D	levels	
55	pa>ents	with	full	
histology	
17	full	sets	
Non-Caucasian	(n=25)	
23	pa>ents	with	
Vitamin	D	levels	
18	pa>ents	with	full	
histology	
Table	1:	Population	Characteristics	
	
	 All	Participants	
(n=103)	
Caucasian	
(n=72)	
Non-Caucasian	
(n=25)	Age	(years)	 		13.4	±	2.9	 13.9	±	2.6	 			11.7	±	3.7	Gender	(%	male)	 			66	 			63	 			72	Weight	(kg)	 				81.8	±	25.0	 		86.7	±	26.5	 			73.1	±	22.2	Height	(cm)	 		163.6	±	14.6	 165.8	±	15.4	 	157.9	±	15.3	BMI	(kg/m2)	 		30.0	±	6.1	 31.0	±	6.7	 	28.6	±	4.2	BMI	centile	 				94.2	±	11.5	 		94.8	±	10.6	 	96.9	±	2.5	BMI	z-score	 				1.9	±	0.6	 		2.0	±	0.6	 			2.0	±	0.4	Cholesterol	(mmol/L)	 				4.4	±	0.9	 		4.3	±	1.0	 			4.4	±	0.9	Triglycerides	(mmol/L)	 				2.2	±	2.6	 		2.0	±	1.6	 			1.7	±	0.9	ALT	(IU/L)	 				61.2	±	39.4	 		71.5	±	42.7	 				43.2	±	21.3	AST	(IU/L)	 				43.2	±	21.5	 		45.8	±	23.3	 			39.5	±	14.5	GGT	(IU/L)	 				34.6	±	28.5	 		38.6	±	32.6	 			28.9	±	11.4	
Histology	 	 	 	Steatosis	 		3	[0-3]	 		3	[0-3]	 		3	[0-3]	Lobular	Inflammation	 		1	[0-2]	 		1	[0-2]	 		1	[0-2]	Ballooning	 		1	[0-2]	 		1	[0-2]	 		2	[0-2]	Fibrosis	 		2	[0-4]	 		2	[0-4]	 		2	[1-3]	NAS	 		4	[0-7]	 		4	[0-7]	 		4	[2-6]		
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3.3.2	Vitamin	D	Status	Patients	 had	 low	 vitamin	 D	 status	 in	 general,	 with	 the	 majority	 (80.8%)	 of	patients	 having	 mean	 serum	 25OHD	 levels	 below	 the	 ‘insufficient’	 threshold	(<50nmol/L)	 and	 a	 quarter	 (25.5%)	 of	 patients	 having	 25OHD	 levels	 below	 the	‘deficient’	 threshold	 (<25nmol/L).	 Cycling	 of	 25OHD	 levels	 throughout	 the	 year	 was	evident;	patients	had	significantly	lower	25OHD	levels	in	winter	months	(mean	[95%CI]	nmol/L:	26.9[22.7-31.2])	when	compared	 to	 summer	 (41.8[36.3-47.2];	p=0.0001)	and	autumn	 (40.8[34.2-47.5];	 p=0.0026)	 months	 (Figure	 3.4).	 Therefore,	 in	 order	 to	normalise	 for	 seasonality,	 samples	 were	 modeled	 using	 a	 recently	 published	 model	(Sachs,	Shoben	et	al.	2013)	to	provide	predicted	August	values	(Figure	3.5).				
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	3.4:	Independent	and	repeated	measures	of	serum	25OHD	levels	of	cohort.		The	current	UK	reference	cut-off	value	for	deficiency	is	shown	as	the	red	line	(25nmol/L),	while	the	USA	reference	point	for	 insufficiency	(50nmol/L)	 is	shown	as	 the	green	 line.	 	All	data	points	are	plotted	as	mean	±	95%	CI;	data	 were	 tested	 for	 normality	 using	 the	 D’Agostino	 &	 Pearson	 omnibus	 normality	 test,	 and	 analysed	using	 Kruskal-Wallis	 test	 with	 Dunn’s	 multiple	 comparisons	 test.	 p<0.05	 is	 considered	 statistically	significant.						
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Figure	3.5:	Patient	25OHD	serum	levels	modeled	using	Sachs	algorithm.		Data	are	presented	as	mean	±	95%	CI.	n=71	for	each	month		Non-Caucasian	 patients	 had	 significantly	 lower	 mean	 25OHD	 serum	 levels	 in	comparison	 to	 Caucasian	 patients	 (35.9	 ±	 2.8	 versus	 40.7	 ±	 1.3nmol/L	 respectively,	p=0.0216;	Fig.	3.6).		Caucasian	non-NASH	patients	trended	higher	levels	of	25OHD	when	compared	 to	 borderline-NASH	 patients,	 although	 this	 did	 not	 reach	 significance	(p=0.0576)	(Figure	3.7).				 								
Figure	 3.6:	 August	 25OHD	 serum	 levels	 in	 Caucasian	 and	 Non-Caucasian	 patients.	 	 Data	 are	expressed	 around	 the	mean.	 	Data	were	 tested	 for	 normality	 using	 the	D’Agostino	&	Pearson	 omnibus	normality	test	and	analysed	using	Mann-Whitney	test.	p<0.05	is	considered	statistically	significant.				
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Serum	25OHD	levels	were	plotted	against	weight,	BMI,	 liver	enzymes	ALT,	AST	and	GGT,	and	cholesterol.		Cholesterol	showed	a	weak	inverse	correlation	with	25OHD	levels	 (Figure	 3.8A),	 while	 BMI	 showed	 a	 moderate	 inverse	 correlation	 with	 25OHD	levels	(Figure	3.8B).								
	
	
	
	
Figure	3.7:	Brunt/Kleiner	grading	versus	predicted	August	25OHD	status	in	all	Caucasian	patients.		Data	are	expressed	around	 the	mean	±	95%	CI;	data	were	 tested	 for	normality	using	 the	D’Agostino	&	Pearson	 omnibus	 normality	 test,	 and	 analysed	 using	 Kruskal-Wallis	 test	 with	 Dunn’s	 multiple	comparisons	test.	p<0.05	is	considered	statistically	significant.	NAFLD	Activity	Score	(NAS)	was	used	to	determine	groups;	Non-NASH	(0-2;	n=6),	Borderline	(3-4;	n=22)	and	NASH	(5-8;	n=22).			 		 		 					
	
Figure	3.8:	Serum	cholesterol	levels,	BMI	and	25OHD	levels	in	Caucasian	patients.	Data	were	tested	for	 normality	 using	 the	 D’Agostino-Pearson	 omnibus	 normality	 test	 and	 Spearman	 correlation	 was	performed	 for	 cholesterol	 (n=65)	 and	 BMI	 (n=44)	 showing	 weak	 and	 moderate	 inverse	 correlations	respectively.	
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3.3.3	Association	of	Genetic	Variants	with	Liver	Histology	Allele	 frequencies	 for	 all	 SNPs	 examined	 in	 this	 study	 (Table	 3.2)	 were	comparable	 to	 those	 reported	 for	 HapMap	 European	 sample	 population,	 except	 for	
PNPLA3	 rs738409	 where	 the	 rare	 (G)	 allele	 showed	 lower	 prevalence	 in	 NAFLD	patients	(77%	versus	44%	for	G	allele).	No	deviation	from	HWE	was	detected	(p>0.05	for	all	genotypes).	
	
Table	3.2:	Genotype	Distributions	
Data	represented	as	actual	values	(%	population).		A	denotes	common	allele,	a	denotes	rare	allele.	MAF:	minor	allele	frequency;	SNP:	single	nucleotide	polymorphism			 The	first	SNP	investigated	was	PNPLA3	rs738409.		In	particular,	presence	of	the	G	allele	was	strongly	associated	with	severity	of	steatosis	(p=0.0125)	and	inflammation	(p=0.0264,	Figure	3.9).		No	association	between	PNPLA3	genotype	and	vitamin	D	status	was	observed.		 The	NADSYN1	gene	variant	rs3829251	A	allele,	DHCR7	rs12785878	G	allele	and	
VDR	rs2228570	A	allele	were	all	associated	with	increased	steatosis	(p<0.05	for	all	gene	variants,	Figure	3.10A-C).		No	other	investigated	SNPs	were	associated	with	steatosis.		 The	 polymorphism	 rs4588	 in	 the	 GC,	 causing	 a	 base	 pair	 change	 of	 C>A	 was	associated	 with	 increased	 inflammation	 (p=0.028,	 Figure	 3.10D).	 No	 SNPs	 were	associated	with	fibrosis	or	ballooning.							
Table	3.2:	Genotype	Distributio 	
 	
Gene	 SNP	 Change	 MAF	 Genotype	Distribution	(%)		 	 	 	 AA	 Aa	 aa	PNPLA3	 rs738409	 		C>G	 0.44	 36	(35.0)	 42	(41.7)	 24	(23.3)	NADSYN1/DHCR7	 rs3829251	 		A>G	 0.75	 10	(9.7)	 32	(31.1)	 61	(59.2)	NADSYN1/DHCR7	 rs12785878	 		T>G	 0.44	 39	(37.9)	 38	(36.9)	 26	(25.2)		GC	 rs2282679	 		G>T	 0.70	 7	(6.8)	 48	(46.6)	 48	(46.6)		 rs4588	 		C>A	 0.32	 44	(42.7)	 52	(50.6)	 7	(6.8)			 rs7041	 		T>G	 0.44	 34	(33.0)	 47	(45.6)	 22	(21.4)	CYP2R1	 rs10741657	 		A>G	 0.57	 21	(20.4)	 46	(44.7)	 36	(35.0)	VDR	 rs2228570	 		C>T	 0.35	 45	(43.7)	 44	(42.7)	 14	(13.6)	
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Figure	 3.9:	 Association	 of	 PNPLA3	 genotype	 and	 histological	 scoring	 in	 Caucasian	 patients.	 A)	Steatosis;	p=0.0125,	B)	Inflammation:	p=0.0264,	C)	Ballooning:	p=0.4205	and	D)	Fibrosis:	p=0.1322.	 	All	data	 are	 representative	 of	 population	 percentages	 and	 were	 assessed	 by	 Chi-square	 test.	 P<0.05	 is	considered	statistically	significant.																	
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Figure	3.10:	Histological	scoring	in	Caucasian	patients	A)	NADYSN1/DHCR7	rs12785878:	p=0.0104,	B)	
NADSYN1/DHCR7	 rs3829251:	 p=0.0451,	 C)	 VDR	 rs2228570:	 p=0.0121	 and	 D)	 GC	 rs4588:	 p=0.0282	genotype.	 	All	data	are	representative	of	population	percentages	and	were	assessed	by	Chi-square	 test.	
P<0.05	is	considered	statistically	significant.	
3.4	Discussion	To	 our	 knowledge,	 this	 is	 the	 first	 report	 to	 show	 significant	 associations	between	 genetic	 variants	 known	 to	 affect	 25OHD	 concentrations	 and	 histology	 in	 a	paediatric	NAFLD	population.		Furthermore,	these	results	show	that	paediatric	patients	exhibit	extensive	 insufficient	vitamin	D	 levels	 throughout	 the	year	and,	 concomitantly	severely	vitamin	D	deficiency	during	winter	months.		The	average	serum	25OHD	level	in	August	in	this	cohort	was	44.1	nmol/L,	much	lower	than	the	60.1	nmol/L	average	found	in	the	2470	UK	adolescents	who	had	25OHD	measures	as	part	of	the	Avon	Longitudinal	Study	 of	 Parents	 and	 Children	 (ALSPAC)	 (Williams,	 Fraser	 et	 al.	 2014).	 	 Additionally,	patients	 in	 our	 cohort	 showed	 an	 inverse	 correlation	 for	BMI	 and	 cholesterol	 against	25OHD	 levels.	 	 Previously,	 one	 study	 had	 shown	 an	 inverse	 correlation	 between	BMI	and	 25OHD	 levels,	 with	 an	 estimated	 decrease	 of	 1.3nmol/L	 25OHD	 with	 each	 BMI	increase	 of	 1kg/m2	 (Stein,	 Strain	 et	 al.	 2009).	 Most	 previous	 studies	 have	 reported	separate	cholesterol	species.	Data	from	this	investigation	reported	a	decrease	in	25OHD	levels	 with	 increasing	 total	 cholesterol.	 In	 support	 of	 this,	 a	 relationship	 between	25OHD	 and	 cholesterol	 has	 previously	 been	 shown	 in	 102	 American	 children,	where	
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children	with	vitamin	D	deficiency	of	insufficiency	presented	with	higher	levels	of	total	cholesterol	in	comparison	to	those	who	had	sufficient	25OHD	levels	(Hourigan,	Abrams	et	al.	2015).			 Studies	 in	 adults	 have	 also	 highlighted	 the	 association	 between	 low	 serum	25OHD	levels	and	risk	of	non-alcoholic	fatty	liver	disease	(Targher,	Bertolini	et	al.	2007,	Barchetta,	Angelico	et	al.	2011,	Grünhage,	Hochrath	et	al.	2012,	Jablonski,	Jovanovich	et	al.	2013,	Rhee,	Kim	et	al.	2013,	Seo,	Eun	et	al.	2013),	with	animal	models	demonstrating	that	 skin	 exposure	 to	 sunlight	 may	 prevent	 NASH	 progression	 through	 reduced	hepatocyte	 inflammation,	 fibrosis	 and	 apoptosis	 (Nakano,	 Cheng	 et	 al.	 2011).	 	 In	addition,	one	study	investigating	a	vitamin	D	deficient	diet	in	an	obese	rat	NAFLD	model	demonstrated	 poorer	 histological	 features	 of	 NAFLD,	 insulin	 resistance,	 and	 up-regulated	gene	expression	of	hepatic	inflammation	and	oxidative	stress	(Roth,	Elfers	et	al.	2012),	while	a	recent	in	vitro	study	examining	the	effect	of	1,25(OH)2D3	on	primary	rat	hepatic	stellate	cells	demonstrated	antifibrotic	and	antiproliferative	effects	on	liver	fibrosis	(Abramovitch,	Dahan-Bachar	et	al.	2011).		 Results	from	our	study	found	no	significant	associations	between	25OHD	status	and	NAS,	or	any	of	the	investigated	SNPs	in	the	vitamin	D	metabolic	pathway	and	serum	25OHD	levels.	 	The	SNPs	 investigated	have	previously	been	associated	with	vitamin	D	status	in	other	populations	(NADSYN1	rs3829251	(Ahn,	Yu	et	al.	2010,	Zhang,	Wang	et	al.	2012),	DHCR7	rs12785878	(Grünhage,	Hochrath	et	al.	2012,	Zhang,	Wang	et	al.	2012),	
GC	rs2282679	(Ahn,	Yu	et	al.	2010,	Wang,	Zhang	et	al.	2010,	Signorello,	Shi	et	al.	2011),	rs4588	(Lu,	Sheng	et	al.	2012,	Zhang,	Wang	et	al.	2012),	rs7041	(Lu,	Sheng	et	al.	2012,	Zhang,	Wang	et	al.	2012),	CYP2R1	rs10741657	(Ramos-Lopez,	Bruck	et	al.	2007,	Zhang,	Wang	 et	 al.	 2012)).	 	 Included	 among	 the	 SNPs	 investigated	 in	 this	 study	 was	 GC	rs2282679,	a	highly	significant	observation	from	two	recent	GWAS	(Ahn,	Yu	et	al.	2010,	Wang,	Zhang	et	al.	2010),	of	which	one	reported	strong	associations	between	presence	of	the	minor	allele	and	decreased	GC	protein	concentrations	(Wang,	Zhang	et	al.	2010).		Although	the	same	association	was	not	observed	in	our	population,	our	group	size	was	relatively	 small,	 and	 power	 limitations	 may	 explain	 why	 we	 failed	 to	 detect	 any	differences	between	genotypes.		 The	 PNPLA3	 rs738409	 variant	 encodes	 a	 cytosine	 to	 guanine	 amino	 acid	substitution	 resulting	 in	 a	 non-synonymous	 codon	 change	 from	 isoleucine	 to	methionine	at	residue	148.		Biological	studies	have	demonstrated	that	the	risk	allele	(G)	
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abolishes	 the	 triglyceride	 hydrolysis	 activity	 of	 PNPLA3	 through	 a	 reduction	 of	substrate-access	to	the	entry	site,	and	therefore	a	decrease	in	the	triglyceride	hydrolysis	activity	of	PNPLA3	due	to	the	longer	side	chain	of	methionine	(He,	McPhaul	et	al.	2010).	The	result	of	the	mutation	limits	the	access	of	triglycerides,	such	as	palmitic	acid	to	the	catalytic	dyad	(Romeo,	Kozlitina	et	al.	2008,	He,	McPhaul	et	al.	2010,	Valenti,	Alisi	et	al.	2010,	Xin,	Zhao	et	al.	2013).	The	consequences	of	 the	 inability	of	 triglyceride	 to	enter	the	 active	 site	 of	 PNPLA3	 have	 previously	 been	 documented	 as	 accumulation	 of	triglyceride	 by	 limiting	 triglyceride	 hydrolysis,	 which	 in	 turn	 enhances	 the	accumulation	 of	 lipids	 in	 the	 hepatocytes.	 This	 genetic	 variant	 has	 previously	 been	strongly	 associated	 with	 increased	 hepatic	 fat	 content	 and	 inflammation	 in	 NAFLD	patients	 through	 GWAS	 (Romeo,	 Kozlitina	 et	 al.	 2008),	 and	 several	 candidate	 gene	studies	have	shown	a	strong	association	with	NAFLD	in	Caucasians	(Valenti,	Al-Serri	et	al.	2010,	Valenti,	Alisi	et	al.	2010).		Research	in	an	Italian	paediatric	population	(n=149)	with	biopsy	proven	NAFLD	further	confirmed	the	link	between	rs738409	and	increased	severity	of	steatosis	with	the	presence	of	NASH	and	fibrosis.		Patients	carrying	the	‘GG’	genotype	had	the	highest	risk	for	progressive	liver	disease	(Valenti,	Alisi	et	al.	2010).	In	agreement	with	previous	 studies,	 this	 study	has	observed	patients	presenting	with	at	least	 one	 copy	 of	 the	 G	 allele	 had	 increased	 steatosis	 and	 inflammation	 scoring	compared	to	patients	with	the	C	allele.		 The	 dehydrocholesterol	 reductase	 7	 (DHCR7)	 gene	 encodes	 the	 rate-limiting	enzyme	responsible	for	the	reduction	of	7-dehydrochlesterol	to	cholesterol	in	the	skin,	resulting	 in	 reduced	 availability	 7-dehydrocholesterol	 for	 the	 synthesis	 of	 vitamin	 D.		The	 rs12785878	 polymorphism	 found	within	 the	DHCR7	 region,	 encodes	 a	 base	 pair	change	of	T>G,	with	 the	 rare	 allele	having	previously	been	associated	with	decreased	circulating	25OHD	concentrations	and	increased	liver	stiffness	as	assessed	by	transient	elastography	in	Caucasian	patients	(Grünhage,	Hochrath	et	al.	2012).		Furthermore,	506	children	of	Han	Chinese	descent	also	genotyped	for	rs12785878	demonstrated	that	the	‘GG’	 genotype	was	 associated	with	 decreased	 25OHD	 levels	 in	 addition	 to	 rs3829251	(Zhang,	 Wang	 et	 al.	 2012).	 	 While	 there	 was	 no	 association	 between	 genotype	 and	25OHD	status	in	our	cohort,	presence	of	the	G	risk	allele	was	associated	with	increased	steatosis	scoring.		 In	 a	 GWAS,	 NADSYN1,	 which	 encodes	 the	 nicotinamide	 adenine	 dinucleotide	((NAD)	synthase-1)	has	previously	been	found	in	linkage	disequilibrium	with	a	SNP	in	
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DHCR7	 (Lu,	 Sheng	 et	 al.	 2012).	 	 NADSYN1	 is	 responsible	 for	 the	 final	 step	 in	 the	biosynthesis	of	NAD,	which	is	used	in	the	production	of	cholesterol	in	the	skin	from	7-dehydrocholesterol,	making	it	unavailable	for	the	vitamin	D	synthetic	pathway	(Ahn,	Yu	et	 al.	 2010).	 	 In	 our	 study,	 patients	 presenting	 with	 at	 least	 one	 copy	 of	 the	 rare	
NADSYN1	allele	showed	 increased	steatosis	grading	as	compared	to	patients	with	 ‘GG’	genotype.	Additionally,	Zhang	et	al.	 investigated	DHCR7/NADSYN1,	showing	significant	associations	 between	 these	 two	 SNPs	 and	 plasma	 25OHD	 status	 in	 a	 paediatric	population	(Zhang,	Wang	et	al.	2012).	 	When	examining	 this	genotype	against	25OHD	status	in	our	study,	results	were	confounded	by	small	sample	size	and	limited	frequency	of	the	‘AA’	genotype,	thus	reducing	the	reliability	of	the	conclusions	that	can	be	drawn.		 The	GC	gene	encodes	the	vitamin	D	binding	protein,	which	is	synthesised	in	the	liver	and	is	responsible	for	the	binding	and	transport	of	vitamin	D	and	its	metabolites	(Speeckaert,	Huang	et	al.	2006).		The	GC	protein	is	responsible	for	the	binding	of	up	to	88%	of	serum	25OHD,	and	 is	 thought	 to	have	anti-inflammatory	roles	 independent	 to	its	 role	 as	 the	 transporter	 of	 vitamin	 D	 (Speeckaert,	 Huang	 et	 al.	 2006,	 Kitson	 and	Roberts	 2012).	 	 Previous	 studies	 have	 investigated	 SNPs	 in	 this	 gene	 and	 their	association	with	25OHD	status.	The	most	widely	 studied	GC	 SNPs	 include	 rs4588	and	rs7041	 as	 they	 are	most	 consistently	 associated	with	 25OHD	 status	 (Lu,	 Sheng	 et	 al.	2012,	Santos,	Mascarenhas	et	al.	2013).	 	These	SNPs	are	11	base	pairs	apart	from	one	another	and	are	described	as	being	in	moderate	linkage	disequilibrium	(Wang,	Zhang	et	al.	2010,	Lu,	Sheng	et	al.	2012).	 	Specifically,	 rs4458	has	been	shown	to	be	associated	with	vitamin	D	status	in	Chinese	populations	(Lu,	Sheng	et	al.	2012,	Li,	Yin	et	al.	2014).			Interestingly,	SNP	genotyping	in	our	study	demonstrate	increased	inflammation	grading	with	the	presence	of	the	rs4588	A	allele.	However,	no	SNPs	in	the	GC	were	associated	with	lower	25OHD	status	and	could	be	due	to	the	small	sample	size	or	different	ethnic	group	investigated.			 CYP2R1	 is	 a	 key	 hydroxylase	 in	 vitamin	 D	 metabolism,	 and	 hydroxylates	cholecalciferol	at	the	25-C	position	to	produce	25OHD	in	the	liver	(Grünhage,	Hochrath	et	 al.	 2012).	 	 While	 no	 associations	 between	 liver	 histology	 and	 genotype	 were	identified	in	our	population,	rs10741657	has	previously	been	associated	with	increased	25OHD	status	and	presence	of	the	‘AA’	genotype	in	712	Caucasian	patients	with	various	chronic	liver	diseases,	including	NAFLD	(Grünhage,	Hochrath	et	al.	2012).	
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	 Previous	 studies	have	 investigated	VDR	 polymorphisms	 in	 the	 context	of	other	liver	diseases,	including	autoimmune	hepatitis	and	primary	biliary	cirrhosis,	where	they	appeared	to	contribute	to	the	risk	and	development	of	liver	disease	(Fan,	Tu	et	al.	2005,	Tanaka,	Nezu	et	al.	2009).		In	addition,	one	study	investigating	the	expression	of	VDR	in	NASH	 patients	 identified	 an	 inverse	 correlation	 with	 steatosis	 severity,	 lobular	inflammation	 and	 NAFLD	 score	 (Barchetta,	 Carotti	 et	 al.	 2012).	 	 Our	 study	demonstrated	similar	associations	between	presence	of	the	VDR	rs2228570	risk	allele	and	increased	steatosis	scoring.		 There	are	 limitations	of	 this	study	that	should	be	addressed	in	 future	research.		The	 study	cohort	 consisted	of	 retrospective	patients	who	had	attended	King’s	College	Hospital	and	had	stored	samples	available.	 	This	limited	sample	size,	it	may	have	been	difficult	 to	 detect	 some	 of	 the	 more	 modest	 associations	 with	 various	 SNPs.	 Future	prospective	 studies	 should	 be	 designed	 to	 specifically	 address	 this	 issue	 of	 statistical	power.	No	previous	 study	was	available	 to	perform	a	power	 calculation	 to	determine	the	 sample	 size	 required.	 	 This	work,	 as	 the	 first	 study	 conducted	 in	 this	 population,	could	provide	valuable	data	for	future	power	calculations	for	sample	numbers.		A	select	number	 of	 SNPs	 were	 investigated	 based	 on	 findings	 from	 previous	 studies.	 	 It	 is	possible	that	these	candidate	SNPs	play	only	a	small	role	in	the	wider	context	of	vitamin	D	 metabolism,	 and	 therefore	 future	 SNP	 analysis	 into	 these	 genes	 should	 still	 be	considered.		In	addition,	there	was	no	suitable	control	group	available	to	compare	either	vitamin	D	status	or	genotype	variation	with.		One	advantage	of	this	study	was	being	able	to	model	our	data	using	Sachs	equation	as	 to	correct	 for	seasonal	variation	 in	25OHD	sampling	 (Sachs,	 Shoben	et	 al.	 2013).	 	This	helped	 to	 reduce	 the	bias	of	 this	 study	as	fewer	patient	samples	were	excluded.		 This	 investigation	 suggests	 that	 genetic	 variants	 in	 the	NADSYN1,	 DHCR7	 and	
VDR	 may	 influence	 steatosis	 severity.	 	 In	 addition,	 genetic	 variation	 in	 the	 GC	 may	influence	severity	of	inflammation	grading	in	paediatric	NAFLD	patients.		This	the	first	study	 conducted	 in	 a	UK	paediatric	population	 to	 find	 a	 relationship	between	genetic	variations	in	the	vitamin	D	metabolic	pathway	and	liver	histology	severity.		In	addition,	our	study	is	the	first	to	confirm	in	a	UK	paediatric	population	the	finding	from	previous	adult	cohorts	that	PNPLA3	genotype	is	associated	with	histological	severity.		While	the	sample	size	 is	a	potential	 limitation	of	 this	work,	gold	standard	techniques	were	used	
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for	 NAFLD	 diagnosis,	 providing	 sufficient	 rationale	 for	 future	 studies	 replicating	 this	analysis	in	different	populations.	
 In	conclusion,	UK	paediatric	NAFLD	patients	have	extremely	low	winter	vitamin	D	status	and	vitamin	D	insufficiency	is	prevalent	throughout	the	year.	Some,	but	not	all,	polymorphisms	 in	 the	vitamin	D	metabolic	pathway	were	associated	with	histological	severity	in	NAFLD	Caucasian	patients.	These	data	suggest	the	need	for	action	to	remedy	the	 extensive	 low	 25OHD	 status	 and	 indicate	 a	 genetic	 link/consequence	 of	 this	 low	vitamin	D	status	on	disease	severity.		Further	research	is	certainly	warranted	given	that	vitamin	D	is	an	inexpensive,	well	tolerated	and	widely	available	dietary	supplement	that	could	 have	 beneficial	 effects	 on	 the	 development	 and	 concomitant	 progression	 of	NAFLD.			 	
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Chapter	4:	Examining	the	In	Vitro	Effects	of	Vitamin	D	
4.1	Background	
4.1.1	Hepatic	Stellate	Cells		 The	healthy	liver	is	largely	formed	from	hepatocytes,	making	up	around	60%	of	the	liver	cells,	and	around	90%	of	the	liver’s	volume	(Rubin	2011),	while	hepatic	stellate	cells	(HSCs)	are	thought	to	represent	between	5	and	8%	of	all	human	liver	cells,	or	1.4%	of	the	total	liver	volume	(Reynaert,	Thompson	et	al.	2002,	Moreira	2007).		In	the	healthy	liver,	HSCs	are	quiescent	and	play	a	central	role	in	hepatic	development,	regeneration,	lipoprotein	 and	 retinoid	metabolism	 in	 normal	 livers.	 	 In	 addition,	HSCs	 serve	 as	 the	main	storage	site	of	vitamin	A	(Gascon-Barre,	Demers	et	al.	2003)	accounting	for	more	than	 70%	 of	 their	 lipid	 content	 (Moriwaki,	 Blaner	 et	 al.	 1988),	 and	 regulate	 the	synthesis	of	extracellular	matrix	(ECM)	components	(Geerts	2001).		 As	a	result	of	 liver	 injury,	 in	particular	 lipid	accumulation	 in	hepatocytes,	HSCs	are	activated	 to	myofibroblast-like	 cells	and	change	 from	a	quiescent	 state,	 to	a	more	fibrogenic	phenotype.		This	is	characterised	by	loss	of	retinoid	and	lipid	stores,	vigorous	proliferation	 in	addition	to	secretion	of	 large	quantities	of	ECM	components	 including	collagen	(Senoo	2004,	Feldstein,	Papouchado	et	al.	2005)	giving	rise	to	its	role	in	liver	fibrosis	 in	various	chronic	 liver	disorders,	as	well	as	a	potential	 target	 for	 therapeutic	interventions	 to	 prevent	 cirrhosis	 development	 (Moreira	 2007).	 In	 animal	 models,	activated	 HSCs	 express	 α-smooth	 muscle	 actin	 (α-SMA),	 considered	 a	 distinctive	myofibroblast	feature	(Yin,	Evason	et	al.	2013).		Previously,	an	investigation	of	the	role	of	 retinol	 for	 the	 treatment	 of	 fibrosis	 resulted	 in	 restored	 lipid	 content,	 suppressed	collagen	production	 and	 inhibited	proliferation	 in	 immortalised	HSCs	 (Lee,	Mak	 et	 al.	2010).	
4.1.2	The	Vitamin	D	Receptor		 The	biological	effects	of	vitamin	D	are	mediated	through	the	interaction	with	the	VDR,	a	nuclear	receptor	with	ligand-activated	transcriptor	factor	activities	(Moore,	Kato	et	 al.	 2006).	 	 The	 VDR	 is	 involved	 in	 the	 immune	 response,	 fibrogenesis,	 and	inflammation,	 and	 is	 associated	with	 a	 liver-protective	 effect	 in	 experimental	models	(Abramovitch,	Dahan-Bachar	et	al.	2011,	Roth,	Elfers	et	al.	2012).		Previous	studies	have	indicated	that	1,25(OH)2D3	(1,25OHD)	has	growth	inhibitory	effects	on	both	kidney	and	
			 92	
lung	 fibrosis	(Tan,	Li	et	al.	2006,	Ramirez,	Wongtrakool	et	al.	2010,	Zhang,	Kong	et	al.	2010)	in	addition	to	the	liver	(Petta,	Camma	et	al.	2010).		Treatment	of	lung	fibroblasts	with	 1,25OHD	 resulted	 in	 reduced	TGF-β1	 induced	proliferation	 in	 a	 dose	 dependent	manner	 (Ramirez,	 Wongtrakool	 et	 al.	 2010)	 while	 in	 a	 murine	 kidney	 model,	 cell	proliferation	and	apoptosis,	alongside	fibronectin	and	type	I	and	type	III	collagen	mRNA	expression,	 were	 all	 reduced	 with	 paricalcitriol	 treatment	 (Tan,	 Li	 et	 al.	 2006).		However,	 vitamin	 D	 cannot	 reverse	 established	 cirrhosis	 (Abramovitch,	 Sharvit	 et	 al.	2015).		 The	liver	as	a	whole	expresses	extremely	low	levels	of	the	VDR;	the	majority	of	the	liver	cell	population	is	made	up	of	hepatocytes,	which	express	extremely	low	levels	of	the	receptor,	while	the	non-parenchymal	cell	populations,	including	HSCs,	are	known	to	express	VDR,	but	are	much	lower	in	abundance	(Gascon-Barre,	Demers	et	al.	2003).		The	 VDR	 acts	 as	 a	 ligand-modulated	 transcription	 factor,	 which	 binds	 to	 specific	sequences	 in	 target	 genes,	 including	 the	 vitamin	 D	 response	 element,	 increasing	 or	decreasing	 their	 transcription	 rates	 through	 the	 interaction	 with	 a	 vast	 array	 of	 co-activators,	 co-repressors	and	 chromatin	modifier	 enzymes	and	 remodeling	 complexes	(Carlberg	and	Seuter	2009,	Carlberg	and	Seuter	2010).			 In	 adult	 rats,	 VDR	 expression	 is	 high	 in	 the	 intestines	 and	 kidneys,	 but	 is	extremely	low	in	the	liver	(Sandgren,	Bronnegard	et	al.	1991).	 	In-depth	analysis	of	all	liver	 cell	 types	 for	 VDR	 expression	 by	 immunoblotting	 and	 semiquantative	 RT-PCR	showed	the	transcripts	and	proteins	were	virtually	absent	in	hepatocytes,	while	clearly	expressed	 in	 non-parenchymal	 cells	 (Gascon-Barre,	 Demers	 et	 al.	 2003).	 	 One	 study	investigating	 the	 VDR	 protein	 expression	 in	 primary	 rat	 HSCs	 demonstrated	 that	quiescent	HSCs	had	high	levels	of	VDR	protein.		After	activation,	VDR	protein	decreased,	and	after	 full	 activation,	VDR	protein	detected	by	Western	Blot	was	 reduced	by	40%,	but	 could	 be	 stimulated	 with	 1,25OHD	 treatment	 (Abramovitch,	 Dahan-Bachar	 et	 al.	2011).	
4.1.3	Vitamin	D	Treatment	in	Murine	Models			 In	choline-deficient	diet-induced	NASH	rats,	intraperitoneal	injections	of	vitamin	D	 over	 12	 weeks	 resulted	 in	 decreased	 free	 fatty	 acids	 (FFAs),	 TG,	 the	 number	 of	apoptotic	 cells	 in	 the	 liver,	 in	 addition	 to	 an	 improvement	 in	 liver	 histology.		Surprisingly,	 the	 highest	 dosage	 of	 1,25OHD	 (10μg/kg	 twice	 weekly)	 led	 to	 adverse	
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effects	including	higher	levels	of	hepatic	α-SMA	positive	cells	as	well	as	lower	levels	of	hepatic	 VDR	 in	 comparison	 to	 5μg/kg	 dosing	 (Han,	 Cui	 et	 al.	 2015).	 In	 a	 separate	choline-deficient	 diet	 induced	model	 of	 NASH	 in	 rats,	 phototherapy	 or	 0.1-0.4	 μg/kg	1α(OH)D3	oral	supplementation	was	assessed	for	6	weeks	(Nakano,	Cheng	et	al.	2011).		Results	showed	that	phototherapy	ameliorated	hepatocyte	apoptosis,	inflammation	and	fibrosis,	while	supplementation	reduced	NASH	progression	in	the	choline-deficient	diet-induced	NASH	model.		Most	notably,	phototherapy	failed	to	ameliorate	both	obesity	and	steatosis,	suggesting	that	phototherapy	may	possess	anti-inflammatory	or	anti-fibrotic	properties	rather	than	anti-steatotic	properties.		 In	a	separate	study,	rats	were	fed	normal	fat	diets,	high	fat	diets	(HFD)	or	HFD	with	 intraperitoneal	 injections	 of	 1,	 2.5	 and	 5μg/kg	 1,25OHD	 every	 other	 day	 for	 8	weeks.		Rats	who	received	1,25OHD	in	conjunction	with	the	HFD	demonstrated	reduced	weight	 gain	 and	 reduced	 liver	 weight	 in	 comparison	 to	 HFD	 fed	 rats.	 	 In	 addition,	1,25OHD	attenuated	hepatic	steatosis	in	a	dose-dependent	manner	(Yin,	Yu	et	al.	2012).	
4.1.4	In	Vitro	Treatment	of	Vitamin	D		 Investigations	 into	 the	 in	vitro	 effects	of	vitamin	D	 treatment	on	hepatocellular	carcinoma	cell	lines	(Horvath,	Lakatos	et	al.	2012)	demonstrated	a	1000-fold	increase	in	HepG2	cellular	expression	of	CYP24A1	 treated	with	1nM	1,25OHD	while	Huh-Neo	cell	lines	 showed	 a	 more	 blunted	 response	 of	 100-fold	 increase.	 	 Huh5-15,	 a	 hepatitis-C	virus	 containing	 cell	 line,	 and	Hep3B,	 a	 human	 hepatoma	 cell	 line	 derived	 from	 an	 8	year	old	black	male,	cells	showed	no	change	in	CYP24A1	mRNA	expression.		In	addition,	HepG2	cells	 showed	a	dramatic	 response	 in	mRNA	 levels	of	CYP24A1	 at	8	hours	after	treatment	with	4nM	1,25OHD,	which	promptly	dropped	at	10	hours,	while	Huh-Neo	cell	mRNA	 levels	 of	CYP24A1	 peaked	 at	 14	 hours	 and	 remained	 high	 for	 10	 hours	 before	mRNA	 levels	dropped.	 	Horvath	and	colleagues	also	 investigated	mRNA	expression	of	
VDR	and	CYP27B1	in	all	four	cell	lines,	but	found	no	change	with	10nM	treatment	after	5	hours	incubation	(Horvath,	Lakatos	et	al.	2012).		 Human	studies	have	also	demonstrated	a	positive	effect	of	vitamin	D	on	hepatic	fibrosis	 through	 the	 mediation	 of	 TGF-β	 (Abramovitch,	 Dahan-Bachar	 et	 al.	 2011,	Beilfuss,	Sowa	et	al.	2015).		In	a	case	control	study,	106	morbidly	obese	NAFLD	patients,	diagnosed	by	liver	biopsy,	were	compared	against	10	healthy	weight	controls.	Baseline	serum	 FFAs	 were	 significantly	 higher	 in	 the	 NAFLD	 cohort,	 while	 serum	 vitamin	 D	
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levels	were	lower.	 	In	addition,	the	hepatic	VDR	mRNA,	assessed	from	biopsy	samples,	was	 significantly	 increased	 in	NASH	patients	 compared	 to	 healthy	 controls.	However,	NAFLD	 patients	 showed	 repressed	 full	 length	 VDR	 protein,	 but	 interestingly	 had	significantly	 higher	 levels	 of	 VDR	 fragment	 in	 liver	 tissue,	 suggestive	 of	 VDR	degradation	 (Beilfuss,	 Sowa	 et	 al.	 2015).	 	 Additionally,	 primary	 human	 HSCs	 were	isolated	 and	 treated	 with	 TGF-β	 with	 and	 without	 vitamin	 D;	 those	 co-treated	 with	vitamin	D	ameliorated	TGF-β	fibrogenesis	(Beilfuss,	Sowa	et	al.	2015).		 The	HSC	 line	LX-2,	derived	from	primary	human	HSCs	 immortalized	with	SV40	large	T	antigen	followed	by	selective	culture	of	early	passaged	cells	in	low	serum	media	conditions	 (Xu,	Hui	 et	 al.	 2005),	 are	 a	 suitable	model	 for	 the	 study	 of	 human	hepatic	fibrosis.	 	 Previous	 studies	 have	 investigated	 the	 effect	 of	 vitamin	 D	 treatment	 on	collagen	 formation	 (Potter,	 Liu	 et	 al.	 2013),	 TGF-	 β	 and	 stress	 ligands	 major	histocompatibility	complex	class	I-related	chain	A	and	B	(MICA/B)	as	assessed	by	qRT-PCR	(Seydel,	Beilfuss	et	al.	2011).		Seydel	et	al.	investigated	the	effect	of	1μM	vitamin	D2	on	LX-2	cells,	which	had	undergone	prior	 lipid	 loading	(2:1	oleic	acid	[OA]	to	palmitic	acid	[PA]).		mRNA	results	showed	TGF-β	expression	in	LX-2	cells,	regardless	of	response	to	 fatty	 acid	 loading,	 was	 reduced	 with	 vitamin	 D2	 treatment	 (Seydel,	 Beilfuss	 et	 al.	2011).		More	recently,	Potter	and	colleagues	investigate	the	effects	of	1,25OHD	in	LX-2	cells.		After	treatment	with	10nM	1,25OHD,	mRNA	levels	of	human	α1	(I)	collagen	were	reduced	suggestive	of	reduced	collagen	synthesis	and	formation	(Potter,	Liu	et	al.	2013).		 Currently	there	is	no	antifibrotic	therapy	available	for	chronic	liver	disease	that	has	been	approved	by	the	Food	and	Drug	Administration	(Cohen-Naftaly	and	Friedman	2011).		Therefore,	a	greater	understanding	of	the	molecular	mechanisms	regulating	the	hepatic	fibrosis	response,	and	the	role	vitamin	D	may	play	in	this,	is	needed	for	future	antifibrotic	therapies.	
4.1.5	Aims			 The	aims	of	this	study	were	firstly	to	assess	and	confirm	VDR	protein	expression	in	LX-2	and	HepG2	cell	lines.		Secondly,	to	characterise	a	time	and	dose	concentration	of	1,25OHD	 for	 treatment	 in	 these	 cell	 lines	 with	 a	 measurable	 response	 (VDR	 and	CYP24A1	mRNA	levels)	and	thirdly,	to	confirm	the	use	of	immortalized	HSCs	as	a	model	of	NAFLD	in	response	to	1,25OHD	treatment.	
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4.1.6	Hypotheses		 LX-2	cells	will	respond	to	 fatty	acid	 loading.	LX-2	cells	will	have	higher	protein	expression	 of	 VDR	 in	 comparison	 to	HepG2	 cells.	 	mRNA	 expression	 of	CYP24A1	 and	
VDR	will	be	increased	in	LX-2	cells	in	response	to	1,25OHD	treatment.		LX-2	will	act	as	a	human	 in	 vitro	 phenotype	 model	 for	 the	 study	 of	 HSCs	 in	 response	 to	 1,25OHD	treatment,	resulting	in	reduced	LX-2	cell	proliferation.		
4.1.7	Objectives	
• To	characterise	the	response	of	fatty	acid	loading	in	LX-2	cells	
• To	measure	basal	VRD	protein	expression	in	LX-2	and	HepG2	cells	
• To	 ascertain	 the	 time/dose	 curves	 for	 1,25OHD	 treatment;	 establishing	 a	measurable	 response	 of	 VDR	 and	 CYP24A1	 mRNA	 expression	 to	 1,25OHD	treatment	in	LX-2	and	HepG2	cell	lines	
• To	characterize	cell	proliferation	in	response	to	1,25OHD	treatment	in	LX-2	and	HepG2	liver	cells,	and	HT-29	positive	control	cells	
4.2	Materials	and	Methods	
4.2.1	Chemicals	High	 glucose	 (4.5g/L,	 25mM)	 containing	 Dulbecco’s	 Modified	 Eagle	 Medium		(DMEM),	 Hyclone	 fetal	 bovine	 serum	 (FBS),	 non-essential	 amino	 acids	 (NEAAs),	penicillin	 streptomycin,	 L-glutamine,	 and	 trypsin	 were	 purchased	 from	 Scientific	Laboratory	 Supplies	 (SLS	 LTD,	 Nottingham,	 UK).	 McCoy’s	 5A	 medium,	 micro	bicinchoninic	acid	(BCA)	kit,	TaqMan	Fast	Advance	Master	Mix,	Superscript	III,	TaqMan	gene	 expression	 assays,	 SYBR	 Safe	 DNA	 gel	 stain,	 5X	 sample	 reducing	 buffer,	 Novex	Sharp	pre-stained	protein	 ladder,	 PVDF	membrane	were	 supplied	by	Fisher	 Scientific	(Loughborough,	UK).	HepG2	cells	were	from	ECACC	via	Sigma	Aldrich	(Dorset,	UK)	and	HT29	 cells	 were	 supplied	 by	 ATCC	 (Middlesex,	 UK).	 1α,25-dihydroxyvitamin	 D3	 was	supplied	by	Sigma	Aldrich	in	the	first	instance,	and	then	by	Cayman	Chemical	(Michigan,	USA);	 Nile	 red	 was	 from	 Invitrogen	 Life	 Technologies	 (Paisley,	 UK).	Radioimmunoprecipitation	assay	(RIPA)	buffer,	acrylamide/	bis-acrylamide	30%,	fatty	acid	 free-bovine	 serum	 albumin	 (FAF-BSA),	 ammonium	 persulphate,	 N,N,N1,N1-tetramethyletheylendiamine	(Temed),	protein	sample	loading	buffer,	palmitic	acid	(PA)	and	oleic	acid	(OA),	crystal	violet	and	DMSO	were	supplied	by	Sigma	Aldrich.	IRDye	was	
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from	 LI-COR	 Biosciences	 (Cambridge,	 UK).	 Vybrant	 MTT	 Cell	 Proliferation	 Assay	 Kit	(Takara,	 Clontech,	 Saint-Germin-en-Laye,	 France).	 DNase	 was	 supplied	 by	 Promega	(Hampshire,	 UK).	 EDTA-free	 protease	 inhibitor	 was	 from	 Roche	 Diagnostics	 Limited	(West	 Sussex,	 UK).	 Phosphate	 buffered	 saline	 (PBS)	 was	 supplied	 by	 Oxoid	 Limited	(Hampshire,	 UK).	 Human	 Reference	 Tissue	 RNA	 was	 purchased	 from	 TaKaRa	 Bio	Europe/Clontech	 (Saint-Germaine-En_Laye,	 France).	 Rabmab	 VDR	 and	 α-tubulin	antibodies	were	purchased	from	Abcam	(Cambridge,	UK).	
4.2.2	Cell	Culture		 LX-2	 cells,	 a	 generous	 donation	 from	 Scott	 Friedman	 (obtained	 via	 material	transfer	in	agreement	with	the	Institute	of	Hepatology),	and	HepG2	cells	were	routinely	cultured	in	high	(4.5g/L,	25mM)	glucose	containing	DMEM.		HT-29	cells,	a	generous	gift	from	 Dr.	 Fiona	 Green,	 were	 cultured	 in	 McCoy’s	 5A	 medium.	 	 DMEM	 media	 was	supplemented	 with	 10%	 FBS,	 1%	 L-glutamine,	 1%	 NEAAs,	 100U/ml	 penicillin,	 and	100µg/ml	streptomycin.	McCoy’s	5A	medium	was	supplemented	as	above	excluding	L-glutamine.	1X	PBS	was	prepared	and	sterilized	and	used	to	wash	cells	prior	to	routine	passage	or	treatment.		Trypsin	was	used	to	detach	HepG2	and	HT29	cells	from	the	flask	at	 1%	 and	 0.25%	 concentrations	 respectively;	 LX-2	 cells	 were	 detached	 in	 1X	 PBS	solution.	 	Following	detachment	of	cells	from	the	cell	culture	flask	and	production	of	a	single	cell	suspension	using	a	19ga	needle,	10µl	of	each	cell	suspension	was	mixed	with	equal	 volumes	 of	 0.4%	w/v	 trypan	 blue	 dye	 (0.2%	 final	 concentration)	 before	 being	read	 by	 an	 automated	 cell	 counter	 (BioRad,	 Hemel	Hempstead,	 UK)	which	 calculated	both	 the	 cell	 count	 and	 the	 percentage	 of	 live	 cells.	 	 	 	 HepG2	 and	 HT29	 cells	 were	routinely	 seeded	 at	 30,000	 cells/cm2	in	 80cm2	 tissue	 culture	 flasks.	 	 LX-2	 cells	 were	routinely	seeded	at	20,000	cells/cm2	with	media	being	changed	after	2	days	of	growth.		
4.2.3	Fatty	Acid	Treatment		 Standard	in-house	fatty	acid	treatment	methods	were	performed	48	hours	after	seeding	 and	 experimental	 assays	 after	 72	 hours	 for	 LX-2	 cells.	 	 Briefly,	 high	 glucose	serum	 free	 (SF)	 DMEM	 media	 was	 supplemented	 with	 1%	 L-Glutamine,	 1%	 NEAAs,	100U/ml	 penicillin,	 and	 100µg/ml	 streptomycin.	 DMSO	 (vehicle),	 PA	 or	 OA	 were	complexed	with	FAF-BSA	for	1	hour	at	37°C,	vortex	mixing	at	10	minute	intervals.		The	complexed	fatty	acid	was	sterilized	by	passing	through	a	0.22μm	filter	before	adding	to	
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SF	media.	 	Cells	were	treated	with	varying	concentrations	of	FA	(100-500μM	PA,	100-500μM	OA	or	200:200μM	PA:OA)	and	incubated	for	24	hours	at	37°C.			
4.2.4	MTT	Assay/Cell	Viability		 The	MTT	(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium	bromide)	assay	kit	was	used	to	determine	cell	viability	and	proliferation.		LX-2	cells	were	seeded	at	20,000	cells/cm2	 while	 HepG2	 cells	 were	 seeded	 at	 30,000	 cells/cm2	 in	 96	 well	 plates	 in	triplicate.		Cells	were	either	treated	with	FA	after	48	hours	of	growth	as	describe	above,	or	with	10nM	vitamin	D,	dissolved	in	DMSO,	in	serum-containing	medium	after	4	hours	of	seeding	and	left	to	grow	for	up	to	168	hours	before	treating	with	MTT.		The	assay	was	carried	out	according	to	manufacturer’s	instructions	and	works	by	reducing	MTT	salt	by	mitochondrial	dehydrogenase	to	insoluble	formazan,	which	can	then	be	dissolved	in	an	organic	solvent,	DMSO	(Carmichael,	DeGraff	et	al.	1987).		Absorbance	was	quantified	at	540nm	on	a	multi-mode	micro-plate	reader	(BMG	Labtech,	UK)	after	incubation	at	37°C	for	10	minutes.	
4.2.5	Intracellular	Lipid	Quantification		 Nile	 red	 staining	 was	 performed	 on	 LX-2	 cells	 to	 quantitatively	 assess	intracellular	 lipid	 accumulation.	 	 Briefly,	 cells	 were	 harvested	 by	 detaching	 the	 cells	from	 the	 flask	and	aliquoting	500,000	cells,	which	were	centrifuged	at	800	x	g	 for	10	minutes	 and	 the	 supernatant	 removed.	 	 500μl	 of	 1μM	Nile	 red	dissolved	 in	PBS,	 pre-warmed	 to	 37°C	was	 added	 to	 the	 pelleted	 cells,	mixed	 thoroughly	 and	 incubated	 at	37°C	for	a	further	10	minutes.		Cells	were	spun	again	at	800	x	g	for	10	minutes	and	the	supernatant	removed	before	pre-warmed	PBS	was	used	to	re-suspend	the	cells.	 	Cells	were	 passed	 through	 at	 19ga	 needle,	 pipetted	 in	 triplicate	 into	 a	 black	 96	well	 plate	(Dutscher	 Scientific,	 Essex,	 UK)	 and	 read	 at	 excitation	 485-12nm	 and	 filter	 emission	520nm	on	a	micro-plate	reader	(BMG	Labtech).	
4.2.6	Protein	Analysis		 Protein	 samples	 were	 collected	 from	 cells	 by	 applying	 RIPA	 buffer	 containing	EDTA-free	protease	inhibitor	directly	onto	the	cells	and	mixing	thoroughly	on	ice.	The	protein	concentrations	of	cell	extracts	were	estimated	using	the	BCA	assay.		A	standard	curve	from	0-2000μg/ml	was	produced	using	BSA	serially	diluted	in	RIPA.		Cell	extracts	were	measured	at	neat,	1:5	and	1:10	dilution	in	RIPA	buffer.		A	volume	of	25μl	of	each	
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concentration	of	BSA,	samples	or	working	reagent	was	pipetted	into	triplicate	wells	of	a	clear	96	well	plate.	 	Working	 reagent	was	made	up	 following	 the	kit	 instructions	and	200μl	was	added	to	each	of	the	wells	containing	standards	or	samples.	 	The	plate	was	incubated	at	37°C	for	30	minutes	before	measuring	the	absorbance	of	the	wells	with	a	micro-plate	reader	(BMG	Labtech)	at	562nm.		 Protein	 extracts	 were	 prepared	 from	 LX-2	 and	 HepG2	 cell	 extracts.	 	 Equal	concentrations	of	proteins,	made	up	to	equal	volumes	using	RIPA	buffer,	were	heated	at	60°C	for	10	minutes	with	5X	sample	reducing	buffer	and	separated	in	12%	acrylamide	gels	 under	 reducing	 conditions	 and	 electro-blotted	 on	 methanol	 activated	 PVDF	membranes	with	 a	Novex	 Sharp	 pre-stained	 protein	 standard.	 	 Equal	 loading	 protein	was	monitored	by	Ponceau	 staining	and	non-specific	binding	 sites	were	blocked	with	TBST	[50	mM	Tris/HCL,	150	mM	NaCl,	0,1%	(v/v)	Tween	20	(pH	7.6)]	containing	0.1%	(w/v)	 non-fat	 milk	 powder.	 	 Antibodies	 specific	 to	 VDR	 (rabbit	 monoclonal,	 1:2000	concentration)	and	α-tubulin	(mouse	monoclonal,	1:5000	concentration)	were	used	to	probe	the	membrane	overnight	at	4°C.		Primary	antibodies	were	detected	with	LI-COR	IRDye	 labeled	 secondary	 antibodies	 (donkey-anti-rabbit	 680;	 1:10,000	 concentration,	and	donkey	anti-mouse	800;	1:10,000	concentration)	for	1	hour	at	room	temperature.		Blots	were	air-dried	before	visualizing	by	Odossey	CLx	Imaging	System	and	quantified	using	Image	Studio	Lite	version	3.1	(LI-COR	biosciences).	
4.2.7	Vitamin	D	Treatment		 1,25OHD	 was	 prepared	 in	 DMSO	 (Sigma	 Aldrich)	 or	 ethanol	 (Cayman)	 and	stored	at	-20°C	in	tubes	flushed	with	nitrogen	gas,	protected	from	light.	 	1,25OHD	was	prepared	in	serum	containing	media	at	a	concentration	of	1μg/well	and	serial	dilutions	were	performed	for	lower	concentrations.	
4.2.8	RNA	Isolation		 Cells	 were	 seeded	 in	 six-well	 tissue	 culture	 plates	 and	 treated	 after	 48	 hours	growth	with	10nM	1,25OHD	in	SF	media.		Total	RNA	was	isolated	at	0,	1,	2,	4,	6,	8,	10,	12	and	 24	 hours	 after	 treatment	 using	 TRIzol	 reagent	 and	 stored	 at	 -80°C	 till	 extracted.		RNA	was	extracted	by	phase	separation	and	subsequent	precipitation	before	 the	RNA	pellet	was	washed	and	re-suspended	in	DEPC-treated	water.	 	The	concentration	of	the	isolated	 RNA	 was	 determined	 spectrophotometrically	 and	 purity	 evaluated	 by	260/230nm	and	260/280nm	optical	density.	 	RNA	integrity	was	confirmed	by	1%	gel	
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electrophoresis	stained	with	SYBR	Safe	and	visualized	on	the	Bio	Rad	Gel	Doc	EZ	system.		Extracted	 RNA	 was	 stored	 at	 -80°C	 till	 required.	 	 RNA	 samples	 were	 DNase	 treated	according	to	manufacturer’s	protocol.	SuperScript	III	First-Strand	Synthesis	System	was	used	 to	 synthesise	 the	 first	 strand	 cDNA	 from	 one	 microgram	 of	 purified	 cell	 RNA	samples	and	human	reference	tissue	RNA	according	to	manufacturer’s	instruction.	RT-qPCR	for	pre-designed	TaqMan	gene	expression	assays	for	CYP24A1	(Hs00167999_m1)	and	VRD	(Hs00172113_m1),	and	18S	(Hs03003631_g1),	used	as	a	reference	gene,	were	prepared	 with	 TaqMan	 Fast	 Advance	 Master	 Mix	 and	 run	 in	 triplicate	 on	 MicroAmp	Optical	384-well	reaction	plates	(Fisher)	on	the	QuantStudio	7	(ThermoFisher	Scientific)	according	 to	 manufacture’s	 instructions	 with	 a	 4-5	 point	 standard	 curve	 run	 in	duplicate	on	each	plate	derived	from	the	human	reference	tissue	RNA.		Variation	in	the	amount	of	mRNA	transcripts	were	corrected	to	the	level	of	expression	of	the	18S	gene	in	each	individual	sample.	
4.2.9	Clonogenic	Assays		 LX-2,	 HT29	 and	 HepG2	 cells	 were	 seeded	 at	 densities	 of	 600,	 800	 and	 2000	cells/well,	respectively,	into	sterile	six-well	tissue	culture	plates	and	left	to	attach	for	24	hours	 in	 serum-containing	 media.	 	 Media	 was	 removed	 and	 cells	 were	 treated	 with	either	fresh	serum-containing	media,	media	with	vehicle	(ethanol),	or	media	with	1μM,	100nM,	10nM	or	1nM	1,25OHD.		LX-2	cells	were	left	for	10	day,	HT29	cells	for	12	days	and	HepG2	 cells	 for	 13	 days	 before	 the	media	was	 removed.	 	 Colonies	were	washed	twice	with	ice-cold	PBS	and	stained	with	0.5%	crystal	violet	dissolved	in	25%	methanol.		The	 numbers	 of	 colonies	 containing	 at	 least	 50	 cells	were	 determined.	 	 Cell	 colonies	were	imaged	using	a	Nikon	Eclipse	TS100	(Nikon,	Surrey,	UK).	
4.2.10	Statistical	Analysis		 The	 results	 are	 presented	 as	 mean	 ±	 standard	 error	 of	 the	 mean	 (SEM)	 and	where	 suitable,	 displayed	 as	 percent	 relative	 to	 vehicle.	 	 All	 statistical	 analysis	 were	carried	out	using	GraphPad	Prims	v6	(California,	USA).	 	 	Comparisons	between	groups	were	measured	through	one-way	or	two-way	ANOVA,	or	non-parametric	equivalents	as	appropriate	based	on	the	distribution	of	the	data.		Significance	was	set	at	p≤0.05.	
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4.3	Results	
4.3.1	Fatty	Acid	Treatment		 The	 effect	 of	 fatty	 acid	 treatment	 on	 LX-2	 cell	 viability	was	 examined	 after	 24	hours	 culture	with	 PA,	 OA	 or	 a	 combination	 of	 the	 two	 fatty	 acids.	 	 LX-2	 cells	 (n=5)	responded	 to	 fatty	 acid	 treatment	 (Figure	 4.1A)	 with	 a	 significant	 reduction	 in	 cell	viability,	 compared	to	DMSO	vehicle,	of	29%	and	22%	observed	at	100μM	PA	and	OA	respectively	(p<0.0001).		The	greatest	effect	on	viability	was	detected	after	a	500μM	PA	treatment	with	a	64%	reduction	in	the	viability	of	LX-2	cells.		In	addition	PA	showed	a	dose-dependent	 trend	 in	 response	 to	 fatty	 acid	 treatment;	 and	 in	 comparison	 to	 OA	showed	 a	 significant	 divergence	 from	 200μM	 concentration	 (p<0.0001).	 In	 contrast,	100μM	OA	reduced	viability	by	22%	where	it	plateaued	and	no	further	reduction	in	cell	viability	was	observed	with	increasing	doses	up	to	500μM.		On	the	other	hand,	while	PA	doses	of	100	and	200μM	showed	a	dose	effect,	the	reduction	in	cell	viability	plateaued	between	300-500μM.		Next	we	assessed	the	viability	of	LX-2	cells	after	24	hours	growth	with	 mixed	 fatty	 acid	 treatment	 (200μM	 PA	 with	 200μM	 OA)	 using	 MTT	 assay.		Combination	treatment	of	PA	and	OA	(Figure	4.1B)	in	LX	2	cells	(n=4)	suggests	that	PA,	rather	than	total	quantity	of	fatty	acids	alone,	was	more	toxic	to	LX-2	cells;	200μM	PA	treatment	showed	a	statistically	significant	reduction	of	viable	cells	to	49%	(p=0.0035).		Next	we	measured	intracellular	lipid	accumulation	for	these	same	treatments	using	Nile	Red.		Fat	accumulation	showed	a	dose	response	effect	with	increasing	intracellular	lipid	with	 increasing	 fatty	 acid	 concentrations	 (Figure	 4.1C)	where	 400μM	 combined	 fatty	acid	treatment	(200μM	PA	with	200μM	OA;	n=3)	showed	the	greatest	intracellular	lipid	accumulation	with	a	2.8	fold	increase	(p=0.0183).										
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Figure	4.1:	Cell	viability	and	lipid	accumulation	in	LX-2	after	24	hours	fatty	acid	treatment.	A)	LX-2	cells	demonstrate	toxic	effects	of	fatty	acid	treatment	for	both	oleic	and	palmitic	acids	treated	separately	and	 	 B)	 in	 combination	 as	 assessed	 by	MTT	 assay.	 C)	 Fatty	 acid	 accumulation	within	 the	 cells	 is	 dose	responsive.	 	Data	are	mean	±	SEM,	n=3-5	 for	each	experiment.	P-values	derived	 from	 two-way	ANOVA	with	Sidak’s	multiple	comparisons	 test	was	performed	on	 for	4.1A.	 	 *	denotes	statistical	 significance	 to	vehicle	^	denotes	statistical	significance	between	fatty	acid	treatments.	 	P-values	derived	from	Kruskal-Wallis	 test	 with	 Dunn’s	 multiple	 comparison	 for	 4.1B	 and	 4.1C.	 	 p<0.05	 is	 considered	 statistically	significant.		
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4.3.2	Vitamin	D	Receptor		 Basal	 levels	of	VDR	protein	expression	were	measured	in	HepG2	and	LX-2	cells	by	 immunoblotting	 and	normalised	 to	 α-tubulin	 protein	 levels.	 	 In	 line	with	 previous	studies	(Gascon-Barre,	Demers	et	al.	2003)	expression	of	VDR	protein	was	much	higher	in	the	hepatic	stellate	cells	(LX-2)	relative	to	hepatocytes		(HepG2;	Figure	4.2).	
		
	
Figure	4.2:	Western	blot	analysis	of	basal	VDR	protein	expression	in	LX-2	and	HepG2	cells.	Western	blot	analysis	showed	a	reduced	baseline	expression	of	VDR	in	HepG2	in	comparison	with	LX-2	cells.	Data	are	represented	as	mean	+	SEM,	n=2.			
4.3.3	Vitamin	D	Treatment			 One	previous	study	demonstrated	an	increase	in	VDR	protein	expression	in	LX-2	cells	after	24	hour	 treatment	with	10nM	1,25OHD	(Potter,	Liu	et	al.	2013).	 	However,	after	treating	LX-2	cells	with	1μM,	100nM	or	10nM	1,25OHD	for	24	hours,	VDR	protein,	as	 assessed	 by	 Western	 Blot	 analysis,	 showed	 no	 difference	 between	 treatment	concentrations	(data	not	shown).		This	led	us	to	hypothesize	that	induction	of	the	VDR	may	 not	 have	 been	 detectable	 at	 the	 protein	 level	 after	 only	 24	 hours,	 therefore	examining	VDR	mRNA	expression	 levels	was	a	next	 logical	step	 in	determining	a	 time	and	concentration	effect.		 Previous	 studies	 investigating	 the	 effect	 of	 1,25OHD	 showed	 alterations	 in	collagen	 Iα1	 mRNA	 expression	 in	 HSC	 mRNA	 expression	 after	 24	 hours	 at	concentrations	ranging	 from	2.5μM	(Abramovitch,	Dahan-Bachar	et	al.	2011)	to	10nM	(Potter,	 Liu	 et	 al.	 2013),	while	HepG2	 cells	 showed	 a	 significant	 changes	 in	 CYP24A1	mRNA	after	treatment	with	1.6nM	1,25OHD	after	 just	4	hours	(Horvath,	Lakatos	et	al.	
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2012).	With	this	 in	mind,	LX-2	and	HepG2	cells	(n=5-6)	were	cultured	 in	high	glucose	media	with	10nM	1,25OHD,	supplied	by	Sigma	Aldrich,	re-suspended	 in	DMSO,	over	a	period	of	24	hours.	RNA	samples	were	isolated	at	0,	1,	2,	4,	6,	8,	10,	12	and	24	hours	to	establish	 an	 appropriate	 dose	 time	point	 for	 responsiveness	 of	 VDR	 to	 treatment.	 	 In	addition,	because	the	literature	suggested	VDR	expression	may	not	respond	to	vitamin	D	 treatment	 in	HepG2	cells	 (Horvath,	Lakatos	et	al.	2012),	we	examined	CYP24A1	 for	maximal	vitamin	D	effect.		Surprisingly,	results	showed	no	change	in	RNA	expression	of	VDR	 or	 CYP24A1	 at	 any	 time	 point	 for	 either	 cell	 line	 (Figure	 4.3).	 	 In	 line	with	 the	protein	 data	 relative	 expression	 of	 VDR	 in	 LX-2	 cells	 was	 significantly	 higher	 in	comparison	 to	 HepG2	 cells	 (p<0.0001;	 Figure	 4.3	 A	 and	 B).	 	 While	 interestingly	CYP24A1	 expression	was	 several	 orders	 of	magnitude	 lower	 in	 LX-2	 cells	 (p<0.0001;	Figure	4.3	C	and	D).		 		 	
		
	 			
	
	
	
	
	
	
Figure	 4.3:	 qRT-PCR	 analysis	 of	 VDR	 and	 CYP24A1	mRNA	 expression	 in	 response	 to	 vitamin	 D	
treatment	in	HepG2	and	LX-2	cells.	mRNA	is	expressed	relative	to	18S.		VDR	expression	in	HepG2	cells	(A)	was	much	 lower	 than	 LX-2	 cells	 (B).	 On	 the	 other	 hand	 CYP24A1	 expression	was	much	 higher	 in	HepG2	 cells	 (C)	 than	 LX-2	 (D).	 There	was	 no	 response	 to	 vitamin	 D	 treatment.	P-values	 derived	 from	Kruskal-Wallis	 test	 with	 Dunn’s	 multiple	 comparison;	 p>0.05	 for	 all.	 Between	 cell	 types,	 tests	 were	
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performed	by	2way	ANOVA	with	Bonferroni	multiple	comparisons	test.	n=5-6	at	each	time	point	for	each	assay.		Data	presented	as	mean	±	SEM.			 Following	the	unexpected	results	from	the	mRNA	experiments,	LX-2	and	HepG2	cells	(n=2)	were	treated	with	1-100nM	new	Sigma	Aldrich	1,25OHD	freshly	dissolved	in	DMSO.	 	Cell	proliferation	was	assessed	by	MTT	assay	every	24	hours	up	to	168	hours.		Both	LX-2	and	HepG2	cells	appeared	to	show	no	response	as	measured	by	reduced	cell	growth	relating	to	concentration	of	vitamin	D	treatment	(Figure	4.4).			
		
	
	
	
	
Figure	4.4:	Cell	proliferation	of	HepG2	(A)	and	LX-2	(B)	cells	in	response	to	vitamin	D	treatment.		Cell	proliferation	was	measured	by	MTT	assay	over	168	hours.	n=2;	data	presented	as	mean	±	SEM.			 After	observing	no	difference	 in	cell	proliferation	by	MTT	assay,	we	decided	 to	perform	the	gold	standard	basic	cell	biology	technique	(Mirzayans,	Andrais	et	al.	2007)	used	 to	 study	 the	 effect	 of	 specific	 agents	 on	 cell	 proliferation,	 to	 confirm	 uptake	 of	1,25OHD	 within	 the	 cells.	 	 A	 third	 batch	 of	 1,25OHD,	 this	 time	 supplied	 by	 Cayman	Chemical,	was	 freshly	dissolved	 in	ethanol	 for	 these	experiments.	 	 LX-2,	HepG2	and	a	control	 cell	 line,	 HT29	 known	 to	 show	 a	 dose-	 and	 time-dependent	 anti-proliferative	response	 to	 1,25OHD	 treatment	 (Murillo,	 Matusiak	 et	 al.	 2007),	 were	 assessed	 for	altered	cell	proliferation	by	clonogenic	assay,	using	crystal	violet	staining.	This	verified	a	 dose	 dependant	 response	 to	 the	 treatment	 (Figure	 4.5	 and	 4.6).	 	 The	 two	 highest	concentrations	 of	 vitamin	 D,	 1μM	 and	 100nM,	 resulted	 in	 a	 statistically	 significant	reduction	 in	LX-2	 cell	 colonies	 (n=4)	 in	 comparison	 to	 ethanol	 vehicle	 (p=0.0005	and	
p=0.016	respectively).	This	reduction	was	visibly	notable	under	the	microscope	with	a	corresponding	95%	and	82%	drop	 in	 colony	numbers	 relative	 to	 vehicle.	 	HT29	 cells	(n=3)	also	showed	the	same	dose	response	trend,	although	this	did	not	reach	statistical	
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significance	(p=0.053;	Figure	4.6),	1μM	treatment	with	vitamin	D	demonstrated	a	91%	reduction	in	colony	numbers.		HepG2	cells	failed	to	survive	at	such	low	seeding	density	(Appendix	 H).	 	 LX-2	 cells	 (n=1)	 were	 also	 treated	 with	 1,25OHD	 supplied	 by	 Sigma	Aldrich,	dissolved	in	DMSO,	which	previously	 failed	to	show	a	response	at	the	cellular	and	RNA	 levels.	 	Although	no	 firm	conclusion	 can	be	made,	 results	 showed	a	blunted	response	to	Sigma	Aldrich	1,25OHD	in	comparison	to	Cayman	1,25OHD	(Appendix	I).		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 4.5:	 Cell	 proliferation	 of	 LX-2	 cells	 in	 response	 to	 treatment	 with	 vitamin	 D.	 	 Cell	proliferation	was	measured	by	clonogenic	assay	after	10	days	of	treatment.	n=4;	data	presented	as	mean	+	 SEM.	 P-values	 from	 Kruskal-Wallis	 with	 Dunn’s	 multiple	 comparisons	 test.	 	 p<0.05	 is	 considered	statistically	significant.	Cell	imaging	is	at	100	X	magnification.		 	
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Figure	 4.6:	 Cell	 proliferation	 of	 HT29	 cells	 in	 response	 to	 treatment	 with	 vitamin	 D.	 	 Cell	proliferation	was	measured	by	clonogenic	assay	after	12	days	of	treatment.	n=3;	data	presented	as	mean	+	 SEM.	 P-values	 from	 Kruskal-Wallis	 with	 Dunn’s	 multiple	 comparisons	 test.	 	 p<0.05	 is	 considered	statistically	significant.	Cell	imaging	is	at	100	X	magnification.	
4.4	Discussion			 Assessing	fibrosis	progression	in	NAFLD	patients	is	the	next	therapy	for	disease	development;	 fibrosis	 is	 suggestive	 of	 more	 severe	 and	 progressive	 liver	 damage	(Angulo	 2002).	 	 HSC	 activation	 is	 a	 critical	 step	 in	 liver	 fibrogenesis,	 and	 could	 be	 a	useful	tool	in	clinical	practice.			OA	and	PA	are	the	most	abundant	plasma	fatty	acids	(Hodson,	Skeaff	et	al.	2008).	In	our	study	LX-2	cells	responded	to	fatty	acid	loading	as	expected.		Previously,	Seydel	
et	al	 treated	LX-2	cells	with	500μM	and	1mM	mixed	fatty	acids	(2:1	OA:PA),	reporting	fatty	 acid	 uptake	 in	 the	 cells	 after	 24	 hour	 incubation	 in	 addition	 to	 a	 change	 in	 cell	morphology	at	1mM	concentrations.	Co-treatment	with	vitamin	D2	did	not	ameliorated	
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any	morphological	changes	from	intracellular	lipid	accumulation	(Seydel,	Beilfuss	et	al.	2011).	 	Our	data	demonstrated	 that	 it	was	 the	 type	of	 fatty	acid,	 rather	 than	quantity	alone	which	determined	 toxicity	 to	 the	 cells;	 400μM	 fatty	 acid	 treatment	 (1:1	OA:PA)	demonstrated	the	greatest	intracellular	lipid	accumulation	with	cell	viability	at	a	similar	reduction	to	200	OA,	indicating	a	possible	protective	effect	of	OA.		This	was	in	line	with	previous	 studies	 investigating	 fatty	 acid	 loading	 in	 hepatocytes,	 where	 PA	 exhibited	greater	 cytotoxic	 effects	 (Ricchi,	 Odoardi	 et	 al.	 2009,	 Pinnick,	 Neville	 et	 al.	 2010).	Although	 co-treatment	 of	 fatty	 acids	with	 1,25OHD	was	 not	 achieved	 in	 this	 study,	 it	remains	an	unanswered	question,	which	should	be	approached	in	future	work.		 Low	levels	of	serum	vitamin	D	are	common	in	patients	with	chronic	liver	disease	(Targher,	Bertolini	et	al.	2007,	Petta,	Camma	et	al.	2010),	specifically	NAFLD	(Jablonski,	Jovanovich	et	al.	2013,	Black,	Jacoby	et	al.	2014,	Nobili,	Giorgio	et	al.	2014).		1,25OHD	is	involved	 in	 the	 regulation	 of	many	 genes,	mediating	 its	 role	 in	 the	 regulation	 of	 cell	proliferation,	differentiation	and	apoptosis	in	both	healthy	and	malignant	cells	(Adams	and	 Hewison	 2010).	 	 Previous	 studies	 have	 investigated	 the	 role	 vitamin	 D	 plays	 in	hepatic	 fibrosis	 and	 cirrhosis	 through	 the	 reduction	 of	 type	 I	 collagen	 formation	(Abramovitch,	 Dahan-Bachar	 et	 al.	 2011,	 Potter,	 Liu	 et	 al.	 2013).	 In	 this	 study	 we	observed	1,25OHD	as	an	antiproliferative	agent	 in	both	 immortalized	human	HSC	and	colon	cancer	cell	lines.		 Basal	protein	expression	of	VDR	in	untreated	LX-2	cells	was	higher	than	HepG2	cells,	as	expected.		However,	LX-2	cells	showed	no	change	to	VDR	protein	expression	in	response	 to	1,25OHD	treatment	over	24	hours	 (data	not	shown)	contrary	 to	previous	findings	of	significant	 increases	 in	VDR	protein	(Potter,	Liu	et	al.	2013).	This	could	be	due	to	the	fact	that	LX-2	cells	are	an	activated	form	of	HSCs,	rather	than	quiescent	(Xu,	Hui	et	al.	2005),	or	due	to	possible	reagent	degradation.		Previously,	work	in	primary	rat	HSCs	 investigated	 the	 change	 in	 VDR	 protein	 expression	 during	 activation.	 	 Results	showed	that	VDR	expression	was	high	on	day	3	(during	the	quiescent	stage)	but	after	7	days	showed	a	40%	reduction	in	VDR	expression,	further	reduced	after	14	days	where	HSCs	 were	 fully	 activated	 (Abramovitch,	 Dahan-Bachar	 et	 al.	 2011).	 However,	Abramovitch	and	colleagues	did	investigate	the	effect	of	1,25OHD	on	activated	stellate	cells,	 treating	with	 2.5μM	 for	 24	 hours	 showing	 a	 non-significant	 stimulation	 of	 VDR	protein	expression.		Therefore	we	sought	to	look	further	upstream	at	mRNA	expression	for	a	measurable	response	to	1,25OHD	dosing.	
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	 Unexpectedly,	we	did	not	identify	any	changes	in	mRNA	expression	of	CYP24A1	or	VDR	in	either	LX-2	or	HepG2	cells	after	24	hour	treatment	with	1,25OHD.		This	was	particularly	surprising	to	us	as	Horvath	et	al.	demonstrated	significant	results	in	HepG2	cells	 treated	 with	 as	 little	 as	 1.6nM	 1,25OHD.	 	 Their	 results	 observed	 an	 800-fold	increase	in	CYP24A1	mRNA	expression	after	a	5	hour	incubation	with	10nM	1,25OHD.		Furthermore,	the	time-course	data	we	based	our	experiment	on	demonstrated	a	5,300-fold	 increase	 in	 CYP24A1	mRNA	 expression	 at	 8	 hours	with	 4nM	1,25OHD	 (Horvath,	Lakatos	et	al.	2012).		Conclusions	for	these	disappointing	sets	of	experiments	led	us	to	believe	that	our	source	of	vitamin	D	may	have	degraded	from	long-term	storage.		 After	 fresh	 1,25OHD	 had	 been	 sourced	 and	 dissolved	 in	 DMSO,	we	 decided	 to	perform	a	less	time	consuming	experiment	to	confirm	the	activity	of	vitamin	D	through	effects	 on	 cell	 proliferation	 as	 detected	 by	 MTT	 assay.	 	 After	 two	 attempts,	 it	 was	apparent	that	there	was	no	difference	in	cell	proliferation	with	varying	concentrations	of	1,25OHD.	 	This	suggested	 two	 things;	either	 the	vitamin	D	was	not	getting	 into	 the	cells,	or	that	when	DMSO	is	frozen,	was	it	possible	that	the	vitamin	D	was	precipitating	out	of	solution.		Either	way,	it	was	apparent	that	no	effect	was	being	seen	in	either	cell	line,	and	therefore	we	assumed	1,25OHD	was	not	entering	the	cells.		 After	 finding	 an	 alternative	 source	 of	 vitamin	 D,	 and	 dissolving	 it	 in	 100%	ethanol	 to	 prevent	 multiple	 freeze	 thaw	 cycles,	 and	 completing	 the	 gold	 standard	technique	for	cell	viability	and	proliferation,	there	was	a	clear	dose-dependent	effect	for	LX-2	and	HT29	cell	growth.		Previous	work	in	HT29	cells	demonstrated	a	dose-response	inhibition	 on	 clonal	 proliferation	with	 increasing	 1,25OHD	 concentrations;	 significant	differences	were	detectable	from	1nM	after	6	days	of	incubation	(Shabahang,	Buras	et	al.	1993).	More	recent	clonogenic	work	also	supports	reduced	HT29	cell	proliferation	in	a	concentration-dependent	manner	where	cells	were	treated	with	up	to	100nM	1,25OHD	for	 10	 to	 14	days	 (Saito,	Okamoto	 et	 al.	 2008),	 confirming	 the	use	 of	HT29	 cells	 as	 a	positive	 control	 for	 vitamin	D	 treatment	 in	 our	 study.	 	 Previous	 studies	 investigating	vitamin	D	treatment	in	LX-2	cells	demonstrated	reduced	stress	factors,	including	MICA,	MICB,	α-SMA	(Seydel,	Beilfuss	et	al.	2011),	TGF-β	and	collagen	1α	(Seydel,	Beilfuss	et	al.	2011,	Potter,	Liu	et	al.	2013),	while	 in	rat	NASH	models,	vitamin	D	treatment	reduced	apoptosis,	 inflammation	 and	 fibrosis	 in	 isolated	 primary	 cells	 (Nakano,	 Cheng	 et	 al.	2011).	
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	 Finally,	 despite	 appearing	 to	 have	 a	 dose-dependent	 effect	 of	 reduced	 cell	proliferation	 in	both	LX-2	and	HT29	cell	 lines,	 it	was	not	possible	 to	 confirm	 that	 the	treatment	doses	were	not	toxic	to	the	cells,	resulting	in	cell	death	rather	than	reduced	cell	proliferation.	The	approximate	normal	range	for	1,25OHD	in	humans	is	between	50-150pM	(Lips	2007),	considerably	lower	than	our	minimum	treatment	concentration	of	1nM.	 	 However,	 super-physiological	 doses	 were	 necessary	 in	 order	 to	 exert	 a	measurable	 effect	 in	 our	 cells.	 	 Previous	 work	 has	 investigated	 treatment	 doses	 of	vitamin	D	up	to	2.5μM	with	no	toxic	side	effects	in	primary	and	immortalized	cell	lines	(Abramovitch,	 Dahan-Bachar	 et	 al.	 2011,	 Seydel,	 Beilfuss	 et	 al.	 2011).	 	 However,	Abramovitch	 et	 al.	noted	 an	 80%	 toxic	 effect	 of	 1,25OHD	when	 treating	 primary	 rat	HSCs	 at	 25μM	 concentrations	 (Abramovitch,	 Dahan-Bachar	 et	 al.	 2011).	 	 While	 the	possible	 toxic	effects	of	1,25OHD	in	our	LX-2	cells	were	not	directly	examined,	 trypan	blue	staining	of	one	LX-2	clonogenic	assay	was	investigated	(data	not	shown).		Results	indicated	 no	 difference	 in	 percentage	 of	 viable	 cells	 between	 treatment	 groups.		However,	as	this	was	only	a	single	replicate,	further	investigations	would	be	required	to	confirm	that	1,25OHD	was	not	toxic	to	the	cells.		 A	 limitation	of	this	study	was	the	use	of	LX-2	cells.	 	These	cells	are	know	to	be	activated,	 and	 therefore	would	 already	 be	 in	 a	 fibrogenic	 state	 (Xu,	 Hui	 et	 al.	 2005).		Data	 has	 shown	 the	 VDR	 expression	 is	 decreased	 in	 activated	 HSCs	 (Abramovitch,	Dahan-Bachar	 et	 al.	 2011),	 and	 although	 treatment	 with	 vitamin	 D	 appeared	 to	 be	unresponsive	 in	 our	 hands,	 possibly	 due	 to	 reagent	 degradation,	 1,25OHD	 treatment	has	been	shown	to	 induce	VDR	protein	expression	 in	activated	primary	HSCs	after	24	hours	(Abramovitch,	Dahan-Bachar	et	al.	2011).	 If	using	primary	HSCs,	we	could	have	investigated	 effects	 of	 1,25OHD	 treatment	 before	 and	 after	 activation,	 and	 this	 is	something	that	could	be	investigated	in	future	studies.		 First	and	foremost,	as	we	have	now	identified	a	suitable	source	and	vehicle	 for	1,25OHD,	 future	 work	 should	 reinvestigate	 the	 mRNA	 time-course	 experiment	 to	characterise	the	most	suitable	time	and	concentration	dose	of	vitamin	D	to	see	an	effect.		Secondly,	 work	 should	 involve	 co-treatment	 of	 fatty	 acids	 with	 1,25OHD	 in	 order	 to	assess	 for	 any	 changes	 in	 mRNA	 expression,	 with	 particular	 interest	 in	 VDR	 and	CYP24A1.	 	 In	particular,	micro-array	work	should	be	used	based	on	previous	work	by	Alvarez-Diaz	 et	al.	 who	 demonstrated	 up-regulation	 of	microRNA-22	 by	 vitamin	 D	 in	colon	cancer	cells,	resulting	in	suppression	of	cell	proliferation	(Alvarez-Diaz,	Valle	et	al.	
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2012).		Results	from	such	studies	could	help	determine	an	immortalized	cell	line	model	of	hepatic	fibrosis.		 In	conclusion,	 this	study	shows	that	LX-2	cells	responded	to	 lipid	 loading,	with	PA	 having	 a	 greater	 toxic	 effect	 on	 cell	 viability	 in	 comparison	 to	 OA.	 	 	 1,25OHD	inhibited	 cell	 proliferation	 in	 human	 LX-2	 stellate	 cells	 in	 a	 dose	 dependent	manner.		Correction	 of	 vitamin	 D	 deficiency	 in	 patients	 with	 fatty	 liver	 disease	 could	 be	 a	potential	therapy	to	inhibit	progression	to	fibrosis	and	warrants	further	study.			 	
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Chapter	5:	Discussion	
5.1	Thesis	Aims	The	 programme	 of	 work	 set	 out	 in	 this	 thesis	 aims	 to	 contribute	 to	 the	understanding	of	the	role	of	vitamin	D	in	a	UK	paediatric	NAFLD	population,	which	is	an	under-researched	area.	This	is	a	unique	cohort	of	patients	as	compared	to	the	study	of	NAFLD	in	adults	as	the	impact	of	known	confounders,	such	as	alcohol	consumption,	 is	greatly	 reduced.	 	 Previous	 work	 in	 adult	 populations	 has	 highlighted	 the	 need	 to	investigate	baseline	serum	25OHD	levels,	which	provides	an	index	of	vitamin	D	status,	for	 several	 reasons,	not	 least	 the	documented	high	 rates	of	25OHD	 insufficiency	have	previously	 been	 highlighted	 in	 adult	 (Barchetta,	 Angelico	 et	 al.	 2011,	 Jablonski,	Jovanovich	 et	 al.	 2013)	 and	 paediatric	 populations	 (Black,	 Jacoby	 et	 al.	 2014,	 Nobili,	Giorgio	 et	 al.	 2014).	 	 As	 I	 previously	 mentioned,	 there	 is	 little	 data	 available	 in	 the	literature	 regarding	 vitamin	 D	 status,	 dietary	 intakes	 and	 physical	 activity	 levels	 in	children	 with	 fatty	 liver	 disease,	 with	 no	 known	 studies	 conducted	 within	 the	 UK.	Additionally,	my	systematic	review	(Chapter	1)	of	all	RCTs	to	date	investigating	dietary	supplementation	and	physical	activity	 in	paediatric	NAFLD	population	highlighted	 the	lack	 of	 human	 intervention	 studies	 investigating	 vitamin	 D	 supplementation.		Furthermore,	 where	 studies	 did	 exist	 there	 were	 inconsistencies	 between	 study	findings	 for	 reported	 supplements.	 	 In	my	 first	 experimental	 study	 (Chapter	2),	 I	 had	four	aims:	firstly	to	compare	anthropometric	measurements	between	UK	biopsy-proven	paediatric	NAFLD	patients	and	ultrasound-cleared	obese	controls;	secondly	to	compare	physical	 activity	 levels	 between	 these	 two	 groups;	 thirdly	 to	 compare	 macro-	 and	micronutrient	 intakes	 from	 24-hour	 and	 7-day	 food	 diaries;	 and	 finally	 to	 establish	eating	 behaviours	 in	 these	 two	 groups.	 The	 second	 experimental	 study	 (Chapter	 3)	aimed	 firstly	 to	 characterise	 serum	 25OHD	 levels	 in	 the	 UK	 paediatric	 NAFLD	population,	 and	 secondly	 to	 investigate	 SNPs	 previously	 associated	 with	 NAFLD	 and	vitamin	 D	 metabolism,	 and	 to	 assess	 genotypes	 relating	 to	 vitamin	 D	 metabolism	against	histological	findings.		Finally,	the	third	experimental	study	(Chapter	4)	aimed	to	investigate	the	mechanistic	roles	of	vitamin	D	in	the	progression	of	fibrosis	within	an	in	
vitro	hepatic	stellate	cell	model	of	NAFLD.	
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5.2	Overview	of	Main	Findings		 Thirteen	RCTs	were	eligible	 for	 inclusion	 in	my	systematic	 review	(Chapter	1).		All	 studies	 investigated	 dietary	 with	 or	 without	 physical	 activity	 levels	 in	 paediatric	NAFLD	 populations.	 	 Supplementation	 included	 vitamin	 E	 (n=6),	 probiotics	 (n=2),	omega-3	(n=5),	dietary	modification	(n=1)	and	reduced	fructose	intake	(n=1).		No	RCTs	examining	 physical	 activity	 interventions	 alone	 were	 identified;	 12	 of	 the	 studies	recommended	 physical	 activity	 as	 a	 co-intervention,	 although	 type	 and	 duration	 of	physical	activity	was	poorly	described.		Diagnosis	of	NAFLD	ranged	from	elevated	ALT	and	 AST	 levels,	 imaging	 through	 ultrasound	 or	 MRS,	 to	 the	 gold	 standard	 of	 biopsy.		Formulations	 and	 doses	 varied	 for	 each	 nutritional	 supplement,	 alongside	 different	treatment	 lengths.	 Vitamin	 E	was	 ineffective	 at	 improving	 ALT	 levels,	while	 omega-3	decreased	 hepatic	 fat	 content.	 Probiotics	 gave	 mixed	 results	 while	 reduced	 fructose	consumption	 did	 not	 improve	 primary	 outcome	measures.	 A	 low	 glycaemic	 load	 diet	and	 a	 low	 fat	 diet	 appeared	 equally	 effective	 in	 decreasing	 hepatic	 fat	 content	 and	transaminases.	 Most	 studies	 were	 classified	 as	 neutral	 quality	 according	 to	 the	American	 Dietetic	 Association	 Quality	 Criteria	 Checklist.	 Of	 the	 studies	 that	 included	lifestyle	 recommendations	 that	 successfully	 led	 to	 a	 decrease	 in	 BMI,	 all	 showed	improved	secondary	outcome	measures,	and	half	showed	improvements	in	the	chosen	primary	 outcome	 including	 decreased	 hepatic	 fat	 content	 in	 omega-3	 trials	 and	improved	ALT	levels	in	vitamin	E	trials.		This	confirms	that	investigations	encouraging	generalised	 healthy	 eating	 strategies	 promoting	 weight	 loss	 are	 still	 an	 appropriate	treatment	 for	overweight	and	obese	children	with	NAFLD,	which	was	not	 reflected	 in	our	dietary	study.	The	 first	 experimental	 study	 (Chapter	 2),	which	 compared	 the	 nutritional	 and	lifestyle	 factors	 of	 NAFLD	 and	 obese	 patients	 attending	 King’s	 College	 Hospital	suggested	 that	 children	 with	 NAFLD	 are	 not	 currently	 following	 current	recommendations	 for	 diet	 and	 physical	 activity.	 	 Despite	 observing	 no	 differences	 in	macro-	 or	 micronutrient	 intakes	 between	 cases	 and	 controls,	 participants	 in	 both	groups	reported	consumption	of	MUFA,	PUFA,	potassium,	calcium,	iron,	zinc	and	folate	below	the	DRVs,	whilst	they	exceeded	recommendations	for	total	energy	derived	from	protein	and	SFA.	Both	NAFLD	and	obese	controls	had	intakes	of	vitamin	D	well	below	the	new	government	recommendation	although	 in	 line	with	 intakes	of	 children	 in	 the	NDNS	 (Bates	 2014).	 	 Contrary	 to	 their	 poor	 diet	 and	despite	 both	 cases	 and	 controls	
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spending	a	considerable	amount	of	time	in	sedentary	behaviour,	children	with	NAFLD	were	more	active	than	their	control	counterparts;	when	assessed	by	both	achievement	of	the	UK	physical	activity	guidelines	(25%	of	NAFLD	compared	to	0%	of	controls)	and	mean	 step	 counts.	 	 One	 of	 the	most	 novel	 aspects	 of	 this	 study	was	 the	 inclusion	 of	measures	of	eating	behaviours	and	subsequently	the	identification	of	greater	restrained	eating	in	children	with	NAFLD	compared	to	obese	controls	(after	controlling	for	BMI	z-score),	 which	 may	 reflect	 potentially	 beneficial	 caution	 regarding	 dietary	 intake.		However,	this	may	indicate	unhealthy	attitudes	to	food	that	could	result	in	subsequent	overeating	 and	 so	 warrants	 further	 research	 in	 order	 to	 confirm	 and	 perhaps	manipulate	these	behaviours	to	promote	positive	dietary	change.		 Building	on	the	evidence	of	 inadequate	dietary	 intakes	of	vitamin	D	in	the	case	control	 study	my	 retrospective	 study	 (Chapter	 3)	 highlighted	 the	 high	 levels	 of	 year-long	 25OHD	 insufficiency	 in	 UK	 paediatric	 NAFLD	 patients,	 with	 deficiency	 during	winter	months.	 The	mean	 25OHD	 levels	 in	 our	 NAFLD	 population	 were	much	 lower	than	 those	observed	 in	 the	ALSPAC	 study,	where	healthy	UK	 children	presented	with	mean	 25OHD	 serum	 concentrations	 of	 60.1nmol/L	 (Williams,	 Fraser	 et	 al.	 2014).		Additionally,	we	confirmed	 the	association	between	 the	PNPLA3	 I148M	G	variant	and	higher	steatosis	and	inflammation	scoring	previously	associated	in	other	adults	NAFLD	populations.	 While	 no	 association	 between	 25OHD	 serum	 levels	 and	 histological	grading	 were	 identified,	 SNPs	 involved	 in	 the	 metabolism	 of	 vitamin	 D,	 namely	NADSYN1,	DHCR7	and	VDR	were	all	independently	associated	with	increased	steatosis	grading,	while	GC	was	associated	with	 increased	 inflammation	which	suggests	altered	histological	findings	in	the	presence	of	these	SNPs.		 The	 final	 study	 (Chapter	 4)	 examined	 the	 in	 vitro	 effects	 of	 1,25OHD	 in	immortalized	HSCs.	LX-2	cells	responded	to	fatty	acid	treatment,	acquiring	intracellular	lipid,	 where	 PA	 showed	 greater	 toxicity	 to	 cells	 in	 comparison	 to	 OA,	 indicating	 the	possible	harmful	effects	of	saturated	fatty	acids	in	cellular	health.		Disappointingly,	LX-2	and	HepG2	cells	appeared	to	show	no	change	in	mRNA	expression	of	VDR	and	CYP24A1	in	response	to	treatment	with	1,25OHD,	and	after	MTT	data	also	showed	no	difference	in	 cell	 growth,	 an	 alternative	 source	 of	 1,25OHD	was	 obtained.	 	 Basic	 cell	 clonogenic	work	demonstrated	a	dose-response	of	1,25OHD	in	LX-2	and	HT29	cells,	which	suggests	1,25OHD	is	entering	the	cell	and	exerting	its	effects.	
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5.3	Strengths	and	Limitations		 It	was	not	easy	to	recruit	patients	into	the	case-control	study.		The	hardest	group	to	recruit	were	the	obese	controls,	mainly	because	they	had	no	disease	associated	with	their	obesity	and	 therefore	had	 less	motivation	 to	make	dietary	and	 lifestyle	changes.		Almost	half	of	all	eligible	obese	control	approached	(12	of	25)	declined	to	participate.		Additionally,	as	obese	controls	had	to	be	ultrasound	cleared	to	be	included	in	the	study,	two	 patients	 demonstrated	 ultrasonographic	 lipid	 accumulation	 deeming	 them	unsuitable	for	inclusion	into	the	study.		Interestingly	though,	obese	controls	had	higher	completion	 rates	 in	 comparison	 to	 the	NAFLD	 group	 (73%	 versus	 63%	 respectively)	suggesting	that	it	is	initial	motivation	that	may	be	crucial	both	for	research	studies	and	clinical	 interventions	 and	 therefore	 perhaps	 awareness	 raising	 activities	 are	 required	amongst	 obese	 populations	 of	 the	 risks	 associated	 with	 their	 weight.	 	 In	 the	 NAFLD	group,	 although	 greater	 numbers	 of	 patients	 met	 the	 inclusion	 criteria	 and	 fewer	patients	 declined	 to	 participate	 at	 baseline,	 a	 large	 number	withdrew	 from	 the	 study	either	 before	 or	 during	 the	 recording	 week	 suggesting	 that	 in	 this	 sub-population	efforts	 must	 focus	 on	 improving	 retention	 since	 participants	 appear	 to	 need	 greater	initial	motivation	to	participate.		 Another	 problem	 encountered	 for	 this	 specific	 study	 was	 the	 lack	 of	 25OHD	measurements	taken,	particularly	in	the	obese	control	group.		NAFLD	patients	at	King’s	College	Hospital	are	more	frequently	having	routine	serum	25OHD	status	measured	to	date.	 	However,	obese	controls	were	not	having	serum	25OHD	levels	measured	unless	specifically	asked	for.		As	some	of	the	patients	were	recruited	into	the	diet	and	physical	activity	 study	 before	 the	 full	 study	 outline	 was	 devised	 (as	 part	 of	 a	 pilot	 study),	historical	 25OHD	 levels	 were	 not	 available	 for	 obese	 controls.	 	 In	 addition,	 patients	recruited	did	not	always	attend	appointments	made	for	blood	sampling,	resulting	 in	a	limited	number	of	25OHD	measurements.		 However,	 it	 is	 important	 to	 note	 that	 this	was	 the	 first	 UK	 study	 investigating	dietary	and	lifestyle	habits	of	paediatric	NAFLD	patients,	with	dietary	data	scrutinised	by	 dietetic	 students	 for	 macro-	 and	 micronutrient	 content	 and	 food	 groupings,	 all	rechecked	 by	 myself	 for	 accuracy.	 	 In	 light	 of	 this,	 no	 power	 calculation	 could	 be	performed	 to	 determine	 a	minimum	 target	 sample	 size	 for	 each	 group.	 	With	 this	 in	mind,	 a	 retrospective	 power	 calculation	 was	 performed	 for	 vitamin	 D	 intakes,	suggesting	that	 for	80%	power	we	needed	24	patients	 in	each	arm	of	 the	study	for	to	
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detect	 a	 0.05	 significant	 change.	 Although	 we	 managed	 to	 recruit	 24	 patients	 in	 the	NAFLD	group,	our	obese	control	group	was	much	smaller	than	this	due	to	difficulties	in	recruitment.		In	fact,	looking	retrospectively	at	recruitment	numbers,	the	study	had	an	estimated	35%	power,	much	lower	that	we	were	expecting.		But	despite	the	shortfall	in	obese	 control	 recruitment,	 data	 from	 this	 study	will	 be	 extremely	 valuable	 for	 future	studies	to	calculate	adequate	participant	numbers.		 Data	 collection	 for	 the	 genotyping	 chapter	 was	 hampered	 by	 availability	 of	samples.	 	Suitable	patients	were	identified	on	the	King’s	child	health	sample	bank,	but	samples	were	not	always	available	 in	 -80°C	storage	and	again	measurement	of	serum	25OHD	 levels	 for	 members	 of	 this	 biobank	 was	 patchy.	 	 Furthermore,	 some	 biopsy	results	from	patients	were	not	available	on	the	system.	 	Despite	the	best	efforts	of	the	King’s	 staff	 to	 rescore	 the	 biopsies	 which	 had	missing	 data,	 samples	 slides	 were	 not	always	available	to	facilitate	this.		 Another	 additional	 limitation	of	 this	 retrospective	 study	was	25OHD	sampling.		Firstly,	samples	were	measured	using	a	chemiluminescent	immunoassay	rather	the	gold	standard	of	measurement,	LC-MS/MS,	as	it	was	not	available	at	King’s	College	Hospital.		Additionally,	outsourcing	for	re-measurement	of	25OHD	levels	was	not	possible	as	not	all	patients	had	stored	plasma	samples	available,	meaning	we	would	have	 further	 lost	numbers.	 	 Therefore,	 in	 order	 to	 reduce	 loss	 of	 patient	 samples,	 any	 ‘new’	 samples	measured	 for	 25OHD	 specifically	 for	 this	 study	 were	 also	 analysed	 via	chemiluminescence	 to	ensure,	 comparable	 results.	 	 Secondly,	 seasonality	of	vitamin	D	sampling	varied,	a	well	known	factor	 influencing	vitamin	D	status.	 	Patients	attending	King’s	 College	 Hospital	 would	 have	 routine	 bloods	 sampled,	 including	 serum	 25OHD	levels,	throughout	the	year.		However,	we	were	able	to	account	for	this	using	the	Sachs	formula	 (Sachs,	 Shoben	 et	 al.	 2013),	 modeling	 and	 adjusting	 out	 data	 according	 to	month	of	blood	draw.	This	meant	all	available	25OHD	samples	could	be	accounted	for	and	 adjusted,	 allowing	 for	 seasonal	 differences	 in	 vitamin	 D	 status	 to	 be	 corrected.	Finally,	a	strength	of	the	study	conducted	in	Chapter	3	was	paired	serum	25OHD	levels	with	a	biopsy	sample.	Biopsy	is	still	considered	the	gold	standard	for	NAFLD	diagnosis.	This	gave	us	a	greater	scope	and	resulted	 in	 the	observed	association	of	 lower	serum	25OHD	levels	and	NASH	diagnosis	compared	to	non-NASH	patients.	
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5.4	Future	Directions		 While	our	studies	produced	some	 interesting	results	with	respect	 to	vitamin	D	intake,	 status	 and	 molecular	 mechanisms,	 we	 have	 further	 exposed	 gaps	 in	 the	literature,	which	warrant	further	study.		Given	sufficient	time	and	funding,	the	following	additional	investigations	could	provide	further	understanding	of	the	role	of	vitamin	D	in	paediatric	NAFLD.		 Previously,	 one	 study	 examining	 dietary	 and	 physical	 activity	 patterns	 of	paediatric	 NAFLD	 patients	 (n=38)	 demonstrated	 increased	 SFA,	 fructose	 and	 sucrose	intakes,	 alongside	 lower	 intakes	 of	 PUFA.	 	 No	 investigation	 into	 intakes	 of	 vitamin	D	were	made	in	this	study.		Although,	as	previously	stated,	the	main	source	of	vitamin	D	is	not	 from	 the	 diet	 but	 from	 cutaneous	 exposure	 to	 UVB	 radiation	 (Holick	 2007),	 new	proposed	UK	RNI	is	set	at	10μg/day	for	the	general	population	(SACN	2016).	With	this	new	RNI	in	mind,	our	cohort	of	patients	demonstrated	vitamin	D	intakes	well	below	this	requirement.		Therefore,	future	studies	should	investigate	the	dietary	intakes	of	vitamin	D,	 albeit	 a	 minor	 contributor	 to	 vitamin	 D	 status,	 in	 addition	 to	 any	 supplements.		Furthermore,	 any	 studies	 investigating	 vitamin	 D	 status	 should	 also	 either	 a)	 be	conduced	within	the	same	UK	season	to	limit	cutaneous	production	of	vitamin	D	or	b)	be	conducted	with	patients	wearing	a	dosimeter,	a	small	badge	like	piece	of	equipment	which	 can	 measure	 UVB	 exposure	 and	 therefore	 be	 used	 to	 adjust	 dietary	 intakes	accordingly.		 Given	 that	 the	 number	 of	 samples	 in	 Chapter	 3	 was	 limited,	 exploring	 the	selected	 SNPs,	 with	 particular	 interest	 in	 those	 where	 a	 histological	 association	 was	found,	 within	 a	 larger	 population	 would	 be	 the	 next	 step.	 	 The	 National	 Institute	 of	Diabetes	and	Digestive	and	Kidney	Diseases	has	a	NAFLD	adult	database,	which	could	serve	 as	 a	 useful	 tool	 for	 establishing	 the	 link	 between	NAFLD	 and	 vitamin	D.	 	 Clear	inclusion	 and	 exclusion	 criteria	 for	 the	 patients	 have	 been	 outlined	 and	 is	 similar	 to	almost	all	aspects	of	our	own	study	with	the	exception	of	age,	where	all	patients	had	to	be	18	years	or	older.		 Now	 that	 a	 suitable	 source	 of	 vitamin	 D	 has	 been	 obtained	 alongside	 an	appropriate	 vehicle,	 repeating	 the	 time	 course	 experiments	 would	 be	 paramount	 in	establishing	 the	 most	 suitable	 concentration	 and	 treatment	 length	 for	 vitamin	 D	 in	suitable	cell	 lines.	mRNA	expression	of	VDR	and	CYP24A1	would	again	be	 targeted	 in	these	 future	experiments	to	confirm	vitamin	D	uptake	and	action.	 	These	experiments	
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would	aim	 to	pre-load	LX-2	cells	with	 fatty	acids	before	co-treatment	with	vitamin	D.		These	 samples	 could	 then	 be	 used	 for	microRNA	 analysis,	 investigating	 specific	 liver	microRNAs	 commercially	 available	 as	 kits,	 which	 include	 microRNA-22,	 previously	highlighted	 as	 being	 regulated	 by	 1,25OHD	 in	 colon	 cancer	 cells	 lines	 (Alvarez-Diaz,	Valle	 et	 al.	 2012)	 having	 previously	 been	 documented	 as	 down-regulated	 in	hepatocellular	carcinoma	(Zhang,	Yang	et	al.	2010).		 Finally,	 King’s	 College	 Hospital	 Institute	 of	 Liver	 Studies	 routinely	 isolates	hepatocytes	from	resected	human	livers.		HSCs	are	not	routinely	isolated,	and	therefore	could	make	a	unique	opportunity	to	obtain	primary	human	HSCs.		With	the	clonogenic	experiments	confirming	uptake	of	1,25OHD	in	cells,	these	experiments	could	lead	on	to	future	work	 treating	primary	human	HSCs	with	vitamin	D.	 	 Specifically,	 primary	 cells	could	 be	 used	 for	 micro-RNA	 work	 investigating	 regulation	 of	 genes	 in	 response	 to	1,25OHD	 treatment.	 This	 would	 be	 an	 ideal	 future	 step	 in	 understanding	 the	 role	 of	vitamin	D	in	the	pathogenesis	and	progression	of	NAFLD.	
5.5	Unique	Contribution	of	this	Thesis		 The	 study	 reported	 in	Chapter	2	 is	 the	 first	 case-control	 study,	 to	 the	 author’s	knowledge,	to	have	been	conducted	in	a	UK	adolescent	NAFLD	population.	 	This	study	identified	 that	 current	 recommendations	 are	 not	 being	 complied	with,	 and	 therefore	weight	 loss	 with	 increase	 physical	 activity	 should	 still	 remain	 as	 the	 main	 focus	 of	NAFLD	management;	work	 is	 required	 to	 facilitate	 uptake	 of	 and	 adherence	 to	 these	guidelines,	 perhaps	 including	 a	 focus	 on	 eating	 behaviours	 as	 well	 as	 absolute	 food	intakes.	 This	 study	 provides	 a	 unique	 contribution	 to	 the	 paediatric	 NAFLD	 diet	 and	activity	 literature.	 	Additionally,	 habitual	 intakes	of	 vitamin	D	have	been	documented	for	the	first	time	in	a	UK	NAFLD	population,	and	demonstrate	the	inadequacy	of	the	diet	with	reference	to	the	new	UK	recommendation	of	10μg/day.		 Chapter	 3	 is,	 to	 the	 author’s	 knowledge,	 the	 first	 study	 to	 assess	 a	 UK	NAFLD	population	 for	 25OHD	 status,	 demonstrating	 the	 year-long	 25OHD	 insuffiency.	 	 In	addition,	this	 is	the	first	study	to	confirm	the	association	between	the	known	PNPLA3	NAFLD	 gene	 variant	 in	 Caucasian	 children	with	 biopsy	 confirmed	 fatty	 liver	 disease,	showing	 that	 presence	 of	 the	 G	 risk	 allele	 was	 associated	 with	 increased	 severity	 of	steatosis	 and	 inflammation.	 	 Finally,	 it	 is	 also	 the	 first	 study	 to	 investigate	 SNPs	associated	 with	 vitamin	 D	 metabolism	 in	 a	 UK	 paediatric	 NAFLD	 population,	
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demonstrating	poorer	histological	findings	with	variants	of	the	NADSYN1/DHCR7,	VDR	and	GC	genes.		 The	molecular	work	 conducted	 in	Chapter	4	 is,	 to	 the	 author’s	 knowledge,	 the	first	study	to	quantitatively	measure	lipid	accumulation,	specifically	PA	and	OA,	in	LX-2	cells.	 Cell	 proliferation	 in	 HSCs	 after	 1,25OHD	 treatment	 has	 not	 been	 conducted	 by	clonogenic	assay,	demonstrating	that	1,25OHD	can	enter	and	exert	its	effects	within	the	cells.	 	While	1,25OHD	treatment	has	been	conducted	in	LX-2	cells	previously,	no	study	has	 investigated	mRNA	expression	of	CYP24A1	or	VDR	in	a	 time-course	 fashion.	 	This	approach	was	important	in	order	to	capture	responses	to	vitamin	D	treatment,	but	still	requires	future	attention	based	on	our	inconclusive	results.		In	conclusion,	this	thesis	adds	to	our	knowledge	concerning	the	physical	activity	and	 nutritional	 factors	 that	may	 play	 a	 role	 in	 NAFLD	 development	 and	 progression	within	the	UK.		Findings	from	our	systematic	review	(Chapter	1)	and	first	experimental	study	 (Chapter	 2)	 do	 not	 currently	 support	 the	 development	 of	 specific	 dietary	 or	physical	activity	guidelines	for	children	with	or	at	risk	of	NAFLD.		However,	to	date	no	study	examining	the	effect	of	vitamin	D	supplementation	in	humans	has	been	conducted.		There	has	been	little	research	into	paediatric	NAFLD	25OHD	status,	where	there	may	be	clinical	 relevance.	 Our	 study	 highlighted	 the	 year-round	 insufficiency	 of	 vitamin	 D	status	in	a	UK	paediatric	NAFLD	cohort,	with	specific	vitamin	D	related	SNPs	associated	with	 increased	 hepatic	 inflammation	 or	 steatosis	 grading.	 	 LX-2	 cells	 respond	 to	1,25OHD	treatment	and	so	the	associated	mechanisms	and	pathways	via	which	vitamin	D	may	have	a	beneficial	effect	on	NAFLD	progression	and	warrant	further	study.		With	progression	of	simple	steatosis	to	steatohepatitis	estimated	to	take	around	8-13	years,	with	 further	 progression	 to	 fibrosis	 and/or	 cirrhosis	 another	 8-13	 years	 (Ekstedt,	Franzen	 et	 al.	 2006),	 young	 children	 presenting	with	 NAFLD	 are	 at	 increased	 risk	 of	future	 complications	 arising	 from	 NAFLD	 progression.	 	 The	 practical	 application	 of	these	findings	could	be	implemented	into	current	NHS	NAFLD	practice,	through	routine	25OHD	screening	and	consequent	supplementation,	knowing	this	population	has	severe	insufficiency	 throughout	 the	 year.	 	 Further	 investigation	 into	 the	mechanistic	 role	 of	vitamin	 D	 in	 NAFLD	 is	 required	 to	 confirm	 if	 there	 is	 a	 histological	 effect	 from	supplementation.		 	
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Information sheet  
Nutritional intake and non-alcoholic fatty liver disease in children: an observational 
study 
 
Date:  
 
Dear  
 
We would like to ask your help with a study we are carrying out in children and teenagers 
who have a problem with their liver.  
 
What are we testing? 
You may have been told that the problem with your child’s liver is called non-alcoholic fatty 
liver disease. Some studies in other countries have shown that eating or drinking either too 
much or not enough of certain things may make people more likely to develop this problem. 
It would be good to find out if this is true as then we can recommend avoiding certain things / 
eating more of certain things etc.  
 
What are we asking you to do? 
We would like you and your child to take part in the study by meeting our dietician when you 
come to clinic. She / he will go through a few questions with you looking at your child meals 
over the past 24 hours, eating patterns and activities. She / he will ask your child to keep a 
food diary for the next 7 days and show you both how to fill this out. We will also give your 
child a disposable camera to take pictures of meals for 1 – 2 days. This way the dietician can 
work out exactly what is in his / her diet (down to tiny amounts of vitamins / minerals etc). 
We will also give your child a pedometer (which measures the number of steps taken) so they 
can measure how much activity they are doing over time. The dietician will do a home visit 
(when and if it suits you) or you can come back to talk to them after this. She will also give 
you lots of advice on healthy lifestyle and tailor this individually to your child.  
At 6 months we will ask you both to come back to the clinic as we would anyway and the 
dietician will see how your child is getting on.  
 
Is there any pain or harm involved? 
No. Meeting the dietician and talking about healthy lifestyles is an important part of every 
clinic visit. This will just be in more detail if you and your child decide to take part in the 
study.  
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Why are we doing this study? 
Having the condition non-alcoholic fatty liver disease means that some fat has gathered in the 
liver and is causing some irritation and scarring. We are not sure why your child is more 
prone to this than any other person. As mentioned above, this could have to do with certain 
things in your child’s diet. Talking to you about your child’s diet for a couple of minutes 
won’t reveal this sort of thing; we need to do a more detailed study asking you to keep a food 
diary etc. so that we can calculate the exact amounts of certain minerals and vitamins that are 
taken daily.  
 
 
We hope that this study will help us find better ways of treating this liver condition and thus 
make things better not only for your child but lots of other children and teenagers with the 
same problem.  
 
As part of the study we will be giving general advice on diet and lifestyle. This is the sort of 
thing that we would be giving anyway. The advantage of the study is that you will get more 
time with the dietician and the plan will likely be more individual to your child.  
 
We will monitor how much things have changed in your child’s liver at your usual 
appointment in 6 months time – using scans and blood tests as we would do anyway.  
 
If you do not want to take part in this study, your care will not be affected in any way. We are 
very happy to answer any questions about the study. We will let also your child’s GP know 
about the study if you are happy for them to take part.  Your child can withdraw from the 
study at any time without giving a reason.  If you do choose to withdraw from the study this 
will not affect your routine care in any way. 
 
 
This study has been reviewed by the South East London 3 Research Ethics Committee 
(reference number 10/H0808/122). 
 
 
 
Dr Emer Fitzpatrick    Professor Anil Dhawan 
Senior Clinical Fellow    Professor of Paediatric Liver Disease 
Paediatric Liver  
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Information sheet  
Nutritional intake and non-alcoholic fatty liver disease in children: an 
observational study 
 
Date:  
 
Dear  
 
We would like to ask your help with a study we are carrying out in children and 
teenagers like you who have a problem with their liver.  
 
What are we testing? 
You may have been told that the problem with your liver is called non-alcoholic fatty 
liver disease. Some studies in other countries have shown that eating or drinking 
either too much or not enough of certain things may make you more likely to develop 
this problem. It would be good to find out if this is true as then we can recommend 
avoiding certain things / eating more of certain things etc.  
 
What are we asking you to do? 
We would like you to take part in the study by meeting our dietician when you come 
to clinic. She / he will go through a few questions with you looking at your meals over 
the past 24 hours, your eating patterns and what activities you do regularly. She / he 
will ask you to keep a food diary for the next 7 days and show you how to fill this out. 
We will also give you a disposable camera to take pictures of your meals for 1 – 2 
days. This way the dietician can work out exactly what is in you diet (down to tiny 
amounts of vitamins / minerals etc). We will also give you a pedometer (to measure 
the number of steps taken) so you can measure how much activity you are doing. The 
dietician will do a home visit (if it suits you) or you can come back to talk to her after 
this. She will also give you lots of advice on healthy lifestyle and tailor this to you 
individually.  
At 6 months we will ask you to come back to the clinic as we would anyway and the 
dietician will meet you again and see how you are getting on.  
 
Is there any pain or harm involved? 
No. Meeting the dietician and talking about healthy lifestyles is an important part of 
every clinic visit. This will just be in more detail if you take part in the study.  
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Why are we doing this study? 
Having the condition non-alcoholic fatty liver disease means that some fat has 
gathered in your liver and is causing some irritation and scarring. We are not sure why 
you are more prone to this than any other person. As mentioned above, this could 
have to do with certain things in your diet. Talking to you about your diet for a couple 
of minutes won’t reveal this sort of thing – we need to do a more detailed study 
asking you to keep a food diary etc so that we can calculate the exact amounts of 
certain minerals and vitamins that you take in your food daily.  
We hope that this study will help us find better ways of treating this liver condition 
and thus make things better not only for you but lots of other children and teenagers 
like you.  
 
As part of the study we will be giving you general advice on diet and lifestyle. This is 
the sort of thing that we would be giving you anyway. The advantage of the study is 
that you will get more time with the dietician and the plan will likely be more 
individual to you.  
We will monitor how much things have changed in your liver at your usual 
appointment in 6 months time – using scans and blood tests as we would do anyway.  
 
If you do not want to take part in this study you do not have to. Talk to your family / 
nurse / doctor about this information leaflet. Ask any questions you like. 
We will let also your GP know about the study if you are happy to take part. 
You can withdraw from the study at any time without giving a reason.  If you do 
choose to withdraw from the study this will not affect your routine care in any way. 
 
This study has been reviewed by the South East London 3 Research Ethics Committee 
(reference number 10/H0808/122). 
 
 
Dr Emer Fitzpatrick    Professor Anil Dhawan 
Senior Clinical Fellow    Professor of Paediatric Liver Disease 
Paediatric Liver 
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Appendix	A.3:	Case-Control	Study	Consent	Form			Version	1.1	(July	2010)	
Consent to participate in the study: 
Dietary assessment of children with Non-alcoholic fatty 
liver disease in childhood: A case-control study.  		I	have	read	and	understood	the	leaflet	called	‘Nutritional	intake	and	non-alcoholic		fatty	liver	disease	in	children:	an	observational	study	‘			I	agree	to	my	child	participating	in	this	study.		I	have	had	the	opportunity	to	discuss	this	study	with	Dr	Fitzpatrick		before	signing	this	consent	form	and	my	questions	have	been	answered		satisfactorily.																																																																																																						I	understand	that	I	can	change	my	mind	at	any	time	before	the	investigation		starts	and	at	any	time	thereafter.		I	have	been	given	a	copy	of	this	consent	form.			I	agree	to	my	GP	being	informed	of	my	participation	in	this	study.				Child’s	name:		Hospital	number:		Date	of	Birth:			Signature	of	parent:		Print	name:		Relationship	to	patient:		Date:			Investigators’	signature:		Print	name:		Date:			  
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Appendix	B:	National	Health	Service	Ethics	Service	(10/H0808/122)	 	
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Appendix	C:	University	of	Surrey	Ethics	Committee	(EC/2010/115/FHMS)	
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Appendix	D:	Case-Control	Study	Food	and	Activity	Diary	
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Appendix	E:	Dutch	Eating	Behaviour	Questionnaire		 Dutch Eating Behaviour Questionnaire (DEBQ) 
 
Participant code_____________________                                     Date___/___/___ 
 
Please answer the following questions as carefully and honestly as possible. 
Read each question and simply fill in the column which best applies to you. 
 
N
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1. If you have put on weight, do you eat less than you usually do? *       
2. Do you have a desire to eat when you are irritated? *       
3. If food tastes good to you, do you eat more than you usually do? *       
4. Do you try to eat less at meal times than you would like to eat? *       
5. Do you have a desire to eat when you have nothing to do? *       
6. Do you have a desire to eat when you are depressed or discouraged? *       
7. If food smells and looks good, do you eat more than you usually eat? *       
8. How often do you refuse food or drink offered because you are concerned about your 
weight? * 
      
9. Do you have a desire to eat when you are feeling lonely? *       
10. If you see or smell something delicious, do you have a desire to eat it? *       
11. Do you watch exactly what you eat? *       
12. Do you have a desire to eat when somebody lets you down? *       
13. If you have something delicious to eat, do you eat it straight away? *       
14. Do you deliberately eat foods that are slimming? *       
15. Do you have a desire to eat when you are cross? *       
16. Do you have a desire to eat when you are approaching something unpleasant to happen? 
*       
17. If you walk past the baker do you have a desire to buy something delicious? *       
18. When you have eaten too much, do you eat less than usual the following days? *       
19. Do you get a desire to eat when you are anxious, worried or tense? *       
20. If you walk past a snack bar or café, do you have a desire to buy something delicious? *       
21. Do you deliberately eat less in order not to become heavier? *       
22. Do you have a desire to eat when things are going against you, or things have gone 
wrong? *       
23. If you see others eating, do you have also the desire to eat? *       
24. How often do you try not to eat between meals because you are watching your weight? *       
25. Do you have a desire to eat when you are frightened? *       
26. Can you resist eating delicious food? *       
27. How often in the evening do you try not to eat because you are watching your weight? *       
28. Do you have a desire to eat when you are disappointed? *       
29. Do you eat more than usual when you see other eating? *       
30. Do you take your weight into account when you eat? *       
31. Do you have a desire to eat when you are emotionally upset? *       
32. When preparing a meal are you inclined to eat something? *       
33. Do you have a desire to eat when you are bored or restless? *       
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The DEBQ was developed in the eighties with the aim of improving the understanding 
of the complex obese eating patterns. This questionnaire focus on three behavioural 
patterns: emotional, external and restrained eating. Emotional eating can be described 
as excessive eating resulting from a state of confusion between internal arousal states, 
such as anger, fear and anxiety, for which the normal response is loss of appetite, and 
hunger. This theory is known as Psychosomatic theory and was initially proposed by 
Bruch in the sixties (Bruch, 1961, 1964 cited in van Strien et al, 1986). In opposition the 
Externality theory proposes that overeating is the result of external eating, this meaning 
“a response to food related stimuli, regardless of the internal status of hunger and 
satiety” (van Strien et al, 1986). Both theories attribute as the causal factor for the 
development of obesity, a distorted perception of the individual’s internal state prior to 
eating. 
Posteriorly a new approach was proposed – the theory of Restrained Eating, which 
states that the conscious restrictive control associated with suppressed eating behaviour 
– restrained eating, may be disrupted by desinhibition factors, such as alcohol or 
depression, resulting in counterregulation and overeating. If this struggle against 
internal sensations (hunger) became constant contact may be lost with internal feelings 
of hunger and satiety. According to this theory both emotional and external eating are 
both regarded as a consequent of chronic dieting, and may or may not be also present 
(van Strien et al, 1986).    
 
 
Structure:  
The DEBQ questionnaire consists of 33 items, all with the same response format – 
never, seldom, sometimes, often and very often, together with a non relevant category in 
items that are presented in a conditional format involving particular experiences. The 33 
items are distributed as follow by the three behavioural patterns groups aimed to be 
investigated: 
 
* Emotional eating – 13 items 
* External eating – 10 items 
* Restrained eating – 10 items 
 
 
Scoring: 
Each item is scored as follows, with the exception of item 26 which scoring has to be 
reversed.  
 
 
Never – 1 
Seldom – 2 
Sometimes – 3 
Often – 4 
Very often – 5 
 
Scores are then added up for each group of items (emotional, external and restrained) 
and the final score for that group calculated, individually for each subject, as follows: 
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e.g. Restrained score = total score from “restrained ” items 
                                           number of restrained group items  
 
e.g. Restrained score =  28    =  2.8 
                                      10 
 
 
If a subject chose the “non relevant” option, this is given a score of 0 and the number of 
items used as the division factor in the above described equation is reduced by 1 for that 
particular group. 
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Appendix	F:	Youth	Physical	Activity	Questionnaire	
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Appendix	G:	Children’s	Physical	Activity	Questionnaire		 	
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Appendix	H:	HepG2	Clonogenic	Assay		
				Cell	proliferation	of	HepG2	cells	in	response	to	treatment	with	vitamin	D.	Cell	proliferation	was	measured	by	 clonogenic	 assay	 after	 13	days	 of	 treatment.	 n=1;	 data	 presented	 as	mean.	 Cell	 imaging	 is	 at	 100	X	magnification.			 	
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Appendix	I:	LX-2	Vitamin	D	Cell	Proliferation	Comparison																
	
	Cell	proliferation	of	LX-2	cells	in	response	to	treatment	with	vitamin	D.		Cell	proliferation	was	measured	by	clonogenic	assay	after	10	days	of	treatment.	n=1;	data	presented	as	mean.			 	
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Abstract: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver
disease in children, with prevalence rising alongside childhood obesity rates. This study aimed to
characterise the habitual diet and activity behaviours of children with NAFLD compared to obese
children without liver disease in the United Kingdom (UK). Twenty-four biopsy-proven paediatric
NAFLD cases and eight obese controls without biochemical or radiological evidence of NAFLD
completed a 24-h dietary recall, a Physical Activity Questionnaire (PAQ), a Dutch Eating Behavior
Questionnaire (DEBQ) and a 7-day food and activity diary (FAD), in conjunction with wearing
a pedometer. Groups were well matched for age and gender. Obese children had higher BMI
z-scores (p = 0.006) and BMI centiles (p = 0.002) than participants with NAFLD. After adjusting
for multiple hypotheses testing and controlling for differences in BMI, no differences in macro- or
micronutrient intake were observed as assessed using either 24-h recall or 7-day FAD (p > 0.001).
Under-reporting was prevalent (NAFLD 75%, Obese Control 87%: p = 0.15). Restrained eating
behaviours were significantly higher in the NAFLD group (p = 0.005), who also recorded more steps
per day than the obese controls (p = 0.01). In conclusion, this is the first study to assess dietary
and activity patterns in a UK paediatric NAFLD population. Only a minority of cases and controls
were meeting current dietary and physical activity recommendations. Our findings do not support
development of specific dietary/ physical activity guidelines for children with NAFLD; promoting
adherence with current general paediatric recommendations for health should remain the focus of
clinical management.
Keywords: non-alcoholic fatty liver disease; nutrition; obesity; physical activity; eating behaviour;
adolescence; children
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is a condition characterised by fat accumulation in
the liver with or without inflammation and fibrosis (non-alcoholic steatohepatitis; NASH), which has
Nutrients 2015, 7, 9721–9733; doi:10.3390/nu7125494 www.mdpi.com/journal/nutrients
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the potential to progress to end stage liver disease and/or hepatocellular carcinoma [1]. NAFLD
is currently the most common form of chronic liver disease in children and adolescents in Western
countries, with prevalence rising alongside rates of childhood obesity [2]. The gold standard for
diagnosis of NASH is liver biopsy, which, due to its invasive nature and associated risks, has
made establishing accurate population prevalence data for paediatric NAFLD difficult [3]. However,
in an autopsy study of 742 children who died from unnatural causes in the United States (US),
Schwimmer et al., found a NAFLD prevalence of 9.6%, which increased to 38% in obese children [4].
Due to a lack of evidence to support pharmacological treatment options for NAFLD, diet and
physical activity play a key role in NAFLD management [5,6]. First-line treatment is currently the
promotion of gradual weight loss through reduced energy intake and increased physical activity,
with the aim of improving liver function tests (LFTs), insulin resistance (IR), fasting glucose and
lipid profiles [5,6]. However, the role of specific dietary nutrients and the influence of physical
activity levels on NAFLD pathogenesis remain uncertain. Nutrients previously investigated in
NAFLD pathogenesis include fructose, saturated fatty acids (SFA), mono-unsaturated fatty acids
(MUFA), polyunsaturated fatty acids (PUFA) and vitamin D. Quality of dietary fat seems likely to
play a role in NAFLD development with a significant body of evidence suggesting that consumption
of an isocaloric diet rich in SFA may contribute to hepatic fat accumulation; whereas a diet rich in
PUFA, in particular omega-3 fatty acids, may impede steatosis development [7].
More recently, there has been increasing research into the role of fructose in NAFLD
pathogenesis [8]. Although high fructose intakes have been shown to alter hepatic insulin sensitivity
and increase lipogenesis, whether or not this contributes to NAFLD pathogenesis independent of
excess energy consumption remains uncertain [8]. Equally, vitamin D has been implicated in NAFLD
development [9] with observational studies demonstrating that low vitamin D status is associated
with NAFLD independently of bodymass index in Australian [10], and Italian [11] paediatric cohorts.
Additionally, physical activity is believed to contribute to NAFLD development with studies in both
adults [12–14] and children [15,16] identifying high rates of physical inactivity amongst individuals
with NAFLD.
In this context, the aims of this study were to characterise and compare the dietary and physical
activity patterns of a group of UK children with NAFLD to obese children without evidence of liver
disease; and furthermore to relate nutrient intakes to UK recommended dietary reference values and
exam if excess intakes or deficiencies of nutrients previously implicated in NAFLD pathogenesis are
evident in a UK paediatric cohort.
2. Materials and Methods
2.1. Participants
All participants were recruited from paediatric clinics at King’s College Hospital, London.
Children with NAFLD were recruited from the Paediatric Liver Centre, whereas obese controls were
recruited from a regional surgical weight loss clinic following a diagnosis of simple non-syndromic
obesity and were invited into the study prior to any lifestyle intervention. All subjects were
less than 18 years of age and did not consume alcohol. Cases required a diagnosis of NAFLD
(initially suspected based on ultrasound or elevated liver enzymes) confirmed by liver biopsy within
3–6 months. Patients underwent a full work up for chronic liver disease including screening for
Hepatitis B and C, Wilson disease (including liver copper quantification), autoimmune liver disease
and alpha 1 antitrypsin deficiency. Cases were excluded in the presence of other chronic liver
disease, or if they had previously received treatment for NAFLD. Controls were excluded if they
had a clinical suspicion of NAFLD, based on abnormality of liver function tests or liver ultrasound.
Written consent from parents/carers and assent from participants was obtained prior to entering the
study. Ethical approval was granted by the National Health Service Ethics Service (10/H0808/122)
and the University of Surrey Ethics Committee (EC/2010/115/FHMS).
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2.2. Demographic and Anthropometric Data
Participant ethnicity was classified according to the Health and Social Care Information Center,
Ethnic Category Code [17]. Weight (to the nearest 0.1 kg) and height without shoes (to the nearest
0.1 cm) were measured using digital scales and a commercial stadiometer (MarsdenWeighing Group,
Rotherham, UK). Body Mass Index (BMI) was calculated as weight (kg)/height (m2). BMI centile
was read from the “Body mass index (BMI) 2–20 years” chart from the Royal College of Paediatrics
and Child Health (RCPCH), using BMI, gender and age [18]. BMI z-score was obtained using
The Children’s Hospital of Philadelphia, “Pediatric Z-Score Calculator” [19]. Weight classification
was determined using BMI ranges published by the National Health Service, National Obesity
Observatory [20]. Waist circumference (WC) was measured at the midway point between the top
of the iliac crest and the bottom of the rib cage, using a commercial tape measure and reading to the
nearest 0.5 cm [21]. If identification of these points was not possible in very overweight participants,
the tape measure was placed around the abdomen at the level of the umbilicus [21]. Mid-upper arm
circumference (MUAC)was recorded to the nearest 0.5 cmwith a commercial tapemeasure and tricep
skinfold thickness was measured to the nearest 0.1 mm using calipers (Holtain Tanner/Whitehouse
Skinfold Caliper, Holtain Limited, Pembrokeshire, UK) [22].
2.3. Dietary Assessment
Dietary intakes were assessed using 24-h dietary recall and a 7-day participant-completed food
diary. The 24-h dietary recall was completed at the time of consent by a research dietitian using
the multiple-pass method [23]. To complete the 7-day food diary, participants were requested to
document all meals, snacks and beverages consumed over 7 consecutive days; stating brand names
where applicable and using household measures or food packaging information to estimate portion
sizes. Participants were asked to photograph all food and beverages consumed on two of their
recording days and to complete the diary during school term time. During the first 2–3 days of their
recording period, participants were offered support via telephone call or home visit. After completing
the food diary, participants were contacted by researchers to ascertain missing information.
Nutritional analyses were done using DietPlan6 (Forestfield Software Limited,West Sussex, UK).
Dietary intakes are presented as a percentage of age- and gender-specific UK dietary reference values
(DRVs) where possible [24]. Mean absolute intakes are given for nutrients that do not have DRVs.
Under-reporting of dietary intake was determined using cut-offs described by Goldberg et al. [25]. If
reported energy intake (EI) in the 7-day food diary was <1.14ˆ Basal Metabolic rate (BMR) or 24-h
recall data indicated an EI <0.92ˆ BMR, the participant was assumed to be under-reporting. BMR
was calculated using equations determined by Schofield et al. [26].
The 33-question Dutch Eating Behaviour Questionnaire (DEBQ) was completed by each
participant at the conclusion of the 7-day recording period to assess eating styles and behaviours
that may influence the likelihood of being overweight [27]. Participants responded to questions
on a 5-point Likert scale. Responses are classified as expressing emotional, external or restrained
eating behaviours. External eating behaviours include eating in response to food stimuli regardless of
internal state of hunger or satiety. Emotional eating is consumption in response to arousal states such
as anger, fear or anxiety; whereas restrained eating involves restricting food intake independently of
emotional or external cues [27].
Following dietary assessment, participants received tailored advice to improve the nutritional
quality of their diet, with a focus on healthy eating for weight management, via telephone call or
home visit.
2.4. Physical Activity Assessment
Physical activity was assessed via a participant-completed 7-day physical activity diary.
Participants were instructed to document all activity in 10 minute intervals on 7 consecutive days.
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Participants were provided with a pedometer (OMRON Step counter Walking style III, OMRON
Healthcare Europe B.V., Hoofddorp, The Netherlands) and were instructed to document their daily
step count on each of the 7 days. Participants received support with diary completion during the first
2–3 days of their recording period, through telephone calls and/or a home visit.
Upon return of the diaries, researchers assigned a metabolic equivalent of task (MET) to each
activity using values described by Ainsworth et al. [28]. Activity was categorised as: sleep (0.9 METs),
sedentary (1.0–1.5 METs), light (1.6–2.9 METs), moderate (3.0–5.9 METs) or vigorous (•6 METs) [28].
Periods of time that had not being recorded were classified as unaccounted time. Absolute minutes
spent in each category were calculated for each participant, along with 7-day, weekday and weekend
averages for each group. Data are presented as a percentage of 24-h.
In addition, participants •15 years of age completed the Youth Physical Activity Questionnaire
(YPAQ) and children §14 years completed the Children’s Physical Activity Questionnaire (C-PAQ)
with the aid of a parent or guardian [29,30]. These questionnaires assessed the number of absolute
minutes spent undertaking sedentary, light, moderate or vigorous exercise per week; with data
presented as a percentage of total time recorded.
2.5. Statistical Analysis
Statistical analysis was completed using SPSS v22 (IBM SPSS Statistics, Hampshire, UK).
Data are expressed as median ˘ interquartile range (IQR) unless otherwise specified. Due to the
small sample size, non-parametric tests were used to reduce the likelihood of a type 1 error. To
identify differences between groups, data were analysed using the Mann-Whitney test. Analysis
of Covariance (ANCOVA) was used to correct for differences in BMI z-score between groups.
Categorical baseline data and differences in the number of under-reporters were analysed using the
Fisher Exact test. The Freidman test was used to assess for differences in types of eating behaviours
within each group; with theWilcoxon paired rank test used to assess differences between eating styles
if p < 0.05. TheWilcoxon paired rank test was used to assess differences in physical activity levels and
pedometer data between weekdays and weekends within each group. The Bonferroni Correction
was used to determine a p-value to assess for group differences in macro- and micronutrient intakes.
Otherwise, a p-value of <0.05 was considered statistically significant.
3. Results
3.1. Study Population
During the study period, 72 children attending King’s College Hospital paediatric clinics with
NAFLD or simple obesity were approached to take part in the study. Of the 51 participants who
consented to participate, 24 patients with NAFLD (63%) and 8 obese controls (61%), who had no
evidence of fatty liver disease on abdominal ultrasound or liver function tests, completed the study
protocol (Figure 1). Anthropometric and demographic data of the participants who completed the
study protocol are outlined in Table 1. Participants ranged from 8 to 18 years of age. Groups
were evenly matched for most characteristics. Although the BMI z-score (p < 0.01) and BMI centile
(p < 0.01) were significantly higher in the obese control group; there were no significant differences
in the distribution of weight classification between groups (p = 0.99). Self- (or Guardian) reported
ethnicity [17] varied between groups with predominantly White British participants in the NAFLD
group (79%) and Black British children in the obese group (75%).
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Figure 1. Participant flow diagram for the case‐control study. 
Table 1. Population characteristics of NAFLD and obese control groups. 
Characteristics 1  Unit  NAFLD (n = 24) Control (n = 8)  p‐Value 2
Gender  n (%) 
Females 12 (50)  Females 5 (62.5) 
0.69 a 
Males 12 (50)  Males 3 (37.5) 
Ethnicity  n (%) 
Black British 0 (0)  Black British 6 (75) 
<0.001 a White 19 (79)  White 2 (25) 
Asian 5 (21)  Asian 0 (0) 
Weight classification  n (%) 
Healthy Weight Range 1 (4) Health Weight Range 0 (0) 
0.99 a 
Overweight 4 (17)  Overweight 1 (12.5) 
Obese6 (25)  Obese 2 (25) 
Extremely Obese 13 (54)  Extremely Obese 5 (62.5) 
Age  years  13.5 (12.0,15.0)  12.0 (9.5,16.5)  0.59 
Weight  kg  83.3 (71.2,105.0)  86.4 (77.2,136.5)  0.27 
Height  cm  163.0 (159.1,170.9)  161.6 (148.1,173.7)  0.61 
BMI  kg/m2  31.0 (27.1,36.5)  38.4 (30.8,44.1)  0.05 
BMI centile  ‐  99.3 (98.0,99.6)  99.6 (98.0,99.6)  0.002
BMI z‐score  ‐  2.1 (1.9,2.3)  2.6 (2.4,2.7)  0.006
Waist circumference  cm  101.0 (97.5,112.0)  113.0 (95.0,133.0)  0.31 
Triceps skinfold  mm  30.5 (23.6,34.5)  37.0 (32.2,43.6)  0.08 
MUAC  cm  32.0 (30.0,36.4)  34.5 (29.1,34.5)  0.62 
1 Characteristic is expressed as median (1st quartile, 3rd quartile) unless otherwise specified. Italics are 
here for the ease of visualisation indicating 1st and 3rd quartile ranges; 2 p‐value derived from 
Mann‐Whitney Test unless otherwise specified;  a Fisher’s exact  test. p < 0.05  in bold  is considered 
statistically significant. BMI: Body Mass Index; MUAC: Mid Upper Arm Circumference. 
3.2. Dietary Intakes 
Overall, participants  in both groups did not meet  the DRV  for most nutrients and had high 
intakes of protein, sodium, vitamin B12 and vitamin C; consuming well above the DRV (Table 2). 
Assessment of the 7‐day diaries indicated that both the control and obese groups reported intakes of 
energy, fat, MUFA, PUFA, potassium, calcium, iron, zinc and folate below their DRVs. Participants 
in the NAFLD group consistently recorded median intakes of PUFA lower than the controls, while 
protein, SFA,  iron,  copper  and zinc  intakes appeared higher  in NAFLD  compared  to  controls as 
compared by 24‐h recall. However, after correction for multiple hypotheses testing, there were no 
significant differences in macro‐ and micronutrient intakes between the NAFLD group and the obese 
(Table 2). There continued to be no difference between groups after correcting for BMI z‐score (p > 
. rti i t fl i -
a le 1. o latio c aracteristics of a o ese co trol ro s.
Characteristics 1 Unit NAFLD (n = 24) Control (n = 8) p-Value 2
Gender n (%)
Females 12 (50) (62.5)
0.69 aMales 12 (50) l s ( 7.5)
Ethnicity n (%)
Black British 0 (0) l c ritis 6 (75)
<0. 01 aWhite 19 (79) ( 5)
Asian 5 (21) sian 0 (0)
Weight classification n (%)
Healthy Weight Range 1 (4) Healt t ange 0 (0)
0.99 a
Overweight 4 (17) r i t (12.5)
Obese6 (25) Obese 2 (25)
Extremely Obese 13 (54) Extremely Obese 5 (62.5)
Age years 13.5 (12.0,15.0) 12.0 (9.5,16.5) 0.59
Weight kg 83.3 (71.2,105.0) 86.4 (77.2,136.5) 0.27
Height cm 163.0 (159.1,170.9) 161.6 (148.1,173.7) 0.61
BMI kg/m2 31.0 (27.1,36.5) 38.4 (30.8,44.1) 0.05
BMI centile - 99.3 (98.0,99.6) 99.6 (98.0,99.6) 0.002
BMI z-score - 2.1 (1.9,2.3) 2.6 (2.4,2.7) 0.006
Waist circumf rence cm 10 .0 (97.5,112.0) 113.0 (95.0,133.0) 0.31
Triceps skinfold m 3 .5 (23.6,34.5) 37. (32.2,43.6) 0. 8
MUAC cm 32.0 (30.0,36.4) 34.5 (29.1,34.5) 0.62
1 Characteristic is expressed as median (1st quartile, 3rd quartile) unless otherwise specified; 2 p-value derived
from Mann-Whitney Test unless otherwise specified; a Fisher’s exact test. p < 0.05 in bold is considered
statistically significant. BMI: Body Mass Index; MUAC: Mid Upper Arm Circumference.
3.2. Dietary Intakes
Overall, participants in both groups did not meet the DRV for most nutrients and had high
intakes of protein, sodium, vitamin B12 and vitamin C; consuming well above the DRV (Table 2).
Assessment of the 7-day diaries indicated that both the control and obese groups reported intakes of
energy, fat, MUFA, PUFA, potassium, calcium, iron, zinc and folate below their DRVs. Participants
in the NAFLD group consistently recorded median intakes of PUFA lower than the controls, while
protein, SFA, iron, copper and zinc intakes appeared higher in NAFLD compared to controls as
compared by 24-h recall. However, after correction for multiple hypotheses testing, there were
no significant differences in macro- and micronutrient intakes between the NAFLD group and the
obese (Table 2). There continued to be no difference between groups after correcting for BMI z-score
(p > 0.001). Under-reporting was prevalent in both groups with 58% of participants with NAFLD
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and 85% of obese controls under-reporting dietary intakes, as assessed by 24-h recall. Additionally,
75% of participants with NAFLD and 87% of obese controls were deemed to have under-reported
their dietary intakes using the 7-day food diary. However, the number of under-reporters did not
significantly differ between groups when assessed using either the 24-h dietary recall (p = 0.37) or the
7-day food diary (p = 0.15).
Table 2. Nutritional intakes recorded via participant completed 7-day food diary or 24-h recall
expressed as % DRV or absolute intake.
Nutritional Intake as per 7-Day Food Diary Nutritional Intake as per 24-h Recall
Nutrient 1 NAFLD (n = 24) Control (n = 8) p-Value 2 NAFLD (n = 24) Control (n = 7) p-Value 2
Intakes of Nutrients Expressed as % DRV
Energy (%) 77.4 (67.0,101.2) 86.0 (74.4,114.1) 0.41 84.7 (56.3,101.7) 52.1 (43.6,93.6) 0.10
Protein (%) 153.6 (120.2,199.5) 169.2 (146.7,233.5) 0.26 148.6 (113.8,215.4) 104.9 (59.4,129.1) 0.02
Fat (%) 82.7 (50.1,105.6) 91.7 (67.1,118.4) 0.28 77.0 (47.3,105.0) 60.7 (39.8,66.5) 0.13
SFA (%) 97.4 (50.3,127.2) 108.3 (85.7,139.4) 0.36 93.6 (56.7,138.5) 61.5 (35.7,73.2) 0.05
MUFA (%) 79.5 (40.6,92.7) 89.7 (58.5,107.5) 0.30 61.9 (40.7,102.5) 53.0 (44.1,60.6) 0.34
PUFA (%) 67.0 (46.6,84.7) 82.0 (51.4,118.5) 0.34 44.0 (33.4,93.4) 57.9 (56.0,83.3) 0.17
Carbohydrate (%) 73.0 (56.0,95.2) 87.3 (65.4,95.3) 0.51 60.2 (44.8,85.2) 51.0 (39.3,83.4) 0.44
Sodium (%) 156.3 (110.9,201.4) 167.9 (106.2,199.3) 0.86 154.1 (91.2,232.0) 109.8 (86.1,131.1) 0.16
Potassium (%) 75.9 (50.5,90.8) 75.8 (63.2,97.7) 0.32 73.3 (51.9,97.23) 52.5 (45.3,78.7) 0.08
Calcium (%) 81.5 (51.1,114.6) 79.1 (72.5,106.3) 0.79 74.0 (32.9,110.8) 57.8 (43.7,77.6) 0.48
Iron (%) 61.4 (48.5,89.7) 72.5 (59.8,91.4) 0.40 63.0 (44.5,79.4) 43.4 (39.3,49.1) 0.05
Copper (%) 100.5 (78.2,148.2) 114.1 (99.7,114.1) 0.41 89.4 (62.5,153.9) 58.8 (52.0,75.0) 0.04
Zinc (%) 78.5 (61.0,118.3) 84.4 (78.4,112.9) 0.43 62.4 (51.4,103.7) 34.3 (33.3,56.6) 0.01
Vitamin E (%) 101.0 (63.7,147.5) 120.4 (86.0,186.2) 0.43 67.5 (40.6,116.1) 109.6 (84.2,155.4) 0.30
Vitamin B12 (%) 258.3 (167.7,330.5) 250.0 (139.3,545.4) 0.76 185.0 (115.3,489.2) 127.5 (55.3,190.0) 0.09
Folate (%) 88.0 (60.6,116.2) 91.6 (81.3,100.8) 0.60 67.7 (48.2,95.5) 50.6 (46.5,77.0) 0.32
Vitamin C (%) 187.1 (77.2,302.0) 211.2 (151.6,312.4) 0.43 181.0 (115.5,331.4) 82.5 (55.0,260.0) 0.19
Intakes of Nutrients Expressed as Absolute Intake
Starch (g) 119.4 (84.7,158.2) 127.4 (101.7,137.6) 0.83 105.4 (80.3,136.9) 107.2 (52.3,148.2) 0.67
Sugar (g) 87.5 (49.5,107.1) 93.0 (82.2,102.9) 0.49 63.5 (44.9,125.0) 49.9 (22.8,80.1) 0.24
NMES (g) 15.6 (5.1,25.0) 20.8 (11.4,28.7) 0.46 16.0 (2.0,36.6) 9.8 (0.0,21.4) 0.32
Fructose (g) 12.7 (8.9,18.4) 16.7 (10.9,19.4) 0.62 12.5 (6.3,20.2) 9.1 (2.1,19.4) 0.38
NSP (g) 10.7 (8.2,13.1) 10.1 (6.3,12.3) 0.41 8.7 (7.0,11.3) 4.1 (4.0,10.9) 0.14
Carotene (g) 1.9 (0.7,3.1) 3.0 (0.6,5.8) 0.32 1.0 (0.2,2.3) 0.4 (0.04,1.3) 0.22
Vitamin D (µg) 1.7 (1.3,2.2) 3.5 (1.0,4.4) 0.32 1.8 (1.2,3.6) 1.9 (0.3,2.9) 0.45
Omega-3 Fatty
Acids (g) 0.5 (0.3,0.9) 0.5 (0.15,1.4) 0.91 0.5 (0.2,0.8) 0.3 (0.2,0.4) 0.59
1 Data are expressed as median (1st quartile, 3rd quartile); 2 p-values from Mann-Whitney Test with
Bonferroni Correction; p < 0.001 is considered statistically significant. DRV: Dietary Reference Value; MUFA:
Monounsaturated Fatty Acids; NSP: non-starch polysaccharide, NMES: Non milk extrinsic sugars; PUFA:
Polyunsaturated Fatty Acids; SFA: Saturated Fatty Acids.
Although, there were no significant differences in the percent of energy derived from total
fat, SFA, MUFA or PUFA between groups, both the obese control and NAFLD group exceeded the
recommended percent of energy derived from saturated fat and received an insufficient proportion
of energy from PUFA andMUFA (Table 3). However, both groups met the recommendations for total
fat intake deriving less than 35% of energy from fat.
Table 3. Percentage of energy derived from total fat, SFA, MUFA and PUFA recorded via participant
completed 7-day food diary.
Nutrients Contributing
to Energy Intake 1
Recommended Daily Allowance
(Expressed as Percentage (%)
Total Energy Intake)
NAFLD (n = 24) Control (n = 8) p-Value 2
Total Fat <35 33.1 (28.2,38.6) 34.1 (32.6,36.6) 0.69
SFA <11 11.7 (9.6,13.7) 12.4 (11.4,13.2) 0.31
MUFA 13 10.4 (8.8,13.6) 11.9 (8.7,12.7) 0.68
PUFA 6.5 4.9 (4.2,6.2) 4.9 (4.2,6.8) 0.88
1 Data are expressed as median (1st quartile, 3rd quartile); 2 p-values from Mann-Whitney Test. p < 0.05 is
considered statistically significant.
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After controlling for differences in BMI z-score, responses to the Dutch Eating Behaviour
Questionnaire indicated that restrained eating behaviours were significantly higher in the NAFLD
group (p = 0.005) (Figure 2). In addition, NAFLD patients reported comparatively higher scores for
external (p = 0.112) and emotional eating behaviours (p = 0.068).
Nutrients 2015, 7, page–page 
7 
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Total Fat  <35  33.1 (28.2,38.6)  34.1 (32.6,36.6)  0.69 
SFA  <11  11.7 (9.6,13.7)  12.4 (11.4,13.2)  0.31 
MUFA  13  10.4 (8.8,13.6)  11.9 (8.7,12.7)  0.68 
PUFA  6.5  4.9 (4.2,6.2)  4.9 (4.2,6.8)  0.88 
1 Data are expressed as median (1st quartile, 3rd quartile); 2 p‐values from Mann‐Whitney Test. p < 0.05 
is considered statistically significant. 
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Figure  2.  Eating  styles  in  NAFLD  and  obese  children  as  assessed  by  Dutch  Eating  Behaviour 
Questionnaires. Data adjusted for differences in BMI Z‐score using ANCOVA and are expressed as 
estimated marginal mean ± standard error of the mean (SEM). NAFLD (n = 23) Control (n = 8). 
3.3. Physical Activity Levels 
Physical activity levels, assessed using both the 7‐day diary and PAQ, indicated that participants 
spent a large proportion of their time in sedentary behaviour with minimal vigorous activity (Table 
4  and  Figure  3).  The  7‐day  activity  diary  suggested  that  NAFLD  patients  spent  more  time  on 
weekdays  in  moderate  activity  (p  =  0.06)  while  controls  had  more  weekday  time  (22%  vs.  5%) 
unaccounted  for  (Table 4).  Interestingly,  twenty‐five percent of participants  in  the NAFLD group 
reported meeting the UK physical activity requirements of 60 min of moderate to vigorous activity 
per day [31], using the physical activity levels recorded in the 7‐day activity diary. In contrast, none 
of the obese controls met these guidelines. However, there were no significant differences between 
groups  in the median amount of time per day (Table 4) or per week (Figure 3) spent undertaking 
sedentary, light, moderate or vigorous activity after controlling for BMI z‐score. 
Table 4. Physical Activity Levels expressed as amount of  time  (%) per day  recorded using 7‐day 
activity diary. 
Physical Activity Levels 1 (% per Day)  NAFLD (n = 22–24) Control (n = 8)  p‐Value 2
Sedentary 
(MET 1.0–1.5) 
7‐day Average  25 (16,32)  20 (13,28)  0.43 
Weekday Average  22 (16,30)  23 (16,31)  0.95 
Weekend Average  29 (6,36)  16 (10,22)  0.22 
Light (MET 1.6–
2.9) 
7‐day Average  18 (9,23)  13 (5,26)  0.73 
Weekday Average  25 (11,28)  16 (6,31)  0.41 
Figure 2. Eating styles in NAFLD and obese c ildren as assessed by Dutch Eating Behaviour
Questionnaires. Data adjusted for differences i I Z-score using ANCOVA and a expressed as
estimated arginal mean ˘ standard error of the ean (SEM). NAFLD (n = 23) Control (n = 8).
3.3. Physical Activity Levels
Physical activity levels, assessed usi g both the 7-day diary and PAQ, indicated that p rticipants
spent a l rge proportion of their time in sedentary behaviour with minimal vigorous activity
(Table 4 and Figure 3). The 7-day activity diary suggested that NAFLD patients spent more time
on weekdays in moderate activity (p = 0.06) while controls had more weekday time (22% vs. 5%)
unaccounted for (Table 4). Interestingly, twenty-five percent of participants in the NAFLD group
reported meeting the UK physical activity requirements of 60 min of moderate to vigorous activity
per day [31], using th physical activity levels record d in the 7-day activity diary. In contrast, none
of the obese controls et these guidelines. However, there were no significant differences between
groups in the median amount of time per day (Table 4) or per week (Figur 3) spent undertaking
sedentary, light, moderate or vigorous activity after controlling for BMI z-score.
Table 4. Physical Activity Levels expressed as amount of time (%) per day recorded using 7-day
activity diary.
Physical Activity Levels 1 (% per Day) NAFLD (n = 22–24) Control (n = 8) p-Value 2
Sedentary (MET 1.0–1.5)
7-day Average 25 (16,32) 20 (13,28) 0.43
Weekday Average 22 (16,30) 23 (16,31) 0.95
Weekend Average 29 (6,36) 16 (10,22) 0.22
Light (MET 1.6–2.9)
7-day Average 18 (9,23) 13 (5,26) 0.73
Weekday Average 25 (11,28) 16 (6,31) 0.41
Weekend Average 6 (1,14) 8 (3,13) 0.71
Moderate (MET 3.0–5.9)
7-day Average 5 (3,7) 3 (3,4) 0.31
Weekday Average 5 (3,7) 2 (1,4) 0.06
Weekend Average 4 (1,8) 7 (5,11) 0.13
Vigorous (MET > 6)
7-day Average 2 (0,3) 1 (0,2) 0.28
Weekday Average 2 (0,4) 1 (0,2) 0.19
Weekend Average 0 (0,3) 0 (0,1) 0.48
Sleep (MET 0.9)
7-day Average 40 (38,43) 42 (38,46) 0.33
Weekday Average 39 (36,42) 41 (37,41) 0.32
Weekend Average 44 (42,46) 45 (39,45) 0.62
Unaccounted
7-day Average 7 (7,22) 19 (5,32) 0.15
Weekday Average 5 (5,10) 22 (5,30) 0.08
Weekend Average 6 (0,21) 20 (9,28) 0.16
1 Data are expressed as median (1st quartile, 3rd quartile); 2 p-values from Mann-Whitney Test. p < 0.05 is
considered statistically significant. MET: Metabolic Equivalent of Task.
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Weekend Average  0 (0,3)  0 (0,1)  0.48 
Sleep (MET 0.9) 
7‐day Average  40 (38,43)  42 (38,46)  0.33 
Weekday Average  39 (36,42)  41 (37,41)  0.32 
Weekend Average  44 (42,46)  45 (39,45)  0.62 
Unaccounted 
7‐day Average  7 (7,22)  19 (5,32)  0.15 
Weekday Average  5 (5,10)  22 (5,30)  0.08 
Weekend Average  6 (0,21)  20 (9,28)  0.16 
1 Data are expressed as median (1st quartile, 3rd quartile); 2 p‐values from Mann‐Whitney Test. p < 0.05 
is considered statistically significant. MET: Metabolic Equivalent of Task. 
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Figure 3. Physical activity levels expressed as amount of time per week (%) calculated using the Youth
or Children’s Physical Activity Questionnaire. Data are expressed as percent time per week. NAFLD
(n = 16) Control (n = 8).
In addition to the physical activity diary, participants recorded step counts assessed by
a pedometer. On average, the NAFLD group took more steps than the obese controls (p = 0.01)
(Figure 4). There was no significant difference between the number of steps taken on a weekday and
a weekend days in the NAFLD group (p = 0.062), whereas participants in the obese control group
took more steps on weekday compared to a weekend (p = 0.046).
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4. Discussion
This is the first study to compare macro- and micronutrient intakes, eating behaviours and
physical activity behaviours of UK paediatric NAFLD patients to obese children without evidence
of liver disease. Anthropometric measurements were similar between groups with the exception of
BMI z-score and BMI centile, which were higher in the obese control group. Accumulation of visceral
fat has been implicated in the development and progression of NAFLD in both adults and children,
suggesting that distribution of adipose tissue may be more influential in determining NAFLD risk
than overall adiposity [33,34]. Despite no difference in waist circumference, further exploration and
comparison of body composition between groups may have provided insight into whether visceral
fat mass influenced NAFLD development in this cohort. A significant association between group
and self/guardian-reported ethnicity was identified. Ethnic variation in NAFLD prevalence has
previously been established, with studies in the USA noting higher prevalence of NAFLD amongst
Hispanics, followed by white European-Americans, with lowest disease prevalence observed in black
African-Americans [35]. This was subsequently associated with ethnic variation in the prevalence of
allelic variants of the patatin-like phospholipase 3 (PNPLA3) gene; with the PNPLA3 rs738409 (G)
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allele strongly associated with increased hepatic steatosis and inflammation [36]. Given that the
majority of participants with NAFLD were White British, compared to a majority of Black British
children in the control group, it would be interesting to explore whether a higher prevalence of
PNPLA3 rs738409 (G) exists in this NAFLD cohort.
After controlling for differences in BMI and correcting for multiple hypotheses testing, we found
no significant differences in macro- or micronutrient intake between groups. This includes nutrients
such as fructose, fatty acids and vitamin D previously implicated in NAFLD pathogenesis. The fact
that there were no statistical differences in fructose intake between groups opposes the results of
a number of previous studies noting increased fructose consumption in NAFLD patients [15,37–39].
However, our findings are consistent with a 2014 systematic review and meta-analysis where
reviewers concluded that any observed detrimental effects of excess dietary fructose might be
attributable to excessive energy intake rather than increased fructose consumption in isolation [40].
While there were no differences between the NAFLD and obese groups, reported intakes of MUFA
and PUFA were below UK recommendations; with low intakes of omega-3 fatty acids. Considering
that previous studies have linked MUFA with reduced hepatic steatosis [41] and improved insulin
sensitivity [41], and PUFA (in particular omega-3) with improvements in LFTs [42,43], serum
triglyceride (TG) and fasting blood glucose levels [42]; dietary deficiencies in MUFA and PUFA
are of concern. Education on accessible dietary sources of unsaturated fatty acids should remain
a priority in this population. Equally, although there were no statistical differences in vitamin D
consumption between groups, vitamin D intakes (1.7–3.5 µg/day) were well below the new proposed
UK recommended nutrient intake for vitamin D of 10 µg/day [44]. As vitamin D is derived both
exogenously, from dietary sources, and endogenously, by dermal synthesis following exposure to
UVB radiation [9], further research should be completed to assess the influence of both vitamin D
intake and serum 25 (OH)D levels on NAFLD pathogenesis in a paediatric UK cohort.
A key observation was the severe degree of under-reporting dietary intakes. Under-reporting is
known to be particularly common in obese subjects, characterised by reporting relatively low intakes
of foods which may be perceived as socially undesirable [45,46]. In addition, under-reporting may
have been unintentional, with reliance onmemory and inexperience of portion size estimation known
to limit accurate dietary recall in children [47]. Despite a lack of significant difference in macro-
and micronutrient intake between groups, the majority of children in this cohort were consuming
well below the DRV for most nutrients. Although, rates of under-reporting were high and reported
intake may be lower than actual intake, there should be a focus on promoting intake of a wide
range of nutritious foods to assist children in consuming sufficient macro- and micronutrients to
meet UK recommendations. While certain eating behaviours are closely linked with obesity [48],
few studies have assessed eating behaviours amongst children with NAFLD. Interestingly, in this
cohort restrained eating behaviours were higher in the NAFLD group after controlling for BMI,
which suggests that children with NAFLD are more cautious of their dietary intake. Hattar et al. [16]
compared nutrition attitudes of obese children with NASH to obese control children and found 35%
of the NASH group consistently read nutritional information labels on food/beverages, compared to
0% of controls. Consequently, the greater awareness of dietary intake by children in the present study
may be a consequence of the NAFLD diagnosis.
Equally notable, children with NAFLD in this study were more physically active and took
more steps than their obese counterparts. Indeed, twenty-five percent of participants with NAFLD
met the UK physical activity guidelines [31], whereas all participants in the control group failed to
meet this recommendation. While the most appropriate duration and intensity of physical activity
for the treatment of NAFLD remains to be established, a number of adult studies have noted
metabolic benefits of regular, moderate-intensity activity in NAFLD patients, including decreases
in visceral adiposity and hepatic TG concentration [49]. As our study noted no clear differences in
activity levels between participants with NAFLD and obese controls, general paediatric guidelines
for physical activity should be encouraged in all overweight/obese children. Additionally, there
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should be a particular emphasis on encouraging physical activity outside of school hours, as we
noted a substantial decline in steps taken on weekends compared to weekdays.
A key strength of this study was the use of liver biopsy to diagnose NAFLD rather than reliance
on LFTs or ultrasound, considered to be low sensitivity diagnostic tools [5]. Although controls were
not precisely BMI-matched to NAFLD participants, both groups were of similar weight status. This is
of key importance in identifying risk factors other than obesity, which may contribute to NAFLD
development. An additional strength was the high levels of support received by participants in
completion of food and activity diaries, through home visits and telephone calls, maximising accuracy
of diary completion. On the other hand, a limitation of this study was the low number of controls
compared to NAFLD participants increasing the risk of a Type 2 error. It was much more difficult to
successfully recruit control subjects, reflecting a wider issue of low compliance in overweight/obese
children with weight reduction initiatives [50]. Additionally, due to the specialised nature of
the paediatric NAFLD clinic, referrals were received from across south-west England whereas the
patients for the multidisciplinary obesity clinic has a significant proportion of individuals from
a region in London with a large population of individuals from African and Caribbean descent [51],
skewing the ethnic distribution between groups. Lastly, some of the subjects might have previously
seen a dietitian, or received dietary advice upon diagnosis, leading to altered eating and physical
activity behaviors during completion of the study protocol. However, all patients were assessed
according to the growth trajectory on Royal College of Paediatrics and Child Health growth charts
to ensure no loss of growth centiles, indicating weight loss, had been seen in the previous months
during diagnosis.
5. Conclusions
In summary, no differences in macro- or micronutrient intakes were observed between children
with NAFLD and obese controls in this study. Under-reporting in both groups was prevalent.
Restrained eating behaviours were significantly higher in the NAFLD group, who were also more
physically active and took more steps than their obese counterparts. Further research is required
to confirm the role of particular nutrients in the development and progression of NAFLD and to
establish optimal physical activity guidelines for children with NAFLD. Only a minority of cases and
controls were meeting current dietary and physical activity recommendations and general healthy
eating advice, alongside a minimum of 60 min moderate-vigorous physical activity per day should
continue to be encouraged [31]. Additionally, the fact that children in the control group were of
significantly higher BMI than children in the NAFLD group suggests excess body weight is not the
only driving factor in NAFLD development. Genetic susceptibility, ethnicity, the gut microbiome and
visceral fat accumulation may all play a role in the risk of developing NAFLD.
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detecting steatosis, cirrhosis, and bile duct alterations in 18%, 13%,
and 21% of patients, respectively; and delayed excretion of contrast
medium in 13% of patients. No significant association between
imaging results and LFTs were found. Vitamin D levels in general
were low. However, neither an association of vitamin D, nor gender
or BMI with liver disease was evident.
Conclusions: About 90% of patients show signs of CFLD after
LuTx assessed by ultrasound. The predominating liver alteration
was steatosis. However, the presence of steatosis might be
overestimated by ultrasound compared to MRI. Liver function tests
are not useful for screening of liver disease in CF patients after
LuTx.
P1268
IMPACT OF DIET ON GUT MICROBIOTA AND LIVER PHENOTYPE
IN CFTR KNOCKOUT MICE
D. Debray1, L. Brot2, H. El Mourabit1, V. Barbu1, D. Rainteau2,
H. Sokol2, C. Housset1. 1UMR_S 938, Centre de Recherche
Saint-Antoine, INSERM & Universite´ Pierre et Maris Curie – Univ
Paris 06, 2ERL U 1057, UMR 7203, INSERM & Universite´ Pierre et
Marie Curie – Univ Paris 06, Paris, France
E-mail: chantal.housset@inserm.fr
Background and Aims: Liver phenotype is highly variable in
cystic fibrosis. We previously showed that Cftr−/− mice fed a
standard chow + polyethyleneglycol (PEG), had no liver injury
but impaired gallbladder emptying and disrupted bile acid
enterohepatic circulation. Here, we assessed the impact of genetic
background and diet on bile acid homeostasis and gut microbiota
in Cftr−/− mice.
Methods: Male Cftr−/− (Cftrtm1Unc) mice and Cftr+/+ littermates in a
C57BL/6J congenic or C57BL/6J;129SvJ mixed background, were fed
a high fat liquid infant formula (Peptamen®) or a standard diet
+ PEG, until 3 months of age. Bile acids were analyzed by HPLC-
MS/MS; fecal microbiota composition, by 16S rRNA qPCR.
Results: A significant increase in liver/body weight ratio and the
presence of bile duct lesions were restricted to Peptamen-fed Cftr−/−
congenic mice. Liver steatosis was observed in Peptamen-fed mice
in the mixed background, irrespective of Cftr status. Gallbladder
emptying was less reduced and the ileal expression of bile acid-
regulated genes less down-regulated in Peptamen-fed compared to
PEG-treated cftr−/− mice. The proportion of secondary bile acids was
also higher under Peptamen, but remained decreased in Cftr−/− vs
Cftr+/+ mice. Compared to PEG-treated animals, Peptamen induced
a marked increase in the proportion of E.coli, even more in Cftr−/−
mice than in Cftr+/+, and a decrease in Bifidobacterium.
Conclusions: Peptamen promotes gallbladder emptying and bile
acid intestinal flux and increases the proportion of E.coli in gut
microbiota. Overall, the present findings suggest a major impact,
mainly via dysbiosis, of diet on the emergence of cystic fibrosis-
related biliary injury.
P1269
VITAMIN D STATUS, PNPLA3 GENOTYPE AND RISK OF
NON-ALCOHOLIC FATTY LIVER DISEASE SEVERITY IN A
UK PAEDIATRIC POPULATION
P.S. Gibson1, E. Fitzpatrick2, A. Quaglia2, A. Dhawan2, K. Hart1,
S. Lanham-New1, J.B. Moore1. 1University of Surrey, School of
Biosciences and Medicine, Guildford, 2Paediatric Liver Centre, Kings
College Hospital, London, United Kingdom
E-mail: p.s.gibson@surrey.ac.uk
Background and Aims: Recent research has identified an
association between low vitamin D status and incidence of non-
alcoholic fatty liver disease (NAFLD). The aims of this study were
to:
i. determine the 25-hydroxvitamin-D [25(OH)D] status and
ii. genotype key polymorphisms related to vitamin D metabolism
and NAFLD in a UK paediatric population.
Methods: Medical records of 121 NAFLD patients from the
King’s College Hospital Paediatric Liver Clinic were retrospectively
analysed. DNA was isolated from archival blood samples for
genotyping polymorphisms in genes (NADSYN1, GC and CYP2R1)
that influence vitamin D status, in addition to PNPLA3 associated
with NAFLD. Plasma 25(OH)D, ALT, AST, GGT levels and histological
scoring data were available for 78 patients.
Results: Cycling of 25(OH)D levels throughout the year was evident,
with the majority of samples in the deficient (UK Department of
Health; <25nmol/l, 31.4%) or insufficient (USA Institute of Medicine;
<50nmol/l, 52.6%) ranges and significantly lower 25(OH)D levels
in winter months when compared to spring, summer and
autumn (p =0.0037, p = 0.0002, p = 0.0052 respectively). In uni-
variate analyses, there was no correlation of 25(OH)D with ALT,
AST, GGT or NAFLD activity score (NAS). The PNPLA3 GC genotype
was associated with increased fibrosis (p = 0.0414, Figure 1a) while
the CYP2R1 G allele was associated with increased NAS (p =0.0414,
Figure 1b).
Figure 1. Genotype and NAFLD severity.
Conclusions: NAFLD patients had significantly lower winter
vitamin D status, and were insufficient throughout the entire year;
there was no correlation between 25(OH)D status and AST, ALT
and GGT levels. Interestingly, presence of the CYP2R1 G allele was
associated with NAS severity and warrants further investigation.
P1270
SEX HORMONES DIFFERENTLY REGULATE HEPATIC HEPCIDIN
EXPRESSION AND SYSTEMIC IRON HOMEOSTASIS IN VIVO
C. Garuti, G. Montosi, S. Barelli, A. Pietrangelo, E. Corradini.
University of Modena and Reggio Emilia, University Hospital of
Modena, Modena, Italy
E-mail: elena.corradini75@unimore.it
Background and Aims: Iron loading has been associated with the
progression of several liver diseases. Moreover, a number of studies
indicate that female and male exhibit differences in the progression
of chronic liver diseases, including hereditary hemochromatosis.
Better understanding of the mechanisms associated with gender-
related differences in iron homeostasis may help to develop new
therapeutic strategies in hepatic diseases.
Hepcidin is the central regulator of iron homeostasis. In humans and
animal models, gender influences hepcidin and body iron levels. So
far data on the role of sex hormones in the control of hepcidin
transcription and iron homeostasis have been controversial. Aim
of this work was to study the effects of androgens and estrogens
on the regulation of hepcidin expression and systemic iron status
in vivo.
Methods: Male and female mice underwent orchiectomy or
ovariectomy. Furthermore, male and female mice were parenterally
treated with androgens or estrogens.
Results: Orchiectomized mice showed higher hepcidin transcrip-
tion, a significant activation of the BMP6-SMAD pathway, and lower
liver iron content in comparison to sham-operated mice. This was
not the case for ovariectomized mice. Yet, androgens administration
led to a 50% decrease of hepcidin mRNA and significant spleen iron
S512 Journal of Hepatology 2014 vol. 60 | S361–S522
			 198	
		Nutrition	Society	2014	(Glasgow);	oral	presentation	
Pr
o
ce
ed
in
gs
o
f
th
e
N
ut
ri
ti
o
n
So
ci
et
y
Summer Meeting, 14–17 July 2014, Carbohydrates in health: friends or foes
Assessment of vitamin D status and genetic variation in vitamin-D related
genes: key ﬁndings from a UK paediatric non-alcoholic fatty liver disease
population
P. Gibson1, E. Fitzpatrick2, A. Quaglia2, A. Dhawan2, H. Wu1, K. Hart1, S. Lanham-New1
and J. B. Moore1
1Department of Nutritional Sciences, Faculty of Health and Medical Sciences, University of Surrey GU2 7XH
and 2Paediatric Liver Centre, Kings College Hospital, SE5 9PJ
There is growing recognition that vitamin D, in addition to being essential for bone health, also plays key roles in maintaining the
balance of human health over disease. Recent research has identiﬁed an association between low vitamin D status and non-alcoholic
fatty liver disease (NAFLD). Speciﬁcally, studies in American(1) and Italian(2) adults with NAFLD have shown low circulating levels
of vitamin D associated with the prevalence of NAFLD, which has also been observed in a small cohort of Italian children(3). The
aims of this study were to determine, in a UK paediatric population: (i) 25-hydroxvitamin-D [25(OH)D] status; (ii) genotype key poly-
morphisms related to vitamin D metabolism and NAFLD.
Medical records of 120 NAFLD patients from the King’s College Hospital Paediatric Liver Clinic were retrospectively analysed.
DNA was isolated from 103 archival blood samples for genotyping polymorphisms in genes (NADSYN1, GC, CYP2R1 and VDR)
that inﬂuence vitamin D status, in addition to PNPLA3 associated with NAFLD. Biopsies were scored by a liver histopathologist
according to the Kleiner/Brunt system(4). Vitamin D seasonality was normalised using the Sachs model(5). 25(OH)D status was
assessed by chemiluminescent immunoassay. The study received full NHS ethical approval and was conducted to the Helsinki
Declaration.
Cycling of 25(OH)D levels throughout the year was evident; with the majority of samples in the deﬁcient (UK Department of
Health; <25 nmol/l, 31·8%) or insufﬁcient (USA Institute of Medicine; <50 nmol/l, 84·1%) ranges. Patients had signiﬁcantly lower
25(OH)D levels in winter months when compared to spring, summer and autumn months (p= 0·0057; p= 0·0001; p= 0·0001 respect-
ively). In uni-variate analyses, there was no correlation of 25(OH)D with ALT, AST, GGT or NAFLD activity score (NAS).
In Caucasian patients, the PNPLA3 G allele was associated with increased steatosis and inﬂammation (p= 0·0125 and p= 0·0264
respectively) whereas the NADSYN1 A allele was associated with increased steatosis (p= 0·0451, Fig. 1a). While no association
between the GC rs2282679 and CYP2R1 rs10741657 polymorphisms and NAFLD histological severity was observed (Fig. 1b and
Fig. 1c); examination of additional variants of the GC and VDR genes is on-going.
In conclusion, UK paediatric NAFLD patients had extremely low winter vitamin D status, and were insufﬁcient throughout the
entire year. Interestingly, presence of the NADSYN1 G allele was associated with steatosis severity in Caucasian patients and war-
rants further investigation.
1. Jablonski et al. (2013) Nutrition, Metabolism and Cardiovascular Disease 8, 792–8.
2. Barchetta et al. (2011) BMC Medicine 9, 85–91.
3. Manco et al. (2010) Hepatology 51, 2229.
4. Kleiner et al. (2005) Hepatology 41 (6), 1313–21.
5. Sachs et al. (2013) American Journal of Clinical Nutrition 97, 1243–51.
Fig.1c. CYP2R1 SteatosisFig.1a. NADSYN1 Steatosis Fig.1b. GC Steatosis
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Association of NADSYN1, DHCR7, GC and VDR Geno-
types With Steatosis And Liver Inflammation in UK Pae-
diatric Non-Alcoholic Fatty Liver Disease Patients
Philippa S. Gibson1, Emer Fitzpatrick2, Alberto Quaglia2, Anil 
Dhawan2, Huihai Wu1, Kathryn Hart1, Susan Lanham-New1, J 
Bernadette Moore1; 1Department of Nutritional Sciences, School of 
Biosciences and Medicine, University of Surrey, Guildford, United 
Kingdom; 2Paediatric Liver Centre, Kings College Hospital, Lon-
don, United Kingdom
BACKGROUND: Genetic variation in the proteins integral to 
vitamin D metabolism plays a significant role in determining 
individual vitamin D status. While it is now recognised that 
vitamin D deficiency is associated with both the prevalence 
and severity of non-alcoholic fatty liver disease (NAFLD), the 
role of polymorphisms determining vitamin D status as mea-
sured by 25-hydroxyvitamin D (25OHD) in NAFLD pathogene-
sis remains unknown. The aims of this study were to determine, 
in a UK paediatric population: (i) the extent of low 25(OH)
D status; (ii) genotype key polymorphisms related to vitamin 
D metabolism and NAFLD. METHODS: Medical records of 
120 NAFLD patients from the King’s College Hospital Paedi-
atric Liver Clinic, London were retrospectively analysed. DNA 
was isolated from 103 archival blood samples for genotyping 
seven polymorphisms in genes that influence vitamin D status 
(NADSYN1, DHCR7, GC, CYP2R1 and VDR), together with 
PNPLA3 which has a known association with NAFLD. Biop-
sies were scored by a liver histopathologist according to the 
Kleiner/Brunt system. Vitamin D seasonality was normalised 
using the Sachs model. RESULTS: Cycling of 25(OH)D levels 
throughout the year was evident, with the majority of samples 
in the deficient (UK Department of Health; <25nmol/l [31.8%]) 
or insufficient (USA Institute of Medicine; <50nmol/l [84.1%]) 
ranges. Patients had significantly lower 25(OH)D levels in win-
ter months when compared to spring, summer and autumn 
months (p=0.006; p=0.0001; p=0.0001 respectively). In 
Caucasian patients, the PNPLA3 G allele was associated with 
increased steatosis (p=0.01) and inflammation (p=0.026). 
For SNPs related to vitamin D metabolism, presence of the 
NADSYN1 A allele, DHCR7 G allele and VDR A allele were 
all independently associated with increased steatosis (p=0.04; 
p=0.01; p=0.01 respectively), while the GC A allele was asso-
ciated with increased inflammation (p=0.028) in Caucasian 
patients. No association between the GC rs2282679, rs7041 
and CYP2R1 rs10741657 polymorphisms and NAFLD histo-
logical severity was found. CONCLUSIONS: This is the first 
study, to our knowledge, to investigate vitamin D status and key 
polymorphisms related to vitamin D metabolism in a paediatric 
NAFLD population. Patients had very low winter vitamin D 
status, and were in the insufficient range throughout the entire 
year. Our novel finding that polymorphisms in four key genes 
determining vitamin D status were associated with NAFLD his-
tological severity warrants further investigation.
Disclosures:
The following people have nothing to disclose: Philippa S. Gibson, Emer Fitz-
patrick, Alberto Quaglia, Anil Dhawan, Huihai Wu, Kathryn Hart, Susan Lan-
ham-New, J Bernadette Moore
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Microarray analysis of laser-captured portal tracts of 
Jag1+/-Rfng+/- liver reveals possible sub-population of 
hepatic progenitors
Lara A. Underkoffler, Emily K. McComb, John Dutton, Anthony Nel-
son, Kathleen M. Loomes, Matthew J. Ryan; Pediatrics, Children’s 
Hospital of Philadelphia, Philadelphia, PA
Background: The ductal plate harbors hepatic progenitors, 
cholangiocytes and periportal hepatocytes. Jag1+/-Rfng+/- 
livers have been identified with abnormal remodeling of the 
ductal plate including aberrant differentiation of Sox9+ pro-
genitors. We sought to better define the Sox9 population in the 
one-week old Jag1+/-Rfng+/- portal tracts using laser capture 
technology and microarray analysis. Methods: Five control 
and Jag1+/-Rfng+/- livers were snap frozen and sectioned 
at 12 μM thickness under RNAse-free conditions and RNA 
prepared. Following Agilent analysis for RIN quality, RNAs 
were converted to cDNA and amplified using the Ovation Pico 
WTA System V2 kit (NuGEN Technologies, San Carlos, CA). 
Templates were labeled and hybridized using the GeneChip® 
Mouse Gene 2.0 ST Arrays (Affymetrix, Santa Clara, CA). 
Significance Analysis of Microarrays (SAM) was applied yield-
ing q-values and fold changes (FC) to identify differentially 
expressed genes. The initial list of differentially expressed 
genes was determined by setting a False Discovery Rate (FDR) 
of 15% and a FC of +/- 1.5 in expression value. The q-value 
corresponds to the minimum FDR at which a test may be called 
significant. Results: Several hepatic progenitor markers were 
identified in the top 15% of differentially expressed genes 
including Muc1, Gabrp, Fn14 and Cldn6. While Muc1 and 
Gabrp were down-regulated (FC of -4.1 and –3.2, respec-
tively; q-val 9.4 each), Fn14 and Cldn6 were up-regulated 
(FC of 1.9 and 2.9, respectively; q-val 14.9 each). Several 
other markers for hepatic progenitors were found to be both 
down-regulated (Spp1, Thy1, Sox9, Epcam, Krt19, Krt7 and 
CD34) and up-regulated (Cldn7, Aplnr and Aldh1a1) with 
at least ±1.5 FC. An additional finding of interest relates to 
Fn14 or the Tweak receptor as Tweak signaling is associated 
with proliferation of hepatic and mesenchymal progenitors. 
Tweak’s down stream target, Ccl2 was up-regulated on our 
array with a FC of 4.1(q-val=8.2). RT-PCR confirmed both Fn14 
(FC=4.7; P=0.04) and Ccl2 (FC=8.8; P=0.04) up-regulation 
demonstrating its activity in the Jag1+/-Rfng+/- livers. Conclu-
sions: The one-week old Jag1+/-Rfng+/- livers demonstrated 
a dichotomous population with one set of hepatic markers 
down-regulated and another up-regulated suggesting the exis-
tence of a subpopulation that is based on a differentiation 
process associated with maturation. Cldn6 and Cldn7 were 
identified previously as progenitor markers and are implicated 
in cholangiocyte differentiation based on this study. Tweak 
signaling is activated in this model, which has been identified 
to play roles in oval cell and mesenchymal cell proliferation 
and differentiation.
Disclosures:
The following people have nothing to disclose: Lara A. Underkoffler, Emily K. 
McComb, John Dutton, Anthony Nelson, Kathleen M. Loomes, Matthew J. Ryan
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Conclusions: The modified IAI, adjusted for sex, is a promising
index for predicting the yearly number of phlebotomies during
maintenance treatment as an expression of the phenotype of
patients with hereditary haemochromatosis homozygous for C282Y.
Due to the retrospective design of the study, information on
factors, such as weight, BMI and diet, were lacking and are
probably of importance because of the fact that HFE related
haemochromatosis is a heterogeneous disorder. Future studies
should be performed to refine this index to make it into a useful
tool to predict the number of phlebotomies in maintenance therapy
more accurately.
P1238
INTERMEDIATE FAMILIAL INTRAHEPATIC CHOLESTASIS (IFIC):
PHENOTYPIC SPECTRUM WITHIN THE BRIC–PFIC SPECTRUM
I. Giovannoni1, F. Callea1, E. Bellacchio2, G. Torre3, V. Nobili4,
J. De Ville De Goyet5, G. Maggiore6, R. Boldrini1, P. Francalanci1.
1Pathology and Molecular Histopathology, 2Research Laboratories,
3Hepatology, Gastroenterology and Nutrition Unit, 4Hepato-Metabolic
Disease Unit, 5Paediatric Surgery and Transplantation, Bambino Gesu`
Children’s Hospital, IRCCS, Rome, 6Clinical and Experimental Medicine
Pediatric Gastroenterology, University Hospital of Pisa, Pisa, Italy
E-mail: isabella.g@fastwebnet.it
Background and Aims: Benign recurrent intrahepatic cholestasis
(BRIC) and progressive familial intrahepatic cholestasis (PFIC)
belong to a spectrum of autosomal liver disorders: familial
intrahepatic cholestases (FIC). Their differentiation is based on
genetic and phenotypic presentation. Clinical transition between
BRIC and PFIC is rarely reported. We hypothesize that patients with
a compound heterozygosity for BRIC and PFIC mutations belong to
an intermediate form of familial intrahepatic cholestasis (IFIC).
Methods: Two cases, a male (case 1), 11 year-old, with intermittent
jaundice since 1 month-old and a female (case 2), 5 year-
old, with intractable pruritus and jaundice, since 5 months old,
underwent liver biopsies, which were analyzed by histology and
immunohistochemistry (IHC) with an anti-BSEP antibody. ABCB11
gene was sequenced. To define the mutation pathogenicity, the
homology modeling was done (Figure).
Results: In case 1, liver biopsy showed preserved architecture and
mild signs of intrahepatic cholestasis. Genetic analysis showed
p.E135K (BRIC mutation) and p.L1099LfsX38 (new mutation). The
homology modeling revealed that p.E135K has an effect on the
N-glycosylation interfering with stability, function and intracellular
trafficking. Conversely, the p.L1099LfsX38 causes the loss of most
of the residues forming the 2nd ABC transporter domain, abolishing
the protein function (PFIC mutation). In case 2, three liver biopsies
displayed progression of cholestasis and IHC revealed persistent
preserved BSEP canalicular staining. Genotyping showed p.R1050C
(BRIC mutation) and p.R1153H (PFIC mutation). The p.R1153H
should impair the protein function influencing the structure of
the Walker motif in the 2nd ABC transporter domain of BSEP. The
p.R1050C, interacting with a site of ubiquitination, will increased
BSEP degradation.
Conclusions: Familial intrahepatic cholestasis is distinguished into
BRIC and PFIC. A clinical progression from benign to severe form is
rarely described. Our cases suggest the existence of a de novo form
of Intermediate FIC, with an intermediate phenotype between the
benign phenotype (BRIC) and the more severe (PFIC), genetically
supported by a compound heterozygosity (BRIC-PFIC). Absence
of phenotype-genotype correlation, at least in our cases, would
suggest the possibility of a IFIC spectrum, depending on mutation
severity.
P1239
ASSESSMENT OF DIET AND PHYSICAL ACTIVITY IN PAEDIATRIC
NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS: A UK
CASE CONTROL STUDY
P.S. Gibson1, E. Fitzpatrick2, D. Kamat2, A. Dhawan2, M.E. Ford-
Adams3, A. Desai3, K. Hart1, J.B. Moore1. 1Nutritional Sciences,
Faculty of Health and Medical Sciences, University of Surrey, Guildford,
2Paediatric Liver Centre, 3Multidisciplinary Obesity Clinic, Department
of Child Health, King’s College Hospital, London, United Kingdom
E-mail: p.s.gibson@surrey.ac.uk
Background and Aims: Non-alcoholic fatty liver disease (NAFLD)
is now the most common cause of chronic liver disease in children
with an estimated prevalence of 10% in the general paediatric
population increasing to 80% in obese children. The aim of this
study was to characterise the habitual diet and activity behaviors of
children with biopsy-confirmed NAFLD compared to obese children
without liver disease.
Methods: Biopsy proven paediatric NAFLD cases and ultrasound
clear obese controls (OC), recruited from King’s College Hospital
specialist paediatric liver and obesity clinics respectively completed
24-hour dietary recall, a Physical Activity Questionnaire (PAQ), a
Dutch Eating Behavior Questionnaire (DEBQ) and a 7-day food
and activity diary (FAD) in conjunction with wearing a pedometer.
Personal diet and lifestyle feedback was provided with the goal of
weight reduction at 6-month follow-up.
Results: 21 NAFLD and 8 OC have completed the study to
date. Groups were well matched for age, gender and baseline
anthropometrics with the majority of patients having a BMI
over the 99.6th\ centile. The NAFLD group were predominantly
Caucasian (80%) while OC group were largely Black (78%)
(p < 0.01). 24-hour recall data highlighted NAFLD patients had
higher intakes of saturated fatty acids (SFA) and iron when
comparing dietary recommended values (p = 0.048 and p=0.021
respectively), while the 7-day FAD demonstrated higher dietary
intakes of vitamin D in the OC compared to NAFLD (3.7mg/d versus
2.1mg/d; p = 0.05). No significant differences in absolute intakes of
fructose, or Vitamins C or E were identified. Under-reporting was
prevalent within the sample (NAFLD: 65%, OC: 75%; p =0.61). In
addition, NAFLD patients showed a greater number of steps taken
(NAFLD: 8,414, OC: 5,965; p =0.02) despite both groups not meeting
the recommended 10,000 steps a day.
Journal of Hepatology 2015 vol. 62 | S263–S864 S821
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Conclusions: This is the first study to assess dietary and
lifestyle activity in a UK paediatric NAFLD population. While
clear differences were not identified between groups, issues of
sample size, under reporting and confounding by ethnicity have
impacted on the findings and are being addressed in the ongoing
study. Development of NAFLD-specific diet and lifestyle guidelines
are currently not supported. The current study demonstrates
that the paediatric population is failing to conform to standard
recommendations for both diet and physical activity, and should
therefore remain the focus of clinical management.
P1240
CLINICAL, BIOCHEMICAL AND HISTOPATHOLOGIC PROFILE
OF SUBJECTS WITH GLYCOGENIC HEPATOPATHY (MAURIAC
SYNDROME)
S. Mukewar1, P. Kamath1, L. Roberts1, Y. Kudva2. 1Gatsroenterology
and Hepatology, 2Endocrinology, Mayo Clinic, Rochester, MN, United
States
E-mail: mukewar.saurabh@mayo.edu
Background and Aims: Glycogenic hepatopathy is a syndrome of
elevated transaminases and liver enlargement in type-1 diabetes
patients. Since its description, there have been mostly case reports
discussing this condition. We aimed to conduct a case series to
describe clinical, biochemical and histo-pathologic profile of these
patients.
Overall (n = 36) Adults (n = 24) Pediatric (n = 12)
Male 8 (22.2%) 5 (20.8%) 3 (25%)
Age at presentation (years) a 20.9±5.8 23.3±5.7 16.3±1.76
Height (cm) b 166.8 (161.8, 169.5) 168 (162.4, 171.6) 161.5 (148.8, 164.9)
Weight (kg) a 64.4±13.3 66±9.7 61.1±18.8
Body mass index (BMI; kg/m2) a 23.5±3.5 23.4±2.7 23.8±4.8
Percentile height for age b 30 (8.5, 49) n/a 30 (8.5, 49)
Percentile weight for age b 78.5 (43.5, 83.8) n/a 77 (62.5, 80.8)
BMI for age b 76 (53, 84) n/a 81.5 (72.3, 89.8)
Clinical features
Abdominal pain 23 (63.9%) 14 (58.3%) 9 (75%)
Vomiting 6 (16.7%) 6 (25%) 0
Abdominal distention 6 (16.7%) 2 (8.3%) 4 (33.3%)
Splenomegaly 2 (5.6%) 0 2 (16.7%)
Hepatomegaly 22 (61.1%) 12 (50%) 10 (83.3%)
Type-1 DM 36 (100%) 24 (100%) 12 (100%)
Age at diagnosis of DM (years) b 8.5 (5, 12) 9.5 (5.5, 12.8) 7.5 (5, 9.25)
Duration of DM (years) a 11.6±5.6 13.3±5.8 8.7±3.6
Requires insulin 35 (97.2%) 23 (95.9%) 12 (100%)
Episodes of DKA 22 (61.1%) 13 (54.2%) 9 (75%)
Imaging findings
Splenomegaly 0 0 0
Hepatomegaly 28 (77.8%) 19 (79.2%) 9 (75%)
Laboratory findings
HBa1c (%) a 11.2±2.4 11.5±2.6 10.7±2
Aspartate transaminase (U/L) b 289 (139, 594) 313 (246, 770) 157 (114, 254)
Alanine transaminase (U/L) b 245 (126, 386) 315 (189, 386) 145 (77, 300)
Alkaline phosphatase (U/L) b 196 (145, 288) 193 (149, 273) 243 (142, 287)
Gamma glutamyl transferase (U/L) b 97 (66, 365) 181 (123, 366) 77 (66, 271)
Total bilirubin (mg/dL) a 0.5±0.3 0.5±0.4 0.5±0.2
Direct bilirubin (mg/dL) a 0.2±0.3 02±0.3 0.2±0.1
Serum albumin a 3.9±0.6 3.7±0.5 4.3±0.4
INR a 0.86±0.07 0.88±0.07 0.82±0.04
Total cholesterol (mg/dL) a 266±95 281±112 242±56
LDL cholesterol (mg/dL) a 112±38 116±39 107±38
HDL cholesterol (mg/dL) a 51±24 52±24 50±24
Triglycerides (mg/dL) b 291 (188, 507) 318 (188, 572) 259 (202, 361)
Biopsy
Performed 20 (55.5%) 16 (66.6%) 4 (33.3%)
Inflammation 3 (15%) 3 (18.75%) 0
Megamitochondria 3 (15%) 2 (12.5%) 1 (8.33%)
Fibrosis 2 (10%) 1 (6.25%) 1 (8.33%)
Follow up
Resolved transaminases 18 (50%) 9 (37.5%) 9 (75%)
Resolving transaminases 3 (8.3%) 2 (8.3%) 1 (8.3%)
No follow up 15 (41.6%) 13 (54.2%) 2 (16.7%)
a Mean ± standard deviation. b Median (interquartile range).
Methods: Electronic medical records at Mayo Clinic, Rochester were
searched from January 1, 1998 to January 1, 2014 using the term
“Mauriac syndrome” and “Glycogenic hepatopathy” and reviewed
in detail. Demographic, clinical, biochemical and histopathologic
data was abstracted.
Results: Results are described in the table. 36 patients were
diagnosed with glycogenic hepatopathy – 24 adults and 12 pediatric
patients. 20 had liver biopsy and 16 were clinically diagnosed.
28 (77.8%) cases were female. Only 2 out of 12 (16.7%) pediatric
patients, both from the clinically diagnosed group, had percentile
height, weight and BMI for age below the third percentile.
Abdominal pain was the most common symptom [23 (63.9%)] and
hepatomegaly was seen in 28 (77.8%) cases on imaging. All patients
had poor control of diabetes (HBA1c – 11.2±2.4). Transaminases
were elevated from 3 to 20 times the upper limit of normal.
Conclusions:
– Growth retardation is uncommon in glycogenic hepatopathy.
– Majority of cases present with abdominal pain, hepatomegaly,
transaminase elevation, hypertriglyceridemia, without any
synthetic liver dysfunction.
– Liver biopsy rarely shows fibrosis, inflammation or megamito-
chondria.
– On follow up, majority of individuals with follow up data had
resolution of transaminases with improved glycemic control.
P1241
JAK/STAT PATHWAY AND SUSCEPTIBILITY TO HEPATITIS B VIRUS
INFECTION AND RELATED LIVER DISEASES
T.V. Hoang1, N.X. Hoan1, A. Clark1, F. Gerlach1, N.L. Toan2,
L.H. Song3, C.-T. Bock4, P.G. Kremsner1, T.P. Velavan1. 1Institute
of Tropical Medicine, University of Tu¨bingen, Tu¨bingen, Germany;
2Department of Pathophysiology, Vietnam Military Medical University,
3Institute of Clinical Infectious Diseases, Tran Hung Dao Hospital,
Hanoi, Vietnam, 4Department of Infectious Diseases, Robert Koch
Institute, Berlin, Germany
E-mail: tong.van-hoang@uni-tuebingen.de
Background and Aims: Hepatitis B virus (HBV) infects
approximately 350 million people worldwide and is the leading
cause for chronic hepatitis, liver cirrhosis and hepatocellular
carcinoma. The activation of JAK/STAT pathway by cytokines
and growth factors is related to different processes such as
cell proliferation, differentiation and apoptosis. Several protein
members of JAK/STAT pathway including SOCS1, SOCS3, STAT1,
STAT3, and STAT5 have been demonstrated to associate with
the HBV infection and modulate the outcomes of liver
diseases. We investigated the influence of polymorphisms in the
JAK/STAT pathway gene members including Cytokine-inducible SRC
homology 2 (SH2) domain protein (CISH), the signal transducers
and activators of transcription 4 (STAT4) and the suppressors of
cytokine signalling 3 (SOCS3) on HBV infection and HBV-related
liver diseases.
Methods: We utilized a Vietnamese cohort (n = 1084) clinically
classified into different subgroups including chronic hepatitis B
carriers, liver cirrhosis, hepatocellular carcinoma and healthy
controls to investigate the effect of the reported variants. The
genotyping of investigated variants was performed by FRET real-
time PCR and sequencing. A multivariate regression analysis was
performed to investigate potential effect of studied variants and to
exclude the confounding effects of other factors such as age and
gender. We also analyzed the influence of studied variants on the
disease outcomes represented by different clinical parameters.
Results: The first results showed that CISH variants −292A/T were
significantly associated to HBV infection (Allelic: OR: 1.22, 95%CI
1–1.49; P =0.04; Recessive: OR: 1.69, 95%CI 1.23–2.54; P =0.007).
A gene dose effect for the risk allele −292T was also observed
(P =0.04). In addition, the STAT4 variant (rs7574865) was marginally
S822 Journal of Hepatology 2015 vol. 62 | S263–S864
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Assessment of diet and lifestyle factors associated with non-alcoholic fatty
liver disease in a UK paediatric population
P.S. Gibson1, E. Fitzpatrick2, D. Kamat2, A. Dhawan2, M.E. Ford-Adams3, A. Desai3,
K. Hart1 and J.B. Moore1
1Nutritional Sciences, Faculty of Health & Medical Sciences, University of Surrey, Guildford, GU2 7XH, 2Paediatric
Liver Centre, King’s College Hospital, London, SE5 9PJ and 3Multidisciplinary Obesity Clinic, Department of Child
Health, King’s College Hospital, London, SE5 9PJ
Non Alcoholic Fatty Liver Disease (NAFLD) is the most common cause of chronic liver disease in Western children, thought to affect
up to 10 %(1) of the general paediatric population and up to 80 % of overweight children(2). This is the ﬁrst UK based study, which
aims to characterise the habitual diet, and activity behaviours of children with biopsy-conﬁrmed NAFLD compared to BMI matched
controls (obese controls, OC) to inform the development of effective prevention and management strategies.
Cases and OC were recruited from the paediatric liver unit and specialist obesity clinic respectively at King’s College Hospital
London, UK. On receipt of consent, children were asked to complete a 7-day Food and Activity Diary (with 7 day pedometer read-
ings), a 24-hour Dietary Recall, a Physical Activity Questionnaire and the Dutch Eating Behaviour Questionnaire (DEBQ). The study
was conducted according to the Helsinki Declaration.
Thirty-eight NAFLD and 12 OC have been recruited to date and dietary data is available for 29 (21 NAFLD; 8 OC). The groups
are well matched for age (NAFLD: 13·1[SD2·2], OC: 12·8 [3·7] years), gender and weight, with the majority of both groups being
above the 99·6th centile for BMI. The NAFLD group were predominantly Caucasian (83 %) whereas the OC group were predom-
inantly Black (75 %) (p < 0·001). NAFLD children scored non-signiﬁcantly higher on all sub scales of the DEBQ, representing
more negative eating behaviours. NAFLD patients were had signiﬁcantly higher intakes of saturated fat and iron as assessed by
24hr recall when expressed as a percentage of their DRVs (p < 0·05 and p = 0·02 respectively, table 1). Interestingly, the 7-day
diary records demonstrated signiﬁcantly lower absolute vitamin D intakes in children with NAFLD (1·875μg versus, 3·785μg p =
0·05). NAFLD children took a greater number of steps per day in comparison to OC (8414 [2843] versus 5965 [2066], p = 0·023).
This is the ﬁrst study to report on the diet and activity behaviours of a UK paediatric NAFLD population. The development
of NAFLD-speciﬁc lifestyle guidelines are not currently supported however this study conﬁrms that the paediatric population are
failing to conform to standard recommendations for diet or activity, which should therefore remain the focus of clinical management
to optimise health and minimise disease progression.
1. Takahashi et al. (2010) World Journal of Gastroenterology 16, 5280–5285
2. Giorgio et al. (2013) BMC Pediatrics 13, 40–49
Table 1
24 Hour Recall 7 Day Food Diary
Nutrient (%) NAFLD OC P value NAFLD OC P value
Energy 81·6[26·8] 66·6[22·8] 0·067 92·6[26·7] 91·8[25·1] 0·944
Fat 84·5[41·4] 56·8[17·9] 0·031 89·8[68·6] 92·4[29·0] 0·854
SFA 110·3[57·8] 59·0[25·0] 0·007 106·6[49·0] 110·8[37·0] 0·950
Protein 159·4[63·5] 113·2[46·4] 0·021 183·4[68·6] 194·3[64·9] 0·714
Iron 86·1[69·4] 62·2[20·7] 0·247 86·3[38·4] 74·4[16·8] 0·417
Zinc 97·8[70·8] 93·6[53·0] 0·691 99·8[36·5] 93·4[21·3] 0·652
Vitamin D* 2·0[2·0] 1·8[1·7] 0·742 2·1[1·4] 3·7[0·9] 0·050
Fructose* 14·6[3·3] 22·8[28·6] 0·289 17·2[13·0] 15·2[5·8] 0·687
Data presented as %DRV [SD] * denotes no DRV available and absolute values expressed.
Proceedings of the Nutrition Society (2015), 74 (OCE5), E324 doi:10.1017/S0029665115003717
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Vitamin D reduces hepatic stellate cell proliferation in vitro. By P. S. Gibson1, K. Hart1,  
E. Fitzpatrick2, A. Dhawan2, S. A. Lanham-New1 and J. B. Moore1,3, 1Nutritional Sciences 
Department, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 
7XH, 2Paediatric Liver Centre, King’s College Hospital, London SE5 9PJ, 3School of Food 
Science and Nutrition, University of Leeds, Leeds LS2 9JT 
 
Activated hepatic stellate cells (HSCs) are a key contributor to liver fibrosis(1) and drive the 
progression to advanced disease for many liver conditions, including non-alcoholic fatty liver 
disease.  Vitamin D has been shown to have anti-proliferative effects on colorectal cancer 
cells(2); however less is known about its effects on hepatic stellate cells.  The aim of these 
experiments were to determine in vitro: (i) basal protein expression of the vitamin D receptor 
(VDR); (ii) confirmation of 1α,25(OH)2D3  (1,25-VD3) phenotypic effect; (iii) the time and 
dose response to 1,25-VD3 treatment. 
Three human immortalised cell lines: HT29, colorectal adenocarcinoma; HepG2, 
hepatocellular carcinoma, and LX-2, hepatic stellate cells, were cultured using standard 
methods. Several sources of 1,25-VD3 were assessed. VDR protein expression was analysed 
by immunoblotting. VDR and CYP24A1 mRNA expression was measured in LX-2 and 
HepG2 cells at 0, 1, 2, 4, 6, 8, 10, 12 and 24 hour time points after treatment with 10nM of 
1,25-VD3. LX-2, HepG2 and HT29 were treated with a range of 1,25-VD3 concentrations 
(1µg-1ng) and cell proliferation was measured by clonogenic assay using crystal violet 
staining.  
Untreated LX-2 cells had a higher abundance of VDR protein than HepG2 cells (Figure 
1A). Correspondingly, basal VDR mRNA expression was higher in LX-2 in comparison to 
HepG2 cells (P<0.0001).  However, mRNA expression for CYP24A1 was much lower in 
LX-2 compared to HepG2 cells (P<0.0001). Treatment with 1,25-VD3 dramatically reduced 
hepatic stellate cell proliferation; a dose-dependent response was observed with 1µM and 
100nM of 1,25-VD3 eliciting a significant reduction in cell colonies (P=0.0005 and P=0.016 
respectively; n 4; Figure 1B) corresponding to 95% and 82% fewer colonies.  The same trend 
was seen in HT29 cells (P=0.053; n 3; Figure 1C). 
 
 
 
 
Figure 1 Basal levels of VDR in LX-2 and HepG2 cells (A).  Cell proliferation of LX-2 (B) and HT29 (C) cells 
in response to 1,25-VD3. Data presented as mean + SEM. V: vehicle; VDR: vitamin D receptor. 
 
Unexpectedly, our initial 1,25-VD3 treatment appeared to have no effect on VDR and 
CYP24A1 mRNA expression. After an alternative vitamin D was sourced, a clear reduction 
in cell proliferation in response to 1,25-VD3 was observed in both LX-2 and HT29 cells. 
Future experiments will determine the associated transcriptional response in co-treatment 
with lipid loading. 
 
1. Moreira RK (2007) Arch Pathol Lab Med 131: 1728-1734 
2. Alvarez-Diaz S, Valle N, Ferrer-Mayorga G et al. (2012) Hum Mol Genet 21 (20): 2157-2165 
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!
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!(n
=2
1)
!
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nt
ro
ls
!(n
=8
)!
P5
va
lu
e!
Age$(ye
ars)$
13.2$±$
2.4$
12.8$±$
3.7$
0.675$
Gender
$(M/F)
$
9/12$
3/5$
1.000$
Ethnici
ty$(Wh
ite/Asi
an/Bla
ck)$
17/4/0
$
2/0/6$
<0
.0
01
%
Weight
$(kg)$
$$87.5$±
$24.9$
100.2$±
$31.8$
0.266$
Height
$(cm)$
162.6$±
$10.2$
160.3$±
$13.4$
0.635$
BMI$(k
g/m2 )$
32.5$±$
6.5$
38.2$±$
7.8$
0.055$
BMI$zJs
core$
$$$2.2$±$
0.3$
$$$2.5$±$
0.3$
0.
00
6%
Waist$c
ircumf
erence
$(cm)$
105.0$±
$11.3$
112.0$±
$19.7$
0.458$
Triceps
$skinfo
ld$(mm
)$
30.9$±$
9.4$
37.8$±$
6.2$
0.118$
MUAC$
(cm)$
34.8$±$
5.6$
36.4$±$
8.7$
0.900$
$
Co
ho
rt
	C
ha
ra
ct
er
ist
ics
!
RN
I!
N
AF
LD
!(n
=2
1)
!
Co
nt
ro
ls
!(n
=7
)!
P7
va
lu
e!
Energy
'(Kcal)
'
1845'
'''1639
'±'553.
0'
''1236'
±'449.1
'
0.093'
Protein
'(g)'
41.2'
''67.7'±
'24.0'
''41.0'±
'18.9'
0.
01
3%
Fat'(g)
'
71.8'
''64.3'±
'28.9'
''45.8'±
'11.1'
0.114'
SFA'(g)
'
20.4'
26.2'±'
3.0'
14.4'±'
4.9'
0.
03
7%
MUFA'
(g)'
24.6'
''19.4'±
'10.4'
15.2'±'
2.2'
0.298'
PUFA'(
g)'
12.3'
''9.0'±'5
.7'
''9.6'±'1
.8'
0.783'
Carboh
ydrates
'(g)'
H'
199.7'±
'82.5'
166.2'±
'77.0'
0.353'
Starch'
(g)'
H'
106.8'±
'40.2'
108.7'±
'60.1'
0.927'
Sugar'(
g)'
H'
'''80.7'±
'58.2'
''50.7'±
'34.5'
0.212'
Free'Su
gars'(g
)'
<46'
'''26.2'±
'37.1'
''12.0'±
'13.8'
0.375'
Fructo
se'
H'
'''16.9'±
'20.2'
''11.5'±
'11.2'
0.510'
NSP'(g
)'
18'
'''9.3'±'
4.0'
''6.6'±'3
.6'
0.136'
Sodium
'(mg)'
1600'
'''2320
'±'1092
'
'''1696
'±'565.
7'
0.163'
Potassi
um'(m
g)'
3100'
''''2260
'±'794.
5'
'''1602
'±'591.
9'
0.055'
Calcium
'(mg)'
800'
'''704.9
'±'512.
4'
''429.9
'±'128.
9'
0.177'
Iron'(m
g)'
14.8'
'''7.7'±'
2.3'
''5.6'±'1
.0'
0.
03
3%
Copper
'(mg)'
0.8'
'''0.9'±'
0.5'
''0.5'±'0
.2'
0.091'
Zinc'(m
g)'
9.0'
'''7.1'±'
4.2'
''3.4'±'1
.3'
0.
02
8%
Carote
ne'(mg
)'
600'
'''1449
'±'1959
'
''1754'
±'3638
'
0.778'
Vitami
n'E'(m
g)'
5'
'''5.0'±'
2.9'
''6.2'±'3
.2'
0.358'
Vitami
n'B12'(
μg)'
1.2'
'''3.1'±'
2.8'
''1.5'±'1
.5'
0.146'
Folate'
(μg)'
200'
'152.1'
±'60.0'
110.1'±
'33.4'
0.092'
Vitami
n'C'(mg
)'
35'
''''66.6'
±'42.8'
''54.3'±
'44.2'
0.518'
Vitami
n'D'(μg
)'
H'
''''2.5'±
'2.1'
''1.8'±'1
.3'
0.376'
'
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